<body style="font-family: Times New Roman; font-size: 13px;"> <document>  <type>   10-K   <sequence>    1    <filename>     vtgn_10k.htm     <description>      ANNUAL REPORT      <text>       <!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->       <!-- Copyright 2021 Issuer Direct Corporation -->       <title>        vtgn_10k       </title>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 21px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000">        <!--style header-->        <br/>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 21px;">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 21px">         UNITED STATES        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 21px">         SECURITIES AND EXCHANGE COMMISSION        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Washington, D.C. 20549        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 21px">         Form 10-K        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 11%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px">              ☒             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Annual Report Pursuant to Section 13 or 15(d) of theSecurities Exchange Act of 1934             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         For the fiscal year ended: March 31, 2021        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         or        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 11%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px">              ☐             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Transition Report Pursuant to Section 13 or 15(d) of theSecurities Exchange Act of 1934             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Commission file number: 001-37761        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 24px">         VistaGen Therapeutics, Inc.        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         (Exact name of registrant as specified in its charter)        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 45%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Nevada             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 8%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              20-5093315             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 45%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              (State or other jurisdiction of             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              incorporation or organization)             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 8%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              (I.R.S. Employer             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Identification No.)             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         343 Allerton Avenue        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         South San Francisco, California 94080        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         (650) 577-3600        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         (Address, including zip code, and telephone number, including areacode, of registrant’s principal executiveoffice)        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         Securities registered pursuant to Section 12(b) of theAct        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: bottom; width: 46%; border-bottom: 2px solid #000000">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Title of each class             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 2%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 52%; border-bottom: 2px solid #000000">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Name of each exchange on which registered             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 46%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              CommonStock, par value $0.001 per share             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 2%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 52%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              TheNasdaq Capital Market             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         Securities registered pursuant to Section 12(g) of theAct        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         None        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Indicate by check mark if the registrant is a well-known seasonedissuer, as defined in Rule 405 of the SecuritiesAct.    Yes         </font>         <font style="color: #000000">          ☐         </font>         <font style="color: #000000">          No         </font>         <font style="color: #000000">          ☒         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Indicate by check mark if the registrant is not required to filereports pursuant to Section 13 or 15(d) of theAct.    Yes         </font>         <font style="color: #000000">          ☐         </font>         <font style="color: #000000">          No         </font>         <font style="color: #000000">          ☒         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Indicate by check mark whether the registrant (1) has filedall reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required tofile such reports), and (2) has been subject to such filingrequirements for the past 90days.    Yes         </font>         <font style="color: #000000">          ☒         </font>         <font style="color: #000000">          No         </font>         <font style="color: #000000">          ☐         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Indicate by check mark whether the registrant has submittedelectronically and posted on its corporate Web site, if any, everyInteractive Data File required to be submitted and posted pursuantto Rule 405 of Regulation S-T (§232.405 of this chapter)during the preceding 12 months (or for such shorter period that theregistrant was required to submit and post suchfiles).    Yes         </font>         <font style="color: #000000">          ☒         </font>         <font style="color: #000000">          No         </font>         <font style="color: #000000">          ☐         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Indicate by check mark whether the registrant is a largeaccelerated filer, an accelerated filer, a non-accelerated filer,or a smaller reporting company. See the definitions of “largeaccelerated filer,” “accelerated filer” and“smaller reporting company” in Rule 12b-2 of theExchange Act.        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 17%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               Large accelerated filer              </font>              <font style="color: #000000">               ☐              </font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: top; width: 15%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               Accelerated filer              </font>              <font style="color: #000000">               ☐              </font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="4" style="vertical-align: top; width: 18%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               Non-accelerated filer              </font>              <font style="color: #000000">               ☐              </font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 16%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Smaller reporting             </font>            </div>            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               company              </font>              <font style="color: #000000">               ☒              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 23%">            <div style="text-align: left; margin-left: 0px; margin-right: 18px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               Emerging Growth Company              </font>              <font style="color: #000000">               ☐              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 17%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="3" style="vertical-align: top; width: 16%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 2%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="5" style="vertical-align: top; width: 58%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          If an emerging growth company, indicate by check mark if theregistrant has elected not to use the extended transition periodfor complying with any new or revised financial accountingstandards provided pursuant to Section 13(a) of the ExchangeAct.         </font>         <font style="color: #000000">          ☐         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Indicate by check mark whether the registrant has filed a report onand attestation to its management’s assessment of theeffectiveness of its internal control over financial reportingunder Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b))by the registered public accounting firm that prepared or issuedits audit report.    Yes         </font>         <font style="color: #000000">          ☐         </font>         <font style="color: #000000">          No         </font>         <font style="color: #000000">          ☒         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Indicate by check mark whether the registrant is a shell company(as defined in Rule 12b-2 of theAct).    Yes         </font>         <font style="color: #000000">          ☐         </font>         <font style="color: #000000">          No         </font>         <font style="color: #000000">          ☒         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The aggregate market value of the common stock of the registrantheld by non-affiliates of the registrant on September 30, 2020, thelast business day of the registrant’s second fiscal quarter,was: $51,365,745.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          As of         </font>         <font style="color: rgb(0, 0, 0);">          June 28, 2021,there were         </font>         <font style="color: rgb(0, 0, 0);">          191,382,350         </font>         <font style="color: rgb(0, 0, 0);">          shares         </font>         <font style="color: #000000">          of the registrant’s common stock, $0.001 parvalue per share, outstanding.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         DOCUMENTS INCORPORATED BY REFERENCE        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Items 10, 11, 12, 13 and 14 of Part III incorporate byreference certain information from VistaGen Therapeutics,Inc.’s definitive proxy statement, to be filed with theSecurities and Exchange Commission on or before July 29,2021.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          TABLE OF CON         </font>         <font style="color: #000000">          TENTS         </font>        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px;">        <table cellpadding="0" cellspacing="0" style="text-align: left; font-family: inherit; font-size: inherit;width: 100%;">         <tbody>          <tr>           <td style="vertical-align: bottom; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: bottom; width: 8%; border-bottom: 2px solid #000000">            <div style="text-align: center; margin-left: 0px; margin-right: 1px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">              Item No.             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000000">            <div style="text-align: center; margin-left: 0px; margin-right: 1px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">              Page No.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Bus">              <font style="color: #0000ff; font-weight: bold; font-size: 13px; font-family: Times New Roman">               PART I              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>          </tr>          <tr style="background-color: #cceeff">           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Bus">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               1.              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Bus">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               Business              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              1             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Risk">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               1A.              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Risk">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               RiskFactors              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              31              <br/>             </font>            </div>           </td>          </tr>          <tr style="background-color: #cceeff">           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Unre">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               1B.              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Unre">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               UnresolvedStaff Comments              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              65              <br/>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Prop">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               2.              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Prop">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               Properties              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              65              <br/>             </font>            </div>           </td>          </tr>          <tr style="background-color: #cceeff">           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Leg">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               3.              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Leg">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               LegalProceedings              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              65              <br/>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Mine">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               4.              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Mine">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               MineSafety Disclosures              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              65              <br/>             </font>            </div>           </td>          </tr>          <tr style="background-color: #cceeff">           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Mark">              <font style="color: #0000ff; font-weight: bold; font-size: 13px; font-family: Times New Roman">               PART II              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <br/>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Mark">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               5.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Mark">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               Marketfor Registrant’s Common Equity, Related Stockholder Mattersand Issuer Purchases of Equity Securities              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              66              <br/>             </font>            </div>           </td>          </tr>          <tr style="background-color: #cceeff">           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Sel">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               6.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Sel">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               SelectedFinancial Data              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              66              <br/>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Man">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               7.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Man">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               Management’sDiscussion and Analysis of Financial Condition and Results ofOperations              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              66              <br/>             </font>            </div>           </td>          </tr>          <tr style="background-color: #cceeff">           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Quan">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               7A.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Quan">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               Quantitativeand Qualitative Disclosures About Market Risk              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              80              <br/>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Fina">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               8.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Fina">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               FinancialStatements and Supplementary Data              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              81              <br/>             </font>            </div>           </td>          </tr>          <tr style="background-color: #cceeff">           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Chan">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               9.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Chan">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               Changesin and Disagreements with Accountants on Accounting and FinancialDisclosure              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              121             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Cont">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               9A.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Cont">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               Controlsand Procedures              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              121             </font>            </div>           </td>          </tr>          <tr style="background-color: #cceeff">           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Oth">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               9B.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Oth">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               OtherInformation              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              121             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Dir">              <font style="color: #0000ff; font-weight: bold; font-size: 13px; font-family: Times New Roman">               PART III              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>          </tr>          <tr style="background-color: #cceeff">           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Dir">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               10.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Dir">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               Directors,Executive Officers and Corporate Governance              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              122             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Exe">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               11.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Exe">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               ExecutiveCompensation              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              122             </font>            </div>           </td>          </tr>          <tr style="background-color: #cceeff">           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Sec">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               12.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Sec">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               SecurityOwnership of Certain Beneficial Owners and Management and RelatedStockholder Matters              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              122             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Cer">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               13.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Cer">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               CertainRelationships and Related Transactions, and DirectorIndependence              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              122             </font>            </div>           </td>          </tr>          <tr style="background-color: #cceeff">           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Prin">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               14.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Prin">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               PrincipalAccounting Fees and Services              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              122             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Exh">              <font style="color: #0000ff; font-weight: bold; font-size: 13px; font-family: Times New Roman">               PART IV              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>          </tr>          <tr style="background-color: #cceeff">           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Exh">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               15.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">             <a href="#Exh">              <font style="color: #0000ff; font-size: 13px; font-family: Times New Roman">               Exhibitsand Financial Statement Schedules              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              123             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 7%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: top; width: 1%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 65%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">             </font>             <font style="font-size: 13px; font-family: Times New Roman">             </font>            </div>           </td>          </tr>          <tr style="background-color: #cceeff">           <td colspan="7" style="vertical-align: top; width: 89%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Exhi">              <font style="color: #0000ff; font-weight: bold; font-size: 13px; font-family: Times New Roman">               EXHIBIT INDEX              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              123             </font>            </div>           </td>          </tr>          <tr>           <td colspan="7" style="vertical-align: top; width: 89%">            <div style="text-align: left; margin-left: 24px; margin-right: 6px; text-indent: -24px">             <a href="#SIG">              <font style="color: #0000ff; font-weight: bold; font-size: 13px; font-family: Times New Roman">               SIGNATURES              </font>             </a>            </div>           </td>           <td colspan="2" style="vertical-align: bottom">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman">              127             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-size: 13px; font-family: Times New Roman">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -i-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Forward-Looking Statements        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          This Annual Report on Form 10-K (         </font>         <font style="font-style: italic; color: #000000">          Annual Report orReport         </font>         <font style="color: #000000">          ) containsforward-looking statements that involve substantial risks anduncertainties. All statements contained in this Annual Report otherthan statements of historical facts, including statements regardingour strategy, future operations, future financial position, futurerevenue, projected costs, prospects, plans, objectives ofmanagement and expected market growth, are forward-lookingstatements. These statements involve known and unknown risks,uncertainties and other important factors that may cause our actualresults, performance or achievements to be materially differentfrom any future results, performance or achievements expressed orimplied by the forward-looking statements.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The words “anticipate,” “believe,”“estimate,” “expect,” “intend,”“may,” “plan,” “predict,”“project,” “target,”“potential,” “will,” “would,”“could,” “should,” “continue,”and similar expressions are intended to identify forward-lookingstatements, although not all forward-looking statements containthese identifying words. These forward-looking statements include,among other things, statements about:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            the continued impact of the  coronavirus(           </font>           <font style="font-style: italic">            COVID           </font>           <font style="font-style: italic; color: #000000">            -19           </font>           <font style="color: #000000">            ) pandemic, efforts to contain the pandemic andresulting economic downturn on or affecting our operations andfinancial condition;           </font>          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           theavailability of capital to satisfy our working capital requirementsand development and commercialization objectives;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           theaccuracy of our estimates regarding expenses, future revenues andcapital requirements;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            our plans to develop and commercialize our productcandidates, including, among other things, PH94B as a potentialacute treatment of anxiety in adults with social anxiety disorder(           </font>           <font style="font-style: italic; color: #000000">            SAD           </font>           <font style="color: #000000">            ) and other anxiety disorders, PH10 as a potentialtreatment for major depressive disorder (           </font>           <font style="font-style: italic; color: #000000">            MDD           </font>           <font style="color: #000000">            ) and other depression-related disorders, andAV-101 as a potential treatment of MDD and depression-relateddisorders and neurological diseases and disorders involving theCentral Nervous System (           </font>           <font style="font-style: italic; color: #000000">            CNS           </font>           <font style="color: #000000">            );           </font>          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           <font style="font-family: Times New Roman; font-size: 13px">            our ability to initiate and complete necessary preclinical andclinical studies to advance the development of our productcandidates, including the PALISADE Phase 3 program and otherstudies, to successfully complete any such preclinical and clinicalstudies, and for those studies to generate positive results;           </font>           <font style="font-family: Times New Roman; font-size: 10">           </font>          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           economic,regulatory and political developments in the U.S. and foreigncountries;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            the performance of our third-party contractmanufacturer(s) (           </font>           <font style="font-style: italic; color: #000000">            CMOs           </font>           <font style="color: #000000">            ), contract research organizations(           </font>           <font style="font-style: italic; color: #000000">            CROs           </font>           <font style="color: #000000">            ) and other third-party preclinical and clinicaldrug development collaborators and regulatory service providers onwhose services we rely to support ouroperations;           </font>          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            our ability to obtain and maintain intellectualproperty (           </font>           <font style="font-style: italic; color: #000000">            IP           </font>           <font style="color: #000000">            ) protection for our core assets, including ourproduct candidates;           </font>          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           thesize of the potential markets for our product candidates and ourability to enter and serve those markets;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           therate and degree of market acceptance of our product candidates forany indication once approved;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           thesuccess of competing products and product candidates in developmentby others that are or become available for the indications that weare pursuing in the markets we seek to enter on our own or withcollaborators;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           theloss of key scientific, clinical or nonclinical development,regulatory, and/or management personnel, internally or from one ormore of our third-party collaborators, CMOs, CROs or other serviceproviders; and          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            other risks and uncertainties, including thoselisted under Part I, Item 1A of this Annual Report titled“           </font>           <font style="font-style: italic; color: #000000">            RiskFactors           </font>           <font style="color: #000000">            .”           </font>          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          These forward-looking statements are only predictions and we maynot actually achieve the plans, intentions or expectationsdisclosed in our forward-looking statements, so you should notplace undue reliance on our forward-looking statements. Actualresults or events could differ materially from the plans,intentions and expectations disclosed in one or more of theforward-looking statements we make in this Annual Report. We havebased these forward-looking statements largely on our currentexpectations and projections about future events and trends that webelieve may affect our business, financial condition and operatingresults. We have included important factors in the cautionarystatements included in this Annual Report, particularly in Part I,Item 1A, titled “         </font>         <font style="font-style: italic; color: #000000">          RiskFactors,         </font>         <font style="color: #000000">          ” that couldcause actual future results or events to differ materially from theforward-looking statements that we make. Our forward-lookingstatements in this Annual Report do not reflect the potentialimpact of any future acquisitions, mergers, dispositions, jointventures or investments we may make.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         You should read this Annual Report and the documents that we havefiled as exhibits to this Annual Report with the understanding thatour actual future results may be materially different from what weexpect. We do not assume any obligation to update anyforward-looking statements in this Annual Report, whether as aresult of new information, future events or otherwise, except asrequired by applicable law.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -ii-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">         </font>        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-weight: bold; color: #000000">          PART I         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">         All brand names or trademarks appearing in this Annual Report arethe property of their respective holders. Unless the contextrequires otherwise, references in this report to“VistaGen,” the “Company,”“we,” “us,” and “our” refer toVistaGen Therapeutics, Inc., a Nevada corporation. All referencesto future quarters and years in this Annual Report refer tocalendar quarters and calendar years, unless reference is madeotherwise.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 7%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Item 1.             </font>            </div>           </td>           <td style="vertical-align: top; width: 93%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              <a name="Bus">               B              </a>              usiness             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Overview         <a name="_Hlk73699212">          <!--anchor-->         </a>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px;">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We are a biopharmaceuticalcompany committed to developing and commercializingdifferentiated new generation medications that go beyond thecurrent standard of care for widespread anxiety, depression andother central nervous system (         </font>         <font style="font-style: italic; color: #000000">          CNS         </font>         <font style="color: #000000">          ) disorders. Our CNS pipeline includes three CNSproduct candidates, PH94B Nasal Spray, PH10 Nasal Spray and AV-101,each with a differentiated profile, favorable safety resultsobserved in all clinical studies to date and therapeutic potentialin multiple CNS indications. PH94B Nasal Spray (         </font>         <font style="font-style: italic; color: #000000">          PH94B         </font>         <font style="color: #000000">          ) is being developed for multiple anxietydisorders. We recently initiated our PH94B Phase 3 developmentprogram, which we refer to as the PALISADE program, withPALISADE-1, a U.S., multi-center, randomized, double-blind,placebo-controlled Phase 3 clinical study to evaluate the efficacyand safety of PH94B for the acute treatment of anxiety in adultswith social anxiety disorder (         </font>         <font style="font-style: italic; color: #000000">          SAD         </font>         <font style="color: #000000">          ), as well as preparations for the additionalstudies required to support our potential U.S. New Drug Application(         </font>         <font style="font-style: italic; color: #000000">          NDA         </font>         <font style="color: #000000">          ) for that indication should the PALISADE Phase 3program be successful. We are also preparing for exploratory Phase2A clinical studies of PH94B in adults experiencing several otheranxiety disorders. PH10 Nasal Spray (         </font>         <font style="font-style: italic; color: #000000">          PH10         </font>         <font style="color: #000000">          ) is being developed as a stand-alone treatmentfor multiple depression disorders. Exploratory Phase 2A clinicaldevelopment of PH10 for major depressive disorder(         </font>         <font style="font-style: italic; color: #000000">          MDD         </font>         <font style="color: #000000">          ) has been completed. We are now preparing forplanned Phase 2B clinical development of PH10 for this indication.We are preparing for a Phase 1B clinical study of AV-101 incombination with probenecid to assess potential future Phase 2Aclinical development of the combination for MDD or certainneurological indications. Our goal is to become a biopharmaceuticalcompany that develops and commercializes innovative CNS therapiesfor highly prevalent neuropsychiatry and neurology indicationswhere current treatments options are inadequate to meet the needsof millions of patients in markets worldwide.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px;">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Our Product Candidates        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         PH94Bis a synthetic investigational neurosteroid developed fromproprietary compounds called pherines. With its novel mechanism ofaction, PH94B is an odorless nasal spray administered atmicrogram-level doses to achieve rapid-onset anti-anxiety, oranxiolytic, effects. The pharmacological activity of PH94B isfundamentally differentiated from that of all FDA-approvedanti-anxiety drugs, including all antidepressants approved by theU.S. Food and Drug Administration (         <font style="font-style: italic">          FDA         </font>         ) for treatment of SAD, as well asall benzodiazepines and beta blockers prescribed on an off-labelbasis. PH94B engages peripheral chemosensory receptors in nasalpassages that trigger a subset of neurons in the main olfactorybulbs (         <font style="font-style: italic">          OB         </font>         ) at the base ofthe brain. The OB neurons then stimulate inhibitory GABAergicneurons in the limbic amygdala, decreasing the activity of thesympathetic nervous system, and facilitating fear extinctionactivity of the limbic-hypothalamic system, the main fear andanxiety center in the brain, as well as in other parts of thebrain. Importantly, PH94B does not require systemic uptake anddistribution to produce its rapid-onset anti-anxiety effects.         <font style="color: #000000">          Our ongoing PALISADE Phase 3 programfor PH94B is designed to further demonstrate its potential as afast-acting, non-sedating, non-addictive acute treatment of anxietyin adults with SAD. We believe PH94B also has potential to bedeveloped as a novel treatment for adjustment disorder withanxiety, postpartum anxiety, post-traumatic stress disorder,procedural anxiety, panic and other anxiety disorders. PH94B hasbeen granted Fast Track designation status by the FDA fordevelopment for the acute treatment of SAD.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         PH10 isa synthetic investigational neurosteroid, which also was developedfrom proprietary compounds called pherines. Its novel, rapid-onsetmechanism of action (         <font style="font-style: italic">          MOA         </font>         )is fundamentally differentiated from the MOA of all currenttreatments for MDD and other depression disorders. PH10 isself-administered at microgram-level doses as an odorless nasalspray. PH10 activates nasal chemosensory cells in the nasalpassages, connected to neural circuits in the brain that produceantidepressant effects. Specifically, PH10 engages peripheralchemosensory receptors in the nasal passages that trigger a subsetof neurons in the main OB that stimulate neurons in the limbicamygdala. This is turn increases activity of thelimbic-hypothalamic sympathetic nervous system and increases therelease of catecholamines. Importantly, unlike all currentlyapproved oral antidepressants (         <font style="font-style: italic">          ADs         </font>         ), PH10 does not require systemicuptake and distribution to produce rapid-onset of antidepressanteffects. In all clinical studies to date, PH10 has not causedpsychological side effects (such as dissociation andhallucinations) or safety concerns that may be associated withrapid-onset ketamine-based therapy (         <font style="font-style: italic">          KBT         </font>         ), including intravenous ketamine orintranasal ketamine (esketamine).         <font style="color: #000000">          Webelieve PH10 has potential to be a new stand-alone treatment forMDD and several other depression disorders.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          AV-101 (4-Cl-KYN) targets the NMDAR (N-methyl-D-aspartatereceptor), an ionotropic glutamate receptor in the brain. AbnormalNMDAR function is associated with numerous CNS diseases anddisorders. AV-101 is an oral prodrug of 7-chloro-kynurenic acid(7-Cl-KYNA), which is a potent and selective full antagonist of theglycine co-agonist site of the NMDAR that inhibits the function ofthe NMDAR. However, unlike ketamine and many other NMDARantagonists, 7-Cl-KYNA is not an ion channel blocker. At dosesadministered in all studies to date, AV-101 has been observed to bewell tolerated and has not exhibited dissociative or hallucinogenicpsychological side effects or safety concerns. In light of theseobservations and findings from preclinical studies, we believe thatAV-101, in combination with FDA-approved probenecid, has potentialto become a new oral treatment alternative for certain CNSindications involving the NMDAR. We are currently preparing toevaluate AV-101 in combination with probenecid in a Phase 1Bclinical study. The FDA has granted Fast Track designation fordevelopment of AV-101 as a potential adjunctive treatment for MDDand as a non-opioid treatment for neuropathic pain(         </font>         <font style="font-style: italic; color: #000000">          NP         </font>         <font style="color: #000000">          ).         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -1-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 201px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         OurStrategy        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 2px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourgoal is to be a leading biopharmaceutical company committed todevelopment and commercialization of novel proprietary CNStherapies that go beyond the current standard of care for treatmentof anxiety, depression and other CNS diseases and disorders withhigh unmet need. Key elements of our strategy to achieve our goalare as follows:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Focus on highlyprevalent anxiety, depression and neurological disorders affectingboth adult and pediatric populations where the current standard ofcare is undesirable or inadequate to meet patientneeds.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Pursue globaldevelopment, on our own in the U.S. and on our own or withcollaborators outside the U.S., of novel           <font style="font-family: Times New Roman; font-size: 13px">            proprietary           </font>           CNS product candidates which are fundamentally differentiated fromcurrently approved therapies;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Emphasizedevelopment and commercialization of           <font style="font-family: Times New Roman; font-size: 13px">            proprietary           </font>           CNS product candidates with potential for (i) rapid-onsettherapeutic effects, (ii) exceptional safety and tolerability, and(iii) significant commercial potential in multiple CNS indicationsin global markets with currently limited, undesirable or inadequatetreatment options;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Commercialize onour own, and retain all commercial rights to, our CNS productcandidates in the U.S. and partner with highly-qualifiedthird-party collaborators to commercialize our CNS productcandidates in selected markets outside the U.S.; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Continue internalresearch and development efforts to (i) evaluate the expandedtherapeutic and commercial potential for our existing CNS productcandidates in the treatment of additional CNS indications and (ii)identify additional proprietary CNS product candidates for our CNSproduct pipeline.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Our CNS Product Pipeline        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefollowing table summarizes the status of our CNS clinicaldevelopment programs as of the filing date of this AnnualReport.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <img src="vtgn_img5.jpg"/>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         PH94B Nasal Spray        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Social Anxiety Disorder        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-family: Times New Roman; font-size: 13px">          Social Anxiety Disorder (          <font style="font-style: italic">           SAD          </font>          ) affects over 23 million Americans.According to the U.S. National Institutes of Health (          <font style="font-style: italic">           NIH          </font>          ), SAD is the third most commonpsychiatric condition after depression and substance abuse. Aperson with SAD feels intense, persistent symptoms of anxiety orfear in certain social situations, such as meeting new people,dating, being on a job interview, answering a question in class, ortalking to a cashier in a store. Doing common everyday things infront of people - such as eating or drinking in front of others orusing a public restroom - causes profound anxiety or fear of beinghumiliated, evaluated, judged, or rejected. The fear that peoplewith SAD have in social situations is so strong that they feel itis beyond their ability to control. SAD can get in the way of goingto work, attending school, or doing a wide variety of things insituations that have a potential for interpersonal interaction.People with SAD may worry about these and other things for weeksbefore they happen. Sometimes, they end up staying away from placesor events where they think they might have to do something thatwill embarrass them. Some people with SAD do not have anxiety insocial situations, but instead have performance anxiety. They feelphysical symptoms of anxiety in performance situations, such asgiving a lecture, a speech or a presentation at school or work, aswell as playing a sports game, or dancing or playing a musicalinstrument on stage. Without treatment, SAD can last for many yearsor a lifetime and          <font style="color: #333333; background-color: #FFFFFF">           lead to avoidance andopportunity costs that can significantly impact a person'semployment, social activities and relationships, and be verydisruptive to overall quality of life.          </font>         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -2-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <font style="font-family: Times New Roman; font-size: 13px">        <br/>       </font>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">         <font style="font-family: Times New Roman; font-size: 13px">          Existing treatments for SAD have not been effective acute treatmentoptions for the large patient population suffering from SAD. Onlythree drugs, all chronic oral antidepressant drugs (          <font style="font-style: italic">           AD          </font>          s), are approved by the FDAspecifically for treatment of SAD, and no drug is FDA-approved foracute, on-demand treatment of anxiety in adults with SAD. TheseFDA-approved chronic oral ADs have slow onset of effect (often manyweeks or months) and significant side effects that may make theminadequate or inappropriate treatment alternatives for manyindividuals affected by acute SAD episodes. Benzodiazepines, oftenreferred to as “benzos,” and beta blockers, both ofwhich have not been studied systematically in controlled studiesfor treatment of SAD. They are not FDA-approved to treat SAD, butare prescribed on an off-label basis by psychiatrists and otherphysicians for the treatment of SAD. Unlike ADs, which can takeseveral weeks to take full effect, benzodiazepines, which act asdirect positive modulators of GABA-A receptors, have a rapid-onseteffect by potentiating GABA-A and slowing the nervous system toinduce a calming effect that can last up to twelve hours. However,the safety concerns and side effects of benzodiazepines, many ofwhich are similar to side effects of alcohol, also can appearrapidly. Extended use of benzodiazepines may lead to physicaldependence and weaning off. Benzodiazepines can take up to manymonths, often resulting in severe withdrawal symptoms, includingmuscle pain, sweating, blurred vision, depression, seizures anddelirium tremens similar to those experienced with alcoholwithdrawal. Benzodiazepines users can also build up a tolerancethat requires increasingly larger doses over time. When taken withopioid drugs, benzodiazepine use may be quite dangerous, so much sothat in September 2020 the FDA issued an update to its 2016 DrugSafety Communication requiring that benzodiazepines display a“black box” label on bottles to warn against theirpotential for dangerous interactions with opioids, as well aspotential risk of abuse, misuse, overuse and addiction. We believePH94B, with its rapid-onset anti-anxiety effects, demonstrated inPhase 2 development without requiring systemic uptake anddistribution, and its lack of benzodiazepine-like side effects andsafety concerns in all clinical studies to date, has potential todisplace both ADs and benzodiazepines in the current treatmentparadigm for SAD, as well as in many other current anxiety disordertreatment paradigms.         </font>         <br/>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In apeer-reviewed, published, randomized, double-blind,placebo-controlled Phase 2 clinical trial (n=91), with Dr. MichaelLiebowitz, the creator of the Liebowitz Social Anxiety Scale(         <font style="font-style: italic">          LSAS         </font>         ), as principalinvestigator, PH94B was significantly more effective than placeboin reducing both public-speaking (performance) anxiety (p=0.002)and social interaction anxiety (p=0.009) in laboratory-inducedchallenges of individuals with SAD, as assessed usingpatient-reported anxiety ratings on the Subjective Units ofDistress Scale (         <font style="font-style: italic">          SUDS         </font>         )within 15 minutes of self-administration of a non-systemic 1.6microgram dose of PH94B.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <img src="vtgn_img2.jpg"/>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <br/>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -3-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <img src="vtgn_img3.jpg"/>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <br/>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In allPhase 1 and Phase 2 studies to date, PH94B’s safety profilehas been exceptional, without indication of abuse potential,psychological side effects (such as dissociation, euphoria orhallucinations), sedation or other side effects and safety concernsthat may be associated with ADs approved by the FDA for treatmentof SAD, as well as with benzodiazepines and beta blockersprescribed off-label.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Basedon its novel mechanism of pharmacological action, rapid-onset oftherapeutic effects and exceptional safety and tolerability profilein all clinical studies to date, we have initiated our PH94BPALISADE Phase 3 development program with PALISADE-1, a U.S.,multi-center, randomized, double-blind, placebo-controlled Phase 3clinical study to evaluate the efficacy and safety of PH94B for theacute treatment of anxiety in adults with SAD, as well aspreparations for the additional studies required to support ourpotential U.S. New Drug Application (         <font style="font-style: italic">          NDA         </font>         ) for that indication should ourPH94B PALISADE Phase 3 development program for SAD be successful.With respect to SAD, our goal is to develop and commercializePH94B, on our own in the U.S. and with collaborators in marketsoutside the U.S., as the first FDA-approved, fast-acting,on-demand, acute treatment of anxiety for adults with SAD. We alsoplan to develop and commercialize PH94B in a similar manner for theacute treatment of anxiety in pediatric patients withSAD.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Adjustment Disorder with Anxiety        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Almosteveryone experiences significant life events, changes, or stressorsand while some individuals adjust to such changes within a fewmonths, others cannot and may struggle with adjustmentdisorder. Adjustment disorder with anxiety (         <font style="font-style: italic">          AjDA         </font>         ) is an emotional or behavioralreaction considered excessive or disproportionate to a suddenchange, stressful event or major life change, such as loss of work,divorce or health setback, occurring within three months of thestressor, and/or significantly impairing a person’s social,occupational and/or other important areas of functioning. Thestress-related disturbance does not represent normal bereavement ormeet the criteria for another mental disorder and is not merely anexacerbation of a preexisting mental disorder.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-family: Times New Roman; font-size: 13px">          The mental health stressors associated with the COVID-19 pandemichave directly or indirectly affected hundreds of millions ofindividuals around the world and have considerably increased theprevalence of AjDA. We believe the mental health impact of theCOVID-19 pandemic will be long-term and varied across a wide rangeof anxiety disorders. PH94B has potential as a novel, treatment ofanxiety for adults with AjDA, including stress and impairedfunctioning as a result of recent-onset of stressors brought on bythe health, safety, economic and social circumstances, including,but not limited to, circumstances related to and consequences ofthe COVID-19 pandemic and civil unrest in 2020. With successfulPhase 2 development of PH94B for acute treatment of anxiety inadults with SAD completed and Phase 3 development for thatindication now underway, we are preparing to initiate exploratoryPhase 2A clinical development of PH94B for treatment of anxiety inadults with AjDA. Dr. Michael Liebowitz, Professor of ClinicalPsychiatry at Columbia University and director of the MedicalResearch Network in New York City, will serve as PrincipalInvestigator of the exploratory Phase 2A study.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Postpartum Anxiety        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Evenbefore the COVID-19 pandemic, there was compelling researchindicating that about approximately 17% of new mothers battleanxiety. Recent research reflects that the prevalence of postpartumanxiety (         <font style="font-style: italic">          PPA         </font>         ) among newmothers increased significantly during the COVID-19 pandemic.Combined with commonly experienced hormone changes and sleepdeprivation, key additional factors contributing to increasingmental health challenges among new mothers during the COVID-19pandemic include job loss, lack of secure housing and access tohealthcare, physical isolation from friends and family, increasedchildcare, educational and household duties, and fear anduncertainty about the state of the world for themselves and theirnewborn children.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -4-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Withits potential to produce rapid-onset therapeutic effects atmicrogram-level doses, without requiring systemic uptake anddistribution to achieve those therapeutic effects, and withoutcausing sedation, we believe PH94B may be ideally suited for newmothers suffering with PPA, especially new mothers who areinterested in breastfeeding and who would prefer a non-systemic,non-sedating therapeutic alternative to currenttherapies.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Incollaboration with clinical investigators at a leading universitymedical center in the U.S., we are exploring opportunities toassess PH94B’s potential as a novel rapid-onset treatment forPPA in a small exploratory Phase 2A clinical study.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Post-Traumatic Stress Disorder        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Post-traumatic stress disorder (         </font>         <font style="font-style: italic; color: #000000">          PTSD         </font>         <font style="color: #000000">          ) is a clinically diagnosed psychiatric disorderthat develops in some people who have experienced or witnessed ashocking, scary, dangerous or life-threatening event, such asmilitary combat, natural disasters, terrorist incidents, seriousaccidents, or physical or sexual assault in adulthood orchildhood. Symptoms of PTSD include flashbacks, nightmares,severe anxiety, uncontrollable intrusive thoughts, and emotionalnumbing after the event. More than 8 million people in the U.S.suffer from PTSD. Anyone can develop PTSD at any age. According tothe National Center for PTSD, about seven or eight out of every 100people will experience PTSD at some point in their lives. Theprevalence of PTSD is even higher in populations at risk forexposure to trauma, such as military service members and firstresponders. PTSD is often accompanied by depression or one or moreof the other anxiety disorders, and PTSD sufferers also have ahigher rate of suicide and often struggle with simultaneousaddiction, leading to an even greater social and economic burden ofthe disorder.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            It is natural to feel afraid during and after atraumatic situation. Fear triggers many split-second changes in thebody to help defend against danger or to avoid it. This“fight-or-flight” response is a typical reaction meantto protect a person from harm. Because PTSD is associated with aheightened “fight or flight” response mediated byincreased sympathetic nervous response to conditioned stimuli, anagent which decreases sympathetic tone may be able to treat somesymptoms of PTSD.  In Phase 2 studies, at microgram doses,PH94B has been shown to have rapid-onset anti-anxiety effects inpatients with both generalized anxiety disorder(           </font>           <font style="font-style: italic; color: #000000">            GAD           </font>           <font style="color: #000000">            )and SAD. PH94B may therefore have utility as an as-needed,rapid-onset treatment of symptoms of PTSD.           </font>           Availabletherapeutic options for PTSD are limited, including only twoFDA-approved antidepressants, which have limited efficacy andundesirable side effects.          </font>         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          <font style="font-family: Times New Roman; font-size: 13px">           Incollaboration with clinical investigators at leading universitymedical centers in the U.S., we are exploring opportunities           <font style="color: #000000">            for exploratory Phase 2A clinicaldevelopment of PH94B as a potential as-needed, on-demand,fast-acting anxiolytic in the PTSD treatmentparadigm.           </font>          </font>         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Generalized Anxiety Disorder        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         GeneralizedAnxiety Disorder (         <font style="font-style: italic">          GAD         </font>         ) is acommon chronic neuropsychiatric disorder characterized bypersistent, debilitating and excessive concern and worry aboutfamily, friends, health, money, work, or other everyday issues andsituations. Individuals with GAD find it difficult to control theirworry and may worry more about actual circumstances than seemsappropriate. They may also expect the worst even when there is noapparent reason to do so. GAD is diagnosed when an individual isunable or finds it difficult to control worry on more days than notfor at least six months and has three or more of the many symptomsof GAD, such as excessive and ongoing worrying and tension, anunrealistic view of problems, restlessness, irritability,difficulty concentrating, or being easily startled. Thisdifferentiates GAD from worry that may be specific to a setstressor or for a more limited period of time. According to theAnxiety and Depression Association, GAD affects approximately 6.8million adults in the U.S. in any given year. GAD comes ongradually and can begin across the life cycle, though the risk ishighest between childhood and middle age.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-family: Times New Roman; font-size: 13px">          People with GAD do not know how to stop the worry cycle and feel itis beyond their control, even though they usually realize thattheir anxiety is more intense than the situation warrants. Manyindividuals with GAD may avoid situations because they have thedisorder or they may not take advantage of important professionalor social opportunities due to their anxiety and worry. When theiranxiety is severe, it is difficult for individuals with GAD tocarry out even the simplest of daily activities. Currently, thestandard of care for GAD includes psychotherapy and certainmedications with limited therapeutic benefits and various sideeffects and safety concerns, including chronic oral antidepressants(SSRIs and SNRIs) and benzodiazepines.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         PH94Bdemonstrated efficacy in a small, exploratory, placebo-controlledPhase 2 clinical study in patients with GAD. Twenty-one patientswere randomized to receive 200 picograms of PH94B or placebo in aone-second aerosol pulse to the chemosensory epithelium of theanterior nasal septum. Thirty minutes after treatment there wasmean reduction of 32.0% for the PH94B group and 19.6% for theplacebo group in the total Hamilton Anxiety Rating Scale(         <font style="font-style: italic">          HAM-A         </font>         ) score.Electrophysiological changes (respiratory, cardiac, andelectrodermal frequency), concordant with the reduction in anxiety,were significantly greater for the PH94B group. We believe thesetransient anti-anxiety effects of PH94B may warrant furtherinvestigation in a larger Phase 2 GAD trial.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We are also assessing PH94B’s potential for exploratory Phase2A clinical studies in pre-procedural anxiety and panicdisorder.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -5-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         PH10 Nasal Spray        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Major Depressive Disorder        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Depressionis a serious medical illness and a global public health concernthat can occur at any time over a person's life. According to theWorld Health Organization (         <font style="font-style: italic">          WHO         </font>         ), depression is the leading causeof disability worldwide, affecting over 300 million people.         <font style="color: #000000">          Statistics from the U.S. NationalInstitute of Mental Health (         </font>         <font style="font-style: italic; color: #000000">          NIMH         </font>         <font style="color: #000000">          ) indicate that a         </font>         n estimated 17.3 millionadults in the U.S., or approximately 7.1% of all adults in theU.S., had at least one major depressive episode in 2017. While mostpeople will experience depressed mood at some point during theirlifetime, MDD is different. MDD is the chronic, pervasive feelingof utter unhappiness and suffering, which impairs dailyfunctioning. In typical depressive episodes, an individualexperiences depressed mood, loss of interest and enjoyment, andreduced energy leading to diminished activity and impaired dailyfunctioning for at least two weeks and often much longer. Symptomsof MDD also may include diminished pleasure in activities, changesin appetite that result in weight changes, insomnia oroversleeping, psychomotor agitation, loss of energy or increasedfatigue, feelings of worthlessness or inappropriate guilt,difficulty thinking, concentrating or making decisions, andthoughts of death or suicide and attempts at suicide.         <font style="color: #000000">          MDD is the psychiatric diagnosis most commonlyassociated with suicide.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Formany people, depression cannot be controlled for any length of timewithout treatment. Current oral ADs available in themulti-billion-dollar global depression market         <font style="color: #000000">          have modest efficacy, substantial lag of onset ofaction, and considerable side effects.         </font>         Approximately two outof every three depression sufferers do not receive adequatetherapeutic benefits from their initial treatment with astandard AD, and the likelihood of achieving remission ofdepressive symptoms declines with each successive AD treatmentattempt. Even after multiple treatment attempts, approximatelyone-third of depression sufferers still fail to find an adequatelyeffective AD. In addition, this trial and error process and thesystemic effects of the various ADs involved may increase the riskof patient tolerability issues and serious side effects, includingsuicidal thoughts and behaviors in certain groups.         <font style="color: #000000">          New generation ADs with different mechanisms ofaction, faster onset activity and fewer side effects areneeded.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Whilecurrent FDA-approved ADs are widely used, about two-thirds ofpatients with MDD do not respond to their initial AD treatment.Inadequate response to current ADs is among the key reasons MDD isone of the leading public health concerns in the United States,creating a significant unmet medical need for new agents withfundamentally different mechanisms of action and safetyprofiles.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In apeer-reviewed, published exploratory Phase 2A clinical study(n=30), PH10, self-administered at a dose of 6.4 micrograms, waswell-tolerated and demonstrated significant (p=0.022) rapid-onsetantidepressant effects, which were sustained over an 8-week period,as measured by the Hamilton Depression Rating Scale-17(         <font style="font-style: italic">          HAM-D-17         </font>         ), without sideeffects or safety concerns that may be caused by certain oral ADsor intravenous or intranasal ketamine-based therapy (         <font style="font-style: italic">          KBT         </font>         ).        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <img src="vtgn_img4.jpg"/>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <br/>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -6-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-family: Times New Roman; font-size: 13px">          With its potential for rapid-onset activity at a microgram-leveldose that does not require systemic uptake and distribution toachieve sustained antidepressant effects, as well as an exceptionalsafety profile, we believe PH10 has transformative potential as anat-home treatment for multiple indications in global depressionmarkets. Based on positive results from the exploratory PH10 Phase2A program, we are conducting two nonclinical studies necessary tosupport submission of our Investigational New Drug (          <font style="font-style: italic">           IND          </font>          ) application to the FDA for ourPhase 2B clinical development program for PH10 as a stand-alone,rapid-onset treatment of MDD. Our goal is to submit our IND for aPhase 2B study of PH10 in MDD before the end of 2021, and, ifauthorized by the FDA, begin Phase 2B clinical development of PH10for MDD in the first half of 2022. Although our initial plan is todevelop PH94B as a new stand-alone rapid-onset therapy for MDD, wealso believe PH10 has potential as a stand-alone therapy fortreatment-resistant depression (          <font style="font-style: italic">           TRD          </font>          ) and postpartum depression(          <font style="font-style: italic">           PPD          </font>          ), and as an adjunctivetherapy to augment current FDA-approved ADs for individuals withMDD, TRD and PPD who have an inadequate response to their currentADs and to prevent relapse following successful treatment withKBT.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Treatment-Resistant Depression        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Treatment-resistant depression is a form of depression that doesnot get better even after an individual has tried adequate andwell-controlled doses of two different oral, FDA-approvedantidepressant therapies taken for a sufficient period of time,usually at least six weeks. Approximately one-third of adultswith MDD battle depression symptoms that do not respond to currentoral AD treatments, including persistent feelings of sadness,disturbances in their sleep patterns, low energy and thoughts ofsuicide. Certain populations, especially women and elderlyindividuals, experience TRD at higher rates than others.Individuals who endure severe or frequently recurring bouts ofdepression also appear to be more susceptible to TRD. Individualswith MDD         </font>         who also have certain underlying medicalconditions, such as thyroid disease, chronic pain, substance abuseand eating or sleep disorders, also may be at greater risk forTRD.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">         <br/>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Whilecertain individuals with TRD may benefit from giving their currentoral antidepressant more time to work or by taking a larger dose,for others, switching to a different class of antidepressant oraugmenting their current AD with an FDA-approved atypicalantipsychotic may lead to remission. In recent years, KBT, whichincludes intravenous ketamine or intranasal esketamine givenadjunctively with a new oral AD, has been effective in treatingTRD. However, KBT has significant drawbacks. Certain patientsreceiving KBT may experience uncomfortable dissociative symptoms,hypertension, or other side effects for a few hours afteradministration. Additionally, because of these potential sideeffects and safety concerns, as well as the potential for abuse,KBT must be administered in a clinical setting.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         PH10,with its potential for rapid-onset antidepressant effects at amicrogram-level dose and without systemic uptake and distribution,and, as demonstrated in the PH10 Phase 2A program for MDD, anexceptional safety profile that is not expected to requireadministration in a clinical setting, has transformative potentialin the treatment paradigm as a new stand-alone therapy for TRD andto prevent relapse following successful treatment for TRD with KBT.After we submit our IND for Phase 2B development of PH10 as astand-alone treatment for MDD, we plan to assess its potential forexploratory Phase 2A development as a stand-alone treatment forTRD.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Postpartum Depression        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Newmothers face many challenges, both practical and emotional, whenadjusting to life following the birth of a newborn child. PPDdevelops around the time a woman gives birth, occurring inapproximately 15% of births, according to the U.S. NationalInstitutes of Mental Health (         <font style="font-style: italic">          NIMH         </font>         ). Women with PPD often strugglewith anxiety, sadness, difficulty eating and sleeping, ordisturbing thoughts of worthlessness, shame, guilt or suicide, allsignificant depressive symptoms that may commence during pregnancyor typically within the first few months following childbirth.Other symptoms of PPD may include agitation, loss of interest indaily activities, feeling overwhelmed and fatigued, and inabilityto concentrate. The current standard of care for PPD involvespsychotherapy and, in certain mothers, off-label use of oral ADs ora recently-approved intravenous neurosteroid, all of which requiresystemic uptake to achieve a therapeutic effect, a potentialcomplication for new mothers who wish to breastfeed their newbornchild. The recently-approved intravenous neurosteroid requires alengthy continuous intravenous infusion (approximately 60 hours)that must be administered in a clinical setting and may also causesedation.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Asdemonstrated in an exploratory Phase 2A study of PH10 in adults,including adult women, PH10, self-administered intranasally inmicrogram-level doses, does not require systemic uptake anddistribution to achieve antidepressant effects and, based on itssafety profile in all studies to date, is not expected to requireinconvenient administration in a clinical setting. PH10 isfundamentally differentiated from the FDA-approved neurosteroid forPPD, as well as all chronic oral ADs used off-label for treatmentof PPD. Based on prior clinical studies of PH10, including theexploratory Phase 2A clinical study of PH10 in MDD, we believe ithas potential to be a rapid-onset, non-systemic stand-alonetreatment for PPD. After we submit our IND for Phase 2B developmentof PH10 as a stand-alone treatment for MDD, we plan to assess itspotential for exploratory Phase 2A development as a treatment forPPD.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -7-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Suicidal Ideation        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-family: Times New Roman; font-size: 13px">          According to the WHO, every year approximately 800,000 peopleworldwide take their own life and many more attemptsuicide. Suicidal ideation (          <font style="font-style: italic">           SI          </font>          ) is characterized as suicidalthoughts and behavior. The U.S. Centers for Disease Control(          <font style="font-style: italic">           CDC          </font>          ) views suicide as amajor public health concern in the U.S. as rates of suicide havebeen increasing for both men and women and across all age groups.Suicide is the 10th leading cause of death in the U.S. and is oneof just three leading causes that are on the rise. Accordingto experts in the field of SI, the number of Americans who die bysuicide is, since 2010, higher than the number of those who die inmotor vehicle accidents. People of all genders, ages, andethnicities can be at risk for suicide. SI is complex and there isno single cause. The NIMH attributes many different factors tosomeone making a suicide attempt, including, but not limited to,depression, other mental health disorders or substanceabuse. Additionally, according to reports released by the VA,the U.S. Military Veteran population is at significantly higherrisk for suicide than the general population.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-family: Times New Roman; font-size: 13px">          We believe PH10 may play a key role in a new treatment paradigm forSI. Accordingly, based on results of various IND-enablingpreclinical studies, and, after appropriate IND submissions, wewill assess potential exploratory Phase 2A development of PH10 forstand-alone treatment of SI and/or adjunctive treatment of SItogether with KBT or other oral AD therapies.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         AV-101 with Probenecid        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-family: Times New Roman; font-size: 13px">          AV-101 (4-Cl-KYN) is a novel, oral prodrug that targets the NMDAR(N-methyl-D-aspartate receptor), an ionotropic glutamate receptorin the brain. Abnormal NMDAR function is associated with numerousCNS diseases and disorders. The active metabolite of AV-101,7-chloro-kynurenic acid (7-Cl-KYNA), is a potent and selective fullantagonist of the glycine coagonist site of the NMDAR that inhibitsthe function of the NMDAR. Unlike ketamine and many other NMDARantagonists, 7-Cl-KYNA is not an ion channel blocker. In clinicaland nonclinical testing, AV-101 has good oral bioavailability, anexcellent pharmacokinetic (          <font style="font-style: italic">           PK          </font>          ) profile, and is not an inhibitor orinducer of the human cytochrome P450 (          <font style="font-style: italic">           CYP          </font>          ) isoforms. No binding of AV-101 or7-Cl-KYNA to off-site targets was identified by an extensivereceptor screening. Moreover, in all clinical trials to date,AV-101 has been safe and very well-tolerated with no psychologicalside effects or safety concerns and no treatment-related seriousadverse events that are often observed with classicchannel-blocking NMDAR antagonists such as ketamine andamantadine.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Recentdiscoveries from successful AV-101 in vivo preclinical studiessuggest that there is a substantial increase in brainconcentrations of AV-101 and 7-Cl-KYNA when AV-101 is giventogether with probenecid, a drug approved by the FDA for treatmentof gout which is known to block activity of certain organic ionefflux transporters in the kidney. These surprising results in thebrain were first revealed in our recent preclinical studies and areconsistent with well-documented clinical studies of probenecidincreasing the therapeutic levels in the blood of several unrelatedclasses of approved drugs, including certain antibacterial,anticancer and antivirals. Many clinical studies demonstrate thatprobenecid is safe and well tolerated. Probenecid administeredadjunctively with AV-101 in an animal model resulted in substantialincreased brain concentrations of AV-101 (7-fold) and 7-Cl-KYNA(35-fold). We also recently identified that these increases inbrain levels could result from blocking of some of the sametransporters in the blood brain barrier that are expressed in thekidney, which are used to regulate drug levels in the blood. This7-Cl-KYNA efflux-blocking effect of probenecid, with the resultingincreased brain levels and duration of 7-Cl-KYNA, suggests thepotential impact of AV-101 with probenecid could result in far moreprofound therapeutic benefits for patients with MDD and otherNMDAR-focused CNS diseases and disorders than was demonstrated inthe Elevate Study. Nonclinical results also indicate that chronicadministration of 4-Cl-KYN induces hippocampal neurogenesis, ahallmark of drugs that have antidepressive effects, and increasesendogenous levels of KYNA, which also is a functional NMDAR glycinesite antagonist.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inaddition, a Phase 1B target engagement clinical study completed bythe Baylor College of Medicine (         <font style="font-style: italic">          Baylor         </font>         ), with financial support fromthe U.S. Department of Veterans Affairs (         <font style="font-style: italic">          VA         </font>         ), involved 10 healthy volunteer U.S.military Veterans who received single doses of AV-101 (720 mg or1440 mg) or placebo, in a double-blind, randomized, cross-overcontrolled trial. The primary goal of the study was to identify anddefine a dose-response relationship between AV-101 and multipleelectrophysiological (         <font style="font-style: italic">          EEG         </font>         )biomarkers related to NMDAR function, as well as blood biomarkersassociated with suicidality (the         <font style="font-style: italic">          Baylor Study         </font>         ). The findings from theBaylor Study suggest that, in healthy Veterans, the higher dose ofAV-101 (1440 mg) was associated with dose-related increase in the40 Hz Auditory Steady State Response (         <font style="font-style: italic">          ASSR         </font>         ), a robust measure of theintegrity of inhibitory interneuron synchronization that isassociated with NMDAR inhibition.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We arepreparing to initiate a Phase 1B clinical study of AV-101 withadjunctive probenecid in the second half of 2021 to evaluate theirsafety in combination and potential for exploratory Phase 2Adevelopment in one or more of the CNS indications for which we haveexisting encouraging preclinical data with AV-101, including MDD,epilepsy, levodopa-induced dyskinesia, and neuropathicpain.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Major Depressive Disorder        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inlate-2019, we completed a double-blind, placebo-controlled, Phase 2clinical trial of AV-101 as a potential adjunctive treatment,together with a standard oral AD, in MDD patients who had aninadequate response to a stable dose of a standard oral AD (the         <font style="font-style: italic">          Elevate Study         </font>         ). Toplineresults of the Elevate Study (n=199) indicated that the AV-101treatment arm (1440 mg) did not differentiate from placebo on theprimary endpoint (change in the Montgomery-Åsberg DepressionRating Scale (         <font style="font-style: italic">          MADRS-10         </font>         )total score compared to baseline). After further analysis, webelieve that this was likely due to sub-therapeutic concentrationsin the brain of 7-Cl-KYNA, the active metabolite of AV-101,resulting from the activity of certain organic ion effluxtransporters which reduce 7-Cl-KYNA concentrations in the brain. Asin all prior clinical studies, in the Elevate Study, AV-101 waswell tolerated, with no psychotomimetic side effects ordrug-related serious adverse events.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <br/>         <br/>        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -8-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thesuccessful Baylor Study and the recent discoveries in ourpreclinical studies involving AV-101 and adjunctive probenecidsuggest that it may be possible to increase therapeuticconcentrations and duration of 7-Cl-KYNA in the brain, and thusincrease NMDAR antagonism in MDD patients with an inadequateresponse to standard ADs when AV-101 and probenecid arecombined.        </font>       </div>       <font style="font-family: Times New Roman; font-size: 13px">       </font>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Neuropathic Pain        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; background-color: #FFFFFF">          Neuropathic pain (         </font>         <font style="font-style: italic; color: #000000; background-color: #FFFFFF">          NP         </font>         <font style="color: #000000; background-color: #FFFFFF">          )affects approximately 33 million people in the United States(excluding patients with back pain) according to an articlepublished in the Journal of Pain Research in2017.         </font>         <font style="font-size: 70%; vertical-align: top; color: #000000">         </font>         <font style="color: #000000; background-color: #FFFFFF">          NPis a complex, chronic pain state characterized by a steady burning"pins and needles" or "electric shock" sensation that results inabnormal neuronal function after nerve damage.         </font>         <font style="color: #000000">          The American Chronic Pain Association hasidentified various causes of NP, including tissue injury, nervedamage or disease, diabetes, infection, toxins, certain types ofdrugs, such as antivirals and chemotherapeutic agents, certaincancers, and even chronic alcohol intake.         </font>         <font style="color: #000000; background-color: #FFFFFF">          Current treatments forNP include antidepressants, anticonvulsants (such as gabapentin andpregabalin), and opioids, among others. However, currentmedications may offer inadequate efficacy, have limiting sideeffects, and be associated with abuse.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theeffects of AV-101 as a potential new treatment for NP were assessedin published peer-reviewed preclinical studies involving fourwell-established models of pain. In these studies, AV-101 wasobserved to have robust, dose-dependent anti-nociceptive effects,as measured by         <font style="background-color: #FFFFFF">          dose-dependent reversal of NP in theChung (nerve ligation), formalin and carrageenan thermal models inrats         </font>         , and was well-tolerated. The publication, titled:“         <font style="font-style: italic">          Characterization of theeffects of L-4-chlorokynurenine on nociception inrodents         </font>         ,” by lead author, Tony L. Yaksh, Ph.D.,Professor in Anesthesiology at the University of California, SanDiego, was published in         <font style="font-style: italic">          TheJournal of Pain         </font>         in April 2017 (J Pain. 18:1184-1196,2017)). In subsequent studies in this preclinical model, AV-101also had positive results using pregabalin as an active control.AV-101 demonstrated robust analgesic effects, similar topregabalin, but fewer side effects as measured in the rotarodassay. In third party literature, gabapentin and pregabalin, oftenprescribed for treatment of NP, have been associated with sedationand mild cognitive impairment. Other commonly prescribedmedications for NP include drugs targeting opioid receptors in thebrain. Unfortunately, misuse of such drugs can lead to asignificantly increased risk of addiction, and, we believe, theirtherapeutic utility for neuropathic pain is unclear.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Basedon successful preclinical studies involving AV-101, compared togabapentin and pregabalin, as well as successful Phase 1Bdevelopment of AV-101 in combination with probenecid, we mayexplore Phase 2A clinical development of AV-101, together withprobenecid, as a potential new generation, non-opioid treatment toreduce debilitating NP. We believe AV-101 in combination withprobenecid has the potential to avoid sedative side effects andcognitive impairment often associated with other NP treatments, andreduce the risk of addiction associated with pain medicationstargeting opioid receptors.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Levodopa-Induced Dyskinesia associated with Therapy forParkinson’s Disease        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Parkinson’s disease (         </font>         <font style="font-style: italic; color: #000000">          PD         </font>         <font style="color: #000000">          ) is the second most common neurodegenerativedisease worldwide, affecting approximately one million people inthe U.S., according to the Parkinson’s Foundation. Althoughthere is no "one-size-fits-all” description of PD, PD is acomplex neurodegenerative disorder that occurs when brain cellsresponsible for making dopamine, a chemical that coordinatesmovement, stop working or die. This results in progressivedeterioration of voluntary motor control. Loss of dopamine neuronsis thought to be due to neurotoxicity associated with misfolding ofproteins and is associated with increased signaling of glutamate,the most abundant excitatory neurotransmitter in the brain.Increased glutamate activity is involved with aberrant neuronalsignaling and excitotoxic death of neurons. Classic PD motorsymptoms include muscular rigidity, resting tremor, and posturaland gait impairment. Typically, PD patients present with acombination of motor and non-motor symptoms. Non-motor symptoms mayinclude cognitive impairment, sleep disorders pain and fatigue.There is currently no medication to slow, delay, stop or cure PD,and currently available treatments are symptomatic. Treatment ofmotor symptoms with oral levodopa, introduced about 50 years ago,remains the gold standard treatment.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Levodopa-induced dyskinesia         </font>         <font style="font-weight: bold; color: #000000">         </font>         <font style="color: #000000">          (         </font>         <font style="font-style: italic; color: #000000">          LID         </font>         <font style="color: #000000">          ) is a disorder that affects people with PD whoare treated with levodopa for an extended period of time. Orallevodopa remains the most effective therapy for motor symptoms ofPD. However, studies published in the         </font>         <font style="font-style: italic; color: #000000">          New England Journal ofMedicine         </font>         <font style="color: #000000">          and         </font>         <font style="font-style: italic; color: #000000">          MovementDisorders         </font>         <font style="color: #000000">          have shown LIDdevelops in approximately 45% of levodopa-treated Parkinson’sdisease patients after five years and 80% after 10 years oflevodopa treatment. Although clinical manifestations of LID areheterogenous, LID is commonly associated with abnormal involuntarymovements, including chorea and dystonia. These motor complicationstend to become more severe as PD progresses and as the duration oflevodopa treatment is extended, until the impact of LID maycompromise the advantage of treatment with levodopa. PD treatmentwith levodopa is routinely delayed due to concerns over LID. OnceLID develops, levodopa-treated PD patients may be faced with achoice between immobility due to untreated and uncontrolled PD, ormobility with the associated LID. In the U.S., there are anestimated 150,000 to 200,000 people with PD who are impacted byLID.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -9-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         AV-101 is not a dopamine-based drug candidate. Rather,AV-101’s active metabolite, 7-Cl-KYNA, is a potent andselective NMDAR glycine site antagonist with neuroprotectiveproperties, which receptor plays a major role in glutamatergicsignaling and has been shown to be a therapeutic target forLID.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In apreclinical study in the “gold standard” MPTP monkeymodel of PD and LID, AV-101’s efficacy against LID wasmeasured through behavioral scores on a dyskinesia scale, and aParkinsonian disability scale was used to measure levodopaanti-parkinsonian efficacy. This study demonstrated that AV-101significantly (p=0.01) reduced LID. Importantly, AV-101 did notreduce the timing, extent, or duration of the therapeutic effectsof levodopa, indicating that AV-101 did not impact theanti-parkinsonian efficacy of levodopa. Moreover,         <font style="color: #000000">          AV-101 did not cause adverse events oftenassociated with amantadine therapy for LID, such as hallucinations,dizziness, and falls. These preclinical results confirmed our prioranti-dyskinesia study in this MPTP monkey model. We believe thesepreclinical data and AV-101’s positive safety profile in allclinical studies to date support the potential of AV-101, togetherwith probenecid, to treat LID, while both maintaining theantiparkinsonian benefits of levodopa and without causinghallucinations or other serious side effects that may be associatedwith amantadine therapy for LID.         </font>         As a result, uponsuccessful Phase 1B development of AV-101 in combination withprobenecid, we may explore Phase 2A clinical development of AV-101,together with probenecid, as a new generation treatment forLID.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Epilepsy        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Epilepsyis one of the most prevalent neurological disorders, affectingalmost 1% of the worldwide population. According to the EpilepsyFoundation, as many as three million Americans have epilepsy, andone-third of those suffering from epilepsy are not effectivelytreated with currently available medications. In addition, standardanticonvulsants can cause significant side effects, whichfrequently interfere with compliance.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Glutamateis a neurotransmitter that is critically involved in thepathophysiology of epilepsy. Through its stimulation of the NMDARsubtype, glutamate has been implicated in the neuropathology andclinical symptoms of the disease. In support of this, NMDARantagonists are potent anticonvulsants. However, as noted, classicion channel-blocking NMDAR antagonists are limited by adverseeffects, such as neurotoxicity, declining mental status, and theonset of psychotic symptoms following administration of the drug.The endogenous amino acid glycine modulates glutamatergicneurotransmission by stimulating the glycine coagonist site of theNMDAR. Glycine site antagonists such as AV-101’s activemetabolite, 7-Cl-KYNA, inhibit NMDAR function and are thereforeanticonvulsant and neuroprotective. Importantly, glycine siteantagonists have fewer and less severe side effects than classicion channel-blocking NMDAR antagonists and other antiepilepticagents, making them a safer potential alternative to, and oneexpected to be associated with greater patient compliance than,currently available anticonvulsant medications.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inaddition, another active metabolite of AV-101,4-Cl-3-hydroxyanthranilic acid, inhibits the synthesis ofquinolinic acid (         <font style="font-style: italic">          QUIN         </font>         ),which is an endogenous NMDAR agonist that causes convulsions andexcitotoxic neuronal damage.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         AV-101has been shown to protect against seizures and neuronal damage inpreclinical animal models of epilepsy. Upon successful Phase 1Bdevelopment of AV-101 in combination with probenecid, we believeexploratory preclinical data in an epilepsy model, together withhuman safety data in all clinical studies to date, may providesupport for exploratory Phase 2A clinical development of AV-101,together with probenecid, as a potential new generation treatmentfor epilepsy.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Intellectual Property        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Westrive to protect the proprietary know-how and technology that webelieve is important to our business, including seeking andmaintaining patents intended to cover our product candidates andrelated pharmaceutical compositions, their therapeutic methods ofuse, including treatment and prognostic methods, as well asprocesses for their manufacture, and any other aspects of ourdiscoveries and inventions that are commercially important to thedevelopment of our business.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We mayalso rely on trade secrets to protect aspects of our business thatare not amenable to, or that we do not consider appropriate for,patent protection. We also utilize know-how, continuingtechnological innovation and in-licensing opportunities to developand maintain our proprietary position. We seek to obtain domesticand international patent protection in appropriate markets, andendeavor to promptly file patent applications for new commerciallyvaluable inventions.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Toprotect our rights to our proprietary technology, we require allemployees, as well as our external collaborators, consultants andCROs when feasible, to enter into agreements that requiredisclosure and assignment to us of ideas, developments, discoveriesand inventions made by these employees, consultants, and CROs inthe course of their service to us.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We planto continue to expand our intellectual property estate by filingpatent applications directed to compositions, methods of use,including treatment and patient selection, formulations andmanufacturing processes created or identified from the ongoingdevelopment of our product candidates.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Patents        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We ownand have licensed granted patents and pending patent applicationsin the U.S. and in certain foreign countries. These patentproperties include, but are not limited to:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -10-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         PH94B (licensed by us from Pherin Pharmaceuticals, Inc.(Pherin))        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Two granted U.S.patents and other foreign patents related to the reduction ofanticipatory anxiety or social phobic response.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheU.S. patents related to PH94B will nominally expire either in 2025or 2028, respectively, and foreign patents nominally expire in2026, subject to extensions that may be available on acountry-by-country basis, including in the U.S.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         PH94B patent application owned by VistaGen        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Pending U.S. andPatent Cooperation Treaty (           <font style="font-style: italic">            PCT           </font>           ) patent applications related to thetreatment of adjustment disorder with anxiety.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Patentsthat may be granted on this patent application nominally willexpire in 2041, including in the U.S.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         PH10 (licensed by us from Pherin)        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           One granted U.S.patent related to treatment of depressive disorders;and          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Granted foreignpatents related to treatment of depressive disorders.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheU.S. and foreign patents related to PH10 nominally expire in 2033,subject to extensions that may be available on a country-by-countrybasis, including in the U.S.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         AV-101        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 48px; display: table;">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Five granted U.S.patents related to the treatment of depression with AV-101, certainunit dose formulations of AV-101 effective to treat depression, andtreatment of dyskinesia induced by the administration of L-DOPA(           <font style="font-style: italic">            LID           </font>           );          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 48px; display: table;">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Pending U.S. patentapplications and foreign granted patents and pending foreign patentapplications related to treatment of various disorders, includingdepression, LID, neuropathic pain (           <font style="font-style: italic">            NP           </font>           ), tinnitus and obsessive-compulsivedisorder;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 48px; display: table;">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Pending PCT patentapplication related to the prognostic identification of high andlow responders to treatment of various CNS disorders with AV-101;and          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 48px; display: table;">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Two granted U.S.patents, and foreign granted patents and pending foreign patentapplications related to the manufacture of AV-10.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheU.S. and foreign patents related to AV-101 nominally expire between2034 and 2040, depending on the particular subject matter, subjectto extensions that may be available on a country-by-country basis,including in the U.S.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Stem Cell Technology (owned by us and/or licensed by us from theUniversity Health Network (Toronto) or Icahn School of Medicine atMount Sinai)        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Cardiac Cells        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           U.S. and foreignpatents and patent applications relating to methods for enrichingpluripotent stem cell-derived cardiomyocyte cells, methods forgenerating epicardium cells, methods for making and usingsino-atrial node-like pacemaker and ventricular-like cardiomyocytesand methods for generation of atrial and ventricular cardiomyocytelineages.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheU.S. and foreign patents and patent applications related to cardiacstem cells nominally expire between 2031 and 2037, subject toextensions that may be available on a country-by-country basis,including in the U.S. Additionally, therapeutic and certain otherfields of use have been licensed by us to Bayer under the BayerAgreement.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Blood Cells        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           U.S. and foreignpatents and patent applications relating mesoderm and definitiveendoderm cell populations, and to populations of hematopoieticprogenitors.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheU.S. and foreign patents and patent applications related to bloodstem cells nominally expire between 2023 and 2032, subject toextensions that may be available on a country-by-country basis,including in the U.S.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Cartilage and Chondrocyte Cells        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           U.S. and foreignpatents and patent applications relating to methods andcompositions for generating chondrocyte lineage cells and cartilagelike tissue.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -11-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheU.S. and foreign patents and patent applications related tocartilage and chrondrocyte cells nominally expire in 2034, subjectto extensions that may be available on a country-by-country basis,including in the U.S.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Liver and Biliary Cells        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           U.S. and foreignpatents and patent applications relating to methods for generatinghepatocytes and cholangiocytes from pluripotent stem cells and totoxicity typing using liver stem cells.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheU.S. and foreign patents and patent applications related to liverand biliary cells nominally expire between 2021 and 2034, includingin the U.S.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Patent Term        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thebase term of a U.S. patent is 20 years from the filing date of theearliest-filed non-provisional patent application from which thepatent claims priority. The term of a U.S. patent can be lengthenedby patent term adjustment, which compensates the owner of thepatent for administrative delays at the U.S. Patent and TrademarkOffice (         <font style="font-style: italic">          PTO         </font>         ). In somecases, the term of a U.S. patent is shortened by a terminaldisclaimer that reduces its term to align with that of a relatedpatent.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Dependingupon the timing, duration and specifics of the FDA approval of ourdrug candidates, if any, some of our U.S. patents may be eligiblefor limited patent term extension under the Drug Price Competitionand Patent Term Restoration Act of 1984, commonly referred to asthe Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit apatent restoration term of up to five years as compensation forpatent term lost during product development and the FDA regulatoryreview process. However, patent term restoration cannot extend theremaining term of a patent beyond a total of 14 years from theproduct’s approval date. The patent term restoration periodis generally one-half the time between the effective date of an INDand the submission date of an NDA (         <font style="font-style: italic">          testing phase         </font>         ), plus the time betweenthe submission date of an NDA and the approval of that application(         <font style="font-style: italic">          approval phase         </font>         ). Thispatent term restoration period may be reduced by the FDA if itfinds that applicant did not act with due diligence during thetesting phase or the approval phase. Only one patent related to anapproved drug is eligible for the extension and the application forthe extension must be submitted prior to the expiration of thepatent. The U.S. PTO, in consultation with the FDA, reviews andapproves the application for any patent term extension orrestoration. In the future, if circumstances permit, we intend toapply for restoration of patent term for our applicable patents, ifany, to extend patent life beyond their normal expiration datesdepending on the length of the clinical trials and other factorsinvolved in the filing of the relevant NDA.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Data Exclusivity        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Some ofour products may also be entitled to certain data exclusivity (thatis not patent-related) under the Federal Food, Drug and CosmeticAct (         <font style="font-style: italic">          FDCA         </font>         ) and its relatedregulations. The FDCA provides a five-year period of non-patentdata exclusivity within the U.S. to the first applicant to obtainapproval of an NDA for a new chemical entity (         <font style="font-style: italic">          NCE         </font>         ). A drug is a new chemical entityif the FDA has not previously approved any other new drugcontaining the same active moiety, which is the moleculeresponsible for the pharmacological action of the drug substance.During the data exclusivity period, an abbreviated new drugapplication (         <font style="font-style: italic">          ANDA         </font>         ), or a505(b)(2) NDA submitted by another company may not be approved bythe FDA for another drug containing the same active moiety,regardless of whether the drug is intended for the same indicationas the original innovator drug or for another indication, where theapplicant does not own or have a legal right of reference to allthe data that served as the basis of granting the originalNDA.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         However,an ANDA or a 505(b)(2) NDA application may be submitted after fouryears if the innovator NDA holder does not have a patent coveringthe product listed with the FDA Orange Book or if the applicationcontains a certification of patent invalidity or non-infringementto one of the patents listed with the FDA Orange Book. The FDCAalso provides three years of data exclusivity for a full NDA, orsupplement to an existing NDA if new clinical investigations, otherthan bioavailability studies, that were conducted or sponsored bythe applicant are deemed by the FDA to be essential to the approvalof the application, for example, for new indications, dosages orstrengths of an existing drug. Three-year exclusivity prevents theFDA from approving ANDAs and 505(b)(2) applications that rely onthe information that served as the basis of granting the new fullor supplemental NDA. This three-year exclusivity covers only themodification for which the drug received approval on the basis ofthe new clinical investigations and does not prohibit the FDA fromapproving ANDAs for drugs containing the active agent for theoriginal indication or condition of use. Five-year and three-yearexclusivity will not delay the submission or approval of a fullNDA. However, an applicant submitting a full NDA would be requiredto conduct or obtain a right of reference to all of the nonclinicalstudies and adequate and well-controlled clinical trials necessaryto demonstrate safety and efficacy.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Someforeign jurisdictions, including Europe and Japan, also have patentterm extension provisions, which allow for extension of the term ofa patent that covers a drug approved by the applicable foreignregulatory agency. In the future, if and when our pharmaceuticalproducts receive FDA approval, we expect to apply for patent termextension on patents covering those products, their methods of use,and/or methods of manufacture.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -12-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Trade Secrets        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inaddition to patents, we may rely on trade secrets to develop andmaintain our competitive position. We protect trade secrets, ifany, and also know-how, by establishing confidentiality agreementsand invention assignment agreements with our employees,consultants, scientific advisors, contractors and partners. Theseagreements provide that all confidential information developed ormade known during the course of an individual’s orentity’s relationship with us must be kept confidentialduring and after the relationship. These agreements also generallyprovide that all relevant inventions resulting from work performedfor us or relating to our business and conceived or completedduring the period of employment or assignment, as applicable, shallbe our exclusive property. In addition, we take other appropriateprecautions, such as physical and technological security measures,to guard against misappropriation of our proprietary information bythird parties.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Trademarks        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheCompany also owns a registered trademark in the U.S. for“VISTAGEN,” for “biotechnology services” ininternational class 42, which was renewed in 2021. We have a U.S.registration application pending for VISTAGEN in internationalclass 10 for “human and veterinary preparations for medicaluses.”         <br/>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Strategic Transactions and Relationships        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Strategiccollaborations are an important cornerstone of our corporatedevelopment strategy. We believe that our highly selectiveoutsourcing of certain research, development, legal, manufacturingand regulatory activities gives us flexible access to a broad rangeof capabilities and expertise at a lower overall cost thandeveloping and maintaining such capabilities and expertiseinternally on a full-time basis. In particular, we retain thirdparties for certain legal manufacturing, nonclinical development,clinical development and regulatory affairs support.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We haveentered into, and may seek multiple additional strategiccollaborations and relationships focused on development andcommercialization of our product candidates in regions outside theU.S.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Commercial Agreements        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 5px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We havecustomary clinical supply agreements with multiple CMOs andcustomary agreements with multiple CROs to assist us withadvancement and management of our nonclinical, includingmanufacturing, and clinical development programs. Each of ourcommercial agreements is non‑exclusive, and we have nomaterial contractual obligations under such agreements, except tothe extent we order supplies or request services to be performedunder specific work orders that we generate with such third-partiesfrom time to time.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Material License Agreements        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">         Exclusive License and Collaboration Agreements withPherin        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In September 2018, we acquired from Pherin Pharmaceuticals, Inc.(         </font>         <font style="font-style: italic; color: #000000">          Pherin         </font>         <font style="color: #000000">          ) an exclusive worldwide license to develop andcommercialize PH94B. In October 2018, we acquired from Pherin anexclusive worldwide license to develop and commercialize PH10.Under the terms of the PH94B and PH10 license agreements, we areobligated to make additional cash payments, and pay royalties, toPherin in connection with our sublicense, development andcommercialization collaborations involving PH94B and/or PH10, aswell as in the event that certain development milestones andcommercial sales are achieved. Additionally, in connection with thelicense agreements, we were obligated to pay to Pherin monthlysupport payments of $10,000 for a term of the earlier of 18 monthsfrom the date of each license agreement or the termination of thelicense agreement; however, no monthly support payment was requiredunder the 18-month period identified in the PH10 license agreementif support payments were already being made under the terms of thePH94B license agreement. In April 2020, we completed all of ourobligations to pay all such monthly support payments to Pherinunder the PH94B license agreement and the PH10 license agreement,and thus the contractual requirements have been fullysatisfied.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">         Exclusive License and Collaboration Agreement with AffaMedTherapeutics, Inc. (formerly EverInsight Therapeutics,Inc.)        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In June 2020, we entered into a license and collaborationagreement (the         </font>         <font style="font-style: italic; color: #000000">          EverInsight LicenseAgreement         </font>         <font style="color: #000000">          )with         </font>         EverInsight Therapeutics Inc., a companyincorporated under the laws of the British Virgin Islands(         <font style="font-style: italic">          EverInsight         </font>         ), pursuant towhich we         <font style="color: #000000">          granted EverInsight an exclusive licenseto develop, manufacture and commercialize PH94B for multipleanxiety-related disorders in Greater China (Mainland China, HongKong, Macau and Taiwan), South Korea and Southeast Asia (Indonesia,Malaysia, Philippines, Thailand and Vietnam) (collectively,the         </font>         <font style="font-style: italic; color: #000000">          Territory         </font>         <font style="color: #000000">          ).         </font>         Subsequent to entering into theEverInsight License Agreement, in October 2020, EverInsight mergedwith AffaMed Therapeutics, Inc., which as a combined, complementaryentity is focusing on developing and commercializing therapeuticsto address ophthalmologic and CNS disorders in Greater China andbeyond. Accordingly, we refer to EverInsight and the EverInsightLicense Agreement as AffaMed and the AffaMed Agreement,respectively.         <font style="color: #000000">          We retained development,manufacturing and commercialization rights for PH94B in the rest ofthe world.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -13-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Under the terms of the AffaMed Agreement, we received anupfront payment of $5.0 million in August 2020. We may also receiveup to an additional $172 million in milestone payments uponAffaMed’s achievement of certain developmental, regulatoryand sales milestone events related to PH94B. In addition, we areentitled to receive certain royalties on net sales, if any, ofPH94B in the Territory following receipt of any required regulatoryapproval. However, AffaMed’s, achievement of any of suchdevelopmental, regulatory and sales milestone events, or commercialsales of PH94B in the Territory, cannot be guaranteed.AffaMed has the right to sublicense to affiliates and thirdparties in the Territory. AffaMed is responsible for all costsrelated to developing, obtaining regulatory approval of andcommercializing PH94B in the Territory. A joint developmentcommittee has been established between the Companyand AffaMed to coordinate and review the development,manufacturing and commercialization plans with respect to PH94B inthe Territory. Unless earlier terminated due to certain materialbreaches of the contract, or otherwise, the AffaMedAgreement will expire on a jurisdiction-by-jurisdictionbasis until the latest to occur of expiration of the last validclaim under a licensed patent of PH94B in such jurisdiction, theexpiration of regulatory exclusivity in such jurisdiction or tenyears after the first commercial sale of PH94B in suchjurisdiction.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Manufacturing and Supply        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 6px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Manufacturingof the drug substance and drug product for our product candidatesis done by third-parties and must comply with FDA current goodmanufacturing practice (         <font style="font-style: italic">          cGMP         </font>         ) regulations. Our productcandidates are comprised of synthetic small molecules made througha series of organic chemistry steps starting with commerciallyavailable organic chemical raw materials. We do not currently ownor operate, nor do we plan to own or operate, any manufacturingfacilities for the production of our drug candidates fornonclinical, clinical or commercial use. We conduct manufacturingactivities under individual project or work orders with independentcontract manufacturing organizations (         <font style="font-style: italic">          CMOs         </font>         ) to supply all of our nonclinicaland clinical trial needs. We or experts from our CROs conductperiodic quality audits of their facilities. We believe that ourexisting suppliers of our product candidate’s activepharmaceutical ingredients and drug products will be capable ofproviding sufficient quantities of each to meet our nonclinical andclinical development needs. Other CMOs may be used in the futurefor nonclinical and clinical supplies and, subject to approval,commercial manufacturing.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 6px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Bydesign, we do not currently have any fixed contractual arrangementsin place for either long-term supply or redundant supply of bulkdrug substance or drug product for our product candidates. If ourproduct candidates are approved, we intend to contract with CMOs toproduce all of our future commercial supplies on our behalf. Weplan to mitigate potential commercial supply risks for any productsthat are approved in the future through inventory management andthrough exploring additional back-up manufacturers, both in theU.S. and outside the U.S., to provide API and/or drugproduct.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Salesand Marketing        </font>       </div>       <div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;">        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px;">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We intend to build a commercial infrastructure inthe United States in advance of anticipated drug approval of ourproduct candidates. We believe that we can cost effectivelyimplement a targeted sales force required to commercialize ourproducts, if approved, in the United States. Support for this teamwill include sales management, internal sales support, distributionsupport, and an internal marketing group. Additional requisitecapabilities will include focused management of key accounts suchas managed care organizations, group purchasing organizations, andgovernment accounts. We may seek co-promotion partners for oursales efforts to achieve broader reach or call frequency withUnited States target physicians. We expect to focus our futuresales and marketing efforts for our product candidates in theUnited States, if FDA-approved, on psychiatrists and select primarycare physicians and, should we receive FDA approval for use inpediatric populations, on select pediatricians who are likely tosee adolescents, as well as nurse practitioners, childpsychiatrists and psychologists who, in some states, are permittedto prescribe medications.         </font>         In order to implement thisinfrastructure, we will have to allocate management resources andmake significant financial investments, including some prior toproduct approval.        </font>       </div>       <div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;">        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We believe that there are significant market opportunities for ourproducts outside of the United States. As a result, as we have doneunder the AffaMed Agreement, we plan to seek strategic partnershipswith third parties, which may have greater reach and resources byvirtue of their size and experience in the field, for thedevelopment and commercialization of our products in selectedmarkets outside the United States. We may elect in the future toutilize additional strategic partners, distributors, or contractsales forces to assist in the development and commercialization ofour products.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Competition        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Our industry is highly competitive and subject to rapid andsignificant technological change. The large size and expandingscope of the CNS markets, especially         </font>         the high unmet need inlarge and growing global markets for anxiety and depressiondisorders,         <font style="color: #000000">          make them attractivetherapeutic areas for biopharmaceutical businesses. Our potentialcompetitors include pharmaceutical, biotechnology, and specialtypharmaceutical companies. While we believe that our employees andconsultants, scientific knowledge, technology, and developmentexperience provide us with competitive advantages, we facepotential competition from many different sources, including majorpharmaceutical, specialty pharmaceutical, and biotechnologycompanies, academic institutions and governmental agencies, andpublic and private research institutions. Several of these entitieshave robust drug pipelines, readily available capital, andestablished research and development organizations. Any productcandidates that we successfully develop and commercialize willcompete with existing therapies and new therapies that may becomeavailable in the future. Many of our competitors may havesignificantly greater financial resources and expertise in researchand development, manufacturing, preclinical testing, conductingclinical trials, obtaining regulatory approvals, and marketingapproved products than we do. Mergers and acquisitions in thepharmaceutical, biotechnology, and diagnostic industries may resultin even more resources being concentrated among a smaller number ofour competitors. These competitors also compete with us inrecruiting and retaining qualified scientific and managementpersonnel and establishing clinical trial sites and patientregistration for clinical trials, as well as in acquiringtechnologies complementary to, or necessary for, our programs.Small or early-stage companies may also prove to be significantcompetitors, particularly through collaborative arrangements withlarge and established companies. The key competitive factorsaffecting the success of all of our product candidates, ifapproved, are likely to be their efficacy, safety, convenience,price, the level of branded and generic competition, and theavailability of reimbursement from government and other third-partypayors.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -14-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Currentlythere are no FDA-approved therapies for SAD with the mechanism ofaction of PH94B, and we are aware of         <font style="color: #000000">          no company developing a potential acute treatmentof anxiety for adults with SAD that is a nasal spray and involvesthe same mechanism of pharmacological action as PH94B. However,although they have not been systematically developed for treatmentof SAD are not FDA-approved for the acute treatment of anxiety inadults with SAD, we may face competition to PH94B for acutetreatment of anxiety in adult and pediatric patients with SAD fromoff-label use of generic benzodiazepines and generic beta blockers.In addition, although there are three oral antidepressants approvedby the FDA for treatment of SAD, such drugs do not achieverapid-onset therapeutic effects and are associated with undesirableside effects.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Patients with MDD are typically treated with a variety of oralantidepressant medications or oral atypical antipsychotics. Thesetreatments often include generic antidepressants such as:Fluoxetine (Prozac), previously marketed by Eli Lilly and Company;sertraline (Zoloft) and venlaxafine (Effexor), both previouslymarketed by Pfizer, Inc.; and paroxetine (Paxil) and bupropion(Wellbutrin), both previously marketed by GlaxoSmithKline.Treatments may also include currently marketed medicationsindicated for MDD such as: Trintellix, with is marketed by TakedaPharmaceuticals America, Inc and H. Lundbeck A/S; Viibryd, which ismarketed by Abbvie; and Rexulti which is marketed by OtsukaAmerica.         </font>         Although currently there are no FDA-approved oraltherapies for MDD with the mechanism of         <font style="color: #000000">          pharmacological         </font>         action of either PH10 orAV-101, we are aware of         <font style="color: #000000">          numerouscompanies that are developing therapies targeting the MDD market,including, among others, Axsome Therapeutics, MinervaNeurosciences, Relmada Therapeutics, and Sage Therapeutics.         </font>         Additionally, with respect to MDD, we expect that PH10 and AV-101will have to compete with a variety of non-pharmacologicalalternatives for treatment of MDD, such as psychotherapy andelectroconvulsive therapy.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Government Regulation and Product Approval        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Governmentauthorities in the U.S., at the federal, state, and local level,and in other countries and supranational regions, extensivelyregulate, among other things, the research, development, testing,manufacture, packaging, storage, recordkeeping, labeling,advertising, promotion, distribution, marketing, import, and exportof pharmaceutical products such as those we are developing. Inaddition, healthcare regulatory bodies in the United States andaround the world impose a range of requirements related to thepayment for pharmaceutical products, including laws intended toprevent fraud, waste, and abuse of healthcare dollars. Thisincludes, for example, requirements that manufacturers ofpharmaceutical products participating in Medicaid and Medicarecomply with mandatory price reporting, discount, rebaterequirements, and other cost control measures, as well asanti-kickback laws and laws prohibiting false claims. Some statesalso have enacted fraud, waste, and abuse laws that parallel (andin some cases apply more broadly than) federal laws, and in somecases price transparency requirements. The processes for obtainingregulatory approvals in the United States and in foreign countries,along with subsequent compliance with applicable statutes andregulations, require the expenditure of substantial time andfinancial resources. Further, healthcare is an active area ofgovernmental scrutiny, and it is reasonable to expect that therequirements may become more stringent within the foreseeablefuture.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         FDA Regulation        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In theU.S., the FDA regulates drugs under the FDCA and its implementingregulations. The process required by the FDA before productcandidates may be marketed in the U.S. generally involves thefollowing:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 36px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ·          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           completion ofpreclinical laboratory tests, animal studies, and formulationstudies in compliance with the FDA’s Good Laboratory Practice(           <font style="font-style: italic">            GLP           </font>           )regulations;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 36px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ·          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           submission to theFDA of an IND application which must become effective before humanclinical trials may begin;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 36px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ·          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           approval by anindependent Institutional Review Board (           <font style="font-style: italic">            IRB           </font>           ) for each clinical site orcentrally, before each trial may be initiated;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 36px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ·          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           adequate andwell‑controlled human clinical trials to establish the safetyand efficacy of the proposed drug candidates for its intended use,performed in accordance with current Good Clinical Practices(           <font style="font-style: italic">            cGCP           </font>           );          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 36px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ·          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           development ofmanufacturing processes in compliance with current cGMPs to ensurethe drug’s identity, strength, quality, andpurity;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 36px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ·          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           compilation ofrequired information and submission to the FDA of anNDA;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 36px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ·          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           satisfactorycompletion of an FDA advisory committee review, ifapplicable;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 36px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ·          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           satisfactorycompletion of an FDA inspection of the manufacturing facility orfacilities at which the product is produced to assess compliancewith cGMPs, and to assure that the facilities, methods, andcontrols are adequate to preserve the drug’s identity,strength, quality, and purity, as well as satisfactory completionof an FDA inspection of selected clinical sites and selectedclinical investigators to determine GCP compliance;and          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 36px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ·          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           FDA review andapproval of the NDA to permit commercial marketing for particularindications for use.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -15-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Preclinical Studies and IND Submission        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thetesting and approval process of product candidates requiressubstantial time, effort, and financial resources. Preclinicalstudies include laboratory evaluation of drug substance chemistry,pharmacology, toxicity, and drug product formulation, as well asanimal studies to assess potential safety and efficacy. Suchstudies must generally be conducted in accordance with theFDA’s GLP regulations. Prior to commencing the first clinicaltrial with a product candidate, an IND sponsor must submit theresults of the preclinical tests and preclinical literature,together with manufacturing information, analytical data, anyavailable clinical data or literature, and proposed clinical studyprotocols, among other things, to the FDA as part of anIND.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         An INDbecomes effective 30 days after receipt by the FDA, unless the FDA,within the 30‑day time period, notifies the applicant ofsafety and/or product quality concerns or questions related to oneor more proposed clinical trials and places the trial on a clinicalhold. In such a case, the IND sponsor and the FDA must resolve anyoutstanding concerns before the clinical trial can begin. Clinicalholds also may be imposed by the FDA at any time before or duringtrials due to safety concerns or noncompliance. As a result,submission of an IND may not result in FDA authorization tocommence a clinical trial.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Clinical Trials        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Clinicaltrials involve the administration of the investigational new drugto human subjects under the supervision of qualified investigatorsin accordance with GCP requirements, which include the requirementsthat all research subjects provide their informed consent inwriting for their participation in any clinical trial, as well asreview and approval of the study by an IRB. Investigators must alsoprovide certain information to the clinical trial sponsors to allowthe sponsors to make certain financial disclosures to the FDA.Clinical trials are conducted under protocols detailing, amongother things, the objectives of the trial, the trial procedures,the parameters to be used in monitoring safety, the effectivenesscriteria to be evaluated, and a statistical analysis plan. Aprotocol for each clinical trial, and any subsequent protocolamendments, must be submitted to the FDA as part of the IND. Inaddition, an IRB at each study site participating in the clinicaltrial or a central IRB must review and approve the plan for anyclinical trial, informed consent forms, and communications to studysubjects before a study commences at that site. An IRB considers,among other things, whether the risks to individuals participatingin the trials are minimized and are reasonable in relation toanticipated benefits and whether the planned human subjectprotections are adequate. The IRB must continue to oversee theclinical trial while it is being conducted.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Once anIND is in effect, each new clinical protocol and any amendments tothe protocol must be submitted for FDA review, and to the IRB forapproval. Progress reports detailing the results of the clinicaltrials must also be submitted at least annually to the FDA and theIRB and more frequently if serious adverse events or othersignificant safety information is found.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Informationabout certain clinical trials, including a description of the studyand study results, must be submitted within specific timeframes tothe NIH for public dissemination on their clinicaltrials.govwebsite.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Additionally,some clinical trials are overseen by an independent group ofqualified experts organized by the clinical trial sponsor, known asa data safety monitoring board or committee. This group regularlyreviews accumulated data and advises the study sponsor regardingthe continuing safety of trial subjects, enrollment of potentialtrial subjects, and the continuing validity and scientific merit ofthe clinical trial. The data safety monitoring board receivesspecial access to unblinded data during the clinical trial and mayadvise the sponsor to halt the clinical trial if it determinesthere is an unacceptable safety risk for subjects or on othergrounds, such as no demonstration of efficacy.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Themanufacture of investigational drugs for the conduct of humanclinical trials (and their active pharmaceutical ingredients) issubject to cGMP requirements. Investigational drugs and activepharmaceutical ingredients imported into the U.S. are also subjectto regulation by the FDA relating to their labeling anddistribution. Further, the export of investigational drug productsoutside of the United States is subject to regulatory requirementsof the receiving country as well as U.S. export requirements underthe FDCA.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -16-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ingeneral, for purposes of NDA approval, human clinical trials aretypically conducted in three sequential phases, which may overlapor be combined.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 36px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ·          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic">            Phase 1           </font>           —Studies are initiallyconducted in healthy human volunteers or subjects with the targetdisease or condition and test the product candidate for safety,dosage tolerance, structure‑activity relationships, mechanismof action, absorption, metabolism, distribution, and excretion. Ifpossible, Phase 1 trials may also be used to gain an initialindication of product effectiveness.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 36px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ·          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic">            Phase 2           </font>           —Controlled studies areconducted in limited subject populations with a specified diseaseor condition to evaluate preliminary efficacy, identify optimaldosages, dosage tolerance and schedule, possible adverse effectsand safety risks, and expanded evidence of safety.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 36px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ·          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic">            Phase 3—           </font>           These adequate andwell‑controlled clinical trials are undertaken in expandedsubject populations, generally at geographically dispersed clinicaltrial sites, to generate enough data to provide statisticallysignificant evidence of clinical efficacy and safety of the productfor approval, to establish the overall risk‑benefit profileof the product, and to provide adequate information for thelabeling of the product. Typically, two successful Phase 3 trialsare required by the FDA for product approval.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         The FDAmay also require, or companies may conduct, additional clinicaltrials for the same indication after a product is approved. Theseso-called Phase 4 studies may be required by the FDA as a conditionof approval of the NDA, to be satisfied after approval. The resultsof Phase 4 studies can confirm the effectiveness of a productcandidate and can provide important safety information. In additionto the above traditional kinds of clinical trial data required forthe approval of an NDA, the 21st Century Cures Act provides forpotential FDA use of different types and sources of data inregulatory decision-making, such as patient experience data,real-world evidence for already approved products, and, forappropriate indications sought through supplemental marketingapplications. Implementation of this law and related initiatives isstill in progress and we do not know the extent to which we may inthe future be able to utilize these types and sources of data. Inthe case of a 505(b)(2) NDA, which is a marketing application inwhich sponsors may rely on investigations that were not conductedby or for the applicant and for which the applicant has notobtained a right of reference or use from the person by or for whomthe investigations were conducted, some of the above describedstudies and preclinical studies may not be required or may beabbreviated. Bridging studies may be needed, however, todemonstrate the applicability of the studies that were previouslyconducted by other sponsors to the drug that is the subject of themarketing application.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Clinicaltrials at any phase may not be completed successfully within anyspecified period, or at all. Regulatory authorities, an IRB, or thesponsor may suspend or discontinue a clinical trial at any time onvarious grounds, including a finding that the subjects are beingexposed to an unacceptable health risk, the clinical trial is notbeing conducted in accordance with the FDA’s or theIRB’s requirements, if the drug has been associated withunexpected serious harm to the subjects, or based on evolvingbusiness objectives or competitive climate.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Concurrentwith clinical trials, companies usually complete additional animalstudies and must also develop additional information about thechemistry and physical characteristics of the product candidate aswell as finalize a process for manufacturing the product incommercial quantities in accordance with cGMP requirements. Themanufacturing process must be capable of consistently producingquality batches of the product candidate and, among other things,the manufacturer must develop methods for testing the identity,strength, quality, potency, and purity of the final product.Additionally, appropriate packaging must be selected and tested,and stability studies must be conducted to demonstrate that theproduct candidate does not undergo unacceptable deterioration overits shelf life.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Duringthe development of a new drug, a sponsor may be able to request aSpecial Protocol Assessment (         <font style="font-style: italic">          SPA         </font>         ) the purpose of which is to reachagreement with the FDA on the Phase 3 clinical trial protocoldesign and analysis that will form the primary basis of an efficacyclaim as well as preclinical carcinogenicity trials and stabilitystudies. An SPA may only be modified with the agreement of the FDAand the trial sponsor or if the director of the FDA reviewingdivision determines that a substantial scientific issue essentialto determining the safety or efficacy of the drug was identifiedafter the testing began. An SPA is intended to provide assurancethat, in the case of clinical trials, if the agreed‑uponclinical trial protocol is followed, the clinical trial endpointsare achieved, and there is a favorable risk‑benefit profile,the data may serve as the primary basis for an efficacy claim insupport of an NDA. However, SPA agreements are not a guarantee ofan approval of a product candidate or any permissible claims aboutthe product candidate. In particular, SPAs are not binding on theFDA if, among other reasons, previously unrecognized public healthconcerns arise during the performance of the clinical trial, othernew scientific concerns regarding the product candidate’ssafety or efficacy arise, or if the sponsoring company fails tocomply with the agreed upon clinical trial protocol.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         NDA Submission, Review by the FDA, and MarketingApproval        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Assumingsuccessful completion of the required clinical and preclinicaltesting, the results of product development, including chemistry,manufacturing, and control (         <font style="font-style: italic">          CMC         </font>         ) information, non-clinical studies,and clinical trial results, including negative or ambiguous resultsas well as positive findings, are all submitted to the FDA, alongwith the proposed labeling, as part of an NDA requesting approvalto market the product for one or more indications. In most cases,the submission of an NDA is subject to a substantial applicationuser fee, authorized every five years by Congress under thePrescription Drug User Fee Act (         <font style="font-style: italic">          PDUFA         </font>         ). User fees must be paid at thetime of the first submission of the application, even if theapplication is being submitted on a rolling basis, and if approved,program fees must be paid on an annual basis. Product candidatesthat are designated as orphan drugs, which are further describedbelow, are not subject to application user fees unless theapplication includes an indication other than the orphanindication.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -17-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inaddition, under the Pediatric Research Equity Act (         <font style="font-style: italic">          PREA         </font>         ) an NDA or supplement to an NDAfor a new active ingredient, indication, dosage form, dosageregimen, or route of administration must contain data that areadequate to assess the safety and effectiveness of the drug for theclaimed indications in all relevant pediatric subpopulations, andto support dosing and administration for each pediatricsubpopulation for which the product is safe and effective. Asponsor who is planning to submit a marketing application for adrug product that includes a new active ingredient, new indication,new dosage form, new dosing regimen or new route of administrationmust submit an initial Pediatric Study Plan (         <font style="font-style: italic">          PSP         </font>         ) within 60 days of an End-of-Phase2 meeting or as may be agreed between the sponsor and the FDA. Theinitial PSP must include an outline of the pediatric study orstudies that the sponsor plans to conduct, including studyobjectives and design, age groups, relevant endpoints andstatistical approach, or a justification for not including suchdetailed information, and any request for a deferral of pediatricassessments or a full or partial waiver of the requirement toprovide data from pediatric studies along with supportinginformation. The FDA and the sponsor must reach agreement on thePSP. A sponsor can submit amendments to an agreed-upon initial PSPat any time if changes to the pediatric plan need to be consideredbased on data collected from preclinical studies, early phaseclinical studies or other clinical development programs. The FDAmay, on its own initiative or at the request of the applicant,grant deferrals for submission of some or all pediatric data untilafter approval of the product for use in adults, or full or partialwaivers from the pediatric data requirements. The FDA also mayrequire submission of a risk evaluation and mitigation strategy(         <font style="font-style: italic">          REMS         </font>         ) to ensure that thebenefits of the drug outweigh the risks of the drug. The REMS plancould include medication guides, physician communication plans, andelements to assure safe use, such as restricted distributionmethods, patient registries, or other risk minimization tools. Anassessment of the REMS must also be conducted at set intervals.Following product approval, a REMS may also be required by the FDAif new safety information is discovered and the FDA determines thata REMS is necessary to ensure that the benefits of the drugcontinue to outweigh the risks of the drug.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Oncethe FDA receives an application, it will determine within 60 dayswhether the NDA as filed is sufficiently complete to permit asubstantive review (with this decision often referred to as the NDAbeing “accepted for filing.”). If the FDA determinesthat the NDA is not sufficiently complete to permit a substantivereview, the application must be resubmitted with additionalinformation requested by the FDA. The resubmitted application isalso subject to review before the FDA accepts it for filing. Oncethe submission is accepted for filing, the FDA begins anin‑depth substantive review of the NDA.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         The FDAhas agreed to a set of performance goals and procedures under PDUFAto review 90% of all applications within ten months from the 60-dayfiling date for its initial review of a standard NDA for a NewMolecular Entity (         <font style="font-style: italic">          NME         </font>         ). Fornon-NME standard applications, the FDA has set the goal ofcompleting its review of 90% of all applications within ten monthsfrom the submission receipt date. Such deadlines are referred to asthe PDUFA date. The PDUFA date is only a goal, thus, the FDA doesnot always meet its PDUFA goal dates. The review process and thePDUFA goal date may also be extended if the FDA requests, or theNDA sponsor otherwise provides, substantial additional informationor clarification regarding the submission.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         The FDAmay refer an application to an advisory committee for review,evaluation and recommendation as to whether the application shouldbe approved, and applications for new molecular entities aregenerally discussed at advisory committee meetings unless the FDAdetermines that this type of consultation is not needed under thecircumstances.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Anadvisory committee is typically a panel that includes cliniciansand other experts, which review, evaluate, and make arecommendation as to whether the application should be approved andunder what conditions. The FDA is not bound by the recommendationsof an advisory committee, but it considers such recommendationscarefully when making decisions and typically follows suchrecommendations.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         The FDAreviews applications to determine, among other things, whether aproduct is safe and effective for its intended use and whether themanufacturing methods and controls are adequate to assure andpreserve the product’s identity, strength, quality, safety,potency, and purity. Before approving an NDA, the FDA typicallywill inspect the facility or facilities where the product ismanufactured, referred to as a Pre‑Approval Inspection. TheFDA will not approve an application unless it determines that themanufacturing processes and facilities, including contractmanufacturers and subcontractors, are in compliance with cGMPrequirements and adequate to assure consistent production of theproduct within required specifications. Additionally, beforeapproving an NDA the FDA will inspect one or more clinical trialsites to assure compliance with GCPs.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theapproval process is lengthy and difficult, and involves numerousFDA personnel assigned to review different aspects of the NDA, andthe FDA may refuse to approve an NDA if the applicable regulatorycriteria are not satisfied or may require additional preclinical,CMC, or other data and information. Uncertainties can be presentedby reviewers’ ability to exercise judgment and discretionduring the review process. Even if such data and information aresubmitted, the FDA may ultimately decide that the NDA does notsatisfy the criteria for approval. Data obtained from clinicaltrials are not always conclusive and the FDA may interpret datadifferently than an applicant interprets the samedata.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -18-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Afterevaluating the NDA and all related information, including theadvisory committee recommendation, if any, and inspection reportsregarding the manufacturing facilities and clinical trial sites,the FDA may issue an approval letter, or, in some cases, a CompleteResponse Letter (         <font style="font-style: italic">          CRL         </font>         ). If aCRL is issued, the applicant may either resubmit the NDA,addressing all of the deficiencies identified in the letter;withdraw the application; or request an opportunity for a hearing.A CRL indicates that the review cycle of the application iscomplete and the application is not ready for approval in itscurrent form and describes all of the specific deficiencies thatthe FDA identified in the NDA. A CRL generally contains a statementof specific conditions that must be met in order to secure finalapproval of the NDA and may require additional clinical orpreclinical testing in order for the FDA to reconsider theapplication. The deficiencies identified may be minor, for example,requiring labeling changes; or major, for example, requiringadditional clinical trials. The FDA has the goal of reviewing 90%of application and efficacy supplement resubmissions in either twoor six months (from receipt) for a Class 1 or Class 2 resubmission,respectively. For non-efficacy supplements (i.e., labeling andmanufacturing supplements), FDA’s goal is to review thesupplement within the same length of time (from receipt) as theinitial review cycle (excluding an extension caused by a majoramendment of the initial supplement).        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Evenwith the submission of additional information, the FDA ultimatelymay decide that the application does not satisfy the regulatorycriteria for approval. If and when the issues identified in a CRLhave been addressed and resolved to the FDA’s satisfaction,the FDA may issue an approval letter. An approval letter authorizescommercial marketing of the drug for specific indications and withspecific prescribing information which was reviewed in connectionwith the NDA.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Even ifthe FDA approves a product, it may limit the approved indicationsfor use of the product, require that contraindications, warnings,or precautions be included in the product labeling, including aboxed warning, require that post‑approval studies, includingPhase 4 clinical trials, be conducted to further assess adrug’s safety and efficacy after approval, require testingand surveillance programs to monitor the product aftercommercialization, or impose other conditions, includingdistribution restrictions or other risk management mechanisms undera REMS which can materially affect the potential market andprofitability of the product. The FDA may also not approve labelstatements that are necessary for successful commercialization andmarketing.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Afterapproval, some types of changes to the approved product, such asadding new indications, manufacturing changes, and additionallabeling claims, are subject to further testing requirements andFDA review and approval. The FDA may also withdraw the productapproval if compliance with the pre‑ and post‑marketingregulatory standards are not maintained or if problems occur afterthe product reaches the marketplace. Further, should new safetyinformation arise, additional testing, product labeling, or FDAnotification may be required.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         505(b)(2) Approval Process        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Section505(b)(2) of the FDCA, provides an alternate regulatory pathway toFDA approval for new or improved formulations or new uses ofpreviously approved drug products. Specifically, Section 505(b)(2)was enacted as part of the Drug Price Competition and Patent TermRestoration Act of 1984, commonly referred to as theHatch‑Waxman Act amendments, and permits the filing of an NDAwhere at least some of the information required for approval comesfrom studies not conducted by or for the applicant and for whichthe applicant has not obtained a right of reference or use from theperson by or for whom the investigations were conducted. Theapplicant may rely, in part, upon the FDA’s prior findings ofsafety and effectiveness for an approved product that acts as thereference listed drug or on published scientific literature, insupport of its application. The FDA may also require 505(b)(2)applicants to perform additional studies or measurements to supportthe changes from the reference listed drug as well as bridgingstudies to the reference listed drug. The FDA may then approve thenew product candidate for all or some of the labeled indicationsfor which the referenced product has been approved, as well as forany new indication sought by the Section 505(b)(2)applicant.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Orange Book Listing        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Section505 of the FDCA describes three types of marketing applicationsthat may be submitted to the FDA to request marketing authorizationfor a new drug. A section 505(b)(1) NDA is an application thatcontains full reports of investigations of safety and efficacy. Asection 505(b)(2) NDA is an application in which the applicant, inpart, relies on investigations that were not conducted by or forthe applicant and for which the applicant has not obtained a rightof reference or use from the person by or for whom theinvestigations were conducted. Section 505(j) establishes anabbreviated approval process for a generic version of approved drugproducts through the submission of an Abbreviated New DrugApplication (         <font style="font-style: italic">          ANDA         </font>         ). An ANDAis an application for marketing of a generic drug product that hasthe same active ingredients, dosage form, strength, route ofadministration, labeling, performance characteristics, and intendeduse, among other things, to a previously approved product. Limitedchanges must be pre‑approved by the FDA via a suitabilitypetition. ANDAs are termed “abbreviated” because theyare generally not required to include preclinical and clinical datato establish safety and efficacy. Instead, generic applicants mustscientifically demonstrate that their product is bioequivalent to,or performs in the same manner as, the innovator drug through invitro, in vivo, or other testing. The generic version must deliverthe same amount of active ingredients into a subject’sbloodstream in the same amount of time as the innovator drug and,under state substitution laws, may be substituted at the pharmacyfor the reference listed drug.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inseeking approval for a drug through an NDA, including a 505(b)(2)NDA, applicants are required to identify to the FDA patents thatcontain claims that are directed to the applicant’s productand/or method(s) of use. Upon approval of an NDA, each of theidentified patents is then listed in         <font style="font-style: italic">          Approved Drug Products with TherapeuticEquivalence Evaluations         </font>         , also known as the OrangeBook.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -19-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Anapplicant who files an ANDA seeking approval of a generic versionof a drug listed in the Orange Book or a 505(b)(2) NDA referencinga drug listed in the Orange Book must make patent certifications tothe FDA that (1) no patent information on the drug or method of usethat is the subject of the application has been submitted to theFDA; (2) the patent has expired; (3) the date on which the patenthas expired and approval will not be sought until after the patentexpiration; or (4) in the applicant’s opinion and to the bestof its knowledge, the patent is invalid, unenforceable, or will notbe infringed upon by the manufacture, use, or sale of the drugproduct for which the application is submitted. The lastcertification is known as a paragraph IV certification. Generally,the ANDA or 505(b)(2) NDA approval cannot be made effective untilall listed patents have expired, except where the ANDA or 505(b)(2)NDA applicant challenges a listed patent through a paragraph IVcertification or if the applicant is not seeking approval of apatented method of use. If the applicant does not challenge thelisted patents or does not indicate that it is not seeking approvalof a patented method of use, the ANDA or 505(b)(2) NDA applicationapproval will not be made effective until all of the listed patentsclaimed by the referenced product have expired.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If thecompetitor has provided a paragraph IV certification to the FDA,the competitor must also send notice of the paragraph IVcertification to the holder of the NDA for the reference listeddrug and the patent owner within 20 days after the application hasbeen accepted for filing by the FDA. The NDA holder or patent ownermay then initiate a patent infringement lawsuit in response to thenotice of the paragraph IV certification. The filing of a patentinfringement lawsuit within 45 days of the receipt of a paragraphIV certification notice prevents the FDA from making the approvalof the ANDA or 505(b)(2) application effective until the earlier of30 months from the date of the lawsuit, expiration of the patent,settlement of the lawsuit, a decision in the infringement case thatis favorable to the applicant or such shorter or longer period asmay be ordered by a court. This prohibition is generally referredto as the automatic 30‑month stay.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inpractice, where an ANDA or 505(b)(2) NDA applicant files aparagraph IV certification, the NDA holder or patent owners oftentake action to trigger the automatic 30‑month stay, resultingin patent litigation that may take many months or years to resolve.Thus, approval of an ANDA or 505(b)(2) application could be delayedfor a significant period of time depending on the patentcertification the applicant makes and the reference drugsponsor’s decision to initiate patentlitigation.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Regulatory Exclusivity        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Regulatoryexclusivity provisions under the FDCA can also delay the submissionor the approval effective date of certain applications. Aregulatory exclusivity can provide the holder of an approved NDAprotection from new competition in the marketplace for theinnovation represented by its approved drug. Five years ofexclusivity are available for NCEs. An NCE is a drug that containsno active moiety that has been approved by the FDA in any otherNDA. An active moiety is the molecule or ion excluding thoseappended portions of the molecule that cause the drug to be anester, salt, including a salt with hydrogen or coordination bonds,or other noncovalent derivatives, such as a complex, chelate, orclathrate, of the molecule, responsible for the therapeuticactivity of the drug substance. During the NCE exclusivity period,the FDA may not accept for review an ANDA or a 505(b)(2) NDAapplication by another company that contains the previouslyapproved active moiety. An ANDA or 505(b)(2) application, however,may be submitted one year before NCE exclusivity expires if aparagraph IV certification is filed.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Threeyears of exclusivity are available to the holder of an NDA,including a 505(b)(2) NDA, for a particular condition of approval,or change to a marketed product, such as a new formulation orindication for a drug product that contains an active moiety thathas been previously approved, when the application contains reportsof new clinical investigations, other than bioavailability studies,conducted by the sponsor that were essential to approval of theapplication. Changes in an approved drug product that affect itsactive ingredient(s), strength, dosage form, route ofadministration or conditions of use may be granted this exclusivityif a new clinical investigation (         <font style="font-style: italic">          NCI         </font>         ) was essential to approval of theapplication containing those changes. During the NCI exclusivityperiod, FDA may not approve an ANDA or 505(b)(2) NDA by anothercompany for the condition of the new drug’s approval. NCE andNCI exclusivities will not delay the submission or approval of afull NDA; however, an applicant submitting a full NDA would berequired to conduct or obtain a right of reference to all of thepreclinical studies and adequate and well‑controlled clinicaltrials necessary to demonstrate safety and efficacy.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Pediatricexclusivity is a regulatory exclusivity in the United States thatprovides for the attachment of an additional six months ofmarketing protection to the term of any existing regulatory andstatutory exclusivity, including the non‑patent exclusivityperiods described above as well as applicable patent terms. Thissix‑month exclusivity may be granted if an NDA sponsorsubmits pediatric data that fairly respond to a written requestfrom the FDA for such data. The data do not need to show theproduct to be effective in the pediatric population studied;rather, if the clinical trial is deemed to fairly respond to theFDA’s request, the additional protection is granted. Ifreports of requested pediatric studies are submitted to andaccepted by the FDA within the required time frames, whateverstatutory or regulatory periods of exclusivity or Orange Booklisted patent protection cover the drug are extended by six months.This is not a patent term extension, but it effectively extends theregulatory period during which the FDA cannot make an ANDA or505(b)(2) application approval effective as a result of regulatoryexclusivity or listed patents. Moreover, pediatric exclusivityattaches to all formulations, dosage forms, and indications forproducts with existing marketing exclusivity or patent life thatcontain the same active moiety as that which wasstudied.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheOrphan Drug Act provides incentives for the development of drugsintended to treat rare diseases or conditions, which generally arediseases or conditions affecting less than 200,000 individualsannually in the United States, or affecting more than 200,000 inthe United States and for which there is no reasonable expectationthat the cost of developing and making the drug available in theUnited States will be recovered from United States sales. If aproduct receives FDA approval for the indication for which it hasorphan designation, the product is generally entitled to orphandrug exclusivity, which means the FDA may not approve any otherapplication to market the same drug for the same indication for aperiod of seven years, except in limited circumstances, such as ashowing of clinical superiority over the product with orphanexclusivity. Orphan drug designation also entitles a party tofinancial incentives such as opportunities for grant fundingtowards clinical study costs, tax advantages, and applicationuser‑fee waivers.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -20-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Special FDA Expedited Review and Approval Programs        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         The FDAhas various programs, including Fast Track designation, PriorityReview and Breakthrough designation, that are intended to expediteor simplify the process for the development and FDA review ofcertain drug products that are intended for the treatment ofserious or life-threatening diseases or conditions, and demonstratethe potential to address unmet medical needs or present asignificant improvement over existing therapy. The purpose of theseprograms is to provide important new drugs to patients earlier thanunder standard FDA review procedures.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         To beeligible for a Fast Track designation, the FDA must determine,based on the request of a sponsor, that a product is intended totreat a serious or life-threatening disease or condition anddemonstrates the potential to address an unmet medical need. TheFDA will determine that a product will fill an unmet medical needif the product will provide a therapy where none exists or providea therapy that may be potentially superior to existing therapybased on efficacy, safety, or public health factors. If Fast Trackdesignation is obtained, drug sponsors may be eligible for morefrequent development meetings and correspondence with theFDA.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inaddition, if an applicant obtains “rolling review,” theFDA may accept and initiate review of sections of an NDA before theapplication submission is complete, although it is not guaranteedthat FDA will commence review before the application submission iscomplete, and the timing of the review depends on a number offactors including availability of review personnel at the FDA, andcompeting agency priorities among other things. The applicant mustprovide, and the FDA must agree to, a schedule for the remaininginformation after the initial section of the NDA.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In somecases, a Fast Track product may be eligible for AcceleratedApproval or Priority Review.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         The FDAmay give a Priority Review designation to drugs that are intendedto treat serious conditions and, if approved, would providesignificant improvements in the safety or effectiveness of thetreatment, diagnosis, or prevention of serious conditions. APriority Review designation means that the goal for the FDA is toreview an application within six months of receipt, rather than thestandard review of ten months under current PDUFA guidelines, ofthe 60‑day filing date for NMEs and within six months of thesubmission receipt date for non‑NMEs. Products that areeligible for Fast Track designation may also be consideredappropriate to receive a Priority Review.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Moreover,under the provisions of the Food and Drug Administration Safety andInnovation Act (         <font style="font-style: italic">          FDASIA         </font>         )enacted in 2012, a sponsor can request designation of a productcandidate as a “breakthrough therapy.” A breakthroughtherapy is defined as a drug that is intended, alone or incombination with one or more other drugs, to treat a serious orlife‑threatening disease or condition, and preliminaryclinical evidence indicates that the drug may demonstratesubstantial improvement over existing therapies on one or moreclinically significant endpoints, such as substantial treatmenteffects observed early in clinical development. Drugs designated asbreakthrough therapies are eligible for the Fast Track designationfeatures as described above, intensive guidance on an efficientdrug development program beginning as early as Phase 1 trials, anda commitment from the FDA to involve senior managers andexperienced review staff in a proactive collaborative,cross‑disciplinary review.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Even ifa product qualifies for one or more of these programs, the FDA maylater decide that the product no longer meets the conditions forqualification or decide that the time period for FDA review orapproval will not be shortened.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Post‑approval Requirements        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Anyproduct manufactured or distributed pursuant to FDA approvals aresubject to pervasive and continuing regulation by the FDA, as wellas other federal and state agencies, including, among other things,requirements related to manufacturing, recordkeeping, andreporting, including adverse experience reporting, drug shortagereporting, and other periodic reporting; drug supply chain securitysurveillance and tracking requirements; product sampling anddistribution; advertising; marketing; promotion; certain electronicrecords and signatures; licensure in certain states for themanufacturing and distribution of drug products; and post-approvalobligations imposed as a condition of approval, such as Phase 4clinical trials, REMS, and surveillance to assess safety andeffectiveness after commercialization.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Afterapproval, most changes to the approved product, such as adding newindications or other labeling claims are subject to prior FDAreview and approval. There are also continuing annual prescriptiondrug program user fee requirements for any approved products. Inaddition, drug manufacturers and other entities involved in themanufacture and distribution of approved drugs are required toregister their establishments with the FDA and certain stateagencies and list their drug products, and are subject to periodicannounced and unannounced inspections by the FDA and these stateagencies for compliance with cGMP and other requirements, whichimpose certain procedural and documentation requirements upon thecompany and third‑party manufacturers.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Changesto the manufacturing process are strictly regulated and oftenrequire prior FDA approval or notification before beingimplemented. FDA regulations also require investigation andcorrection of any deviations from cGMP and product specificationsand impose reporting and documentation requirements upon thesponsor and any third‑party manufacturers that the sponsormay decide to use. Accordingly, manufacturers must continue toexpend time, money, and effort in the area of production andquality control to maintain cGMP compliance.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -21-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         The FDAalso strictly regulates marketing, labeling, advertising, andpromotion of products that are placed on the market. A company canmake only those claims relating to safety and efficacy, purity, andpotency that are approved by the FDA. Physicians, in theirindependent professional medical judgment, may prescribe legallyavailable products for unapproved indications that are notdescribed in the product’s labeling and that differ fromthose tested and approved by the FDA. Pharmaceutical companies,however, are required to promote their drug products only for theapproved indications and in accordance with the provisions of theapproved label. The FDA and other agencies actively enforce thelaws and regulations prohibiting the promotion of off‑labeluses, and a company that is found to have improperly promotedoff‑label uses may be subject to significant liability,including, but not limited to, criminal and civil penalties underthe FDCA and False Claims Act, exclusion from participation infederal healthcare programs, mandatory compliance programs undercorporate integrity agreements, debarment, and refusal ofgovernment contracts. Recent court decisions have impacted theFDA’s enforcement activity regarding off-label promotion inlight of First Amendment considerations; however, there are stillsignificant risks in this area in part due to the potential FalseClaims Act exposure. Further, the FDA has not materially changedits position on off-label promotion following legal setbacks onFirst Amendment grounds and the Department of Justice hasconsistently asserted in FCA briefings that “speech thatserves as a conduit for violations of the law is notconstitutionally protected.”        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheDrug Supply Chain Security Act (         <font style="font-style: italic">          DSCSA         </font>         ) imposes obligations onmanufacturers of prescription biopharmaceutical products forcommercial distribution, regulating the distribution of theproducts at the federal level, and sets certain standards forfederal or state registration and compliance of entities in thesupply chain (manufacturers and repackagers, wholesaledistributors, third-party logistics providers, and dispensers). TheDSCSA preempts certain previously enacted state pedigree laws andthe pedigree requirements of the Prescription Drug Marketing Act(         <font style="font-style: italic">          PDMA         </font>         ). Trading partnerswithin the drug supply chain must now ensure certain producttracing requirements are met that they are doing business withother authorized trading partners; and they are required toexchange transaction information, transaction history, andtransaction statements. Further, the DSCSA limits the distributionof prescription pharmaceutical products and imposes requirements toensure overall accountability and security in the drug supplychain. Product identifier information (an aspect of the producttracing scheme) is also now required. The DSCSA requirements,development of standards, and the system for product tracing havebeen and will continue to be phased in over a period of yearsthrough 2023, and subject companies will need to continue theirimplementation efforts. Many states still have in place licensureand other requirements for manufacturers and distributors of drugproducts. The distribution of product samples continues to beregulated under the PDMA, and some states also impose regulationson drug sample distribution.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Laterdiscovery of previously unknown problems with a product, includingadverse events of unanticipated severity or frequency, or withmanufacturing processes, or failure to comply with regulatoryrequirements, may result in significant regulatory actions. Suchactions may include refusal to approve pending applications,license suspension or revocation, withdrawal of an approval,imposition of a clinical hold or termination of clinical trials,warning letters, untitled letters, modification of promotionalmaterials or labeling, provision of corrective information,imposition of post‑market requirements including the need foradditional testing, imposition of distribution or otherrestrictions under a REMS, product recalls, product seizures ordetentions, refusal to allow imports or exports, total or partialsuspension of production or distribution, FDA debarment,injunctions, fines, consent decrees, corporate integrityagreements, debarment from receiving government contracts and neworders under existing contracts, exclusion from participation infederal and state healthcare programs, restitution, disgorgement,or civil or criminal penalties including fines and imprisonment,and may result in adverse publicity, among other adverseconsequences.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Fraud and Abuse, and Transparency Laws and Regulations        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Followingproduct approval, our business activities, including but notlimited to research, sales, promotion, marketing, distribution,medical education, sponsorships, relationships with prescribers andother referral sources, and other activities will be subject toregulation by numerous federal and state regulatory and lawenforcement authorities in the United States in addition to theFDA, including potentially the Department of Justice, theDepartment of Health and Human Services and its various divisions,including the Centers for Medicare &amp; Medicaid Services(         <font style="font-style: italic">          CMS         </font>         ), the Office ofInspector General (         <font style="font-style: italic">          OIG         </font>         ),and the Health Resources and Services Administration (         <font style="font-style: italic">          HRSA         </font>         ), the Department of VeteransAffairs, the Department of Defense, and certain state and localgovernments. Our business activities must comply with numeroushealthcare laws, including but not limited to, anti‑kickbackand false claims laws and regulations as well as data privacy andsecurity laws and regulations, which are describedbelow.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefederal Anti-Kickback Statute prohibits, among other things, anyperson or entity, from knowingly and willfully offering, paying,soliciting, or receiving any remuneration, directly or indirectly,overtly or covertly, in cash or in kind, to induce or in return forpurchasing, leasing, ordering, or arranging for or recommending thepurchase, lease, furnishing, or order of any item or servicereimbursable under Medicare, Medicaid, or other federal healthcareprograms, in whole or in part. The term “remuneration”has been interpreted broadly to include anything of value. TheAnti-Kickback Statute has been interpreted to apply to arrangementsbetween pharmaceutical manufacturers on one hand and prescribers,purchasers, formulary managers, and beneficiaries on the other.There are certain statutory exceptions and regulatory safe harborsprotecting some common activities from prosecution. The exceptionsand safe harbors are drawn narrowly, and practices that involveremuneration that may be alleged to be intended to induceprescribing, purchases, or recommendations may be subject toscrutiny if they do not qualify for an exception or safe harbor.Failure to meet all of the requirements of a particular applicablestatutory exception or regulatory safe harbor, however, does notmake the conduct per se illegal under the Anti-Kickback Statute.Instead, the legality of the arrangement will be evaluated on acase by case basis based on a cumulative review of all of its factsand circumstances to determine whether one purpose of anarrangement involving remuneration is to induce referrals offederal healthcare covered business. The Patient Protection andAffordable Care Act (         <font style="font-style: italic">          ACA         </font>         )of 2010, as amended, modified the intent requirement under theAnti-Kickback Statute to a stricter standard, such that a person orentity no longer needs to have actual knowledge of the statute orspecific intent to violate it in order to have committed aviolation. The ACA further amended the federal civil False ClaimsAct to provide that a claim that includes items or servicesresulting from a violation of the federal Anti-Kickback Statuteconstitutes a false or fraudulent claim under the False Claims Act.Therefore, either the federal government or private citizens underthe False Claims Act’s qui tam provisions (discussed furtherbelow) can bring an action under the False Claims Act forviolations of the Anti-Kickback Statute, potentially exposing analleged violator to substantial monetary damages and penalties.Certain Anti-Kickback safe harbor provisions that protect therebates paid by drug manufacturers to third parties may also berepealed or materially revised, as contemplated in a recentregulatory proposal.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -22-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thegovernment has asserted False Claims Act liability againstmanufacturers by alleging that improper arrangements with orderingphysicians caused them or another provider to file false claims inviolation of the False Claims Act or that manufacturers’support of patient assistance programs improperly inducedbeneficiaries to choose their products in violation of theAnti-Kickback Statute. Sales, marketing and business arrangementsin the healthcare industry are also subject to extensive laws andregulations intended to prevent fraud, kickbacks, self-dealing andother abusive practices. These laws and regulations may restrict orprohibit a wide range of pricing, discounting, marketing andpromotion, sales commission, customer incentive programs, patientassistance programs, and other business arrangements. MedicareAdvantage and Medicaid managed care plan regulations prohibitcertain forms of marketing to enrollees that are designed todiscriminate against beneficiaries on the basis of their healthconditions or history. These regulations may require regulatoryreview of marketing materials, and coordination with health plan orgovernmental regulators. Additionally, the federal government haspursued electronic health record (         <font style="font-style: italic">          EHR         </font>         ) vendors and pharmaceuticalmanufacturers for remunerative relationships involving the EHRplatform’s recommendation of particular drugs and“prompting” technology to increase prescribing ofparticular drugs.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         The ACAfurther created new federal requirements for reporting under thePhysician Payments Sunshine Act (the         <font style="font-style: italic">          Sunshine Act         </font>         ) by applicablemanufacturers of covered drugs, payments and other transfers ofvalue to physicians and teaching hospitals, and ownership andinvestment interests held by physicians and their immediate familymembers. 2018 legislation extended the Sunshine Act to coverpayments and transfers of value to physician assistants, nursepractitioners, and other mid-level practitioners (with reportingrequirements going into effect in 2022 for payments and transfersof value made in 2021).        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefederal civil False Claims Act (         <font style="font-style: italic">          FCA         </font>         ) prohibits, among other things, anyperson or entity from knowingly presenting, or causing to bepresented, a false or fraudulent claim for payment to, or approvalby, the federal government, knowingly making, using, or causing tobe made or used a false record or statement material to a false orfraudulent claim to the federal government, or avoiding,decreasing, or concealing an obligation to pay money to the federalgovernment. A claim includes “any request or demand”for money or property presented to the U.S. government. The civilFCA has been used to assert liability on the basis of kickbacks andother improper referrals, improperly reported government pricingmetrics such as Best Price or Average Manufacturer Price, orsubmission of inaccurate information required by governmentcontracts, improper use of Medicare provider or supplier numberswhen detailing a provider of services, improper promotion ofoff-label uses not expressly approved by the FDA in a drug’slabel, and allegations as to misrepresentations with respect to theproducts supplied or services rendered. Several pharmaceutical andother healthcare companies have further been sued under these lawsfor allegedly providing free product to customers with theexpectation that the customers would bill federal programs for theproduct. Intent to deceive is not required to establish liabilityunder the civil FCA; however, a November 2017 Department of Justicememorandum now prohibits the use of subregulatory guidancedocuments to impose new or more stringent requirements on entitiesoutside the Executive Branch of the federal government. Because theDepartment has experienced recent administration changes, it isunclear whether the new Attorney General will continue this policy.Civil FCA actions may be brought by the government or may bebrought by private individuals on behalf of the government, called“qui tam” actions. If the government decides tointervene in a qui tam action and prevails in the lawsuit, theindividual will share in the proceeds from any fines or settlementfunds. If the government declines to intervene, the individual maypursue the case alone, subject to governmental review and certainapprovals. Qui tam complaints are filed under seal, and the casesmay progress for a number of years before a complaint is unsealedand a manufacturer becomes aware of its existence. Since 2004,these FCA lawsuits against pharmaceutical companies have increasedsignificantly in volume and breadth, leading to several substantialcivil and criminal settlements, as much as $3.0 billion, regardingcertain sales practices and promoting off-label drug uses. Forexample, civil FCA liability may be imposed for Medicare orMedicaid overpayments arising out of claims that were filed byproviders but alleged to have been caused by manufacturers’incentives, impermissible discounts, or overpayments caused byunderstated rebate amounts. FCA enforcement may also arise fromclaims filed as the result of manufacturing marketing materialsthat contained inaccurate statements or provided certainreimbursement guidance.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thegovernment may further prosecute conduct constituting a false claimunder the criminal FCA. The criminal FCA prohibits the making orpresenting of a claim to the government knowing such claim to befalse, fictitious, or fraudulent and, unlike the civil FCA,requires proof of intent to submit a false claim.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -23-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Similarly,the criminal healthcare fraud statutes impose criminal liabilityfor, among other things, knowingly and willfully attempting orexecuting a scheme to defraud any healthcare benefit program,including private third-party payors, obtaining money or propertyof a benefit program by false or fraudulent means, or falsifying,concealing, or covering up a material fact or submitting amaterially false statement in connection with the delivery of, orpayment from healthcare benefits, items, or services. Thesestatutes are not limited to items and services reimbursed by agovernmental health care program and have been used to prosecutecommercial insurance fraud as well.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thecivil monetary penalties statute is another potential statute underwhich biopharmaceutical companies may be subject to enforcement.Among other things, the civil monetary penalties statue imposesfines against any person who is determined to have presented, orcaused to be presented, claims to a federal healthcare program thatthe person knows, or should know, is for an item or service thatwas not provided as claimed or is false or fraudulent.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theexclusion statute requires the exclusion of entities andindividuals who have been convicted of federal- program relatedcrimes or health care felony fraud or controlled substance charges.The statute also permits the exclusion of those that have beenconvicted of any form of fraud, the anti-kickback statute, forobstructing an investigation or audit, misdemeanor controlledsubstance charges, those whose health care license has been revokedor suspended, and those who have filed claims for excessive chargesor unnecessary services. If a company were to be excluded, itsproducts would be ineligible for reimbursement from any federalprograms, including Medicare and Medicaid, and no other entityparticipating in those programs would be permitted to enter intocontracts with the company. Further, employment or contracting withan individual or entity that has been excluded from participationin federal healthcare programs could serve as a basis to invalidateclaims for items or services submitted by that entity and toexclude that entity from participation in such programs as well. Inorder to preserve access to beneficial drugs, the government mayelect to exclude officers and key employees of manufacturers,rather than excluding the organization. Such enforcement actionswould prohibit the Company from engaging those individuals, whichcould adversely affect operations, and could result in significantreputational harm.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Paymentor reimbursement of prescription drugs by Medicaid or Medicarerequires manufacturers of the drugs to submit pricing informationto CMS. The Medicaid Drug Rebate statute requires manufacturers tocalculate and report price points, which are used to determineMedicaid rebate payments shared between the states and the federalgovernment and Medicaid payment rates for certain drugs. For drugspaid under Medicare Part B, manufacturers must also calculate andreport their Average Sales Price, which is used to determine theMedicare Part B payment rate for the drug. Drugs that are approvedunder a Biologic License Application (         <font style="font-style: italic">          BLA         </font>         ) or an NDA, including 505(b)(2)drugs, are subject to an additional inflation penalty which cansubstantially increase rebate payments. In addition, for BLA andNDA drugs, the Veterans Health Care Act (         <font style="font-style: italic">          VHCA         </font>         ) requires manufacturers tocalculate and report to the VA a different price called theNon‑Federal Average Manufacturing Price, which is used todetermine the maximum price that can be charged to certain federalagencies, referred to as the Federal Ceiling Price, or FCP. Likethe Medicaid rebate amount, the FCP includes an inflation penalty.A Department of Defense regulation requires manufacturers toprovide this discount through prescription rebates on drugsdispensed by retail pharmacies when paid by the TRICARE Program.All of these price reporting requirements create a risk ofsubmitting false information to the government resulting inpotential FCA liability.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheVHCA also requires manufacturers of covered drugs participating inthe Medicaid program to enter into Federal Supply Schedulecontracts with the VA through which their covered drugs must besold to certain federal agencies at FCP and to report pricinginformation. This necessitates compliance with applicable federalprocurement laws and regulations and subjects us to contractualremedies as well as administrative, civil, and criminal sanctions.In addition, the VHCA requires manufacturers participating inMedicaid to agree to provide different mandatory discounts tocertain Public Health Service grantees and other safety nethospitals and clinics under the 340B Drug Pricing Program andreport the ceiling price to the HRSA within Department of Healthand Human Services. Manufacturers can be audited by the HRSA and besubjected to civil monetary penalties for knowingly andintentionally overcharging covered entities for drugs.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefederal Health Insurance Portability and Accountability Act of 1996(         <font style="font-style: italic">          HIPAA         </font>         ) also createdfederal criminal statutes that prohibit knowingly and willfullyexecuting, or attempting to execute, a scheme to defraud or toobtain, by means of false or fraudulent pretenses, representations,or promises, any of the money or property owned by, or under thecustody or control of, a healthcare benefit program, regardless ofwhether the payor is public or private, knowingly and willfullyembezzling or stealing from a health care benefit program,willfully obstructing a criminal investigation of a health careoffense, and knowingly and willfully falsifying, concealing, orcovering up by any trick or device a material fact or making anymaterially false statements in connection with the delivery of, orpayment for, healthcare benefits, items, or services relating tohealthcare matters. The ACA, as amended, modified the intentrequirement under the certain portions of these federal criminalstatutes such that a person or entity no longer needs to haveactual knowledge of the statute or specific intent to violateit.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Further,we may be subject to data privacy and security regulation by boththe federal government and the states in which we conduct ourbusiness. HIPAA, as amended by the Health Information Technologyfor Economic and Clinical Health Act (         <font style="font-style: italic">          HITECH         </font>         ) and its respective implementingregulations, extended certain requirements relating to the privacy,security, and transmission of individually identifiable healthinformation directly to business associates of HIPAA-coveredentities. A business associate is defined as a person ororganization, other than a member of a covered entity’sworkforce, that performs certain functions or activities thatinvolve the use or disclosure of protected health information onbehalf of, or provides services to, a covered entity. We are not acovered entity under HIPAA but in certain limited situations, wemay be considered a business associate. HITECH also strengthenedthe civil and criminal penalties that may be imposed againstcovered entities, business associates, and individuals, and gavestate attorneys general new authority to file civil actions fordamages or injunctions in federal courts to enforce the federalHIPAA laws and seek attorneys’ fees and costs associated withpursuing federal civil actions. In addition, other federal andstate laws may govern the privacy and security of health and otherinformation in certain circumstances, many of which differ fromeach other in significant ways and may not have the same effect,thus complicating compliance efforts.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -24-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Evenfor entities that are not deemed “covered entities” or“business associates” under HIPAA, according to theUnited States Federal Trade Commission (         <font style="font-style: italic">          FTC         </font>         ) failing to take appropriate stepsto keep consumers' personal information secure constitutes unfairacts or practices in or affecting commerce in violation of Section5(a) of the Federal Trade Commission Act (         <font style="font-style: italic">          FTCA         </font>         ) 15 USC § 45(a). The FTCexpects a company's data security measures to be reasonable andappropriate in light of the sensitivity and volume of consumerinformation it holds, the size and complexity of its business, andthe cost of available tools to improve security and reducevulnerabilities. Medical data is considered sensitive data thatmerits stronger safeguards. The FTC's guidance for appropriatelysecuring consumers' personal information is similar to what isrequired by the HIPAA Security Rule. The FTC’s authorityunder Section 5 is concurrent with HIPAA’s jurisdiction andwith any action taken under state law.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inaddition, other federal and state laws may govern the privacy andsecurity of health and other information in certain circumstances,many of which differ from each other in significant ways and maynot have the same effect, thus complicating compliance efforts. Forexample, California recently enacted legislation – theCalifornia Consumer Privacy Act         <font style="font-style: italic">          (CCPA         </font>         ) was made effective January 1,2020. The CCPA, among other things, created new data privacyobligations for covered companies and provided new privacy rightsto California residents, including the right to opt out of certaindisclosures of their information. The CCPA also created a privateright of action with statutory damages for certain data breaches,thereby potentially increasing risks associated with a data breach.The California Attorney General will issue clarifying regulations.Although the law includes limited exceptions, including for certaininformation collected as part of clinical trials as specified inthe law, it may regulate or impact our processing of personalinformation depending on the context, and it remains unclear whatlanguage the final Attorney General regulations will contain or howthe statute and the regulations will be interpreted.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Manystates have also adopted laws similar to each of the above federallaws, which may be broader in scope and apply to items or servicesreimbursed by any third‑party payor, including commercialinsurers, and some have transparency laws that require reportingprice increases and related information. Certain state laws alsoregulate manufacturers’ use of prescriber‑identifiabledata. Certain states also require implementation of commercialcompliance programs and compliance with the pharmaceuticalindustry’s voluntary compliance guidelines and the applicablecompliance guidance promulgated by the federal government, orotherwise restrict payments or the provision of other items ofvalue that may be made to healthcare providers and other potentialreferral sources; impose restrictions on marketing practices; orrequire drug manufacturers to track and report information relatedto payments, gifts, and other items of value to physicians andother healthcare providers. These laws may affect our future sales,marketing, and other promotional activities by imposingadministrative and compliance burdens.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Becauseof the breadth of these laws and the narrowness of the statutoryexceptions and regulatory safe harbors available under such laws,it is possible that certain business activities could be subject tochallenge under one or more of such laws. The scope and enforcementof each of these laws is uncertain and subject to rapid change inthe current environment of healthcare reform, especially in lightof the lack of applicable precedent and regulations. Federal andstate enforcement bodies have recently increased their scrutiny ofinteractions between pharmaceutical companies and providers andpatients, which has led to a number of investigations,prosecutions, convictions and settlements in the healthcareindustry. Ensuring that business arrangements with third partiescomply with applicable healthcare laws, as well as responding topossible investigations by government authorities, can be time- andresource-consuming and can divert management’s attention fromthe business, even if investigators ultimately find that noviolation has occurred.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If ouroperations are found to be in violation of any of the laws orregulations described above or any other laws that apply to us, wemay be subject penalties or other enforcement actions, includingcriminal and significant civil monetary penalties, damages, fines,disgorgement, imprisonment, exclusion from participation ingovernment healthcare programs, corporate integrity agreements,debarment from receiving government contracts or refusal of neworders under existing contracts, reputational harm, diminishedprofits and future earnings, and the curtailment or restructuringof our operations, any of which could adversely affect our abilityto operate our business and our results of operations.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         To theextent that any of our products are sold in a foreign country, wemay be subject to similar foreign laws and regulations, which mayinclude, for instance, applicable post‑marketingrequirements, including safety surveillance, anti‑fraud andabuse laws, and implementation of corporate compliance programs andreporting of payments or transfers of value to healthcareprofessionals.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -25-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Coverage and Reimbursement Generally        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thecommercial success of our product candidates and our ability tocommercialize any approved product candidates successfully willdepend in part on the extent to which governmental payor programsat the federal and state levels, including Medicare and Medicaid,private health insurers, and other third‑party payors providecoverage for and establish adequate reimbursement levels for ourproduct candidates. Government authorities, private healthinsurers, and other organizations generally decide which drugs theywill pay for and establish reimbursement levels and potentialaccess restrictions. Medicare is a federally funded program managedby the Centers for Medicare and Medicaid Services (         <font style="font-style: italic">          CMS         </font>         ) through local contractors thatadminister coverage and reimbursement for certain healthcare itemsand services furnished to the elderly and disabled. Medicaid is aninsurance program for certain categories of patients whose incomeand assets fall below state‑defined levels and who areotherwise uninsured that is both federally and state funded andmanaged by each state. The federal government sets generalguidelines for Medicaid and each state creates specific regulationsthat govern its individual program, including supplemental rebateprograms that prioritize coverage for drugs on the state PreferredDrug List. Similarly, government laws and regulations establish theparameters for coverage of prescription drugs by Tricare, thehealth care program for military personnel, retirees, and relatedbeneficiaries. Many states have also created pharmacy assistanceprograms for individuals who do not qualify for federal programs.In the United States, private health insurers and otherthird‑party payors often provide reimbursement for productsand services based on the level at which the government providesreimbursement through the Medicare or Medicaid programs for suchproducts and services.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In theU.S. and other potentially significant markets for our productcandidates, government authorities and third‑party payors areincreasingly attempting to limit or regulate the price of medicalproducts and services, particularly for new and innovative productsand therapies, which often has resulted in average selling priceslower than they would otherwise be. For example, in the U.S.,federal and state governments reimburse covered prescription drugsat varying rates generally below average wholesale price.Governmental and private payors may also establish certain accessrestrictions, such as prior approvals or evidence of failure onexisting medications or therapies.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theserestrictions and limitations influence the purchase of healthcareservices and products. Third‑party payors are developingincreasingly sophisticated methods of controlling healthcare costs.Third‑party payors may limit coverage to specific drugproducts on an approved list, or formulary, which might not includeall of the FDA‑approved drug products for a particularindication. Third‑party payors also control costs byrequiring prior authorization or imposing other dispensingrestrictions before covering certain products and by broadeningtherapeutic classes to increase competition. Third‑partypayors are increasingly challenging the price and examining themedical necessity and cost‑effectiveness of medical productsand services, in addition to their safety and efficacy. Absentclinical differentiators, third‑party payors may treatproducts as therapeutically equivalent and base formulary decisionson net cost. To lower the prescription cost, manufacturersfrequently rebate a portion of the prescription price to thethird‑party payors.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Federalprograms also impose price controls through mandatory ceilingprices on purchases by federal agencies and federally fundedhospitals and clinics and mandatory rebates on retail pharmacyprescriptions paid by Medicaid and Tricare. These restrictions andlimitations influence the purchase of healthcare services andproducts. Legislative proposals to reform healthcare or reducecosts under government programs may result in lower reimbursementfor our product candidates or exclusion of our product candidatesfrom coverage. In addition, government programs like Medicaidinclude substantial penalties for increasing commercial prices overthe rate of inflation which can affect realization and return oninvestment.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Privatepayors often rely on the lead of the governmental payors inrendering coverage and reimbursement determinations. Therefore,achieving favorable CMS coverage and reimbursement is usually asignificant gating issue for successful introduction of a newproduct. In addition, many government programs as a condition ofparticipation mandate fixed discounts or rebates from manufacturersregardless of formulary position or utilization, and then rely oncompetition in the market to attain further price reductions, whichcan greatly reduce realization on the sale.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Further,the increased emphasis on managed healthcare in the U.S. and oncountry and regional pricing and reimbursement controls in theEuropean Union will put additional pressure on product pricing,reimbursement, and utilization, which may adversely affect ourfuture product sales and results of operations. These pressures canarise from rules and practices of managed care groups and healthtechnology assessment bodies, competition within therapeuticclasses, availability of generic equivalents, judicial decisionsand governmental laws and regulations related to Medicare,Medicaid, and healthcare reform, pharmaceutical coverage andreimbursement policies, and pricing in general. Patients who areprescribed treatments for their conditions and providers performingthe prescribed services generally rely on third‑party payorsto reimburse all or part of the associated healthcare costs. Salesof our product candidates will therefore depend substantially, bothdomestically and abroad, on the extent to which the costs of ourproducts will be paid by health maintenance, managed care, pharmacybenefit and similar healthcare management organizations, orreimbursed by government health administration authorities, such asMedicare and Medicaid, private health insurers, and otherthird‑party payors.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         As aresult of the above, we may need to conduct expensivepharmacoeconomic studies in order to demonstrate the medicalnecessity and cost‑effectiveness of our products, in additionto the costs required to obtain the FDA and other comparableforeign regulatory authority approvals. Our product candidates maynot be considered medically necessary or cost‑effective, orthe rebate percentages required to secure coverage may not yield anadequate margin over cost.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -26-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thereis often pressure to renegotiate pricing and reimbursement levels,including, in particular, in connection with changes to Medicare.Third-party payors continue to demand discounted fee structures,and the trend toward consolidation among third-party payors tendsto increase their bargaining power over price structures. Ifthird-party payors reduce their rates for our products, then ourrevenue and profitability may decline and our operating marginswill be reduced. Because some third-party payors rely on all orportions of Medicare payment systems to determine payment rates,changes to government healthcare programs that reduce paymentsunder these programs may negatively impact payments fromthird-party payors. Our inability to maintain suitable financialarrangements with third-party payors could have a material adverseimpact on our business. Additionally, the reimbursement process iscomplex and can involve lengthy delays. Third party payors maydisallow, in whole or in part, providers’ requests forreimbursement based on determinations that certain amounts are notreimbursable under plan coverage, that the drugs provided were notmedically necessary, or that additional supporting documentation isnecessary. Retroactive adjustments may change amounts realized fromthird party payors. Delays and uncertainties in the reimbursementprocess may adversely affect market acceptance and utilization ofour products, resulting in reduced revenues. The unavailability orinadequacy of third-party coverage and reimbursement couldnegatively affect the market acceptance of our products and thefuture revenues we may expect to receive from those products. Inaddition, we are unable to predict what additional legislation orregulation relating to the healthcare industry or third-partycoverage and reimbursement may be enacted in the future, or whateffect such legislation or regulation would have on our business.Many hospitals implement a controlled and defined process fordeveloping and approving formularies. Any marketing efforts thatare determined to have violated such policies could result in thedenial or removal of our products from that hospital’sformulary.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Moreover,a payor’s decision to provide coverage for a drug productdoes not imply that an adequate reimbursement rate will beapproved. Adequate third‑party reimbursement may not beavailable to enable us to maintain price levels sufficient torealize an appropriate return on our investment in drugdevelopment. Legislative proposals to reform healthcare or reducecosts under government insurance programs may result in lowerreimbursement for our products and product candidates or exclusionof our products and product candidates from coverage. The costcontainment measures that healthcare payors and providers areinstituting and any healthcare reform could significantly reduceour revenues from the sale of any approved product candidates. Wecannot provide any assurances that we will be able to obtain andmaintain third‑party coverage or adequate reimbursement forour product candidates in whole or in part.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Pharmacybenefit managers (         <font style="font-style: italic">          PBM         </font>         )rebates and pricing transparency are key areas of legislative andregulatory focus and there may be changes in the regulatorylandscape that could have a significant impact on thepharmaceutical supply chain and drug pricing more generally, whichcould affect our business operations and prospects in unknown andmaterial ways.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Healthcare Reform Measures        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheU.S. and some foreign jurisdictions are considering or have enacteda number of legislative and regulatory proposals designed to changethe healthcare system in ways that could affect our ability to sellour products profitably. Among policy makers and payors in theUnited States and elsewhere, there is significant interest inpromoting changes in healthcare systems with the stated goals ofcontaining healthcare costs, improving quality, and expandingaccess. In the United States, the pharmaceutical industry has beena particular focus of these efforts and has been significantlyaffected by major legislative initiatives.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Forexample, the Medicare Prescription Drug, Improvement, andModernization Act of 2003 (         <font style="font-style: italic">          MMA         </font>         ) established a prescription drugbenefit program for Medicare beneficiaries. Under Part D, Medicarebeneficiaries may enroll in prescription drug plans offered byprivate entities that provide coverage of outpatient prescriptiondrugs. Part D plans include both standalone prescription drugbenefit plans and prescription drug coverage as a supplement toMedicare Advantage plans. Unlike Medicare Part A and B, which donot utilize formularies to restrict coverage, Part D coveragevaries by plan. With some exceptions, Part D prescription drug plansponsors are not required to pay for all covered Part D drugs, andeach drug plan can develop its own drug formulary that identifieswhich drugs it will cover and at what tier or level. However, PartD prescription drug formularies must include drugs within eachtherapeutic category and class of covered Part D drugs, though notnecessarily all the drugs in each category or class. Any formularyused by a Part D prescription drug plan must be developed andreviewed by a pharmacy and therapeutic committee. Governmentpayment for some of the costs of prescription drugs may increasedemand for any products for which we receive marketing approval.However, Part D plans use competition for coverage to leveragemanufacturer rebates. Further, the law requires manufacturers toabsorb a significant percentage of the prescription price paid forNDA drugs, including 504(b)(2) drugs, during a beneficiary’scoverage gap. The Bipartisan Budget Act of 2018 permanentlyincreased manufacturer liability for the prescription price in thecoverage gap from 50% to 70% beginning in 2019, whilesimultaneously accelerating closure of the gap. These costreduction initiatives and other provisions of the legislation, aswell as any negotiated price discounts for our future productscovered by a Part D prescription drug plan, may decrease thecoverage and reimbursement rate that we receive, lower the netprice realized on our sales to pharmacies, or both. Moreover, whilethe MMA applies only to drug benefits for Medicare beneficiaries,private payors often follow Medicare coverage policy and paymentlimitations in setting their own payment rates. Any reduction inpayment that results from Medicare Part D may result in a similarreduction in payments from non‑governmentalpayors.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         The ACAestablished the Patient-Centered Outcome Research Institute toorganize and coordinate federally funded research to compare theeffectiveness of different treatments for the same illness.Although the results of the comparative effectiveness studies arenot intended to mandate coverage policies for public or privatepayors, it is not clear what effect, if any, the research will haveon the sales of any product, if any such product or the conditionthat it is intended to treat is the subject of a study. It is alsopossible that comparative effectiveness research demonstratingbenefits in a competitor’s product could adversely affect thesales of our product candidates. If third‑party payors do notconsider our product candidates to be cost‑effective comparedto other available therapies, they may not cover our productcandidates, once approved, as a benefit under their plans or, ifthey do, the level of payment may not be sufficient to allow us tosell our products on a profitable basis.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -27-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         The ACAmade other changes intended to broaden access to health insurance,reduce or constrain the growth of healthcare spending, enhanceremedies against fraud and abuse, add new transparency requirementsfor healthcare and health insurance industries, impose new taxesand fees on the health care industry, and impose additional healthpolicy reforms. The law expanded the eligibility criteria forMedicaid programs, thereby potentially increasing both the volumeof sales and manufacturers’ Medicaid rebate liability. Thelaw also expanded the entities eligible for discounts under the340B Drug Discount Program, which mandates discounts to certainhospitals, community centers, and other qualifying providers,although, with the exception of children’s hospitals, thesenewly eligible entities are not eligible to receive discounted 340Bpricing on orphan drugs and the Health Resources and ServicesAdministration has narrowed its interpretation of whichbeneficiaries may fill prescriptions through 340B inventories. Thelaw additionally extended manufacturer’s Medicaid rebateliability to covered drugs dispensed to patients enrolled inMedicaid managed care organizations, increased the statutoryminimum rebates a manufacturer must pay under the Medicaid DrugRebate program, and created an alternative rebate formula forcertain new formulations of certain existing products, which isintended to increase the amount of rebates due on those drugs. Therevisions to the Medicaid rebate formula can have the furthereffect of increasing the required 340B discounts. Finally, the ACAimposes a significant annual fee on companies that manufacture orimport branded prescription drug products. Substantial newprovisions affecting compliance have also been enacted through theACA and otherwise, including the reporting of drug sampledistribution, which may require us to modify our business practiceswith healthcare practitioners. Moreover, in the coming years,additional changes could be made to governmental healthcareprograms that could significantly impact the success of our productcandidates.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         The ACAalso imposed an affirmative obligation to report and repay anyoverpayments, including those payments that resulted fromviolations of the Anti-Kickback Statute, false claims act, or civilmonetary penalties statute, within sixty (60) days after suchoverpayment has been identified. Corresponding case law imposes anobligation on entities to exercise reasonable diligence inidentifying such overpayments. The failure to timely report andrepay is, itself, considered to constitute a violation of the FalseClaims Act.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thecost of pharmaceuticals continues to generate substantialgovernmental and third-party payor interest, and pharmaceuticalpricing and marketing currently received a great deal ofCongressional and administrative attention. There have beennumerous initiatives on the federal and state levels in the UnitedStates for comprehensive reforms affecting the payment for, theavailability of, and reimbursement for, healthcare services. Inparticular, there have been a number of federal and state proposalsduring the last few years regarding the pricing of pharmaceuticaland biopharmaceutical products, limiting coverage and reimbursementfor drugs and other medical products, government control and otherchanges to the healthcare system in the United States.Congressional inquiries and proposed and enacted federal and statelegislation have also been released and are designed to, amongother things, bring more transparency to drug pricing, reduce thecost of prescription drugs under Medicare, review the relationshipbetween pricing and manufacturer patient programs and reformgovernment program reimbursement methodologies for drugs. Recentfederal budget proposals have included measures to permit MedicarePart D plans to negotiate the price of certain drugs under MedicarePart B, to allow some states to negotiate drug prices underMedicaid, and to eliminate cost sharing for generic drugs forlow-income patients. Current and future U.S. legislative healthcarereforms may result in price controls and other restrictions for anyapproved products, if covered, and could seriously harm ourbusiness. Drug pricing is and will remain a key bipartisan issue inthe coming year. Drug pricing reform policies may be pursued in thefuture and may be more aggressive, regardless of which partycontrols the White House. Given that drug pricing controls is a keylegislative and administration priority, it is likely thatadditional pricing controls will be enacted and could harm ourbusiness, financial condition and results of operations. At thestate level, legislatures have increasingly passed legislation andimplemented regulations designed to control pharmaceutical andbiological product pricing, including price or patientreimbursement constraints, discounts, restrictions on certainproduct access and marketing cost disclosure and transparencymeasures, and, in some cases, designed to encourage importationfrom other countries and bulk purchasing. Some states, such asCalifornia, have enacted transparency laws that requiremanufacturers to report drug price increases and relatedinformation. The boom in state laws targeting drug pricing isunprecedented and the requirements are not uniform from state tostate, creating additional compliance and commercializationchallenges for manufacturers. We further expect that thepharmaceutical industry will experience pricing pressures due tothe trend toward managed healthcare, the increasing influence ofmanaged care organizations, judicial interpretation of health carereform efforts, and additional legislative and regulatory proposalsresulting in ongoing, relatively rapid changes to applicable lawsand regulations. Our results of operations could be adverselyaffected by current and future healthcare reforms.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Governmentand private payors also increasingly require pre‑approval ofcoverage for new or innovative devices or drug therapies orcondition coverage on unsuccessful alternative treatment beforethey will reimburse healthcare providers that use such therapies.For some specialty drugs, payors are conditioning payment onsuccessful treatment measured by objective metrics. While we cannotpredict whether any proposed cost‑containment measures willbe adopted or otherwise implemented in the future, the announcementor adoption of these proposals could have a material adverse effecton our ability to obtain adequate prices for our product candidatesand operate profitably.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Congress and the former Trump Administration, from 2017 –2020, engaged in various efforts to repeal or materially modifyvarious aspects of ACA. The results and effects of such ongoingefforts were varied after facing judicial and Congressionalchallenges, but could affect our business operations and prospectsin unknown ways, and it is unclear how ACA and other lawsultimately will be implemented. For example, in the case of Texasv. Azar, a federal district court in Texas struck down the ACA inits entirety, finding that the Tax Cuts and Jobs Act of 2017rendered the individual mandate unconstitutional. The December 15,2019 opinion concluded that since the individual mandate is“essential” to the ACA, it could not be severed fromthe rest of the ACA and therefore, the entire ACA wasunconstitutional. Despite its decision, however, the court did notissue an injunction and therefore, immediate compliance was notrequired. Following appeal of the Fifth Circuit’s decisionupholding the ruling of the federal district court, on June 17,2021, the Supreme Court reversed the decision of the Fifth Circuitand remanded the case back to the lower court with instructions todismiss the case.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -28-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Despite the Supreme Court’s recent ruling in California v.Texas (formerly Texas v. Azar), it remains unclear how futuredecisions from the Supreme Court and the various other courtsacross the country, if any, to repeal and replace the ACA willimpact the ACA and our business. It is also unclear how regulationsand sub-regulatory policy, which fluctuate continually, may affectinterpretation and implementation of the ACA and its practicaleffects on our business.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In the future, there may continue to be additional proposalsrelating to the reform of the U.S. healthcare system, some of whichcould further limit the prices we will be able to charge for ourproduct candidates, or the amounts of reimbursement available forour product candidates. If future legislation were to impose directgovernmental price controls or access restrictions, it could have asignificant adverse impact on our business. Additionally, with thechange in administration it is possible that President Biden mayissue Executive Orders with the potential to change a number ofprior executive branch actions on drug pricing. We continue tomonitor the potential impact of proposals to lower prescriptiondrug costs at the federal and state level. Managed careorganizations, as well as Medicaid and other government agencies,continue to seek price discounts. Some states have implemented, andother states are considering, measures to reduce costs of theMedicaid program, and some states are considering implementingmeasures that would apply to broader segments of their populationsthat are not Medicaid-eligible. Due to the volatility in thecurrent economic and market dynamics, we are unable to predict theimpact of any unforeseen or unknown legislative, regulatory, payoror policy actions, which may include cost containment andhealthcare reform measures. Such policy actions could have amaterial adverse impact on our profitability.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theseand other healthcare reform initiatives may result in additionalreductions in Medicare and other healthcare funding, which couldhave a material adverse effect on our financial operations. Weexpect that additional state and federal healthcare reform measureswill be adopted in the future, any of which could limit the amountsthat federal and state governments will pay for healthcare productsand services, which could result in reduced demand for our productcandidates or additional pricing pressures.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         The Foreign Corrupt Practices Act        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-family: Times New Roman; font-size: 13px">          <font style="font-size: 13px">           The Foreign Corrupt Practices Act(          </font>          <font style="font-style: italic; font-size: 13px">           FCPA          </font>          <font style="font-size: 13px">           ) prohibits any U.S. individual or business frompaying, offering, or authorizing payment or offering of anything ofvalue, directly or indirectly, to any foreign official, politicalparty, or candidate for the purpose of influencing any act ordecision of the foreign entity in order to assist the individual orbusiness in obtaining or retaining business. The FCPA has beenapplied to the marketing of drugs and the conduct of clinicaltrials outside the United States. The FCPA also obligates companieswhose securities are listed in the United States to comply withaccounting provisions requiring the company to maintain books andrecords that accurately and fairly reflect all transactions of thecorporation, including international subsidiaries, and to deviseand maintain an adequate system of internal accounting controls forinternational operations. Activities that violate the FCPA, even ifthey occur wholly outside the United States, can result in criminaland civil fines, imprisonment, disgorgement, oversight, anddebarment from government contracts.          </font>         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Foreign Regulation        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         To theextent we choose to develop or sell any products outside of theU.S., we will be subject to a variety of foreign regulatoryrequirements of other countries regarding safety and efficacy andgoverning, among other things, clinical trials, marketingauthorization, commercial sales, and distribution of our products.For example, in the European Union (         <font style="font-style: italic">          EU         </font>         ) we must obtain authorization of aclinical trial application in each member state in which we intendto conduct a clinical trial prior to the pending introduction of aEU portal for EU-wide approvals. Whether or not we obtain FDAapproval for a product, we would need to obtain the necessaryapprovals by the comparable regulatory authorities of foreigncountries before we can commence clinical trials or marketing ofthe product in those countries. The approval process varies fromcountry to country and can involve additional product testing andadditional administrative review periods. The time required toobtain approval in other countries might differ from and be longerthan that required to obtain FDA approval. The requirementsgoverning the conduct of clinical trials, product licensing,pricing, and reimbursement vary greatly from country to country.Regulatory approval in one country does not ensure regulatoryapproval in another, but a failure or delay in obtaining regulatoryapproval in one country may negatively impact the regulatoryprocess in others. As in the U.S., post‑approval regulatoryrequirements, such as those regarding product manufacture,marketing, or distribution, would apply to any product that isapproved outside the U.S.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Subsidiaries and Inter-Corporate Relationships        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          VistaGen Therapeutics. Inc., a California corporation, dbaVistaStem Therapeutics (         </font>         <font style="font-style: italic; color: #000000">          VistaStem         </font>         <font style="color: #000000">          ), is our wholly-owned subsidiary and has awholly-owned subsidiary, Artemis Neuroscience, Inc., a corporationincorporated pursuant to the laws of the State of Maryland. Theoperations of VistaStem, and its wholly owned subsidiary aremanaged by our senior management team based in South San Francisco,California.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -29-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Corporate History        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          VistaGen Therapeutics, Inc., a California corporation incorporatedon May 26, 1998, dba VistaStem, is our wholly-owned subsidiary.Excaliber Enterprises, Ltd. (         </font>         <font style="font-style: italic; color: #000000">          Excaliber         </font>         <font style="color: #000000">          ), a publicly-held company (formerly OTCBB: EXCA)was incorporated under the laws of the State of Nevada on October6, 2005. Pursuant to a strategic merger transaction on May 11,2011, Excaliber acquired all outstanding shares of VistaStem inexchange for 341,823 shares of our common stock and assumed all ofVistaStem’s pre-Merger obligations (the         </font>         <font style="font-style: italic; color: #000000">          Merger         </font>         <font style="color: #000000">          ). Shortly after the Merger, Excaliber’sname was changed to “VistaGen Therapeutics, Inc.” (aNevada corporation).         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         VistaStem, as the accounting acquirer in the Merger, recorded theMerger as the issuance of common stock for the net monetary assetsof Excaliber, accompanied by a recapitalization.  Theaccounting treatment for the Merger was identical to that resultingfrom a reverse acquisition, except that we recorded no goodwill orother intangible assets. A total of 78,450 shares of our commonstock, representing the shares held by stockholders of Excaliberimmediately prior to the Merger are reflected as outstanding forall periods presented in the Consolidated Financial Statements ofthe Company included in Item 8 of this AnnualReport. Additionally, the Consolidated Balance Sheets reflectthe $0.001 par value of Excaliber’s commonstock.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          The Consolidated Financial Statements included in Item 8 of thisAnnual Report represent the activity of VistaStem from May 26,1998, and the consolidated activity of VistaStem and Excaliber (nowVistaGen Therapeutics, Inc., a Nevada corporation), from May 11,2011 (the date of the Merger) through March 31, 2021. TheConsolidated Financial Statements also include the accounts ofVistaStem’s two inactive wholly-owned subsidiaries, ArtemisNeuroscience, Inc., a Maryland corporation (         </font>         <font style="font-style: italic; color: #000000">          Artemis         </font>         <font style="color: #000000">          ), and VistaStem Canada, Inc., a corporationorganized under the laws of Ontario, Canada (         </font>         <font style="font-style: italic; color: #000000">          VistaStemCanada         </font>         <font style="color: #000000">          ).         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Research and Development        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Conductingresearch and development is central to our business model. We haveinvested and expect to continue to invest significant time andcapital in our research and development operations. Our researchand development expenses were $12.5 million and $13.4 million forthe fiscal years ended March 31, 2021 and 2020, respectively. Weplan to increase our research and development expenses for theforeseeable future as we seek to complete the development of PH94B,PH10 and AV-101.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Employees        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; font-family: Times New Roman; font-size: 13px">          Asof June 29, 2021, we employed 21 full-time employees, nine femalesand 12 males. Ten of our employees have doctorate degrees. Thirteenfull-time employees work in research and development and laboratorysupport services and eight full-time employees work in businessdevelopment, commercialization and general and administrativeroles. Staffing for other functional areas is achieved through ourdiverse network of strategic relationships with multiple CROs,CDMOs, and other third-party service providers and consultants.These service providers and consultants provide us with supportservices on a flexible, real-time, as-needed basis, includingservices related to, among others, payroll, information technology,legal, investor and public relations, manufacturing, productdevelopment, regulatory affairs and FDA program management tocomplement our internal resources in theseareas.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We have never had a work stoppage, and none of our employees isrepresented by a labor organization or under any collectivebargaining agreement. We consider our employee relations to begood.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Facilities        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We lease our office and laboratory space, which consists ofapproximately 10,900 square feet located in South San Francisco,California, under a lease expiring on July 31, 2022 which alsoprovides a five-year option to renew.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Legal Proceedings        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         None.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Environmental Regulation        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our business does not require us to comply with any extraordinaryenvironmental regulations.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Available Information        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We filereports and other information with the SEC, as required by theExchange Act. We make available free of charge through our website(         <font style="text-decoration: underline; color: #9454C3">          http://www.vistagen.com         </font>         )our annual reports on Form 10-K, quarterly reports on Form 10-Q,current reports on Form 8-K and amendments to those reports filedor furnished pursuant to Sections 13(a) and 15(d) of the ExchangeAct. We make these reports available through our website as soon asreasonably practicable after we electronically file such reportswith, or furnish such reports to, the SEC. In addition, weregularly use our website to post information regarding ourbusiness, product development programs and governance, and weencourage investors to use our website, particularly theinformation in the section entitled “Investors,” as asource of information about us. The foregoing references to ourwebsite are not intended to, nor shall they be deemed to,incorporate information on our website into this Annual Report onForm 10-K by reference.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -30-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <br/>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Item 1A.          <a name="Risk">           R          </a>          isk Fa         </font>         <font style="color: #000000">          ctors         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Risk Factor Summary        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">         Our business is subject to substantial risk and an investment inour securities involves various risks. Some of the material risksinclude those set forth below. You should consider carefully theserisks, and those discussed under “Risk Factors” below,before investing in our securities. These risks include, amongothers:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 11%">            <div style="margin-left: 48px; text-indent: 24px">             <font style="font-size: 13px">              ●             </font>             <font id="tab2" style="letter-spacing: 12px; color: black">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the COVID-19 pandemic has, and continues to have, an impact on ourbusiness, including delays in manufacturing of certain drugsubstance and drug products and potential delays in recruitment andenrollment in the PALISADE Phase 3 clinical program and otherplanned clinical studies of PH94B;             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%">            <div style="margin-left: 48px; text-indent: 24px">             <font style="font-size: 13px">              ●             </font>             <font id="tab2" style="letter-spacing: 12px; color: black">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              we are a development stage biopharmaceutical company with norecurring revenues from product sales or approved products, andlimited experience developing or commercializing new drugcandidates, which makes it difficult to assess our futureviability;             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%">            <div style="margin-left: 48px; text-indent: 24px">             <font style="font-size: 13px">              ●             </font>             <font id="tab2" style="letter-spacing: 12px; color: black">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              we depend heavily on the success of our three CNS productcandidates PH94B, PH10 and AV-101, and we cannot be certain that wewill be able to obtain regulatory approval for, or successfullycommercialize, any of our current or future productcandidates;             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%">            <div style="margin-left: 48px; text-indent: 24px">             <font style="font-size: 13px">              ●             </font>             <font id="tab2" style="letter-spacing: 12px; color: black">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              failures or delays in the commencement or completion of our plannedclinical trials, including, among others, clinical studies in ourPALISADE Phase 3 program, could delay, prevent or limit our abilityto generate revenue and continue our business;             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%">            <div style="margin-left: 48px; text-indent: 24px">             <font style="font-size: 13px">              ●             </font>             <font id="tab2" style="letter-spacing: 12px; color: black">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              we face significant competition, and if we are unable to competeeffectively, we may not be able to achieve or maintain significantmarket penetration or improve our results ofoperations;             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%">            <div style="margin-left: 48px; text-indent: 24px">             <font style="font-size: 13px">              ●             </font>             <font id="tab2" style="letter-spacing: 12px; color: black">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              if we are unable to adequately protect our proprietary technology,or obtain and maintain issued patents that are sufficient toprotect our product candidates, others could compete against usmore directly, which would have a material adverse impact on ourbusiness, results of operations, financial condition andprospects;             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%">            <div style="margin-left: 48px; text-indent: 24px">             <font style="font-size: 13px">              ●             </font>             <font id="tab2" style="letter-spacing: 12px; color: black">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              we have incurred significant net losses since inception and we willcontinue to incur substantial operating losses for the foreseeablefuture;             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%">            <div style="margin-left: 48px; text-indent: 24px">             <font style="font-size: 13px">              ●             </font>             <font id="tab2" style="letter-spacing: 12px; color: black">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              although we are taking steps to mitigate them, we have identifiedmaterial weaknesses in our internal control over financialreporting, and our business and stock price may be adverselyaffected if we do not adequately address those weaknesses or if wehave other material weaknesses or significant deficiencies in ourinternal control over financial reporting;             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%">            <div style="margin-left: 48px; text-indent: 24px">             <font style="font-size: 13px">              ●             </font>             <font id="tab2" style="letter-spacing: 12px; color: black">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              we require additional financing to execute our long-term businessplan, including further development and commercialization of ourCNS pipeline, and to continue to operate as a goingconcern;             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%">            <div style="margin-left: 48px; text-indent: 24px">             <font style="font-size: 13px">              ●             </font>             <font id="tab2" style="letter-spacing: 12px; color: black">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              raising additional capital will cause substantial dilution to ourexisting stockholders, may restrict our operations or require us torelinquish rights, and may require us to seek stockholder approvalto authorize additional shares of our common stock;and             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%">            <div style="margin-left: 48px; text-indent: 24px">             <font style="font-size: 13px">              ●             </font>             <font id="tab2" style="letter-spacing: 12px; color: black">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               other risks and uncertainties, including those describedunder “              </font>              <font style="font-style: italic; color: #000000">               RiskFactors              </font>              <font style="color: #000000">               ”below.              </font>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         If we are unable to effectively manage the impact of these andother risks, our ability to operate and execute our business planwould be substantially impaired. In turn, the value of oursecurities would be materially reduced.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%">          <font style="font-family: Times New Roman; font-size: 11px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -31-          </font>         </div>        </div>        <div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000">         <!--page break line-->        </div>        <div id="hdr">         <div style="text-align: right; width: 100%">          <font style="font-family: Times New Roman; font-size: 11px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Risk Factors        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">         You should consider carefully the risks and uncertainties describedbelow, together with all of the other information in this AnnualReport before investing in our securities. The risks describedbelow are not the only risks facing ourCompany.  Additional risks and uncertainties notcurrently known to us or that we currently deem to be immaterialmay also materially adversely affect our business, financialcondition and/or operating results. If any of the followingrisks are realized, our business, financial condition andresults of operations could be materially and adverselyaffected.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         The COVID-19 pandemic has adversely impacted, and may continue toadversely impact our business.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Beginning in late 2019, a new strain of coronavirus(         </font>         <font style="font-style: italic; color: #000000">          COVID-19         </font>         <font style="color: #000000">          ) spread across the world, and the outbreak hassince been declared a pandemic by the World Health Organization.The U.S. Secretary of Health and Human Services has also declared apublic health emergency in the United States in response to theoutbreak. Considerable uncertainty still surrounds COVID-19 and itspotential effects, and the extent of and effectiveness of responsestaken on international, national and local levels. Measures takento limit the impact of COVID-19, including shelter-in-place orders,social distancing measures, travel bans and restrictions, andbusiness and government shutdowns resulted in significant negativeeconomic impacts on a global basis.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Although the negative effects of the COVID-19 pandemic appear to belessening, we cannot at this time accurately predict the effects ofthese conditions on our operations. Uncertainties remain as to theduration of the pandemic, the success of treatments and vaccinesdesigned to combat the pandemic, and the length and scope of thetravel restrictions and business closures imposed by thegovernments of impacted countries and localities. The continuedCOVID-19 pandemic, the spread of variants of the COVID-19 virus oranother highly transmissible and pathogenic infectious disease maylead to the implementation of further responses, includingadditional travel restrictions, government-imposed quarantines orstay-at-home orders, and other public health safety measures, whichmay result in further disruptions to our business and operations.The COVID-19 pandemic has impacted our business and may continue todo so as the pandemic persists. Additionally, future outbreaks mayhave several adverse effects on our business, results of operationsand financial condition.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left">        <table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="font-weight: bold; font-style: italic">               Delayed product development:              </font>              We have faced, and may continueto face, delays and other disruptions to our ongoing developmentprograms for PH94B, PH10 and AV-101 due to the ongoing COVID-19pandemic. In addition, regulatory oversight and actions regardingour products may be disrupted or delayed in regions impacted byCOVID-19, including the United States and elsewhere, which mayimpact review and approval timelines for products in development.Although we remain invested in continuing our development programsfor our current product candidates, our research and developmentefforts may be impacted if our employees, our contract researchorganizations (              <font style="font-style: italic">               CROs              </font>              ) andour third-party contract manufacturer(s) (              <font style="font-style: italic">               CMOs              </font>              ) are advised to continue to workremotely as part of social distancing measures. Additionally,social distancing measures, stay-at-home orders and othergovernmental restrictions designed to combat the COVID-19 pandemicmay impair our ability to conduct studies in our PALISADE Phase 3 program for PH94B in a timely manner.             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left">        <table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="font-weight: bold; font-style: italic">               Negative impacts on our suppliers and employees              </font>              : COVID-19has impacted, and COVID-19, variants of COVID-19 or another highlytransmissible and pathogenic infectious disease, may impact orcontinue to impact the health of our employees, contractors orsuppliers, reduce the availability of our workforce or those ofcompanies with which we do business, divert our attention towardsuccession planning, or create disruptions in our supply ordistribution networks. Since the beginning of the COVID-19pandemic, we have experienced delays of the delivery of supplies ofactive pharmaceutical product (              <font style="font-style: italic">               API              </font>              ) required to continue developmentof PH94B and PH10. Although our supply of raw materials and APIremains sufficiently operational, we may experience adverse effectsof such events, which may result in a significant, materialdisruption to clinical development programs and our operations.Additionally, having substantially shifted to remote workingarrangements, we also face a heightened risk of cybersecurityattacks or data security incidents and are more dependent oninternet and telecommunications access andcapabilities.             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          COVID-19 has also created significant disruption and volatility innational, regional and local economies and markets. Uncertaintiesrelated to, and perceived or experienced negative effects fromCOVID-19, may cause significant volatility or decline in thetrading price of our securities, capital markets conditions andgeneral economic conditions. Our future results of operations andliquidity could be adversely impacted by supply chain disruptionsand operational challenges faced by our CROs, CMOs and othercontractors. The ongoing COVID-19 pandemic, or another highlytransmissible and pathogenic infectious disease,         </font>         <font style="color: #000000">          could result in a widespread healthcrisis that could adversely affect the economies and financialmarkets of many countries, resulting in a further economic downturnor a global recession. Such events may limit or restrict ourability to access capital on favorable terms, or at all, lead toconsolidation that negatively impacts our business, weaken demand,increase competition, cause us to reduce our capital spend further,or otherwise disrupt our business or make it more difficult toimplement our strategic plans.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Risks Related to Product Development, Regulatory Approval andCommercialization        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         We depend heavily on the success of one or more of our current CNSdrug candidates and we cannot be certain that we will be able toobtain regulatory approval for, or successfully commercialize anyof our product candidates.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We currently have no drug products for sale and may never be ableto develop and commercialize marketable drug products. Our businesscurrently depends heavily on the successful development,manufacturing, regulatory approval and commercialization of one ormore of our current CNS drug candidates, as well as, but to a morelimited extent, our ability to acquire, license or produce, developand commercialize additional product candidates. Each of ourcurrent CNS drug candidates will require substantial additionalnonclinical and clinical development, manufacturing and regulatoryapproval before any of them may be commercialized, and there can beno assurance that any of them will ever achieve regulatoryapproval. Any new chemical entity (         </font>         <font style="font-style: italic; color: #000000">          NCE         </font>         <font style="color: #000000">          ) we may produce through drug rescue activitieswill require substantial nonclinical development, all phases ofclinical development, manufacturing and regulatory approval beforeit may be commercialized. The nonclinical and clinical developmentof our product candidates are, and the manufacturing and marketingof our product candidates will be, subject to extensive andrigorous review and regulation by numerous government authoritiesin the U.S. and in other countries where we or our collaboratorsintend to test and, if approved, market any product candidate.Before obtaining regulatory approvals for the commercial sale ofany product candidate, we must demonstrate through numerousnonclinical and clinical studies that the product candidate is safeand effective for use in each target indication. Research anddevelopment of product candidates in the pharmaceutical industry isa long, expensive and uncertain process, and delay or failure canoccur at any stage of any of nonclinical or clinical studies. Thisprocess takes many years and may also include post-marketingstudies, surveillance obligations and drug safety programs, whichwould require the expenditure of substantial resources beyond theproceeds we have raised to date. Of the large number of drugcandidates in development in the U.S., only a small percentage willsuccessfully complete the required FDA regulatory approval processand will be commercialized. Accordingly, we cannot assure you thatany of our current drug candidates or any future product candidateswill be successfully developed or commercialized in the U.S. or anymarket outside the U.S.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -32-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We are not permitted to market our product candidates in the U.S.until we receive approval of a New Drug Application(         </font>         <font style="font-style: italic; color: #000000">          NDA         </font>         <font style="color: #000000">          ) from the FDA, or in any foreign countries untilwe receive the requisite approval from such countries. ObtainingFDA approval of a NDA is a complex, lengthy, expensive anduncertain process. The FDA may refuse to permit the filing of ourNDA, delay, limit or deny approval of a NDA for many reasons,including, among others:         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              if we submit a NDA and it is reviewed by a FDA advisory committee,the FDA may have difficulties scheduling an advisory committeemeeting in a timely manner or the advisory committee may recommendagainst approval of our application or may recommend that the FDArequire, as a condition of approval, additional nonclinical orclinical studies, limitations on approved labeling or distributionand use restrictions;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               a FDA advisory committee may recommend, or the FDA may require, aRisk Evaluation and Mitigation Strategies (              </font>              <font style="font-style: italic; color: #000000">               REMS              </font>              <font style="color: #000000">               ) safety program as a condition of approval orpost-approval;              </font>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              a FDA advisory committee or the FDA or applicable regulatory agencymay determine that there is insufficient evidence of overalleffectiveness or safety in a NDA and require additional clinicalstudies;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               the FDA or the applicable foreign regulatory agency may determinethat the manufacturing processes or facilities of third-partycontract manufacturers with which we contract do not conform toapplicable requirements, including current Good ManufacturingPractices (              </font>              <font style="font-style: italic; color: #000000">               cGMPs              </font>              <font style="color: #000000">               ); or              </font>             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the FDA or applicable foreign regulatory agency may change itsapproval policies or adopt new regulations.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Any of these factors, many of which are beyond our control, couldjeopardize our ability to obtain regulatory approval for andsuccessfully commercialize any current or future drug productcandidate we may develop. Any such setback in our pursuit ofregulatory approval for any product candidate would have a materialadverse effect on our business and prospects.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In addition, we anticipate that certain of our product candidates,including PH94B and PH10, will be subject to regulation ascombination products, which means that they are composed of both adrug product and device product. Although we do not contemplatedoing so, if marketed individually, each component would be subjectto different regulatory pathways and reviewed by different centerswithin the FDA. Our product candidates that are considered to bedrug-device combination products will require review andcoordination by FDA’s drug and device centers prior toapproval, which may delay approval. In the U.S.,         </font>         <font style="color: #231F20">          a combination product with a drugprimary mode of action generally would be reviewed and approvedpursuant to the drug approval processes under the Federal Food,Drug and Cosmetic Act of 1938. In reviewing the NDA application forsuch a product, however, FDA reviewers in the drug center couldconsult with their counterparts in the device center to ensure thatthe device component of the combination product met applicablerequirements regarding safety, effectiveness, durability andperformance.         </font>         <font style="color: #000000">          Under FDAregulations, combination products are subject to cGMP requirementsapplicable to both drugs and devices, including the Quality System(         </font>         <font style="font-style: italic; color: #000000">          QS         </font>         <font style="color: #000000">          ) regulations applicable to medical devices.Problems associated with the device component of the combinationproduct candidate may delay or preventapproval.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We have been granted Fast Track designation from the FDA fordevelopment of PH94B for the treatment of social anxiety disorder(SAD) and AV-101 for the adjunctive treatment of major depressivedisorder (MDD) and for the treatment of neuropathic pain (NP).However, these designations may not actually lead to fasterdevelopment or regulatory review or approval processes for PH94B orAV-101. Further, there is no guarantee the FDA will grant FastTrack designation for PH94B or AV-101 as a treatment option forother CNS indications or for any of our other product candidates inthe future.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The Fast Track designation is a program offered by the FDA,pursuant to certain mandates under the FDA Modernization Act of1997, designed to facilitate drug development and to expedite thereview of new drugs that are intended to treat serious orlife-threatening conditions. Compounds selected must demonstratethe potential to address unmet medical needs. The FDA’s FastTrack designation allows for close and frequent interaction withthe FDA. A designated Fast Track drug may also be considered forpriority review with a shortened review time, rolling submission,and accelerated approval if applicable. The designation does not,however, guarantee FDA approval or expedited approval of anyapplication for the product candidate.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -33-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In December 2017, the FDA granted Fast Track designation fordevelopment of AV-101 for the adjunctive (add-on) treatment of MDDin patients with an inadequate response to current antidepressants.In September 2018, the FDA granted Fast Track designation fordevelopment of AV-101 for the treatment of NP. In December 2019,the FDA granted Fast Track designation for development of PH94B forthe treatment of SAD. However, these FDA Fast Track designationsmay not lead to a faster development or regulatory review orapproval process for PH94B or AV-101 and the FDA may withdraw FastTrack designation of PH94B or AV-101 if it believes that therespective designation is no longer supported by data from ourclinical development programs.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In addition, we may apply for Fast Track designation for PH94B,PH10 and AV-101 as a treatment option for other CNS indications.The FDA has broad discretion whether or not to grant a Fast Trackdesignation, and even if we believe PH94B, PH10, AV-101 or otherproduct candidates may be eligible for this designation, we cannotbe sure that the FDA will grant it.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Results of earlier clinical trials may not be predictive of theresults of later-stage clinical trials.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The results of preclinical studies and early clinical trials ofPH94B, PH10, AV-101 and/or our other future product candidates, ifany, including positive results, may not be predictive of theresults of later-stage clinical trials. PH94B, PH10, AV-101 or anyother future product candidates in later stages of clinicaldevelopment may fail to show the desired safety and efficacyresults despite having progressed through nonclinical studies andinitial clinical trials. Many companies in the biopharmaceuticalindustry have suffered significant setbacks in later-stage clinicaltrials due to adverse safety profiles or lack of efficacy,notwithstanding promising results in earlier studies. Similarly,our future clinical trial results may not be successful for theseor other reasons.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Moreover, nonclinical and clinical data are often susceptible tovarying interpretations and analyses, and many companies thatbelieved their product candidates performed satisfactorily innonclinical studies and clinical trials nonetheless failed toobtain FDA approval or approval from a similar regulatory authorityin another country. With respect to our current product candidates,if our PALISADE Phase 3 program, including the PALISADE-1 Phase 3clinical study of PH94B for acute treatment of anxiety in adultswith SAD, any future nonclinical or clinical study of PH94B, PH10or AV-101 fail(s) to produce positive results, the developmenttimeline and regulatory approval and commercialization prospectsfor PH94B, PH10 or AV-101 and, correspondingly, our business andfinancial prospects, could be materially adverselyaffected.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         This drug candidate development risk is heightened by any changesin planned timing or nature of clinical trials compared tocompleted clinical trials. As product candidates are developedthrough preclinical to early- and late-stage clinical trialstowards regulatory approval and commercialization, it is customarythat various aspects of the development program, such asmanufacturing and methods of administration, are altered along theway in an effort to optimize processes and results. While thesetypes of changes are common and are intended to optimize theproduct candidates for later stage clinical trials, approval andcommercialization, such changes do carry the risk that they willnot achieve these intended objectives.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         For example, the results of planned clinical trials have beenaffected by supply chain disruptions experienced by certain of ourCMOs as a result of the ongoing COVID-19 pandemic. In addition,clinical development of our products may be further affected if weor any of our collaborators seek to optimize and scale-upproduction of a product candidate. In such case, we will need todemonstrate comparability between the newly manufactured drugsubstance and/or drug product relative to the previouslymanufactured drug substance and/or drug product. Demonstratingcomparability may cause us to incur additional costs or delayinitiation or completion of our clinical trials, including the needto initiate a dose escalation study and, if unsuccessful, couldrequire us to complete additional nonclinical or clinical studiesof our product candidates. In addition, health and safetyprecautions at clinical sites related to the COVID-19 pandemiccould cause us to incur additional costs or delay initiation orcompletion of planned nonclinical and clinical trials.        </font>       </div>       <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         If serious adverse events or other undesirable side effects orsafety concerns attributable to our product candidates occur,including PH94B in the PALISADE Phase 3 program, they may adverselyaffect or delay our clinical development and commercialization ofPH94B, PH10 or AV-101.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Undesirable side effects or safety concerns caused by our productcandidates could cause us or regulatory authorities to interrupt,delay or halt our clinical trials and could result in a morerestrictive label or the delay or denial of regulatoryapproval. Although no treatment-related serious adverse events(         </font>         <font style="font-style: italic; color: #000000">          SAEs         </font>         <font style="color: #000000">          ) were observed in any clinical trials of any ofour product candidates to date, if treatment-related SAEs or otherundesirable side effects or safety concerns, or unexpectedcharacteristics attributable to PH94B, PH10 and/or AV-101, areobserved in any future clinical trials, including clinical studiesin the PALISADE Phase 3 program, and/or other clinical trialsinvolving our drug candidates, they may adversely affect or delayour clinical development and commercialization of the effectedproduct candidate, and the occurrence of these events could have amaterial adverse effect on our business and financial prospects.Results of our future clinical trials could reveal a high andunacceptable severity and prevalence of adverse side effects. Insuch an event, our trials could be suspended or terminated and theFDA or other regulatory agency could order us to cease furtherdevelopment of or deny approval of our product candidates for anyor all targeted indications. The drug-related side effects couldaffect patient recruitment or the ability of enrolled patients tocomplete the trial or result in potential product liabilityclaims.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -34-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Additionally, if any of our product candidates receives marketingapproval and we or others later identify undesirable orunacceptable side effects or safety concerns caused by theseproduct candidates, a number of potentially significant negativeconsequences could result, including:        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="display: table;">        <div style="display: table-row;">         <div style="text-align: left; display: table-cell; width: 24px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            ●           </font>          </font>         </div>         <div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           regulatoryauthorities may withdraw, suspend, or limit approvals of suchproduct and require us to take them off the market;          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="display: table;">        <div style="display: table-row;">         <div style="text-align: left; display: table-cell; width: 24px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            ●           </font>          </font>         </div>         <div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           regulatoryauthorities may require the addition of labeling statements,specific warnings, a contraindication or field alerts to physiciansand pharmacies;          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="display: table;">        <div style="display: table-row;">         <div style="text-align: left; display: table-cell; width: 24px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            ●           </font>          </font>         </div>         <div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           regulatoryauthorities may require a medication guide outlining the risks ofsuch side effects for distribution to patients, or that weimplement a REMS or REMS-like plan to ensure that the benefits ofthe product outweigh its risks;          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="display: table;">        <div style="display: table-row;">         <div style="text-align: left; display: table-cell; width: 24px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            ●           </font>          </font>         </div>         <div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           wemay be required to change the way a product is distributed oradministered, conduct additional clinical trials or change thelabeling of a product;          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="display: table;">        <div style="display: table-row;">         <div style="text-align: left; display: table-cell; width: 24px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            ●           </font>          </font>         </div>         <div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           wemay be required to conduct additional post-marketing studies orsurveillance;          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="display: table;">        <div style="display: table-row;">         <div style="text-align: left; display: table-cell; width: 24px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            ●           </font>          </font>         </div>         <div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">           </font>           we may be subject to limitations on how we may promote theproduct;          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="display: table;">        <div style="display: table-row;">         <div style="text-align: left; display: table-cell; width: 24px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            ●           </font>          </font>         </div>         <div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           salesof the product may decrease significantly;          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="display: table;">        <div style="display: table-row;">         <div style="text-align: left; display: table-cell; width: 24px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            ●           </font>          </font>         </div>         <div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           wemay be subject to regulatory investigations, government enforcementactions, litigation or product liability claims; and          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="display: table;">        <div style="display: table-row;">         <div style="text-align: left; display: table-cell; width: 24px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            ●           </font>          </font>         </div>         <div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           ourproducts may become less competitive or our reputation maysuffer.          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         <br/>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Any of these events could prevent us or any collaborators fromachieving or maintaining market acceptance of our productcandidates or could substantially increase commercialization costsand expenses, which in turn could delay or prevent us fromgenerating significant revenue from the sale of our productcandidates.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Failures or delays in the commencement or completion of our plannednonclinical and clinical studies of PH94B, PH10, AV-101 or otherour product candidates could result in increased costs to us andcould delay, prevent or limit our ability to generate revenue andcontinue our business.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In addition to the PALISADE-1 Phase 3 clinical study, we will needto complete at least one additional Phase 3 clinical study ofPH94B, additional toxicology and other standard nonclinical andclinical safety studies, as well as certain other clinical studiesprior to our submission of an NDA for regulatory approval of PH94Bas an acute treatment of anxiety in adults with SAD, or for anyother anxiety disorder or phobia. For PH10, at present, we believewe will need to complete at least one additional Phase 2 clinicalstudy, two pivotal Phase 3 clinical trials, additional toxicologyand other standard nonclinical and clinical safety studies, as wellas certain standard smaller clinical studies prior to thesubmission of an NDA for regulatory approval of PH10 as astand-alone rapid-onset treatment for MDD, or any other depressiondisorder. For AV-101 in combination with probenecid, at present,for treatment of any CNS indication, we believe we will need tocomplete at least one Phase 1B clinical study, two Phase 2 clinicalstudies, two pivotal Phase 3 clinical trials, additional toxicologyand other standard nonclinical and clinical safety studies, as wellas certain standard smaller clinical studies prior to thesubmission of an NDA for regulatory approval. Successful completionof our nonclinical and clinical trials is a prerequisite tosubmitting an NDA and, consequently, the ultimate approval requiredbefore commercial marketing of any product candidate we maydevelop. We do not know whether any of our future-plannednonclinical and clinical trials of PH94B, PH10, AV-101 or any otherproduct candidate will be completed on schedule, if at all, as thecommencement and completion of nonclinical and clinical trials canbe delayed or prevented for a number of reasons, including, amongothers:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              delays due to events resulting from the ongoing COVID-19pandemic;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the regulatory authority may deny permission to proceed withplanned clinical trials or any other clinical trials we mayinitiate, or may place a planned or ongoing clinical trial onhold;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              delays in filing or receiving approvals from regulatory authoritiesof additional INDs that may be required;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              negative or ambiguous results from nonclinical or clinicalstudies;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              delays in reaching or failing to reach agreement on acceptableterms with prospective CROs, investigators and clinical trialsites, the terms of which can be subject to extensive negotiationand may vary significantly among different CROs, investigators andclinical trial sites;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              delays in the manufacturing of, or insufficient supply of productcandidates necessary to conduct nonclinical or clinical trials,including delays in the manufacturing of sufficient supply of drugsubstance or finished drug product;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              inability to manufacture or obtain clinical supplies of a productcandidate meeting required quality standards;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -35-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               difficulties obtaining Institutional Review Board(              </font>              <font style="font-style: italic; color: #000000">               IRB              </font>              <font style="color: #000000">               ) approval to conduct a clinical trial at aprospective clinical site or sites;              </font>             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              challenges in recruiting and enrolling patients to participate inclinical trials, including the proximity of patients to clinicaltrial sites;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              eligibility criteria for a clinical trial, the nature of a clinicaltrial protocol, the availability of approved effective treatmentsfor the relevant disease and competition from other clinical trialprograms for similar indications;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              severe or unexpected adverse drug-related side effects experiencedby patients in a clinical trial;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              delays in validating any endpoints utilized in a clinicaltrial;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the regulatory authority may disagree with our clinical trialdesign and our interpretation of data from prior nonclinicalstudies or clinical trials, or may change the requirements forapproval even after it has reviewed and commented on the design forour clinical trials;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              reports from nonclinical or clinical testing of other CNSindications or therapies that raise safety or efficacy concerns;and             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              difficulties retaining patients who have enrolled in a clinicaltrial but may be prone to withdraw due to rigors of the clinicaltrial, lack of efficacy, side effects, personal issues or loss ofinterest.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Clinical trials may also be delayed or terminated prior tocompletion as a result of ambiguous or negative interim results. Inaddition, a clinical trial may be suspended or terminated by us,the regulatory authority, the IRBs at the sites where the IRBs areoverseeing a clinical trial, a data and safety monitoring board(         </font>         <font style="font-style: italic; color: #000000">          DSMB         </font>         <font style="color: #000000">          ), overseeing the clinical trial at issue or otherregulatory authorities due to a number of factors, including, amongothers:         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              failure to conduct the clinical trial in accordance with regulatoryrequirements or approved clinical protocols;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              inspection of the clinical trial operations or trial sites by theregulatory authority that reveals deficiencies or violations thatrequire us to undertake corrective action, including the impositionof a clinical hold;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              unforeseen safety issues, including any that could be identified innonclinical carcinogenicity studies, adverse side effects or lackof effectiveness;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              changes in government regulations or administrativeactions;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              problems with clinical supply materials that may lead to regulatoryactions; and             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              lack of adequate funding to continue nonclinical or clinicalstudies.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Changes in regulatory requirements, regulatory guidance orunanticipated events during our nonclinical studies and clinicaltrials of PH94B, PH10, AV-101 or other CNS product candidates mayoccur, which may result in changes to nonclinical studies andclinical trial protocols or additional nonclinical studies andclinical trial requirements, which could result in increased coststo us and could delay our development timeline.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Changes in regulatory requirements, guidance or unanticipatedevents during our nonclinical studies and clinical trials of PH94B,PH10, AV-101 or other CNS product candidates may force us to amendnonclinical studies and clinical trial protocols or the regulatoryauthority may impose additional nonclinical studies and clinicaltrial requirements. Amendments or changes to our clinical trialprotocols would require resubmission to the regulatory authorityand IRBs for review and approval, which may adversely impact thecost, timing or successful completion of clinical trials.Similarly, amendments to our nonclinical studies may adverselyimpact the cost, timing, or successful completion of thosenonclinical studies. If we experience delays completing, or if weterminate, any of our nonclinical studies or clinical trials, or ifwe are required to conduct additional nonclinical studies orclinical trials, the commercial prospects for PH94B, PH10, AV-101or other CNS product candidates may be harmed and our ability togenerate product revenue will be delayed.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We rely, and expect that we will continue to rely, on third partiesto conduct our nonclinical and clinical trials of our current CNSproduct candidates and will continue to do so for any other futureCNS product candidates. If these third parties do not successfullycarry out their contractual duties and/or meet expected deadlines,completion of our nonclinical or clinical trials and development ofPH94B, PH10, AV-101 or other CNS future product candidates may bedelayed and we may not be able to obtain regulatory approval for orcommercialize PH94B, PH10, AV-101 or other future CNS productcandidates and our business could be substantiallyharmed.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -36-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         By strategic design, we do not have the extensive internal staffresources to independently conduct nonclinical and clinical trialsof our product candidates completely on our own. We rely on ournetwork of strategic relationships with various academic researchcenters, medical institutions, nonclinical and clinicalinvestigators, contract laboratories, CROs and other third partiesto assist us to conduct and complete nonclinical and clinicaltrials of our product candidates. We enter into agreements withthird-party CROs to provide monitors for and to manage data for ourclinical trials, as well as provide other services necessary toprepare for, conduct and complete clinical trials. We rely heavilyon these and other third-parties for execution of nonclinical andclinical trials for our product candidates and we control onlycertain aspects of their activities. As a result, we have lessdirect control over the conduct, timing and completion of thesenonclinical and clinical trials and the management of datadeveloped through nonclinical and clinical trials than would be thecase if we were relying entirely upon our own internal staffresources. Communicating with outside parties can also bechallenging, potentially leading to mistakes as well asdifficulties in coordinating activities. CROs and other outsideparties may:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              experience disruptions to their operations, such as reducedstaffing and supply chain disruptions, as a result of the ongoingCOVID-19 pandemic;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              have staffing difficulties and/or undertake obligations beyondtheir anticipated capabilities and resources;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              fail to comply with contractual obligations;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              experience regulatory compliance issues;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              undergo changes in priorities or become financially distressed;or             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              form relationships with other entities, some of which may be ourcompetitors.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          These factors may materially adversely affect the willingness orability of third parties to conduct our nonclinical and clinicaltrials and may subject us to unexpected cost increases that arebeyond our control. Nevertheless, we are responsible for ensuringthat each of our nonclinical studies and clinical trials isconducted and completed in accordance with the applicable protocol,legal, regulatory and scientific requirements and standards, andour reliance on CROs, or independent investigators does not relieveus of our regulatory responsibilities. We and our CROs, and anyinvestigator in an investigator-sponsored study are required tocomply with regulations and guidelines, including current GoodClinical Practice regulations (         </font>         <font style="font-style: italic; color: #000000">          cGCPs         </font>         <font style="color: #000000">          ) for conducting, monitoring, recording andreporting the results of clinical trials to ensure that the dataand results are scientifically credible and accurate, and that thetrial patients are adequately informed of the potential risks ofparticipating in clinical trials. These regulations are enforced bythe FDA, the Competent Authorities of the Member States of theEuropean Economic Area and comparable foreign regulatoryauthorities for any products in clinical development. The FDAenforces cGCP regulations through periodic inspections of clinicaltrial sponsors, principal investigators and trial sites. If we, anyof our CROs or any of our third-party collaborators fail to complywith applicable cGCPs, the clinical data generated in clinicaltrials involving our product candidates may be deemed unreliableand the FDA or comparable foreign regulatory authorities mayrequire us to perform additional clinical trials before approvingour marketing applications. We cannot assure you that, uponinspection, the FDA will determine that any of our clinical trialscomply with cGCPs. In addition, our clinical trials must beconducted with product candidates produced under cGMPs and willrequire a large number of test patients. Our failure or the failureof our CROs or other third-party collaborators to comply with theseregulations may require us to repeat clinical trials, which woulddelay the regulatory approval process and could also subject us toenforcement action up to and including civil and criminalpenalties.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Although we design our clinical trials for our product candidates,our clinical development strategy involves having CROs and otherthird-party investigators and medical institutions conduct clinicaltrials of our product candidates. As a result, many importantaspects of our drug development programs are outside of our directcontrol. In addition, although CROs, or independent investigatorsor medical institutions, as the case may be, may not perform all oftheir obligations under arrangements with us or in compliance withapplicable regulatory requirements, under certain circumstances, wemay be responsible and subject to enforcement action that mayinclude civil penalties up to and including criminal prosecutionfor any violations of FDA laws and regulations during the conductof clinical trials of our product candidates. If such third partiesdo not perform clinical trials of our product candidates in asatisfactory manner, breach their obligations to us or fail tocomply with applicable regulatory requirements, the development andcommercialization of our product candidates may be delayed or ourdevelopment program materially and irreversibly harmed. In certaincases, including the Baylor Study and other investigator-sponsoredclinical studies, we cannot control the amount and timing ofresources these third-parties devote to clinical trials involvingour product candidates. If we are unable to rely on nonclinical andclinical data collected by our third-party collaborators, we couldbe required to repeat, extend the duration of, or increase the sizeof our clinical trials and this could significantly delaycommercialization and require significantly greaterexpenditures.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         If our relationships with one or more of our third-partycollaborators terminates, we may not be able to enter intoarrangements with alternative third-partycollaborators.  If such third-party collaborators,including our CROs, do not successfully carry out their contractualduties or obligations or meet expected deadlines, if they need tobe replaced or if the quality or accuracy of the clinical data theyobtain is compromised due to their failure to adhere to applicableclinical protocols, regulatory requirements or for other reasons,any clinical trials that such third-parties are associated with maybe extended, delayed or terminated, and we may not be able toobtain regulatory approval for or successfully develop andcommercialize our product candidates. As a result, we believe thatour financial results and the commercial prospects for our productcandidates in the subject indication would be harmed, our costswould increase and our ability to generate revenue would bedelayed.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -37-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We rely completely on third-parties to manufacture, formulate,analyze, hold and distribute supplies of our CNS product candidatesfor all nonclinical and clinical studies, and we intend to continueto rely on third parties to produce all nonclinical, clinical andcommercial supplies of our CNS product candidates in thefuture.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         By strategic design, we do not currently have, nor do we plan toacquire or develop, extensive internal infrastructure or technicalcapabilities to manufacture, formulate, analyze, hold or distributesupplies of our product candidates, for use in nonclinical andclinical studies or commercial scale.  As a result, withrespect to all of our product candidates, we rely, and willcontinue to rely, completely on CMOs to manufacture API andformulate, hold and distribute final drug product. The facilitiesused by our CMOs to manufacture PH94B, PH10 and AV-101 API andformulate PH94B, PH10 and AV-101 final drug product are subject toa pre-approval inspection by the FDA and other comparable foreignregulatory agencies to assess compliance with applicable regulatoryguidelines and requirements, including cGMPs, and may be requiredto undergo similar inspections by the FDA or other comparableforeign regulatory agencies, after we submit INDs, NDAs or relevantforeign regulatory submission equivalent to the applicableregulatory agency.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We do not directly control the manufacturing process or the supplyor quality of materials used in the manufacturing, analysis andformulation of our product candidates, and, with respect to all ofour product candidates, we are completely dependent on our CMOs tocomply with all applicable cGMPs for the manufacturing of both APIand finished drug product. If our CMOs cannot secure adequatesupplies of suitable raw materials or successfully manufacture ourproduct candidates, including PH94B, PH10 and AV-101 API andfinished drug product, that conforms to our specifications and thestrict regulatory requirements of the FDA or applicable foreignregulatory agencies, production of sufficient supplies of ourproduct candidates, including PH94B, PH10 and AV-101 API andfinished drug product, may be delayed and our CMOs may not be ableto secure and/or maintain regulatory approval for theirmanufacturing facilities, or the FDA may take other actions,including the imposition of a clinical hold. In addition, we haveno direct control over our CMOs’ ability to maintain adequatequality control, quality assurance and qualified personnel. All ofour CMOs are engaged with other companies to supply and/ormanufacture materials or products for such other companies, whichexposes our CMOs to regulatory risks for the production of suchmaterials and products. As a result, failure to satisfy theregulatory requirements for the production of those materials andproducts may affect the regulatory clearance of our CMO’sfacilities generally or affect the timing of manufacture of PH94B,PH10 and AV-101 for required or planned nonclinical and/or clinicalstudies. If the FDA or an applicable foreign regulatory agencydetermines now or in the future that our CMOs’ facilities arenoncompliant, we may need to find alternative manufacturingfacilities, which would adversely impact our ability to develop,obtain regulatory approval for or market our product candidates.Our reliance on CMOs also exposes us to the possibility that they,or third parties with access to their facilities, will have accessto and may appropriate our trade secrets or other proprietaryinformation.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         With respect to PH94B, PH10 and AV-101, we do not yet havelong-term supply agreements in place with our CMOs and each batchof PH94B, PH10 and AV-101 is or will be individually contractedunder a separate supply agreement. If we engage new CMOs, suchcontractors must complete an inspection by the FDA and otherapplicable foreign regulatory agencies. We plan to continue to relyupon CMOs and, potentially, collaboration partners, to manufactureresearch and development scale, and, if approved, commercialquantities of our product candidates. Although we believe ourcurrent scale of API manufacturing for AV-101, and our contemplatedscale of API manufacturing for PH94B and PH10, and the current andprojected supply of PH94B, PH10 and AV-101 API and finished drugproduct will be adequate to support our planned nonclinical andclinical studies of PH94B, PH10 and AV-101, no assurance can begiven that unanticipated supply shortages or CMO-related delays inthe manufacture and formulation of PH94B, PH10 or AV-101 API and/orfinished drug product will not occur in the future.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Additionally, we anticipate that PH94B and PH10 will be considereddrug-device combination products. Third-party manufacturers may notbe able to comply with cGMP requirements applicable to drug/devicecombination products, including applicable provisions of theFDA’s or a comparable foreign regulatory authority’sdrug cGMP regulations, device cGMP requirements embodied in theQuality System Regulation (         </font>         <font style="font-style: italic; color: #000000">          QSR         </font>         <font style="color: #000000">          ) or similar regulatory requirements outside theU.S. Our failure, or the failure of our third-party manufacturers,to comply with applicable regulations could result in sanctionsbeing imposed on us, including clinical holds, fines, injunctions,civil penalties, delays, suspension or withdrawal of approvals,license revocation, seizures or recalls of product candidates,operating restrictions and criminal prosecutions, any of whichcould significantly affect supplies of our product candidates. Thefacilities used by our CMOs to manufacture our product candidatesmust be approved by the FDA and comparable foreign regulatoryauthorities pursuant to inspections that will or may be conductedafter we submit our NDA. We do not control the manufacturingprocess of, and are completely dependent on, our CMO partners forcompliance with cGMPs and QSRs. If our CMOs cannot successfullymanufacture material that conforms to our specifications and thestrict regulatory requirements of the FDA or other comparableforeign regulatory authorities, they will not be able to secureand/or maintain regulatory approval for their manufacturingfacilities. In addition, we have no control over the ability of ourcontract manufacturers to maintain adequate quality control,quality assurance and qualified personnel. If the FDA or acomparable foreign regulatory authority does not approve thesefacilities for the manufacture of our product candidates or if itwithdraws any such approval in the future, we may need to findalternative manufacturing facilities, which would significantlyimpact our ability to develop, obtain regulatory approval for ormarket our product candidates, if approved. CMOs may facemanufacturing or quality control problems causing drug substanceproduction and shipment delays or a situation where the contractormay not be able to maintain compliance with the applicable cGMP andQSR requirements. Any failure to comply with cGMP or QSRrequirements or other FDA, EMA and comparable foreign regulatoryrequirements could adversely affect our clinical researchactivities and our ability to develop our product candidates andmarket our products following approval.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -38-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Even if we receive marketing approval for PH94B, PH10, AV-101 orany other CNS product candidate in the U.S., we may never receiveregulatory approval to market PH94B, PH10, AV-101 or any other CNSproduct candidate outside of the U.S.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In order to market PH94B, PH10, AV-101 or any other CNS productcandidate outside of the U.S., we must establish and comply withthe numerous and varying safety, efficacy and other regulatoryrequirements of other countries. Approval procedures vary amongcountries and can involve additional product candidate testing andadditional administrative review periods. The time required toobtain approvals in other countries might differ from that requiredto obtain FDA approval. The marketing approval processes in othercountries may implicate all of the risks detailed above regardingFDA approval in the U.S. as well as other risks. In particular, inmany countries outside of the U.S., products must receive pricingand reimbursement approval before the product can becommercialized. Obtaining this approval can result in substantialdelays in bringing products to market in such countries. Marketingapproval in one country does not ensure marketing approval inanother, but a failure or delay in obtaining marketing approval inone country may have a negative effect on the regulatory process inothers. Failure to obtain marketing approval in other countries orany delay or other setback in obtaining such approval would impairour ability to market our product candidates in such foreignmarkets. Any such impairment would reduce the size of our potentialmarket, which could have a material adverse impact on our business,results of operations and prospects.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         If any of our CNS product candidates are ultimately regulated ascontrolled substances, we, our CMOs, as well as futuredistributors, prescribers, and dispensers will be required tocomply with additional regulatory requirements which could delaythe marketing of our product candidates, and increase the cost andburden of manufacturing, distributing, dispensing, and prescribingour product candidates.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Before we can commercialize our product candidates in the U.S. orany market outside the U.S., the U.S. Drug EnforcementAdministration (         </font>         <font style="font-style: italic; color: #000000">          DEA         </font>         <font style="color: #000000">          ) or its foreign counterpart may need to determinewhether such product candidates will be considered to be acontrolled substance, taking into account the recommendation of theFDA or its foreign counterpart, as the case may be. This may bea lengthy process that could delay our marketing of a productcandidate and could potentially diminish any regulatory exclusivityperiods for which we may be eligible, which would increase the costassociated with commercializing such products and, in turn, mayhave an adverse impact on our results of operations. Although wecurrently do not know whether the DEA or any foreign counterpartwill consider any of our current or future product candidate to becontrolled substances, we cannot yet give any assurance that suchproduct candidates, including PH94B, PH10 and AV-101 will not beregulated as controlled substances.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         If any of our product candidates are regulated as controlledsubstances, depending on the DEA controlled substance schedule inwhich the product candidates are placed or that of its foreigncounterpart, we, our CMOs, and any future distributers,prescribers, and dispensers of the scheduled product candidates maybe subject to significant regulatory requirements, such asregistration, security, recordkeeping, reporting, storage,distribution, importation, exportation, inventory, quota and otherrequirements administered by the DEA or a foreign counterpart ofthe DEA as the case may be. Moreover, if any of our productcandidates are regulated as controlled substances, we and our CMOswould be subject to initial and periodic DEA inspection. If we orour CMOs are not able to obtain or maintain any necessary DEAregistrations or comparable foreign registrations, we may not beable to commercialize any product candidates that are deemed to becontrolled substances or we may need to find alternative CMOs,which would take time and cause us to incur additional costs,delaying or limit our commercialization efforts.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Because of their restrictive nature, these laws and regulationscould limit commercialization of our product candidates, shouldthey be deemed to contain controlled substances. Failure to complywith the applicable controlled substance laws and regulations canalso result in administrative, civil or criminal enforcement. TheDEA or its foreign counterparts may seek civil penalties, refuse torenew necessary registrations, or initiate administrativeproceedings to revoke those registrations. In some circumstances,violations could result in criminal proceedings or consent decrees.Individual states also independently regulate controlledsubstances.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         If we are unable to establish broad sales and marketingcapabilities on our own or enter into agreements with third partiesto market and sell our CNS product candidates, we may not be ableto generate any revenue.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We currently have limited internal resources for the sale,marketing and distribution of pharmaceutical products, and we maynot be able to create broad internal capabilities in theforeseeable future. Therefore, to market our CNS productcandidates, if approved by the FDA or any other regulatory body, wemust establish broad internal capabilities related to sales,marketing, managerial and other non-technical capabilities relatingto the commercialization of our product candidates, or makecontractual arrangements with third parties to perform services,prior to market approval. If we are unable to establish adequateinternal sales, marketing and distribution capabilities, or if weare unable to do so contractually on commercially reasonable terms,our business, results of operations, financial condition andprospects will be materially adversely affected.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -39-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Even if we receive marketing approval for our CNS productcandidates, our product candidates may not achieve broad marketacceptance, which would limit the revenue that we generate fromtheir sales.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The commercial success of our CNS product candidates, if approvedby the FDA or other regulatory authorities, will depend upon theawareness and acceptance of our product candidates among themedical community, including physicians, patients and healthcarepayors. Market acceptance of our product candidates, if approved,will depend on a number of factors, including, amongothers:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the efficacy and safety of our product candidates as demonstratedin clinical trials, and, if required by any applicable regulatoryauthority in connection with the approval for the applicableindications, to provide patients with incremental health benefits,as compared with other available therapies;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              limitations or warnings contained in the labeling approved for ourproduct candidates by the FDA or other applicable regulatoryauthorities;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the clinical indications for which our product candidates areapproved;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              availability of alternative treatments already approved or expectedto be commercially launched in the near future;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the potential and perceived advantages of our product candidatesover current treatment options or alternative treatments, includingfuture alternative treatments;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the willingness of the target patient population to try newtherapies and of physicians to prescribe thesetherapies;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the strength of marketing and distribution support and timing ofmarket introduction of competitive products;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              publicity concerning our products or competing products andtreatments;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              pricing and cost effectiveness;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the effectiveness of our sales and marketingstrategies;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              our ability to increase awareness of our product candidates throughmarketing efforts;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              our ability to obtain sufficient third-party coverage orreimbursement; or             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the willingness of patients to pay out-of-pocket in the absence ofthird-party coverage.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -40-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         If our CNS product candidates are approved but do not achieve anadequate level of acceptance by patients, physicians and payors, wemay not generate sufficient revenue from our product candidates tobecome or remain profitable. Before granting reimbursementapproval, healthcare payors may require us to demonstrate that ourproduct candidates, in addition to treating these targetindications, also provide incremental health benefits to patients.Our efforts to educate the medical community and third-party payorsabout the benefits of our product candidates may requiresignificant resources and may never be successful.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Our CNS product candidates may cause undesirable safety concernsand side effects that could delay or prevent their regulatoryapproval, limit the commercial profile of an approved label, orresult in significant negative consequences following marketingapproval, if any.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         If our product candidates are determined to cause undesirable sideeffects and safety concerns, we or regulatory authorities mayinterrupt, delay or halt nonclinical studies and clinical trialsand could result in a more restrictive label or the delay or denialof regulatory approval by regulatory authorities.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Further, clinical trials by their nature utilize a sample ofpotential patient populations. With a limited number of patientsand limited duration of exposure, rare and severe side effects ofour product candidates may only be uncovered with a significantlylarger number of patients exposed to the product candidate. If ourproduct candidates receive marketing approval and we or othersidentify undesirable safety concerns or side effects caused by suchproduct candidates (or any other similar products) after suchapproval, a number of potentially significant negative consequencescould result, including:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              regulatory authorities may withdraw or limit their approval of suchproduct candidates;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              regulatory authorities may require the addition of labelingstatements, such as a “black box” warning or acontraindication;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              we may be required to change the way such product candidates aredistributed or administered, conduct additional clinical trials orchange the labeling of the product candidates;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              we may be subject to regulatory investigations and governmentenforcement actions;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              we may decide to remove such product candidates from themarketplace;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              we could be sued and held liable for injury caused to individualsexposed to or taking our product candidates; and             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              our reputation may suffer.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -41-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We believe that any of these events could prevent us from achievingor maintaining market acceptance of the affected product candidatesand would substantially increase the costs of commercializing ourproduct candidates and significantly impact our ability tosuccessfully commercialize our product candidates and generaterevenues.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Even if we receive marketing approval for our CNS productcandidates, we may still face future development and regulatorydifficulties.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Even if we receive marketing approval for our CNS productcandidates, regulatory authorities may still impose significantrestrictions on our product candidates, indicated uses or marketingor impose ongoing requirements for potentially costly post-approvalstudies. Our product candidates will also be subject to ongoingregulatory requirements governing the labeling, packaging, storageand promotion of the product and record keeping and submission ofsafety and other post-market information. The FDA and otherregulatory authorities have significant post-marketing authority,including, for example, the authority to require labeling changesbased on new safety information and to require post-marketingstudies or clinical trials to evaluate serious safety risks relatedto the use of a drug. The FDA and other regulatory authorities alsohave the authority to require, as part of an NDA or post-approval,the submission of a REMS or comparable safety program. Any REMS orcomparable safety program required by the FDA or other regulatoryauthority may lead to increased costs to assure compliance with newpost-approval regulatory requirements and potential requirements orrestrictions on the sale of approved products, all of which couldlead to lower sales volume and revenue.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Manufacturers of drug and device products and their facilities aresubject to continual review and periodic inspections by the FDA andother regulatory authorities for compliance with cGMPs and otherregulations. If we or a regulatory agency discover problems withour product candidates, such as adverse events of unanticipatedseverity or frequency, or problems with the facility where ourproduct candidates are manufactured, a regulatory agency may imposerestrictions on our product candidates, the manufacturer or us,including requiring withdrawal of our product candidates from themarket or suspension of manufacturing. If we, our productcandidates, or the manufacturing facilities for our productcandidates fail to comply with applicable regulatory requirements,a regulatory agency may, among other things:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              issue warning letters or untitled letters;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              seek an injunction or impose civil or criminal penalties ormonetary fines;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              suspend or withdraw marketing approval;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              suspend any ongoing clinical trials;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              refuse to approve pending applications or supplements toapplications submitted by us;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              suspend or impose restrictions on operations, including costly newmanufacturing requirements; or             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              seize or detain products, refuse to permit the import or export ofproducts, or require that we initiate a productrecall.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Competing therapies could emerge adversely affecting ouropportunity to generate revenue from the sale of our CNS productcandidates.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The pharmaceutical industry is highly competitive. There are manypublic and private pharmaceutical companies, universities,governmental agencies and other research organizations activelyengaged in the research and development of product candidates thatmay be similar to and compete with our product candidates oraddress similar markets. It is probable that the number ofcompanies seeking to develop product candidates similar to andcompetitive with our product candidates will increase in thefuture.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Currently, management is unaware of any FDA-approved rapid-onset,acute treatment of anxiety in adults with SAD having the samemechanism of pharmacological action and safety profile as ourPH94B. Also, management is currently unaware of any FDA-approvedoral treatment for MDD having the same mechanism of pharmacologicalaction and safety profile as our intranasally-administered PH10 orour orally-administered AV-101 in combination with probenecid.However, new antidepressant products with other mechanisms ofpharmacological action or products approved for other indications,including the FDA-approved anesthetic ketamine hydrochlorideadministered intravenously, are being or may be used for treatmentof MDD, as well as other CNS indications for which PH10 or AV-101in combination with probenecid may have therapeutic potential.Additionally, other non-pharmaceutical treatment options, suchpsychotherapy and electroconvulsive therapy (         </font>         <font style="font-style: italic; color: #000000">          ECT         </font>         <font style="color: #000000">          ) are used before or instead of standardantidepressant medications to treat patients withMDD.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -42-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         With respect to PH94B and current treatment options for SAD in theU.S., our competition may include, but is not limited to, currentgeneric oral antidepressants approved by the FDA for treatment ofSAD, as well as certain classes of drugs prescribed on an off-labelbasis for treatment of SAD, including benzodiazepines such asalprazolam, and beta blockers such as propranolol. In the field ofnew generation, oral treatments for adult patients with MDD, webelieve our principal competitors may be Axsome, Alkermes, Relmadaand Sage. Additional potential competitors may include, but not belimited to, academic and private commercial clinics providingintravenous ketamine therapy on an off-label basis andJanssen’s intranasally-administered esketamine.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; font-family: Times New Roman; font-size: 13px">          Manyof our potential competitors, alone or with their strategicpartners, have substantially greater financial, technical and humanresources than we do and significantly greater experience in thediscovery, and development of product candidates, obtaining FDA andother regulatory approvals of treatments and the commercializationof those treatments.  With respect to PH94B, in additionto potential competition from certain current FDA-approvedantidepressants and off-label use of benzodiazepines and betablockers, we believe additional drug candidates in development forSAD may include, but potentially not be limited to, an oral fattyacid amide hydrolase inhibitor in development by Janssen. Withrespect to PH10 and AV-101 in combination with probenecid fortreatment of depression disorders, including MDD, and AV-101 incombination with probenecid for treatment of certain neurologicaldisorders, including levodopa-induced dyskinesia associated withtherapy for Parkinson’s disease, neuropathic pain, andepilepsy, we believe a range of pharmaceutical and biotechnologycompanies have programs to develop drug candidates and/or medicaldevice technologies for such indications, including, but notlimited to, Abbott Laboratories, Acadia, Allergan, Alkermes,Aptynix, AstraZeneca, Axsome, Eli Lilly, GlaxoSmithKline,IntraCellular, Janssen, Lundbeck, Merck, Neurocrine, Novartis, Ono,Otsuka, Pfizer, Relmada, Roche, Sage, Sumitomo Dainippon, andTakeda, as well as any affiliates of the foregoingcompanies.   Mergers and acquisitions in thebiotechnology and pharmaceutical industries may result in even moreresources being concentrated among a smaller number of ourcompetitors. Our commercial opportunity could be reduced oreliminated if our competitors develop and commercialize productsthat are safer, more effective, have fewer or less severe sideeffects, are more convenient or are less expensive than anyproducts that we may develop. Our competitors also may obtain FDAor other regulatory approval for their products more rapidly thanwe may obtain approval for ours, which could result in ourcompetitors establishing a strong market position before we areable to enter the market.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         We may seek to establish collaborations, and, if we are not able toestablish them on commercially reasonable terms, we may have toalter our development and commercialization plans.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our drug development programs and the potential commercializationof our product candidates will require substantial additional cashto fund expenses. For some of our product candidates, we may decideto collaborate with pharmaceutical and biotechnology companies forthe development and potential commercialization of those productcandidates, such as the License and Collaboration Agreement weentered into with AffaMed Therapeutics (formerly EverInsightTherapeutics) in June 2020 for the development andcommercialization of PH94B in Greater China, South Korea andSoutheast Asia.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We may derive revenue from research and development fees, licensefees, milestone payments and royalties under any collaborativearrangement into which we enter, including the AffaMed Agreement.However, our ability to generate revenue from such arrangementswill depend on our collaborators’ abilities to successfullyperform the functions assigned to them in these arrangements. Inaddition, our collaborators have the right to abandon research ordevelopment projects and terminate applicable agreements, includingfunding obligations, prior to or upon the expiration of the agreedupon terms. As a result, we can expect to relinquish some or all ofthe control over the future success of a product candidate that welicense to a third party in the territories included in thelicenses.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We face significant competition in seeking appropriatecollaborators. Whether we reach additional definitive agreementsfor collaborations will depend, among other things, upon ourassessment of the collaborator’s resources and expertise, theterms and conditions of the proposed collaboration and the proposedcollaborator’s evaluation of a number of factors. Thosefactors may include the design or results of nonclinical andclinical trials, the likelihood of approval by the FDA or similarregulatory authorities outside the United States, the potentialmarkets for the subject product candidate, the costs andcomplexities of manufacturing and delivering such product candidateto patients, the potential of competing products, the existence ofuncertainty with respect to our ownership of technology, which canexist if there is a challenge to such ownership without regard tothe merits of the challenge and industry and market conditionsgenerally. The collaborator may also consider alternative productcandidates or technologies for similar indications that may beavailable to collaborate on and whether such collaboration could bemore attractive than the one with us for our product candidate. Theterms of any collaboration or other arrangements that we mayestablish may not be favorable to us.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We may also be restricted under existing collaboration agreementsfrom entering into future agreements on certain terms withpotential collaborators. Collaborations are complex andtime-consuming to negotiate and document. In addition, there havebeen a significant number of recent business combinations amonglarge pharmaceutical companies that have resulted in a reducednumber of potential future collaborators.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -43-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We may not be able to negotiate additional collaborations on atimely basis, on acceptable terms, or at all. If we are unable todo so, we may have to curtail the development of the productcandidate for which we are seeking to collaborate, reduce or delayits development program or one or more of our other developmentprograms, delay its potential commercialization or reduce the scopeof any sales or marketing activities, or increase our expendituresand undertake development or commercialization activities at ourown expense. If we elect to increase our expenditures to funddevelopment or commercialization activities on our own, we may needto obtain additional capital, which may not be available to us onacceptable terms or at all. If we do not have sufficient funds, wemay not be able to further develop our product candidates or bringthem to market and generate product revenue.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In addition, any future collaboration that we enter into may not besuccessful. The success of our collaboration arrangements willdepend heavily on the efforts and activities of our collaborators.Collaborators generally have significant discretion in determiningthe efforts and resources that they will apply to thesecollaborations. Disagreements between parties to a collaborationarrangement regarding clinical development and commercializationmatters can lead to delays in the development process orcommercializing the applicable product candidate and, in somecases, termination of the collaboration arrangement. Thesedisagreements can be difficult to resolve if neither of the partieshas final decision-making authority. Collaborations withpharmaceutical or biotechnology companies and other third partiesoften are terminated or allowed to expire by the other party. Anysuch termination or expiration would adversely affect usfinancially and could harm our business reputation.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         We may not be successful in our efforts to identify or discoveradditional CNS product candidates, or we may expend our limitedresources to pursue a particular product candidate or indicationand fail to capitalize on product candidates or indications thatmay be more profitable or for which there is a greater likelihoodof success.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The success of our business depends primarily upon our ability toidentify, develop and commercialize CNS product candidates withcommercial and therapeutic potential. We may fail to pursueadditional development opportunities for PH94B, PH10 or AV-101, oridentify additional CNS product candidates for development andcommercialization for a number of reasons. Our research methodologymay be unsuccessful in identifying new product candidates or ourproduct candidates may be shown to have harmful side effects or mayhave other characteristics that may make the products unmarketableor unlikely to receive marketing approval.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We strategically focus on a limited number of research anddevelopment programs and product candidates and are currentlyfocused primarily on development of PH94B, PH10 and AV-101. As aresult, we may forego or delay pursuit of opportunities with otherproduct candidates or for other potential CNS-related indicationsfor PH94B, PH10 and/or AV-101 that later prove to have greatercommercial potential. Our resource allocation decisions may causeus to fail to capitalize on viable commercial drugs or profitablemarket opportunities. Our spending on current and future researchand development programs and product candidates for specificindications may not yield any commercially viable drugs. If we donot accurately evaluate the commercial potential or target marketfor a particular product candidate, we may relinquish valuablerights to that product candidate through future collaboration,licensing or other royalty arrangements in cases in which it wouldhave been more advantageous for us to retain sole development andcommercialization rights to such product candidate.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         If any of these events occur, we may be forced to abandon ourdevelopment efforts for a program or programs, which would have amaterial adverse effect on our business and could potentially causeus to cease operations. Research and development programs toidentify and advance new product candidates require substantialtechnical, financial and human resources. We may focus our effortsand resources on potential programs or product candidates thatultimately prove to be unsuccessful.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         We are subject to healthcare laws and regulations, which couldexpose us to criminal sanctions, civil penalties, contractualdamages, reputational harm and diminished profits and futureearnings.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Although we do not currently have any products on the market, oncewe begin commercializing our CNS product candidates, we may besubject to additional healthcare statutory and regulatoryrequirements and enforcement by the federal government and thestates and foreign governments in which we conduct our business.Healthcare providers, physicians and others will play a primaryrole in the recommendation and prescription of our productcandidates, if approved. Our future arrangements with third-partypayors will expose us to broadly applicable fraud and abuse andother healthcare laws and regulations that may constrain thebusiness or financial arrangements and relationships through whichwe market, sell and distribute our product candidates, if we obtainmarketing approval. Restrictions under applicable federal and statehealthcare laws and regulations include the following:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              The federal anti-kickback statute prohibits, among other things,persons from knowingly and willfully soliciting, offering,receiving or providing remuneration, directly or indirectly, incash or in kind, to induce or reward either the referral of anindividual for, or the purchase, order or recommendation of, anygood or service, for which payment may be made under federalhealthcare programs such as Medicare and Medicaid.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              The federal False Claims Act imposes criminal and civil penalties,including those from civil whistleblower or qui tam actions,against individuals or entities for knowingly presenting, orcausing to be presented, to the federal government, claims forpayment that are false or fraudulent or making a false statement toavoid, decrease, or conceal an obligation to pay money to thefederal government.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              The federal Health Insurance Portability and Accountability Act of1996, as amended by the Health Information Technology for Economicand Clinical Health Act, imposes criminal and civil liability forexecuting a scheme to defraud any healthcare benefit program andalso imposes obligations, including mandatory contractual terms,with respect to safeguarding the privacy, security and transmissionof individually identifiable health information.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -44-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              The federal false statements statute prohibits knowingly andwillfully falsifying, concealing or covering up a material fact ormaking any materially false statement in connection with thedelivery of or payment for healthcare benefits, items orservices.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              The federal transparency requirements, sometimes referred to as the“Sunshine Act,” under the Patient Protection andAffordable Care Act, require manufacturers of drugs, devices,biologics and medical supplies that are reimbursable underMedicare, Medicaid, or the Children’s Health InsuranceProgram to report to the Department of Health and Human Servicesinformation related to physician payments and other transfers ofvalue and physician ownership and investmentinterests.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Analogous state laws and regulations, such as state anti-kickbackand false claims laws and transparency laws, may apply to sales ormarketing arrangements and claims involving healthcare items orservices reimbursed by non-governmental third-party payors,including private insurers, and some state laws requirepharmaceutical companies to comply with the pharmaceuticalindustry’s voluntary compliance guidelines and the relevantcompliance.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Guidance promulgated by the federal government in addition torequiring drug manufacturers to report information related topayments to physicians and other healthcare providers or marketingexpenditures and drug pricing.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              ForeignCorrupt Practices Act and its application to marketing and sellingpractices as well as to clinical trials.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Ensuring that our future business arrangements with third partiescomply with applicable healthcare laws and regulations could becostly. It is possible that governmental authorities will concludethat our business practices do not comply with current or futurestatutes, regulations or case law involving applicable fraud andabuse or other healthcare laws and regulations. If our operationswere found to be in violation of any of these laws or any othergovernmental regulations that may apply to us, we may be subject tosignificant civil, criminal and administrative penalties, damages,fines and exclusion from government funded healthcare programs,such as Medicare and Medicaid, any of which could substantiallydisrupt our operations. If any of the physicians or other providersor entities with whom we expect to do business are found to be outof compliance with applicable laws, they may be subject tocriminal, civil or administrative sanctions, including exclusionsfrom government funded healthcare programs.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         The FDA and other regulatory agencies actively enforce the laws andregulations prohibiting the promotion of off-label uses. If we arefound to have improperly promoted off-label uses, we may becomesubject to significant liability.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The FDA and other regulatory agencies strictly regulate thepromotional claims that may be made about prescription products,such as PH94B, PH10 and AV-101, if approved. In particular, aproduct may not be promoted for uses that are not approved by theFDA or such other regulatory agencies as reflected in theproduct’s approved labeling. For example, if we receive FDAmarketing approval for PH94B as an acute treatment of anxiety inadults with SAD, physicians may prescribe PH94B to their patientsin a manner that is inconsistent with the FDA-approved label.However, if we are found to have promoted such off-label uses, wemay become subject to significant liability. The federal governmenthas levied large civil and criminal fines against companies foralleged improper off-label promotion and has enjoined severalcompanies from engaging in off-label promotion. The FDA has alsorequested that companies enter into consent decrees or imposedpermanent injunctions under which specified promotional conduct ischanged or curtailed. If we cannot successfully manage thepromotion of our product candidates, if approved, we could becomesubject to significant liability, which would materially adverselyaffect our business and financial condition.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Even if approved, reimbursement policies could limit our ability tosell our CNS product candidates.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Market acceptance and sales of our product candidates will dependheavily on reimbursement policies and may be affected by healthcarereform measures. Government authorities and third-party payors,such as private health insurers and health maintenanceorganizations, decide which medications they will pay for andestablish reimbursement levels for those medications. Costcontainment is a primary concern in the United States healthcareindustry and elsewhere. Government authorities and thesethird-party payors have attempted to control costs by limitingcoverage and the amount of reimbursement for particularmedications. We cannot be sure that reimbursement will be availablefor our product candidates and, if reimbursement is available, thelevel of such reimbursement. Reimbursement may impact the demandfor, or the price of, our product candidates. If reimbursement isnot available or is available only at limited levels, we may not beable to successfully commercialize our productcandidates.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In some foreign countries, particularly in Canada and Europeancountries, the pricing of prescription pharmaceuticals is subjectto strict governmental control. In these countries, pricingnegotiations with governmental authorities can take six months orlonger after the receipt of regulatory approval and product launch.To obtain favorable reimbursement for the indications sought orpricing approval in some countries, we may be required to conduct aclinical trial that compares the cost-effectiveness of our productcandidates with other available therapies. If reimbursement for ourproduct candidates is unavailable in any country in which we seekreimbursement, if it is limited in scope or amount, if it isconditioned upon our completion of additional clinical trials, orif pricing is set at unsatisfactory levels, our operating resultscould be materially adversely affected.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -45-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         We may seek FDA Orphan Drug designation for one or more of our CNSproduct candidates. Even if we have obtained FDA Orphan Drugdesignation for a product candidate, there may be limits to theregulatory exclusivity afforded by such designation.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We may, in the future, choose to seek FDA Orphan Drug designationfor one or more of our current or future CNS product candidates.Even if we obtain Orphan Drug designation from the FDA for aproduct candidate, there are limitations to the exclusivityafforded by such designation. In the U.S., the company that firstobtains FDA approval for a designated orphan drug for the specifiedrare disease or condition receives orphan drug marketingexclusivity for that drug for a period of seven years. This orphandrug exclusivity prevents the FDA from approving anotherapplication, including a full NDA to market the same drug for thesame orphan indication, except in very limited circumstances,including when the FDA concludes that the later drug is safer, moreeffective or makes a major contribution to patient care. Forpurposes of small molecule drugs, the FDA defines “samedrug” as a drug that contains the same active moiety and isintended for the same use as the drug in question. To obtain OrphanDrug status for a drug that shares the same active moiety as analready approved drug, it must be demonstrated to the FDA that thedrug is safer or more effective than the approved orphan designateddrug, or that it makes a major contribution to patient care. Inaddition, a designated orphan drug may not receive orphan drugexclusivity if it is approved for a use that is broader than theindication for which it received orphan designation. In addition,orphan drug exclusive marketing rights in the U.S. may be lost ifthe FDA later determines that the request for designation wasmaterially defective or if the manufacturer is unable to assuresufficient quantity of the drug to meet the needs of patients withthe rare disease or condition or if another drug with the sameactive moiety is determined to be safer, more effective, orrepresents a major contribution to patient care.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Our future growth may depend, in part, on our ability to penetrateforeign markets, where we would be subject to additional regulatoryburdens and other risks and uncertainties.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our future profitability may depend, in part, on our ability tocommercialize our product candidates in foreign markets for whichwe may rely on collaboration with third parties such as ourcollaboration with AffaMed to develop and commercialize PH94B inkey Asian markets. If we commercialize our product candidates inforeign markets, we would be subject to additional risks anduncertainties, including:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              our customers’ ability to obtain reimbursement for ourproduct candidates in foreign markets;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              our inability to directly control commercial activities because weare relying on third parties;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the burden of complying with complex and changing foreignregulatory, tax, accounting and legal requirements;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              different medical practices and customs in foreign countriesaffecting acceptance in the marketplace;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              import or export licensing requirements;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              longer accounts receivable collection times;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              longer lead times for shipping;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              language barriers for technical training;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              reduced protection of intellectual property rights, differentstandards of patentability and different availability of prior artin some foreign countries as compared with the U.S.;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the existence of additional potentially relevant third partyintellectual property rights;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              foreign currency exchange rate fluctuations; and             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the interpretation of contractual provisions governed by foreignlaws in the event of a contract dispute.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Foreign sales of our product candidates could also be adverselyaffected by the imposition of governmental controls, political andeconomic instability, trade restrictions and changes intariffs.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -46-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <br/>        </font>        <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">          We are a development stage biopharmaceutical company with norecurring revenues from product sales or approved products, andlimited experience developing new therapeutic product candidates,including conducting clinical trials and other areas required forthe successful development and commercialization of therapeuticproducts, which makes it difficult to assess our futureviability.         </font>        </div>        <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px;">         </font>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We are a development stage biopharmaceutical company. We currentlyhave no approved products and no recurring revenues from productsales, and we have not yet fully demonstrated an ability toovercome many of the fundamental risks and uncertainties frequentlyencountered by development stage companies in new and rapidlyevolving fields of technology, particularly biotechnology. Toexecute our business plan successfully, we will need to accomplishor continue to accomplish the following fundamental objectives,either on our own or with collaborators:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              develop and obtain required regulatory approvals forcommercialization of PH94B, PH10, AV-101 and/or other CNS productcandidates;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              maintain, leverage and expand our intellectual propertyportfolio;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              establish and maintain sales, distribution and marketingcapabilities, and/or enter into strategic partnering arrangementsto access such capabilities;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              gain market acceptance for our product candidates; and             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              obtain adequate capital resources and manage our spending as costsand expenses increase due to research, production, development,regulatory approval and commercialization of productcandidates.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">          Our future success is highly dependent upon our ability tosuccessfully develop and commercialize any of our current CNSproduct candidates, acquire or license additional CNS productcandidates, and we cannot provide any assurance that we willsuccessfully develop and commercialize PH94B, PH10, AV-101 oracquire or license additional CNS product candidates, or that, ifproduced, PH94B, PH10, AV-101 or any other CNS product candidatewill be successfully commercialized.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; font-family: Times New Roman; font-size: 13px">          Businessdevelopment and research and development programs designed toidentify, acquire or license additional product candidates requiresubstantial technical, financial and human resources, whether ornot any additional CNS product candidate is acquired orlicensed.         </font>        </font>        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Weare in the beginning stages of building a sales and marketinginfrastructure, including hiring certain executive officers andother employees that have pharmaceutical sales, marketing ordistribution experience. In addition, if beneficial, we may seek tocollaborate with others to develop and commercialize PH94B, PH10,AV-101, and/or other CNS product candidates if and when they areacquired and developed, or we may seek to establish thosecommercial capabilities ourselves.  If we enter intoarrangements with third parties to perform sales, marketing anddistribution services for our products, the resulting revenues orthe profitability from these revenues to us are likely to be lowerthan if we had sold, marketed and distributed our productsourselves. In addition, we may not be successful entering intoarrangements with third parties to sell, market and distributePH94B, PH10, AV-101, or other CNS product candidates or may beunable to do so on terms that are favorable to us.  Welikely will have little control over such third parties, and any ofthese third parties may fail to devote the necessary resources andattention to sell, market and distribute our productseffectively.  If we do not establish sales, marketing anddistribution capabilities successfully, either on our own or incollaboration with third parties, we will not be successful incommercializing our product candidates.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <br/>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -47-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         If we fail to comply with environmental, health and safety laws andregulations, we could become subject to fines or penalties or incurcosts that could have a material adverse effect on the success ofour business.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We are subject to numerous environmental, health and safety lawsand regulations, including those governing laboratory proceduresand the handling, use, storage, treatment and disposal of hazardousmaterials and wastes. Our operations involve the use of hazardousand flammable materials, including chemicals and biologicalmaterials. Our operations also produce hazardous waste products. Wegenerally contract with third parties for the disposal of thesematerials and wastes. We cannot eliminate the risk of contaminationor injury from these materials. In the event of contamination orinjury resulting from our use of hazardous materials, we could beheld liable for any resulting damages, and any liability couldexceed our resources. We also could incur significant costsassociated with civil or criminal fines and penalties.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Although we maintain workers' compensation insurance to cover usfor costs and expenses we may incur due to injuries to ouremployees resulting from the use of hazardous materials, thisinsurance may not provide adequate coverage against potentialliabilities. We do not maintain insurance for environmentalliability or toxic tort claims that may be asserted against us inconnection with our storage or disposal of biological, hazardous orradioactive materials.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In addition, we may incur substantial costs to comply with currentor future environmental, health and safety laws and regulations.These current or future laws and regulations may impair ourresearch, development, or production efforts. Failure to complywith these laws and regulations also may result in substantialfines, penalties, or other sanctions, which could have a materialadverse effect on our operations.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <br/>        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -48-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Risks Related to Our Financial Position        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         We have incurred significant net losses since inception and we willcontinue to incur substantial operating losses for the foreseeablefuture. We may never achieve or sustain profitability, which woulddepress the market price of our common stock and could cause you tolose all or a part of your investment.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We have incurred significant net losses in each fiscal year sinceour inception in 1998, including net losses of approximately $17.9million and $20.8 million during our fiscal years ended March 31,2021 and 2020, respectively. At March 31, 2021, we had anaccumulated deficit of approximately $242.8 million. We do not knowwhether or when we will become profitable. Substantially all of ouroperating losses have resulted from costs incurred in connectionwith our research and development programs and from general andadministrative costs associated with our operations. We expect toincur increasing levels of operating losses over the next severalyears and for the foreseeable future. Our prior losses, combinedwith expected future losses, have had and will continue to have anadverse effect on our stockholders’ equity and workingcapital. We expect our research and development expenses tosignificantly increase in connection with nonclinical studies andclinical trials of our product candidates. In addition, if weobtain marketing approval for our product candidates, we may incursignificant sales, marketing and outsourced-manufacturing expensesshould we elect not to collaborate with one or more third partiesfor such services and capabilities. As a public company, we incuradditional costs associated with operating as a public company. Asa result, we expect to continue to incur significant and increasingoperating losses for the foreseeable future. Because of thenumerous risks and uncertainties associated with developingpharmaceutical products, we are unable to predict the extent of anyfuture losses or when we will become profitable, if at all. Even ifwe do become profitable, we may not be able to sustain or increaseour profitability on a quarterly or annual basis.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our ability to become profitable depends upon our ability togenerate recurring revenues. Through March 31, 2021, we havegenerated approximately $22.7 million in revenues, consisting ofreceipts of non-dilutive cash payments from collaborators,sublicense revenue, including the $5.0 million cash paymentreceived under the AffaMed Agreement during the quarter endedSeptember 30, 2020, the majority of which has been recorded asdeferred revenue at March 31, 2021, and research and developmentgrant awards from the NIH. We have not yet commercialized anyproduct or generated any revenues from product sales, and we do notknow when, or if, we will generate any revenue from product sales.We do not expect to generate significant revenue unless and untilwe obtain marketing approval of, and begin to experience sales of,PH94B, PH10, AV-101 or another future CNS product candidate, or weenter into one or more development and commercialization agreementswith respect to PH94B, PH10, AV-101 or one or more other future CNSproduct candidates. Our ability to generate recurring revenuedepends on a number of factors, including, but not limited to, ourability to:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              initiate and successfully complete nonclinical and clinical trialsthat meet their prescribed endpoints;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              initiate and successfully complete all safety studies required toobtain U.S. and foreign marketing approval for our CNS productcandidates;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              timely complete and compose successful regulatory submissions suchas NDAs or comparable documents for both the U.S. and foreignjurisdictions;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              commercialize our CNS product candidates, if approved, bydeveloping a sales force or entering into collaborations with thirdparties for sales and marketing capabilities; and             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              achieve market acceptance of our CNS product candidates in themedical community and with third-party payors.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -49-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         If our Phase 3 studies of PH94B for the acute treatment of anxietyin adults with SAD are successful, unless we enter into acontractual arrangement for the commercialization of PH94B in theU.S., we expect to incur significant sales and marketing costs aswe prepare to commercialize PH94B on our own in the U.S. Even if weinitiate and successfully complete Phase 3 clinical trials of PH94Band our other CNS product candidates, and all of our CNS productcandidates are approved for commercial sale, and despite expendingsubstantial capital for sales and marketing costs, PH94B and ourother product candidates may not be commercially successful. We maynot achieve profitability soon after generating product sales, ifever. If we are unable to generate product revenue, we will notbecome profitable and may be unable to continue operations withoutcontinued funding.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         We require additional financing to execute our long-term businessplan.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Since our inception, a substantial portion of our resources havebeen dedicated to research and development of AV-101 andVistaStem’s stem cell technology platform. In particular, (i)for AV-101, we have expended substantial resources on research anddevelopment of methods and processes relating to the production ofAPI and drug product, IND-enabling preclinical studies, Phase 1clinical safety studies, and a Phase 2 clinical study completed in2019 and (ii) for VistaStem, development of         </font>         <font style="color: #000000">          cardiac stem cell technology. In addition,beginning in 2018, we have expended a considerable portion of ourresources for research, development, manufacturing and regulatoryexpenses related to the development and production of PH94B,including costs related to the PALISADE Phase 3 program, and PH10.We expect to continue to expend substantial resources for theforeseeable future developing and commercializing our CNS productcandidates on our own or in collaborations. These expenditures willinclude costs associated with general and administrative costs,facilities costs, research and development, acquiring newtechnologies, manufacturing product candidates, conductingnonclinical experiments and clinical trials and obtainingregulatory approvals, as well as commercializing any productsapproved for sale.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         At March 31, 2021, we had cash and cash equivalents ofapproximately $103.1 million. We believe this amount is sufficientto enable us to fund our planned operations for at least the twelvemonths following the issuance of the financial statements includedelsewhere in this Report.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Although we received the $5 million non-dilutive cash upfrontpayment under the AffaMed Agreement in August 2020 and expect torecognize that amount as revenue in future periods, we have noother recurring source of revenue or recurring cash flows fromproduct sales to sustain our present activities, and we do notexpect to generate sustainable positive operating cash flows until,and unless, we (i) out-license or sell a product candidate to athird-party that is subsequently successfully developed andcommercialized, (ii) enter into additional license arrangementsinvolving our stem cell technology, or (iii) obtain approval fromthe FDA or other regulatory authorities and successfullycommercialize PH94B, on our own or through a future collaboration,or one of our other product candidates.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         As the outcome of our ongoing research and development activities,including the outcome of future anticipated nonclinical studies andclinical trials is highly uncertain, we cannot reasonably estimatethe actual amounts necessary to successfully complete thedevelopment and commercialization of our current CNS productcandidates, on our own or in collaboration with others. As in priorperiods, we will continue to incur substantial costs associatedwith other development programs for PH94B, PH10 and AV-101. Inaddition, other unanticipated costs may arise. As a result of theseand other factors, we will need to seek additional capital to meetour future operating plans and requirements, including capitalnecessary to develop, obtain regulatory approval for, and tocommercialize our CNS product candidates, and may seek additionalcapital in the event there exists favorable market conditions orstrategic considerations, even if we believe we have sufficientfunds for our current or future operating plans and requirements.We have completed in the past a range of potential financingtransactions, including public or private equity or debtfinancings, government or other third-party funding, marketing anddistribution arrangements and other collaborations, strategicalliances and licensing arrangements or a combination of theseapproaches, and we may pursue and complete additional financingarrangements in the future. Even if we believe we have sufficientfunds for our current or future operating plans and requirements,we may seek additional capital if market conditions are favorableor if we have specific strategic considerations.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -50-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our future capital requirements may depend on many factors,including:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the number and characteristics of the product candidates wepursue;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the scope, progress, results and costs of researching anddeveloping our product candidates, and conducting preclinical andclinical studies;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the timing of, and the costs involved in, obtaining regulatoryapprovals for our product candidates;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the cost of commercialization activities if any of our productcandidates are approved for sale, including marketing, sales anddistribution costs;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the cost of manufacturing and formulating our product candidatesand any products we successfully commercialize;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              our ability to establish and maintain strategic partnerships,licensing or other collaborative arrangements and the financialterms of such agreements;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              market acceptance of our product candidates;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the effect of competing technological and marketdevelopments;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              our ability to obtain government funding for our research anddevelopment programs;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the costs involved in obtaining, maintaining and enforcing patentsto preserve our intellectual property;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the costs involved in defending against such claims that weinfringe third-party patents or violate other intellectual propertyrights and the outcome of such litigation;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the timing, receipt and amount of potential future licensee fees,milestone payments, and sales of, or royalties on, our futureproducts, if any; and             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the extent to which we may acquire or invest in additionalbusinesses, product candidates and technologies.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Any additional fundraising efforts will divert certain members ofour management team from their day-to-day activities, which mayadversely affect our ability to develop and commercialize ourproduct candidates. We cannot guarantee that future financing willbe available in sufficient amounts, in a timely manner, or on termsacceptable to us, if at all. The terms of any future financing mayadversely affect the holdings or the rights of our stockholders andthe issuance of additional securities, whether equity or debt, byus, or the possibility of such issuance, may cause the market priceof our shares to decline. The sale of additional equity securitiesand the conversion, exchange or exercise of certain of ouroutstanding securities will dilute all of our stockholders. Theincurrence of debt could result in increased fixed paymentobligations and we could be required to agree to certainrestrictive covenants, such as limitations on our ability to incuradditional debt, limitations on our ability to acquire, sell orlicense intellectual property rights and other operatingrestrictions that could adversely impact our ability to conduct ourbusiness. We could also be required to seek funds througharrangements with collaborative partners or otherwise at an earlierstage than otherwise would be desirable and we may be required torelinquish rights to some of our technologies or product candidatesor otherwise agree to terms unfavorable to us, any of which mayhave a material adverse effect on our business, operating resultsand prospects.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         When necessary, if we are unable to obtain additional funding on atimely basis and on acceptable terms, we may be required tosignificantly curtail, delay or discontinue one or more of ourresearch or product development programs or the commercializationof any product candidate or be unable to continue or expand ouroperations or otherwise capitalize on our business opportunities,as desired, which could materially affect our business, financialcondition and results of operations.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Current volatile and/or recessionary economic conditions in theU.S. or abroad could adversely affect our business or our access tocapital markets in a material manner.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; background-color: #FFFFFF">          To date, our principal sources of capital used to fund ourdevelopment programs and other operations have been the netproceeds we received from sales of equitysecurities.         </font>         <font style="color: #000000">          We have andwill continue to use significant capital for the development andcommercialization of our product candidates, and, as such, weexpect to seek additional capital from future issuance(s) of oursecurities, which may consist of issuances of equity and/or debtsecurities, to fund our planned operations.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Accordingly, our results of operations and the implementation ofboth our short-term and long-term business plan could be adverselyaffected by general conditions in the global economy, includingconditions that are outside of our control, such as the impact ofhealth and safety concerns from the current COVID-19 pandemic. Theongoing COVID-19 pandemic has resulted in extreme volatility anddisruptions in the capital and credit markets. A prolonged economicdownturn could result in a variety of risks to our business and mayhave a material adverse effect on us, including limiting orrestricting our ability to access capital on favorable terms, or atall, which would limit our ability         </font>         <font style="color: #000000; background-color: #FFFFFF">          to obtain adequatefinancing to maintain our operations.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -51-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic; color: #000000">          We have identifiedmaterial weaknesses in our internal control over financialreporting, and our business and stock price may be adverselyaffected if we do not adequately address those weaknesses or if wehave other material weaknesses or significant deficiencies in ourinternal control over financial reporting         </font>         <font style="color: #000000">          .         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">         We have identified and are now taking steps to correct materialweaknesses in our internal control over financial reporting. Inparticular, we concluded that (i) the size of our staff has notallowed appropriate segregation of duties to (a) permit appropriatereview of accounting transactions and/or accounting treatment bymultiple qualified individuals, and (b) prevent one individual fromoverriding the internal control system by initiating, authorizingand completing all transactions, and (ii) we have utilizedaccounting software that did not prevent erroneous or unauthorizedchanges to previous reporting periods and/or could be adjusted soas to not provide an adequate auditing trail of entries made in theaccounting software.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; background-color: #FFFFFF">          T         </font>         <font style="color: #000000">          he existence of one or morematerial weaknesses or significant deficiencies could result inerrors in our financial statements, and substantial costs andresources may be required to rectify any internal controldeficiencies. If we cannot produce reliable financial reports,investors could lose confidence in our reported financialinformation, we may be unable to obtain additional financing tooperate and expand our business and our business and financialcondition could be harmed.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Raising additional capital will cause substantial dilution to ourexisting stockholders, may restrict our operations or require us torelinquish rights, and may require us to seek stockholder approvalto authorize additional shares of our common stock.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We may pursue private and public equity offerings, debt financings,strategic collaborations and licensing arrangements in the future.To the extent that we raise additional capital through the sale ofcommon stock or securities convertible or exchangeable into commonstock, or to the extent, for strategic purposes, we convert orexchange certain of our outstanding securities into common stock,our current stockholders’ ownership interest in our companywill be substantially diluted. In addition, the terms of any suchsecurities may include liquidation or other preferences thatmaterially adversely affect rights of our stockholders. Debtfinancing, if available, would increase our fixed paymentobligations and may involve agreements that include covenantslimiting or restricting our ability to take specific actions, suchas incurring additional debt, making capital expenditures ordeclaring dividends. If we raise additional funds throughcollaboration, strategic partnerships and licensing arrangementswith third parties, we may have to relinquish valuable rights toour product candidates, our intellectual property, future revenuestreams or grant licenses on terms that are not favorable tous.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         We may be required to raise additional financing by issuing newsecurities with terms or rights superior to those of our existingsecurityholders, which could adversely affect the market price ofshares of our common stock and our business.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We will require additional financing to fund future operations,including our research and development activities for our CNSproduct candidates and our anticipated pre-launch commercializationactivities, assuming our clinical development programs aresuccessful and we receive necessary approvals from the FDA. We maynot be able to obtain financing on favorable terms, if at all. Ifwe raise additional funds by issuing equity securities, thepercentage ownership of our current stockholders will be reduced,and the holders of the new equity securities may have rightssuperior to those of our existing security holders, which couldadversely affect the market price of our common stock and thevoting power of shares of our common stock. If we raise additionalfunds by issuing debt securities, the holders of these debtsecurities would similarly have some rights senior to those of ourexisting securityholders, and the terms of these debt securitiescould impose restrictions on operations and create a significantinterest expense for us, which could have a materially adverseeffect on our business.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Our ability to use net operating losses to offset future taxableincome is subject to certain limitations.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          As of March 31, 2021, we had federal and state net operatingloss carryforwards of approximately $139.2 million and $64.6million, respectively, which have begun to expire in fiscal 2022and will continue to expire in future periods.  UnderSection 382 of the Internal Revenue Code of 1986, as amended(the         </font>         <font style="font-style: italic; color: #000000">          Code         </font>         <font style="color: #000000">          ), changes in our ownership may limit the amountof our net operating loss carryforwards that could be utilizedannually to offset our future taxable income, if any. Thislimitation would generally apply in the event of a cumulativechange in ownership of our company of more than 50% within athree-year period. Any such limitation may significantly reduce ourability to utilize our net operating loss carryforwards and taxcredit carryforwards before they expire. Any such limitation,whether as the result of future offerings, prior privateplacements, sales of our common stock by our existing stockholdersor additional sales of our common stock by us in the future, couldhave a material adverse effect on our results of operations infuture years. We have not completed a study to assess whether anownership change for purposes of Section 382 has occurred, orwhether there have been multiple ownership changes since ourinception, due to the significant costs and complexities associatedwith such study.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -52-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         General Company-Related Risks        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         If we fail to attract and retain senior management and keyscientific personnel, we may be unable to successfully produce,develop and commercialize our product candidates.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our success depends in part on our continued ability to attract,retain and motivate highly qualified management and scientific andtechnical personnel. We are highly dependent upon our ChiefExecutive Officer, President and Chief Scientific Officer, ChiefMedical Officer, Chief Financial Officer, Chief Commercial Officerand Senior Vice President – Head of CMC, as well as our otheremployees, advisors, consultants and scientific and clinicalcollaborators. As of the date of this Report, we have 21 full-timeemployees, which may make us more reliant on our individualemployees than companies with a greater number of employees. Theloss of services of any of these individuals could delay or preventthe successful development of our product candidates or disrupt ouradministrative functions.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Although we have not historically experienced unique difficultiesattracting and retaining qualified employees, we could experiencesuch problems in the future. For example, competition for qualifiedpersonnel in the pharmaceuticals field is intense. We will need tohire additional personnel to expand our administrative, researchand development and commercial activities. We may not be able toattract and retain quality personnel on acceptableterms.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In addition, we rely on a broad and diverse range of strategicconsultants and advisors, including manufacturing, nonclinical andclinical development and regulatory advisors and CMOs and CROs, toassist us in designing and implementing our research anddevelopment and regulatory strategies and plans for our productcandidates. Our consultants and advisors may be employed byemployers other than us and may have commitments under consultingor advisory contracts with other entities that may limit theiravailability to us.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         As we seek to advance development of our product candidates, we mayneed to expand our research and development capabilities and/orcontract with third parties to provide these capabilities for us.As our operations expand, we expect that we will need to manageadditional relationships with various strategic partners and otherthird parties. Future growth will impose significant addedresponsibilities on members of management. Our future financialperformance and our ability to develop and commercialize ourproduct candidates and to compete effectively will depend, in part,on our ability to manage any future growth effectively. To thatend, we must be able to manage our research and development effortseffectively and hire, train and integrate additional management,administrative, commercial and technical personnel. The hiring,training and integration of new employees may be more difficult,costly and/or time-consuming for us because we have fewer resourcesthan a larger organization. We may not be able to accomplish thesetasks, and our failure to accomplish any of them could prevent usfrom successfully growing the company.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         If product liability lawsuits are brought against us, we may incursubstantial liabilities and may be required to limitcommercialization of our product candidates.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         As we develop our product candidates. either on our own or incollaboration with others, we will face inherent risks of productliability as a result of the required clinical testing of suchproduct candidates, and will face an even greater risk if we or ourcollaborators commercialize any such product candidates. Forexample, we may be sued if PH94B, PH10, AV-101, or any otherproduct candidate we or our collaborators develop allegedly causesinjury or is found to be otherwise unsuitable during producttesting, manufacturing, marketing or sale. Any such productliability claims may include allegations of defects inmanufacturing, defects in design, a failure to warn of dangersinherent in the product, negligence, strict liability, and a breachof warranties. Claims could also be asserted under state consumerprotection acts. If we cannot successfully defend ourselves againstproduct liability claims, we may incur substantial liabilities orbe required to limit commercialization of our product candidates.Even successful defense would require significant financial andmanagement resources. Regardless of the merits or eventual outcome,liability claims may result in:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              decreased demand for product candidates that we maydevelop;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              injury to our reputation;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              withdrawal of clinical trial participants;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              costs to defend the related litigation;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              a diversion of management's time and our resources;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              substantial monetary awards to trial participants or patients;or             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              product recalls, withdrawals or labeling, marketing or promotionalrestrictions.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -53-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our inability to obtain and retain sufficient product liabilityinsurance at an acceptable cost to protect against potentialproduct liability claims could prevent or inhibit thecommercialization of products we develop. Although we maintaingeneral and product liability insurance, any claim that may bebrought against us could result in a court judgment or settlementin an amount that is not covered, in whole or in part, by ourinsurance or that is in excess of the limits of our insurancecoverage. Our insurance policies also have various exclusions, andwe may be subject to a product liability claim for which we have nocoverage. We will have to pay any amounts awarded by a court ornegotiated in a settlement that exceed our coverage limitations orthat are not covered by our insurance, and we may not have, or beable to obtain, sufficient capital to pay suchamounts.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Unfavorable global economic or political conditions could adverselyaffect our business, financial condition or results ofoperations.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our results of operations could be adversely affected by globalpolitical conditions, as well as general conditions in the globaleconomy and in the global financial and stock markets. Globalfinancial and political crises cause extreme volatility anddisruptions in the capital and credit markets. A severe orprolonged economic downturn, such as the recent economic downturntriggered by the ongoing COVID-19 pandemic, could result in avariety of risks to our business, including, weakened demand forour product candidates and our ability to raise additional capitalwhen needed on acceptable terms, if at all. A weak or decliningeconomy could also strain our suppliers, possibly resulting insupply disruption, or cause our customers to delay making paymentsfor our services. Any of the foregoing could harm our business andwe cannot anticipate all of the ways in which the current economicclimate and financial market conditions could adversely impact ourbusiness.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         We or the third parties upon whom we depend may be adverselyaffected by natural disasters and our business continuity anddisaster recovery plans may not adequately protect us from aserious disaster.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Natural disasters could severely disrupt our operations, and have amaterial adverse effect on our business, results of operations,financial condition and prospects. If a natural disaster, poweroutage or other event occurred that prevented us from using all ora significant portion of our headquarters, that damaged criticalinfrastructure, such as the manufacturing facilities of ourthird-party CMOs, or that otherwise disrupted operations, it may bedifficult or, in certain cases, impossible for us to continue ourbusiness for a substantial period of time. The disaster recoveryand business continuity plans we have in place may prove inadequatein the event of a serious disaster or similar event. We may incursubstantial expenses as a result of the limited nature of ourdisaster recovery and business continuity plans, which could have amaterial adverse effect on our business.        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic; color: #000000">          Our business andoperations would suffer in the event of cybersecurity or othersystem failures.  Our business depends on complex informationsystems, and any failure to successfully maintain these systems orimplement new systems to handle our changing needs could result ina material disruption of our product candidates’ developmentprograms or otherwise materially harm ouroperations.         </font>         <font style="color: #000000">         </font>        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In the ordinary course of our business, we collect and storesensitive data, including intellectual property, our proprietarybusiness information and that of our suppliers, as well aspersonally identifiable information of employees. Similarly, ourthird-party CROs, CMOs and other contractors and consultantspossess certain of our sensitive data. The secure maintenance ofthis information is material to our operations and businessstrategy. Despite the implementation of security measures, ourinternal computer systems and those of our third-party CROs, CMOsand other contractors and consultants are vulnerable to attacks byhackers, damage from computer viruses, unauthorized access, breachdue to employee error, malfeasance or other disruptions, naturaldisasters, terrorism and telecommunication and electricalfailures.         </font>         Additionally, having shifted substantially toremote working arrangements, we also face a heightened risk ofcybersecurity attacks or data security incidents and are moredependent on internet and telecommunications access andcapabilities.         <font style="color: #000000">          Any such attack orbreach could compromise our networks and the information storedthere could be accessed, publicly disclosed, lost or stolen. Thelegislative and regulatory landscape for privacy and dataprotection continues to evolve, and there has been an increasingamount of focus on privacy and data protection issues with thepotential to affect our business, including recently enacted lawsin a majority of states requiring security breach notification.Thus, any access, disclosure or other loss of information,including our data being breached at our partners or third-partyproviders, could result in legal claims or proceedings andliability under laws that protect the privacy of personalinformation, disruption of our operations, and damage to ourreputation, which could adversely affect ourbusiness.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         While we have not experienced any such system failure, accident, orsecurity breach to date, if such an event were to occur and causeinterruptions in our operations, it could result in a materialdisruption of our programs. For example, the loss of clinical trialdata for PH94B, PH10, AV-101 or other product candidates couldresult in substantial delays in our regulatory approval efforts andsignificantly increase our costs to recover or reproduce the data.To the extent that any disruption or security breach results in aloss of or damage to our data or applications or other data orapplications relating to our technology or product candidates, orinappropriate disclosure of confidential or proprietaryinformation, we could incur liabilities and the further developmentof our product candidates could be delayed.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -54-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         We may acquire businesses or product candidates, or form strategicalliances, in the future, and we may not realize the benefits ofsuch acquisitions.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We may acquire additional businesses or CNS product candidates,form strategic alliances or create joint ventures with thirdparties that we believe will complement or augment our existingbusiness. If we acquire businesses with promising markets ortechnologies, we may not be able to realize the benefit ofacquiring such businesses if we are unable to successfullyintegrate them with our existing operations and company culture. Wemay encounter numerous difficulties in developing, manufacturingand marketing any new product candidates resulting from a strategicalliance, licensing transaction or acquisition that delay orprevent us from realizing their expected benefits or enhancing ourbusiness. We cannot assure you that, following any such acquisitionor licensing transaction, we will achieve the expected synergies tojustify the transaction.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Current politics in the U.S. could diminish the value of thepharmaceutical industry, thereby diminishing the value of oursecurities.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The current political environment in the U.S. has led manyincumbents and political candidates to propose various measures toreduce the prices for pharmaceuticals. As a result of the U.S.presidential 2020 elections, it is likely that these proposals willreceive increasing publicity which, in turn, may cause theinvesting public to reduce the perceived value of pharmaceuticalcompanies. Any decrease in the overall perception of thepharmaceutical industry may have an adverse impact on our shareprice and may limit our ability to raise capital needed to continueour drug development programs.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Risks Related to Our Intellectual Property Rights        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         If we are unable to adequately protect our proprietary technologyor obtain and maintain issued patents that are sufficient toprotect our product candidates, others could compete against usmore directly, which would have a material adverse impact on ourbusiness, results of operations, financial condition andprospects.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We strive to protect and enhance the proprietary technologies thatwe believe are important to our business, including seeking patentsintended to cover our product candidates, their compositions andformulations, their methods of use and methods of manufacturing andany other inventions we consider important to the development ofour business. We also rely on trade secrets to protect aspects ofour business that are not amenable to, or that we do not considerappropriate for, patent protection.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our success will depend significantly on our ability to obtain andmaintain patent and other proprietary protection for commerciallyimportant technology, inventions and know-how related to ourbusiness, to defend and enforce our patents, to preserve theconfidentiality of our trade secrets and to operate withoutinfringing the valid and enforceable patents and proprietary rightsof third parties. We also rely on know-how, continuingtechnological innovation and in-licensing opportunities to develop,strengthen and maintain the proprietary position of our productcandidates. We own and have licensed patents and patentapplications related to product candidates PH94B, PH10, AV-101 andalso to certain stem cell technology.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Although we own and have licensed issued and allowed patents andpatent applications relating to PH94B, PH10 and AV-101 in the U.S.,selected countries in the EU and other jurisdictions, we cannot yetprovide any assurances that any of our pending U.S. and additionalforeign patent applications will mature into issued patents and, ifthey do, that any of our patents will include claims with a scopesufficient to protect our product candidates or otherwise provideany competitive advantage.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Moreover, other parties may have developed technologies that may berelated or competitive to our approach and may have filed or mayfile patent applications and may have received or may receivepatents that may overlap or conflict with our patent properties,for example, either by claiming the same methods or formulations orby claiming subject matter that could dominate our patent position.Such third-party patent positions may limit or even eliminate ourability to obtain or maintain patent protection.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The uncertainty about adequate protection includes changes to thepatent laws through either legislative action to change statutorypatent law or court action that may reinterpret existing law inways affecting the scope or validity of issued patents. Moreover,relevant laws differ from country-to-country.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         The patent positions of biotechnology and pharmaceutical companies,including our patent portfolio with respect to our productcandidates, involve complex legal and factual questions, and,therefore, the issuance, scope, validity and enforceability of anypatent claims that we may be granted cannot be predicted withcertainty.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our ability to obtain valid and enforceable patents depends, amongother factors, on whether the differences between our technologyand the prior art allow our inventions to be patentableover relevant prior art. Such prior art includes, for example,scientific publications, investment blogs, granted patents andpublished patent applications. Patent uncertainty cannot beeliminated because of the potential existence of other prior art,about which we are currently unaware, that may be relevant to ourpatent applications and patents and that may prevent a pendingpatent application from being granted or result in an issued patentbeing held invalid or unenforceable. Moreover, the relevantstandards for granting and reviewing patents varies among countriesin which we pursue patents.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -55-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In addition, some patent-related uncertainty exists because of thechallenge in finding and addressing all of the relevant andmaterial prior art in the biotechnology and pharmaceuticalfields. For example, there are numerous reports in the scientificliterature of compounds that target similar cellular receptors asdo certain of our product candidates or that were evaluated inearly (often pre-clinical) studies that did not progress toregulatory approval. In addition, even some reports in the tradepress and public announcements made by us before the filing date ofour AV-101 patent applications mentioned that AV-101 was indevelopment for certain therapeutic purposes. For example, wepublished a web post on the NIH clinical trials website prior tothe filing of our initial AV-101 patent application, whichdescribes unit doses for a then future study, but does not mentiontreatment of depression and does not provide any preclinical orclinical study data relating to depression or any other medicalcondition, disease or disorder. This post was not submitted to theUnited States Patent and Trademark Office (         </font>         <font style="font-style: italic; color: #000000">          USPTO         </font>         <font style="color: #000000">          ) in our two granted U.S. patents related to (i)unit dose formulations of AV-101 effective to treat depression and(ii) methods of treating depression with AV-101, respectively.However, it was submitted in two continuation depression-relatedAV-101 patent applications that have similar claims and the USPTOdid not make further rejection based on that post. Another sourceof uncertainty pertains to patent properties that were in-licensedby us for which prior art submissions were under the control of thelicensor. We rely on these licensors to have satisfied the relevantdisclosure obligations.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In the event any previously published prior art is deemed to beinvalidating prior art, it may cause certain of our issuedpatents to be invalid and/or unenforceable, which would cause us tolose at least part, and perhaps all, of the patent protection onrelevant product candidates. Such a loss of patent protection wouldhave a material adverse impact on our business.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Obtaining and maintaining our patent protection depends oncompliance with various procedural, document submission, feepayment and other requirements imposed by governmental patentagencies, and our patent protection could be reduced or eliminatedfor non-compliance with these requirements.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          The USPTO, the European Patent Office (         </font>         <font style="font-style: italic; color: #000000">          EPO         </font>         <font style="color: #000000">          ) and various other foreign governmental patentagencies require compliance with a number of procedural,documentary, fee payment and other provisions during the patentprocess. There are situations in which noncompliance can result inabandonment or lapse of a patent or patent application, resultingin partial or complete loss of patent rights in the relevantjurisdiction. In such an event, competitors might be able to enterthe market earlier than would otherwise have been thecase.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Even if patents do successfully issue, third parties may challengethe validity, enforceability or scope of such issued patents or anyother issued patents we own or license, which may result in suchpatents being narrowed, invalidated or heldunenforceable.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          United States and foreign patents and patent applications may besubject to various types of infringement and validity proceedings,including interference proceedings,         </font>         <font style="font-style: italic; color: #000000">          ex parte         </font>         <font style="color: #000000">          reexamination,         </font>         <font style="font-style: italic; color: #000000">          interpartes         </font>         <font style="color: #000000">          review proceedings,supplemental examination and challenges in district court. Patentsmay be subjected to opposition, post-grant review, invalidityactions, or comparable proceedings lodged in various foreign, bothnational and regional, patent offices or courts. These proceedingscould result in loss of the patent or denial of the patentapplication or loss or reduction in the scope of one or more of theclaims of the patent or patent in such a way that they no longercover our product candidates or competitiveproducts.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Furthermore, though an issued patent is presumed valid andenforceable, its issuance is not conclusive as to its validity orits enforceability and it may not provide us with adequateproprietary protection or competitive advantages againstcompetitors with similar products. Even if a patent issues and isheld to be valid and enforceable, competitors may be able to designaround our patents, for example, by using pre-existing or newlydeveloped technology. Other parties may develop and obtain patentprotection for more effective technologies, designs ormethods.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         If we or one of our licensing partners initiated legal proceedingsagainst a third-party to enforce a patent covering one of ourproduct candidates, including patents related to PH94B, PH10 orAV-101, the defendant could counterclaim that the patent coveringour product candidate is invalid and/or unenforceable. In patentlitigation in the United States, defendant counterclaims alleginginvalidity and/or unenforceability are commonplace. Grounds for avalidity challenge include alleged failures to meet any of severalstatutory requirements, including lack of novelty, obviousness ornon-enablement. Grounds for unenforceability assertions includeallegations that someone connected with prosecution of the patentwithheld relevant information from the USPTO or made a misleadingstatement during prosecution. Third parties may also raise similarclaims before administrative bodies in the United States or abroad,even outside the context of litigation. If a defendant were toprevail on a legal assertion of invalidity and/or unenforceability,we would lose at least part, and perhaps all, of the patentprotection on our product candidates. Such a loss of patentprotection would have a material adverse impact on ourbusiness.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In addition, such patent-related proceedings may be costly. Thus,any patent properties that we may own or exclusively licenseultimately may not provide commercially meaningful protectionagainst competitors. Furthermore, an adverse decision in aninterference proceeding can result in a third party receiving thepatent right sought by us, which in turn could affect our abilityto develop, market or otherwise commercialize our productcandidates.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -56-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We may not be able to prevent the unauthorized disclosure or use ofour technical knowledge or trade secrets by consultants, vendors,or former or current employees. The laws of some foreign countriesdo not protect our proprietary rights to the same extent as thelaws of the United States, and we may encounter significantproblems in protecting our proprietary rights in these countries.If these developments were to occur, they could have a materialadverse effect on our sales.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our ability to enforce our patent rights also depends on ourability to detect infringement. It is difficult to detectinfringers who do not advertise the components or manufacturingprocesses that are used in their products. Moreover, it may bedifficult or impossible to obtain evidence of infringement in acompetitor’s or potential competitor’s product. Anylitigation to enforce or defend our patent rights, even if we wereto prevail, could be costly and time-consuming and would divert theattention of our management and key personnel from our businessoperations. We may not prevail in any lawsuits that we initiate andthe damages or other remedies awarded if we were to prevail may notbe commercially meaningful.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In addition, proceedings to enforce or defend our patents could putour patents at risk of being invalidated, held unenforceable, orinterpreted narrowly. Such proceedings could also provoke thirdparties to assert claims against us, including that some or all ofthe claims in one or more of our patents are invalid or otherwiseunenforceable. If any patents covering our product candidates areinvalidated or found unenforceable, our financial position andresults of operations would be materially and adversely impacted.In addition, if a court found that valid, enforceable patents heldby third parties covered our product candidates, our financialposition and results of operations would also be materially andadversely impacted.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Overall, the degree of future protection for our proprietary rightsis uncertain, and we cannot ensure that:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               any issued patents related to PH94B, PH10, AV-101 or anypending patent applications, if issued and challenged by others,will include or maintain claims having a scope sufficient toprotect PH94B, PH10, AV-101 or any other products or productcandidates against generic or other competition, particularlyconsidering that any patent rights to these compounds              </font>              <font style="font-style: italic; color: #000000">               per se              </font>              <font style="color: #000000">               have expired;              </font>             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              any of our pending patent applications will issue as patents atall;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              we will be able to successfully commercialize our productcandidates, if approved, before our relevant patentsexpire;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              we were the first to make the inventions covered by each of ourpatents and pending patent applications;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              we were the first to file patent applications for theseinventions;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              others will not develop similar or alternative technologies that donot infringe our patents;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              others will not use pre-existing technology to effectively competeagainst us;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              any of our patents, if issued, will ultimately be found to be validand enforceable, including on the basis of prior art relating toour patent applications and patents;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              any patents currently held or issued to us in the future willprovide a basis for an exclusive market for our commercially viableproducts, will provide us with any competitive advantages or willnot be challenged by third parties;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              we will develop additional proprietary technologies or productcandidates that are separately patentable; or             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              our commercial activities or products will not infringe upon thepatents or proprietary rights of others.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We also rely upon unpatented trade secrets, unpatented know-how andcontinuing technological innovation to develop and maintain ourcompetitive position, which we seek to protect, in part, byconfidentiality agreements with our employees and our collaboratorsand consultants. It is possible that technology relevant to ourbusiness will be independently developed by a person that is not aparty to such an agreement.  Furthermore, if theemployees, collaborators and consultants who are parties to theseagreements breach or violate the terms of these agreements, we maynot discover or have adequate remedies for any such breach orviolation, and we could lose our trade secrets through suchbreaches or violations. Further, our trade secrets could otherwisebecome known or be independently discovered by ourcompetitors.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Third parties may initiate legal proceedings against us allegingthat we infringe their intellectual property rights, which mayprevent or delay our product development efforts and stop us fromcommercializing candidate products or increase the costs ofcommercializing them, if approved. Also, we may file counterclaimsor initiate other legal proceedings against third parties tochallenge the validity or scope of their intellectual propertyrights, the outcomes of which also would be uncertain and couldhave a material adverse effect on the success of ourbusiness.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We cannot assure that our business, product candidates and methodsdo not or will not infringe the patents or other intellectualproperty rights of third parties. Third parties may initiate legalproceedings against us or our licensors or collaborators allegingthat we or our licensors or collaborators infringe theirintellectual property rights. In addition, we or our licensors orcollaborators may file counterclaims in such proceedings orinitiate separate legal proceedings against third parties tochallenge the validity or scope of their intellectual propertyrights, including in oppositions, interferences,reexaminations,         </font>         <font style="font-style: italic; color: #000000">          inter partes         </font>         <font style="color: #000000">          reviews or derivation proceedingsbefore the United States or otherjurisdictions.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -57-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our success will depend in part on our ability to operate withoutinfringing the intellectual property and proprietary rights ofthird parties. Success also will depend on our ability to prevailin litigation if we are sued for infringement or to resolvelitigation matters with rights and at costs favorable tous.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The pharmaceutical industry is characterized by extensivelitigation regarding patents and other intellectual propertyrights. Other parties may allege that our product candidates or theuse of our technologies infringes patent claims or otherintellectual property rights held by them or that we are employingtheir proprietary technology without authorization. As we continueto develop and, if approved, commercialize our current productcandidates and future product candidates, competitors may claimthat our technology infringes their intellectual property rights aspart of their business strategies designed to impede our successfulcommercialization. There may be third-party patents or patentapplications with claims to materials, formulations, methods ofmanufacture or methods for treatment related to the use ormanufacture of our product candidates. Because patent applicationscan take many years to issue, third parties may have currentlypending patent applications that later result in issued patentsthat our product candidates may infringe, or that such thirdparties assert are infringed by our technologies.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The foregoing types of proceedings can be expensive andtime-consuming and many of our own or our licensors’ orcollaborators’ adversaries in these proceedings may have theability to dedicate substantially greater resources to prosecutingthese legal actions than we or our licensors or collaboratorscan. Our defense of litigation or other proceedings may failand, even if successful, may result in substantial costs anddistract our management and other employees. We may not be able toprevent, alone or with our licensors, misappropriation of ourintellectual property rights, particularly in countries where thelaws may not protect those rights as fully as in the United Statesor European Union.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The outcome of intellectual property litigation is subject touncertainties that cannot be adequately quantified in advance. Thecoverage of patents is subject to interpretation by the courts, andthe interpretation is not always uniform. If we are sued for patentinfringement, we would need to demonstrate that our productcandidates, products or methods either do not infringe the patentclaims of the relevant patent or that the patent claims areinvalid, and we may not be able to do this. Even if we aresuccessful in these proceedings, we may incur substantial costs andthe time and attention of our management and scientific personnelcould be diverted in pursuing these proceedings, which could have amaterial adverse effect on us. In addition, we may not havesufficient financial resources to bring these actions to asuccessful conclusion.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         An unfavorable outcome in the foregoing kinds of proceedings couldrequire us or our licensors or collaborators to cease using therelated technology or developing or commercializing our productcandidates, or to attempt to license rights to it from theprevailing party. Our business could be harmed if the prevailingparty does not offer us or our licensors or collaborators a licenseon commercially reasonable terms or at all. Even if we or ourlicensors or collaborators obtain a license, it may benon-exclusive, thereby giving our competitors access to the sametechnologies licensed to us or our licensors orcollaborators.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In addition, we could be found liable for monetary damages,including treble damages and attorneys’ fees, if we are foundto have willfully infringed a patent. A finding of infringementcould prevent us from commercializing our product candidates orforce us to cease some of our business operations, which couldmaterially harm our business.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Furthermore, because of the substantial amount of discoveryrequired in connection with intellectual property litigation, thereis a risk that some of our confidential information could becompromised by disclosure during this type of litigation. Therecould also be public announcements of the results of hearings,motions or other interim proceedings or developments. If securitiesanalysts or investors perceive these results to be negative, itcould have a material adverse effect on the price of our commonstock.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Patent and other types of intellectual property litigation caninvolve complex factual and legal questions, and their outcomes areuncertain. Any claim relating to intellectual property infringementthat is successfully asserted against us may require us to paysubstantial damages, including treble damages and attorney’sfees if we are found to have willfully infringed a thirdparty’s patents, for past use of the asserted intellectualproperty and royalties and other consideration going forward if weare forced to take a license. In addition, if any such claim issuccessfully asserted against us and we could not obtain such alicense, we may be forced to stop or delay developing,manufacturing, selling or otherwise commercializing our productcandidates.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Patent litigation is costly and time-consuming. We may not havesufficient resources to bring these actions to a successfulconclusion. Even if we are successful in these proceedings, we mayincur substantial costs and divert management time and attention inpursuing these proceedings, which could have a material adverseeffect on us. If we are unable to avoid infringing the patentrights of others, we may be required to seek a license, defend aninfringement action or challenge the validity of the patents incourt, or redesign our products.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -58-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In addition, intellectual property litigation or claims could forceus to do one or more of the following:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              cease developing, selling or otherwise commercializing our productcandidates;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              pay substantial damages for past use of the asserted intellectualproperty;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              obtain a license from the holder of the asserted intellectualproperty, which license may not be available on reasonable terms,if at all; and             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              in the case of trademark claims, redesign, or rename, some or allof our product candidates to avoid infringing the intellectualproperty rights of third parties, which may not be possible and,even if possible, could be costly and time-consuming.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Any of these risks coming to fruition could have a material adverseeffect on our business, results of operations, financial conditionand prospects.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We may be subject to claims challenging the inventorship orownership of our patents and other intellectualproperty.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We enter into confidentiality and intellectual property assignmentagreements with our employees, consultants, outside scientificcollaborators, sponsored researchers and other advisors. Theseagreements generally provide that inventions conceived by the partyin the course of rendering services to us will be our exclusiveproperty. However, these agreements may not be honored and may noteffectively assign intellectual property rights to us. For example,even if we have a consulting agreement in place with an academicadvisor pursuant to which such academic advisor is required toassign any inventions developed in connection with providingservices to us, such academic advisor may not have the right toassign such inventions to us, as it may conflict with his or herobligations to assign their intellectual property to his or heremploying institution.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Litigation may be necessary to defend against these and otherclaims challenging inventorship or ownership. If we fail indefending any such claims, in addition to paying monetary damages,we may lose valuable intellectual property rights, such asexclusive ownership of, or right to use, valuable intellectualproperty. Such an outcome could have a material adverse effect onour business. Even if we are successful in defending against suchclaims, litigation could result in substantial costs and be adistraction to management and other employees.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         We do not seek to protect our intellectual property rights in alljurisdictions throughout the world and we may not be able toadequately enforce our intellectual property rights even in thejurisdictions where we seek protection.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Filing, prosecuting and defending patents on product candidates inall countries and jurisdictions throughout the world isprohibitively expensive, and our intellectual property rights insome countries outside the U.S. could be less extensive than thosein the United States, assuming that rights are obtained in the U.S.In addition, the laws of some foreign countries do not protectintellectual property rights to the same extent as federal andstate laws in the U.S. Consequently, we may not be able to preventthird parties from practicing our inventions in all countriesoutside the U.S., or from selling or importing products made usingour inventions in and into the United States or otherjurisdictions. The statutory deadlines for pursuing patentprotection in individual foreign jurisdictions are based on thepriority date of each of our patent applications. For the pendingpatent applications relating to AV-101, as well as for other of thepatent families that we own or license, the relevant statutorydeadlines have not yet expired. Thus, for each of the patentfamilies that we believe provide coverage for our lead productcandidates or technologies, we will need to decide whether andwhere to pursue protection outside the U.S.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Competitors may use our technologies in jurisdictions where we donot pursue and obtain patent protection to develop their ownproducts and further, may export otherwise infringing products toterritories where we have patent protection, but enforcement is notas strong as that in the U.S. These products may compete with ourproducts and our patents or other intellectual property rights maynot be effective or sufficient to prevent them from competing. Evenif we pursue and obtain issued patents in particular jurisdictions,our patent claims or other intellectual property rights may not beeffective or sufficient to prevent third parties from socompeting.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The laws of some foreign countries do not protect intellectualproperty rights to the same extent as the laws of the U.S. Manycompanies have encountered significant problems in protecting anddefending intellectual property rights in certain foreignjurisdictions. The legal systems of some countries, particularlydeveloping countries, do not favor the enforcement of patents andother intellectual property protection, especially those relatingto biotechnology and pharmaceuticals. This could make it difficultfor us to stop the infringement of our patents, if obtained, or themisappropriation of our other intellectual property rights. Forexample, many foreign countries have compulsory licensing lawsunder which a patent owner must grant licenses to third partiesunder certain circumstances. In addition, many countries limit theenforceability of patents against third parties, includinggovernment agencies or government contractors. In these countries,patents may provide limited or no benefit. Patent protection mustultimately be sought on a country-by-country basis, which is anexpensive and time-consuming process with uncertain outcomes.Accordingly, we may choose not to seek patent protection in certaincountries, and we will not have the benefit of patent protection insuch countries.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -59-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         An unfavorable outcome could require us or our licensors orcollaborators to cease using the related technology or developingor commercializing our product candidates, or to attempt to licenserights to it from the prevailing party. Our business could beharmed if the prevailing party does not offer us or our licensorsor collaborators a license on commercially reasonable terms or atall. Even if we or our licensors or collaborators obtain a license,it may be non-exclusive, thereby giving our competitors access tothe same technologies licensed to us or our licensors orcollaborators. In addition, we could be found liable for monetarydamages, including treble damages and attorneys’ fees, if weare found to have willfully infringed a patent. A finding ofinfringement could prevent us from commercializing our productcandidates or force us to cease some of our business operations,which could materially harm our business.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Furthermore, because of the substantial amount of discoveryrequired in connection with intellectual property litigation, thereis a risk that some of our confidential information could becompromised by disclosure during this type of litigation. Therecould also be public announcements of the results of hearings,motions or other interim proceedings or developments. If securitiesanalysts or investors perceive these results to be negative, itcould have a material adverse effect on the price of our commonstock.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Furthermore, proceedings to enforce our patent rights in foreignjurisdictions could result in substantial costs and divert ourefforts and attention from other aspects of our business, could putour patents at risk of being invalidated or interpreted narrowly,could put our patent applications at risk of not issuing and couldprovoke third parties to assert claims against us. We may notprevail in any lawsuits that we initiate and the damages or otherremedies awarded, if any, may not be commercially meaningful.Accordingly, our efforts to enforce our intellectual propertyrights around the world may be inadequate to obtain a significantcommercial advantage from the intellectual property that we developor license.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         We are dependent, in part, on licensed intellectual property. If wewere to lose our rights to licensed intellectual property, we maynot be able to continue developing or commercializing our productcandidates, if approved. If we breach any of the agreements underwhich we license the use, development and commercialization rightsto our product candidates or technology from third parties or, incertain cases, we fail to meet certain development or paymentdeadlines, we could lose license rights that are important to ourbusiness.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         For PH94B, PH10 and certain stem cell technologies, we are a partyto a number of license agreements under which we are granted rightsto intellectual properties that are or could become important toour business. Our existing license agreements impose, and we expectthat any future license agreements will impose on us, variousdevelopment, regulatory and/or commercial diligence obligations,payment of fees, milestones and/or royalties and other obligations.If we fail to comply with our obligations under these agreements,or we are subject to a bankruptcy, the licensor may have the rightto terminate the license, in which event we would not be able todevelop or market products, which could be covered by the license.Our business could suffer, for example, if any current or futurelicenses terminate, if the licensors fail to abide by the terms ofthe license, if the licensed patents or other rights are found tobe invalid or unenforceable, or if we are unable to enter intonecessary licenses on acceptable terms.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         As we have done previously, we may need to obtain licenses fromthird parties to advance our research or allow commercialization ofour product candidates, and we cannot provide any assurances thatthird-party patents do not exist that might be enforced against ourcurrent product candidates or future products in the absence ofsuch a license. We may fail to obtain any of these licenses oncommercially reasonable terms, if at all. Even if we are able toobtain a license, it may be non-exclusive, thereby giving ourcompetitors access to the same technologies licensed to us. In thatevent, we may be required to expend significant time and resourcesto develop or license replacement technology. If we are unable todo so, we may be unable to develop or commercialize the affectedproduct candidates, which could materially harm our business andthe third parties owning such intellectual property rights couldseek either an injunction prohibiting our sales, or, with respectto our sales, an obligation on our part to pay royalties and/orother forms of compensation.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Licensing of intellectual property is of critical importance to ourbusiness and involves complex legal, business and scientificissues. Disputes may arise between us and our licensors regardingintellectual property subject to a license agreement,including:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the scope of rights granted under the license agreement and otherinterpretation-related issues;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              whether and the extent to which our technology and processesinfringe on intellectual property of the licensor that is notsubject to the licensing agreement;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              our right to sublicense patent and other rights to third partiesunder collaborative development relationships;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              our diligence obligations with respect to the use of the licensedtechnology in relation to our development and commercialization ofour product candidates, and what activities satisfy those diligenceobligations; and             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the ownership of inventions and know-how resulting from the jointcreation or use of intellectual property by our licensors and usand our partners.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         If disputes over intellectual property that we have licensedprevent or impair our ability to maintain our current licensingarrangements on acceptable terms, we may be unable to successfullydevelop and commercialize the affected productcandidates.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -60-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We have entered into several licenses, both in-license agreementsand out-license agreements, to support and leverage our variousstem cell technology-related programs. We may enter into additionallicense(s) to third-party intellectual property that are necessaryor useful to our business. Our current licenses, and any futurelicenses that we may enter into, impose various royalty payments,milestone, and other obligations on us. For example, the licensormay retain control over patent prosecution and maintenance under alicense agreement, in which case, we may not be able to adequatelyinfluence patent prosecution or prevent inadvertent lapses ofcoverage due to failure to pay maintenance fees. If we fail tocomply with any of our obligations under a current or futurelicense agreement, our licensor(s) may allege that we have breachedour license agreement and may accordingly seek to terminate ourlicense with them. In addition, future licensor(s) may decide toterminate our license at will. Termination of any of our current orfuture licenses could result in our loss of the right to use thelicensed intellectual property, which could materially adverselyaffect our ability to develop and commercialize a product candidateor product, if approved, as well as harm our competitive businessposition and our business prospects.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In addition, if our licensors fail to abide by the terms of thelicense, if the licensors fail to prevent infringement by thirdparties, if the licensed patents or other rights are found to beinvalid or unenforceable, or if we are unable to enter intonecessary licenses on acceptable terms our business couldsuffer.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Some intellectual property which we have licensed may have beendiscovered through government funded programs and thus may besubject to federal regulations such as “march-in”rights, certain reporting requirements, and a preference for U.S.industry. Compliance with such regulations may limit our exclusiverights, subject us to expenditure of resources with respect toreporting requirements, and limit our ability to contract withnon-U.S. manufacturers.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Some of the intellectual property rights we have licensed or willlicense in the future may have been generated through the use ofU.S. government funding and may therefore be subject to certainfederal regulations. As a result, the U.S. government may havecertain rights to intellectual property embodied in our current orfuture product candidates pursuant to the Bayh-Dole Act of 1980(         </font>         <font style="font-style: italic; color: #000000">          Bayh-DoleAct         </font>         <font style="color: #000000">          ). These U.S. governmentrights in certain inventions developed under a government-fundedprogram include a non-exclusive, non-transferable, irrevocableworldwide license to use inventions for any governmentalpurpose.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In addition, the U.S. government has the right to require us togrant exclusive, partially exclusive, or non-exclusive licenses toany of these inventions to a third party if it determines that:(i) adequate steps have not been taken to commercialize theinvention; (ii) government action is necessary to meet publichealth or safety needs; or (iii) government action isnecessary to meet requirements for public use under federalregulations (also referred to as “march-in rights”).The U.S. government also has the right to take title to theseinventions if we fail, or the applicable licensor fails, todisclose the invention to the government and fail to file anapplication to register the intellectual property within specifiedtime limits. Also, the U.S. government may acquire title to theseinventions in any country in which a patent application is notfiled within specified time limits.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Intellectual property generated under a government funded programis further subject to certain reporting requirements, compliancewith which may require us, or the applicable licensor, to expendsubstantial resources. In addition, the U.S. government requiresthat any products embodying the subject invention or producedthrough the use of the subject invention be manufacturedsubstantially in the U.S. The manufacturing preference requirementcan be waived if the owner of the intellectual property can showthat reasonable but unsuccessful efforts have been made to grantlicenses on similar terms to potential licensees that would belikely to manufacture substantially in the U.S. or that under thecircumstances domestic manufacture is not commercially feasible.This preference for U.S. manufacturers may limit our ability tocontract with non-U.S. product manufacturers for products coveredby such intellectual property.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In the event we apply for additional U.S. government funding, andwe discover compounds or drug candidates as a result of suchfunding, intellectual property rights to such discoveries may besubject to the applicable provisions of the Bayh-DoleAct.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         If we do not obtain additional protection under the Hatch-WaxmanAmendments and similar foreign legislation by extending the patentterms and obtaining data exclusivity for our product candidates,our business may be materially harmed.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In the U.S., depending upon the timing, duration and specifics ofFDA marketing approval of our product candidates, one or more ofthe U.S. patents we own or license may be eligible for limitedpatent term restoration under the Drug Price Competition and PatentTerm Restoration Act of 1984, referred to as the Hatch-WaxmanAmendments. The Hatch-Waxman Amendments permit a patent restorationterm of up to five years as compensation for patent term lostduring product development and the FDA regulatory review process.However, we may not be granted an extension because of, forexample, failing to apply within applicable deadlines, failing toapply prior to expiration of relevant patents or otherwise failingto satisfy applicable requirements. For example, we may not begranted an extension if the active ingredient of PH94B, PH10 orAV-101 is used in another drug company’s product candidateand that product candidate is the first to obtain FDAapproval.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Moreover, the applicable time period or the scope of patentprotection afforded could be less than we request. If we are unableto obtain patent term extension or restoration or the term of anysuch extension is less than we request, our competitors may obtainapproval of competing products following our patent expiration, andour ability to generate revenues could be materially adverselyaffected.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Similar kinds of patent term and regulatory and data protectionperiods are available outside of the U.S. We will pursue suchopportunities to extend the exclusivity of our products, but wecannot predict the availability of such exclusivity pathways orthat we will be successful in pursuing them.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -61-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-weight: bold; font-style: italic; color: #000000">          Changes in U.S         </font>         <font style="color: #000000">          .         </font>         <font style="font-weight: bold; font-style: italic; color: #000000">          patent lawcould diminish the value of patents in general, thereby impairingour ability to protect our products.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         As is the case with other pharmaceutical and biotechnologycompanies, our success is heavily dependent on intellectualproperty, particularly patents. Obtaining and enforcing patents inthe biotechnology industry involve both technological and legalcomplexity, and is therefore costly, time-consuming and inherentlyuncertain. In addition, the U.S. in recent years enacted and iscurrently implementing wide-ranging patent reform legislation: theLeahy-Smith America Invents Act, referred to as the America InventsAct. The America Invents Act includes a number of significantchanges to U.S. patent law. These include provisions that affectthe way patent applications will be prosecuted and may also affectpatent litigation. It is not yet clear what, if any, impact theAmerica Invents Act will have on the operation of our business.However, the America Invents Act and its implementation couldincrease the uncertainties and costs surrounding the prosecution ofour patent applications and the enforcement or defense of anypatents that may issue from our patent applications, all of whichcould have a material adverse effect on our business and financialcondition.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In addition, recent U.S. Supreme Court rulings have narrowed thescope of patent protection available in certain circumstances andweakened the rights of patent owners in certain situations. Thefull impact of these decisions is not yet known. For example, onMarch 20, 2012 in         </font>         <font style="font-style: italic; color: #000000">          Mayo Collaborative Services,DBA Mayo Medical Laboratories, et al. v. Prometheus Laboratories,Inc.         </font>         <font style="color: #000000">          , the Court held thatseveral claims drawn to measuring drug metabolite levels frompatient samples and correlating them to drug doses were notpatentable subject matter. The decision appears to impactdiagnostics patents that merely apply a law of nature via a seriesof routine steps and it has created uncertainty around the abilityto obtain patent protection for certain inventions. Additionally,on June 13, 2013 in         </font>         <font style="font-style: italic; color: #000000">          Association for MolecularPathology v. Myriad Genetics, Inc         </font>         <font style="color: #000000">          ., the Court held that claims to isolated genomicDNA are not patentable, but claims to complementary DNA moleculesare patent eligible because they are not a natural product. Theeffect of the decision on patents for other isolated naturalproducts is uncertain.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Additionally, on March 4, 2014, the USPTO issued a memorandumto patent examiners providing guidance for examining claims thatrecite laws of nature, natural phenomena or natural products underthe Myriad and Prometheus decisions. This guidance did not limitthe application of Myriad to DNA but, rather, applied the decisionto other natural products. Further, in 2015,in         </font>         <font style="font-style: italic; color: #000000">          Ariosa Diagnostics, Inc. v.Sequenom, Inc         </font>         <font style="color: #000000">          ., the Court ofAppeals for the Federal Circuit held that methods for detectingfetal genetic defects were not patent eligible subject matter.Other more recent court decisions and related USPTO examinationguidelines must be taken into account, particularly as they relateto changes in what types of inventions are eligible for patentprotection. Foreign patent and intellectual property laws also areevolving and are not predictable as to their impact on the Companyand other biopharmaceutical companies.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In addition to increasing uncertainty regarding our ability toobtain future patents, this combination of events has createduncertainty with respect to the value of patents, once obtained.Depending on these and other decisions by the U.S. Congress, thefederal courts and the USPTO, the laws and regulations governingpatents could change in unpredictable ways that would weaken ourability to obtain new patents or to enforce any patents that mayissue in the future.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         We may be subject to damages resulting from claims that we or ouremployees have wrongfully used or disclosed alleged trade secretsof their former employers.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Certain of our current employees have been, and certain of ourfuture employees may have been, previously employed at otherbiotechnology or pharmaceutical companies, including ourcompetitors or potential competitors. We also engage advisors andconsultants who are concurrently employed at universities or whoperform services for other entities.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Although we are not aware of any claims currently pending orthreatened against us, we may be subject to claims that we or ouremployees, advisors or consultants have inadvertently or otherwiseused or disclosed intellectual property, including trade secrets orother proprietary information, of a former employer or other thirdparty. We have and may in the future also be subject to claims thatan employee, advisor or consultant performed work for us thatconflicts with that person’s obligations to a third party,such as an employer, and thus, that the third party has anownership interest in the intellectual property arising out of workperformed for us. Litigation may be necessary to defend againstthese claims. Even if we are successful in defending against theseclaims, litigation could result in substantial costs and be adistraction to management. If we fail in defending such claims, inaddition to paying monetary claims, we may lose valuableintellectual property rights or personnel. A loss of key personnelor their work product could hamper or prevent our ability tocommercialize our product candidates, which would materiallyadversely affect our commercial development efforts.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Numerous factors may limit any potential competitive advantageprovided by our intellectual property rights.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The degree of future protection afforded by our intellectualproperty rights is uncertain because intellectual property rightshave limitations, and may not adequately protect our business,provide a barrier to entry against our competitors or potentialcompetitors, or permit us to maintain our competitive advantage.Moreover, if a third party has intellectual property rights thatcover the practice of our technology, we may not be able to fullyexercise or extract value from our intellectual property rights.The following examples are illustrative:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -62-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              others may be able to develop and/or practice technology that issimilar to our technology or aspects of our technology but that isnot covered by the claims of patents, should such patents issuefrom our patent applications;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              we might not have been the first to make the inventions covered bya pending patent application that we own;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              we might not have been the first to file patent applicationscovering an invention;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              others may independently develop similar or alternativetechnologies without infringing our intellectual propertyrights;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              pending patent applications that we own or license may not lead toissued patents;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              patents, if issued, that we own or license may not provide us withany competitive advantages, or may be held invalid or unenforceableor be narrowed, as a result of legal challenges by ourcompetitors;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              third parties may compete with us in jurisdictions where we do notpursue and obtain patent protection;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              we may not be able to obtain and/or maintain necessary or usefullicenses on reasonable terms or at all; and             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the patents of others may have an adverse effect on ourbusiness.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Should any of these events occur, they could significantly harm ourbusiness and results of operations.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         With regard to our stem cell technology, if, instead of identifyinga potential NCE candidate based on information available to us inthe public domain, we seek to in-license a NCE candidate frombiotechnology, medicinal chemistry and pharmaceutical companies,academic, governmental and nonprofit research institutions,including the NIH, or other third parties, there can be noassurances that we will obtain material ownership or economicparticipation rights over intellectual property we may derive fromsuch licenses or similar rights to the NCEs that we may produce anddevelop. If we are unable to obtain ownership or substantialeconomic participation rights over intellectual property related toNCEs we produce and develop, our business may be adverselyaffected.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Risks Related to our Securities        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Market volatility may affect our stock price and the value of yourinvestment.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The market price for our common stock, similar to that of otherbiopharmaceutical companies, is likely to remain highly volatile.The market price of our common stock may fluctuate significantly inresponse to a number of factors, most of which we cannot control,including, among others:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              volatility resulting from uncertainty and general economicconditions caused by the ongoing COVID-19 pandemic;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              plans for, progress of or results from nonclinical and clinicaldevelopment activities related to our productcandidates;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the failure of the FDA or other regulatory authority to approve ourproduct candidates;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              announcements of new products, technologies, commercialrelationships, acquisitions or other events by us or ourcompetitors;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              the success or failure of other CNS therapies;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              regulatory or legal developments in the U.S. and othercountries;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              announcements regarding our intellectual propertyportfolio;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              failure of our product candidates, if approved, to achievecommercial success;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              fluctuations in stock market prices and trading volumes of similarcompanies;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              general market conditions and overall fluctuations in U.S. equitymarkets;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              variations in our quarterly operating results;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              changes in our financial guidance or securities analysts’estimates of our financial performance;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              changes in accounting principles;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -63-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              our ability to raise additional capital and the terms on which wecan raise it;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              sales or purchases of large blocks of our common stock, includingsales or purchases by our executive officers, directors andsignificant stockholders;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              establishmentof short positions by holders or non-holders of our stock orwarrants;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              additions or departures of key personnel;             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              discussion of us or our stock price by the press and by onlineinvestor communities; and             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 2%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: middle; width: 98%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              other risks and uncertainties described in these riskfactors.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Future sales and issuances of our common stock may cause our stockprice to decline.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Sales or issuances of a substantial number of shares of our commonstock in the public market, or the perception that such sales orissuances are occurring or might occur, could significantly reducethe market price of our common stock and impair our ability toraise adequate capital through the sale of additional equitysecurities.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The stock market in general, and small biopharmaceutical companieslike ours in particular, have frequently experienced significantvolatility in the market prices for securities that often has beenunrelated to the operating performance of the underlying companies.These broad market and industry fluctuations may adversely affectthe market price of our common stock, regardless of our actualoperating performance. In certain situations in which the marketprice of a stock has been volatile, holders of that stock haveinstituted securities class action litigation against the companythat issued the stock. If any of our stockholders were to bring alawsuit against us, the defense and disposition of the lawsuitcould be costly and divert the time and attention of our managementand harm our operating results. Additionally, if the trading volumeof our common stock remains low and limited there will be anincreased level of volatility and you may not be able to generate areturn on your investment.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         A portion of our total outstanding shares are restricted fromimmediate resale but may be sold into the market in the nearfuture. Future sales of shares by existing stockholders could causeour stock price to decline, even if our business is doingwell.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Sales of a substantial number of shares of our common stock in thepublic market could occur at any time. These sales, or theperception in the market that the holders of a large number ofshares intend to sell shares, could reduce the market price of ourcommon stock. Future sales and issuances of a substantial number ofshares of our common stock in the public market, including sharesissued upon the conversion of our Series A Preferred, Series BPreferred or Series C Preferred, and the exercise of outstandingoptions and warrants for common stock which are issuable uponexercise, in the public market, or the perception that these salesand issuances are occurring or might occur, could significantlyreduce the market price for our common stock and impair our abilityto raise adequate capital through the sale of equitysecurities.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         If equity research analysts do not publish research or reportsabout our business or if they issue unfavorable commentary ordowngrade our common stock, the price of our common stock coulddecline.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The trading market for our common stock relies in part on theresearch and reports that equity research analysts publish about usand our business. We do not control these analysts. The price ofour common stock could decline if one or more equity researchanalysts downgrade our common stock or if such analysts issue otherunfavorable commentary or cease publishing reports about us or ourbusiness.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         There may be additional issuances of shares of preferred stock inthe future.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Our Restated Articles of Incorporation, as amended(the         </font>         <font style="font-style: italic; color: #000000">          Articles         </font>         <font style="color: #000000">          ), permit us to issue up to 10.0 million shares ofpreferred stock. Our Board has authorized the issuance of (i)500,000 shares of Series A Preferred, all of which shares areissued and outstanding as of the date of this Report; (ii) 4.0million shares of Series B 10% Convertible Preferred stock, ofwhich approximately 1.1 million shares remain issued andoutstanding as of the date of this Report; (iii) 3.0 million sharesof Series C Convertible Preferred Stock, of which approximately 2.3million shares are issued and outstanding as of the date of thisReport; and (iv) 2.0 million shares of Series D ConvertiblePreferred stock, of which no shares were issued or outstanding asof the date of this Report. Our Board could authorize the issuanceof additional series of preferred stock in the future and suchpreferred stock could grant holders preferred rights to our assetsupon liquidation, the right to receive dividends before dividendswould be declared to holders of our common stock, and the right tothe redemption of such shares, possibly together with a premium,prior to the redemption of the common stock. In the event and tothe extent that we do issue additional preferred stock in thefuture, the rights of holders of our common stock could be impairedthereby, including without limitation, with respect toliquidation.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -64-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         We do not intend to pay dividends on our common stock and,consequently, our stockholders’ ability to achieve a returnon their investment will depend on appreciation in the price of ourcommon stock.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We have never declared or paid any cash dividend on our commonstock and do not currently intend to do so in the foreseeablefuture. We currently anticipate that we will retain future earningsfor the development, operation and expansion of our business and donot anticipate declaring or paying any cash dividends in theforeseeable future. Therefore, the success of an investment inshares of our common stock will depend upon any future appreciationin their value. There is no guarantee that shares of our commonstock will appreciate in value or even maintain the price at whichour stockholders purchased them.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         We incur significant costs to ensure compliance with corporategovernance, federal securities law and accountingrequirements.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We are subject to the reporting requirements of the SecuritiesExchange Act of 1934, as amended (         </font>         <font style="font-style: italic; color: #000000">          ExchangeAct         </font>         <font style="color: #000000">          ), which requires that wefile annual, quarterly and current reports with respect to ourbusiness and financial condition, and the rules and regulationsimplemented by the SEC, the Sarbanes-Oxley Act of 2002, theDodd-Frank Act, and the Public Company Accounting Oversight Board,each of which imposes additional reporting and other obligations onpublic companies.  We have incurred and will continue toincur significant costs to comply with these public companyreporting requirements, including accounting and related auditcosts, legal costs to comply with corporate governance requirementsand other costs of operating as a public company. These legal andfinancial compliance costs will continue to require us to divert asignificant amount of resources that we could otherwise use toachieve our research and development and other strategicobjectives.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The filing and internal control reporting requirements imposed byfederal securities laws, rules and regulations on companies thatare not “smaller reporting companies” under federalsecurities laws are rigorous and, once we are no longer a smallerreporting company, we may not be able to meet them, resulting in apossible decline in the price of our common stock and our inabilityto obtain future financing. Certain of these requirements mayrequire us to carry out activities we have not done previously andcomplying with such requirements may divert management’sattention from other business concerns, which could have a materialadverse effect on our business, results of operations, financialcondition and cash flows. Any failure to adequately comply withapplicable federal securities laws, rules or regulations couldsubject us to fines or regulatory actions, which may materiallyadversely affect our business, results of operations and financialcondition.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In addition, changing laws, regulations and standards relating tocorporate governance and public disclosure are creating uncertaintyfor public companies, increasing legal and financial compliancecosts and making some activities more time consuming. These laws,regulations and standards are subject to varying interpretations,in many cases due to their lack of specificity, and, as a result,their application in practice may evolve over time as new guidanceis provided by regulatory and governing bodies. This could resultin continuing uncertainty regarding compliance matters and highercosts necessitated by ongoing revisions to disclosure andgovernance practices. We will continue to invest resources tocomply with evolving laws, regulations and standards, however thisinvestment may result in increased general and administrativeexpenses and a diversion of management’s time and attentionfrom revenue-generating activities to compliance activities. If ourefforts to comply with new laws, regulations and standards differfrom the activities intended by regulatory or governing bodies dueto ambiguities related to their application and practice,regulatory authorities may initiate legal proceedings against usand our business may be adversely affected.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Item 1B.          <a name="Unre">           U          </a>          nresolved Staff Com         </font>         <font style="color: #000000">          ments         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The disclosures in this section are not required since we qualifyas a smaller reporting company.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Item 2.          <a name="Prop">           P          </a>         </font>         <font style="color: #000000">          roperties         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our corporate headquarters and laboratories are located at 343Allerton Avenue, South San Francisco, California 94080, where weoccupy approximately 10,900 square feet of office and lab spaceunder a lease expiring on July 31, 2022, which contains a 5-yearoption to renew. We believe that our facilities are suitable andadequate for our current and foreseeable needs.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Item 3.          <a name="Leg">           L          </a>          egal Pro         </font>         <font style="color: #000000">          ceedings         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         None.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Item 4.          <a name="Mine">           M          </a>          ine         </font>         <font style="color: #000000">          SafetyDisclosures         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Not applicable.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -65-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          P         </font>         <font style="color: #000000">          ART II         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Item 5.          <a name="Mark">           M          </a>          arket for Registrant’s Common Equity,Rel         </font>         <font style="color: #000000">          ated Stockholder Matters andIssuer Purchases of Equity Securities         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Market Information        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our common stock was approved for listing and has traded since May11, 2016 on The Nasdaq Capital Market under the symbol“VTGN”.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Belowis the range of high and low sales prices for our common stockfor the periods indicated as reported by the Nasdaq CapitalMarket.         <font style="color: #000000">          The market quotationsreflect inter-dealer prices, without retail mark-up, mark-down orcommissions and may not necessarily represent actualtransactions.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                High               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Low               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              YearEnded March 31, 2021             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              First quarter endedJune 30, 2020             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.68             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.35             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Second quarterended September 30, 2020             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.06             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.46             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Third quarter endedDecember 31, 2020             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.96             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.6088             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Fourth quarterended March 31, 2021             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3.18             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.83             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              YearEnded March 31, 2020             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              First quarter endedJune 30, 2019             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.35             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.52             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Second quarterended September 30, 2019             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.32             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.38             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Third quarter endedDecember 31, 2019             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.49             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.29             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Fourth quarterended March 31, 2020             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.90             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.30             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          On June         </font>         <font style="color: rgb(0, 0, 0);">          28, 2021 theclosing price of our common stock on the Nasdaq Capital Market was$2.84         </font>         <font style="color: #000000">          pershare.         </font>        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="background-color: #ffffff">         <font style="font-family: Times New Roman; font-size: 13px">          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           Asof          </font>          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           June28, 2021, we had          </font>          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           191,382,350          </font>          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           sharesof common stock outstanding and approximately 20,000 stockholdersof record.  On the same date, two stockholders held all500,000 outstanding restricted shares of our Series A PreferredStock (          </font>          <font style="font-style: italic; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           SeriesA Preferred          </font>          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           ),which shares are convertible into 750,000 shares of common stock;one stockholder held 1,131,669 outstanding shares of our Series B10% Convertible Preferred Stock (          </font>          <font style="font-style: italic; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           SeriesB Preferred          </font>          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           ),which shares are convertible into 1,131,669 shares of common stock,excluding shares of our common stock which may be issued in paymentof accrued dividends upon conversion of the Series B Preferred; andone stockholder held all 2,318,012 outstanding shares of our SeriesC Convertible Preferred Stock (          </font>          <font style="font-style: italic; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           SeriesC Preferred          </font>          <font style="color: #000000">           ), which shares areconvertible into 2,318,012 shares of commonstock.          </font>         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Dividend Policy        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We have never paid or declared any cash dividends on our commonstock, and we do not anticipate paying any cash dividends onour common stock in the foreseeable future. Our Series BPreferred accrues dividends at a rate of 10% per annum, whichdividends are payable solely in unregistered shares of our commonstock at the time the Series B Preferred is converted into commonstock.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Recent Sales of Unregistered Securities        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         None.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold">         <font style="font-family: Times New Roman; font-size: 13px">          <font style="color: #000000">           Item 6.           <a name="Sel">            S           </a>           electedFinancial Data          </font>         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The disclosures in this section are not required because we qualifyas a smaller reporting company under federal securitieslaws.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Item 7.          <a name="Man">           M          </a>          anag         </font>         <font style="color: #000000">          ement’sDiscussion and Analysis of Financial Condition and Results ofOperations         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Cautionary Note Regarding Forward-Looking Statements        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">         This Annual Report on Form 10-K (Annual Report or Report) includesforward-looking statements. All statements contained in this AnnualReport other than statements of historical fact, includingstatements regarding our future results of operations and financialposition, our business strategy and plans, and our objectives forfuture operations, are forward- looking statements. The words“believe,” “may,” “estimate,”“continue,” “anticipate,”“intend,” “expect” and similar expressionsare intended to identify forward-looking statements. We have basedthese forward- looking statements largely on our currentexpectations and projections about future events and trends that webelieve may affect our financial condition, results of operations,business strategy, short-term and long-term business operations andobjectives, and financial needs. These forward-looking statementsare subject to a number of risks, uncertainties and assumptions.Our business is subject to significant risks including, but notlimited to, our ability to obtain additional financing, the resultsof our research and development efforts, the results of nonclinicaland clinical testing, the effect of regulation by the United StatesFood and Drug Administration (FDA) and other agencies, the impactof competitive products, product development, commercialization andtechnological difficulties, the effect of our accounting policies,and other risks as detailed in the section entitled “RiskFactors” in this Annual Report.  Further, even ifour product candidates appear promising at various stages ofdevelopment, our share price may decrease such that we are unableto raise additional capital without significant dilution or otherterms that may be unacceptable to our management, Board ofDirectors (our Board) and stockholders.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -66-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Moreover, we operate in a very competitive and rapidly changingenvironment. New risks emerge from time to time. It is not possiblefor our management or Board to predict all risks, nor can we assessthe impact of all factors on our business or the extent to whichany factor, or combination of factors, may cause actual results todiffer materially from those contained in any forward-lookingstatements we may make. In light of these risks, uncertainties andassumptions, the future events and trends discussed in this AnnualReport may not occur and actual results could differ materially andadversely from those anticipated or implied in the forward-lookingstatements.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         You should not rely upon forward-looking statements as predictionsof future events. The events and circumstances reflected in theforward-looking statements may not be achieved or occur. Althoughwe believe that the expectations reflected in the forward-lookingstatements are reasonable, we cannot guarantee future results,levels of activity, performance or achievements. We are under noduty to update any of these forward-looking statements after thedate of this Annual Report or to conform these statements to actualresults or revised expectations. If we do update one or moreforward-looking statements, no inference should be drawn that wewill make additional updates with respect to those or otherforward-looking statements.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Business Overview        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <br/>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We are a biopharmaceutical company committed todeveloping and commercializing differentiated new generationmedications that go beyond the current standard of care forwidespread anxiety, depression and other central nervous system(         </font>         <font style="font-style: italic; color: #000000">          CNS         </font>         <font style="color: #000000">          ) disorders. Our CNS pipeline includes three CNSproduct candidates, PH94B Nasal Spray, PH10 Nasal Spray and AV-101,each with a differentiated profile, favorable safety resultsobserved in all clinical studies to date and therapeutic potentialin multiple CNS indications. PH94B Nasal Spray (         </font>         <font style="font-style: italic; color: #000000">          PH94B         </font>         <font style="color: #000000">          ) is being developed for multiple anxietydisorders. We recently initiated our PH94B Phase 3 developmentprogram, which we refer to as the PALISADE program, withPALISADE-1, a U.S., multi-center, randomized, double-blind,placebo-controlled Phase 3 clinical study to evaluate the efficacyand safety of PH94B for the acute treatment of anxiety in adultswith social anxiety disorder (         </font>         <font style="font-style: italic; color: #000000">          SAD         </font>         <font style="color: #000000">          ), as well as preparations for the additionalstudies required to support our potential U.S. New Drug Application(         </font>         <font style="font-style: italic; color: #000000">          NDA         </font>         <font style="color: #000000">          ) for that indication should the PALISADE Phase 3program be successful. We are also preparing for exploratory Phase2A clinical studies of PH94B in adults experiencing several otheranxiety disorders. PH10 Nasal Spray (         </font>         <font style="font-style: italic; color: #000000">          PH10         </font>         <font style="color: #000000">          ) is being developed as a stand-alone treatmentfor multiple depression disorders. Exploratory Phase 2A clinicaldevelopment of PH10 for major depressive disorder(         </font>         <font style="font-style: italic; color: #000000">          MDD         </font>         <font style="color: #000000">          ) has been completed. We are now preparing forplanned Phase 2B clinical development of PH10 for this indication.We are preparing for a Phase 1B clinical study of AV-101 incombination with probenecid to assess potential future Phase 2Aclinical development of the combination for MDD or certainneurological indications. Our goal is to become a biopharmaceuticalcompany that develops and commercializes innovative CNS therapiesfor highly prevalent neuropsychiatry and neurology indicationswhere current treatments options are inadequate to meet the needsof millions of patients in markets worldwide.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Our Product Candidates        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify">        <font style="font-family: Times New Roman; font-size: 13px">         PH94B is asynthetic investigational neurosteroid developed from proprietarycompounds called pherines. With its novel mechanism of action,PH94B is an odorless nasal spray administered at microgram-leveldoses to achieve rapid-onset anti-anxiety, or anxiolytic, effects.The pharmacological activity of PH94B is fundamentallydifferentiated from that of all FDA-approved anti-anxiety drugs,including all antidepressants approved by the U.S. Food and DrugAdministration (         <font style="font-style: italic">          FDA         </font>         ) fortreatment of SAD, as well as all benzodiazepines and beta blockersprescribed on an off-label basis. PH94B engages peripheralchemosensory receptors in nasal passages that trigger a subset ofneurons in the main olfactory bulbs (         <font style="font-style: italic">          OB         </font>         ) at the base of the brain. TheOB neurons then stimulate inhibitory GABAergic neurons in thelimbic amygdala, decreasing the activity of the sympathetic nervoussystem, and facilitating fear extinction activity of thelimbic-hypothalamic system, the main fear and anxiety center in thebrain, as well as in other parts of the brain. Importantly, PH94Bdoes not require systemic uptake and distribution to produce itsrapid-onset anti-anxiety effects.         <font style="color: #000000">          Ourongoing PALISADE Phase 3 program for PH94B is designed to furtherdemonstrate its potential as a fast-acting, non-sedating,non-addictive acute treatment of anxiety in adults with SAD. Webelieve PH94B also has potential to be developed as a noveltreatment for adjustment disorder with anxiety, postpartum anxiety,post-traumatic stress disorder, procedural anxiety, panic and otheranxiety disorders. PH94B has been granted Fast Track designationstatus by the FDA for development for the acute treatment ofSAD.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: justify">        <font style="font-family: Times New Roman; font-size: 13px">         PH10 is a syntheticinvestigational neurosteroid, which also was developed fromproprietary compounds called pherines. Its novel, rapid-onsetmechanism of action (         <font style="font-style: italic">          MOA         </font>         )is fundamentally differentiated from the MOA of all currenttreatments for MDD and other depression disorders. PH10 isself-administered at microgram-level doses as an odorless nasalspray. PH10 activates nasal chemosensory cells in the nasalpassages, connected to neural circuits in the brain that produceantidepressant effects. Specifically, PH10 engages peripheralchemosensory receptors in the nasal passages that trigger a subsetof neurons in the main OB that stimulate neurons in the limbicamygdala. This is turn increases activity of thelimbic-hypothalamic sympathetic nervous system and increases therelease of catecholamines. Importantly, unlike all currentlyapproved oral antidepressants (         <font style="font-style: italic">          ADs         </font>         ), PH10 does not require systemicuptake and distribution to produce rapid-onset of antidepressanteffects. In all clinical studies to date, PH10 has not causedpsychological side effects (such as dissociation andhallucinations) or safety concerns that may be associated withrapid-onset ketamine-based therapy (         <font style="font-style: italic">          KBT         </font>         ), including intravenous ketamine orintranasal ketamine (esketamine).         <font style="color: #000000">          Webelieve PH10 has potential to be a new stand-alone treatment forMDD and several other depression disorders.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          AV-101 (4-Cl-KYN) targets the NMDAR (N-methyl-D-aspartatereceptor), an ionotropic glutamate receptor in the brain. AbnormalNMDAR function is associated with numerous CNS diseases anddisorders. AV-101 is an oral prodrug of 7-chloro-kynurenic acid(7-Cl-KYNA), which is a potent and selective full antagonist of theglycine co-agonist site of the NMDAR that inhibits the function ofthe NMDAR. However, unlike ketamine and many other NMDARantagonists, 7-Cl-KYNA is not an ion channel blocker. At dosesadministered in all studies to date, AV-101 has been observed to bewell tolerated and has not exhibited dissociative or hallucinogenicpsychological side effects or safety concerns. In light of theseobservations and findings from preclinical studies, we believe thatAV-101, in combination with FDA-approved probenecid, has potentialto become a new oral treatment alternative for certain CNSindications involving the NMDAR. We are currently preparing toevaluate AV-101 in combination with probenecid in a Phase 1Bclinical study. The FDA has granted Fast Track designation fordevelopment of AV-101 as a potential adjunctive treatment for MDDand as a non-opioid treatment for neuropathic pain(         </font>         <font style="font-style: italic; color: #000000">          NP         </font>         <font style="color: #000000">          ).         </font>        </font>       </div>       <div>        <font>        </font>        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -67-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         Critical Accounting Policies and Estimates        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We consider certain accounting policies related to revenuerecognition, determination of right of use assets under leasetransactions and related lease obligations, impairment oflong-lived assets, research and development, stock-basedcompensation, warrant liability and income taxes to be criticalaccounting policies that require the use of significant judgmentsand estimates relating to matters that are inherently uncertain andmay result in materially different results under differentassumptions and conditions. The preparation of financial statementsin conformity with United States generally accepted accountingprinciples (         </font>         <font style="font-style: italic; color: #000000">          GAAP         </font>         <font style="color: #000000">          ) requires us to make estimates and assumptionsthat affect the amounts reported in the financial statements andaccompanying notes to the consolidated financial statements. Theseestimates include, but are not limited to, those relating tostock-based compensation, revenue recognition, research anddevelopment expenses, determination of right of use assets underlease transactions and related lease obligations, andthe assumptions used to value warrants, warrant modifications,and useful lives for property and equipment and relateddepreciation calculations. Our actual results could differ fromthese estimates.         </font>        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Revenue Recognition        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We have historically generated revenue principally fromcollaborative research and development arrangements, licensing andtechnology access fees and government grants.         </font>         We adoptedAccounting Standards Update (         <font style="font-style: italic">          ASU         </font>         ) No. 2014-09,         <font style="font-style: italic">          Revenue from Contracts with Customers (Topic606)         </font>         and its related amendments, collectively referred to asASC (         <font style="font-style: italic">          Accounting StandardsCodification         </font>         ) Topic 606, as of April 1, 2018, using themodified retrospective transition method.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: -4px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         UnderASC Topic 606, we recognize revenue when our customer obtainscontrol of promised goods or services, in an amount that reflectsthe consideration that we expect to receive in exchange for thosegoods or services. To determine revenue recognition forarrangements that we determine are within the scope of Topic 606,we perform the following five steps: (i) identify the contract witha customer; (ii) identify the performance obligations in thecontract; (iii) determine the transaction price, including variableconsideration, if any; (iv) allocate the transaction price to theperformance obligations in the contract; and (v) recognize revenuewhen (or as) we satisfy a performance obligation. We only apply thefive-step model to contracts when it is probable that we willcollect the consideration to which we are entitled in exchange forthe goods or services we transfer to a customer.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: -4px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Once acontract is determined to be within the scope of Topic 606, weassess the goods or services promised within each contract anddetermine those that are performance obligations. Arrangements thatinclude rights to additional goods or services that are exercisableat a customer’s discretion are generally considered options.We assess whether these options provide a material right to thecustomer and if so, they are considered performance obligations.The exercise of a material right may be accounted for as a contractmodification or as a continuation of the contract for accountingpurposes.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: -4px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Weassess whether each promised good or service is distinct for thepurpose of identifying the performance obligations in the contract.This assessment involves subjective determinations and requiresjudgments about the individual promised goods or services andwhether such are separable from the other aspects of thecontractual relationship. Promised goods and services areconsidered distinct provided that: (i) the customer can benefitfrom the good or service either on its own or together with otherresources that are readily available to the customer (that is, thegood or service is capable of being distinct) and (ii) our promiseto transfer the good or service to the customer is separatelyidentifiable from other promises in the contract (that is, thepromise to transfer the good or service is distinct within thecontext of the contract). In assessing whether a promised good orservice is distinct in the evaluation of a collaborationarrangement subject to Topic 606, we consider factors such as theresearch, manufacturing and commercialization capabilities of thecollaboration partner and the availability of the associatedexpertise in the general marketplace. We also consider the intendedbenefit of the contract in assessing whether a promised good orservice is separately identifiable from other promises in thecontract. If a promised good or service is not distinct, we arerequired to combine that good or service with other promised goodsor services until we identify a bundle of goods or services that isdistinct.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -68-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: -4px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thetransaction price is then determined and allocated to theidentified performance obligations in proportion to theirstandalone selling prices (         <font style="font-style: italic">          SSP         </font>         ) on a relative SSP basis. SSP isdetermined at contract inception and is not updated to reflectchanges between contract inception and satisfaction of theperformance obligations. Determining the SSP for performanceobligations requires significant judgment. In developing the SSPfor a performance obligation, we consider applicable marketconditions and relevant Company-specific factors, including factorsthat were contemplated in negotiating the agreement with thecustomer and estimated costs. In certain circumstances, we mayapply the residual method to determine the SSP of a good or serviceif the standalone selling price is considered highly variable oruncertain. We validate the SSP for performance obligations byevaluating whether changes in the key assumptions used to determinethe SSP will have a significant effect on the allocation ofarrangement consideration between multiple performanceobligations.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: -4px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If theconsideration promised in a contract includes a variable amount, weestimate the amount of consideration to which we will be entitledin exchange for transferring the promised goods or services to acustomer. We determine the amount of variable consideration byusing the expected value method or the most likely amount method.We include the unconstrained amount of estimated variableconsideration in the transaction price. The amount included in thetransaction price is constrained to the amount for which it isprobable that a significant reversal of cumulative revenuerecognized will not occur. At the end of each subsequent reportingperiod, we re-evaluate the estimated variable considerationincluded in the transaction price and any related constraint, andif necessary, adjust our estimate of the overall transaction price.Any such adjustments are recorded on a cumulative catch-up basis inthe period of adjustment.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: -4px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If anarrangement includes development and regulatory milestone payments,we evaluate whether the milestones are considered probable of beingreached and estimate the amount to be included in the transactionprice using the most likely amount method. If it is probable that asignificant revenue reversal would not occur, the associatedmilestone value is included in the transaction price. Milestonepayments that are not within our control or the licensee’scontrol, such as regulatory approvals, are generally not consideredprobable of being achieved until those approvals arereceived.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: -4px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Indetermining the transaction price, we adjust consideration for theeffects of the time value of money if the timing of paymentsprovides us with a significant benefit of financing. We do notassess whether a contract has a significant financing component ifthe expectation at contract inception is such that the periodbetween payment by the licensee and the transfer of the promisedgoods or services to the licensee will be one year or less. Forarrangements with licenses of intellectual property that includesales-based royalties, including milestone payments based on thelevel of sales, and the license is deemed to be the predominantitem to which the royalties relate, we recognize royalty revenueand sales-based milestones at the later of (i) when the relatedsales occur, or (ii) when the performance obligation to which theroyalty has been allocated has been satisfied.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: -4px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We thenrecognize as revenue the amount of the transaction price that isallocated to the respective performance obligation when (or as)each performance obligation is satisfied at a point in time or overtime, and if over time, based on the use of an output or inputmethod.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Right of use assets and lease obligations        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We adopted Accounting Standards Update No. 2016-02,“         </font>         <font style="font-style: italic">          Leases (Topic842)”         </font>         <font style="color: #000000">          (         </font>         <font style="font-style: italic; color: #000000">          ASU2016-02         </font>         <font style="color: #000000">          ) effective April 1,2019         </font>         <font style="font-style: italic">          .         </font>         ASU 2016-02requires that we determine, at the inception of an arrangement,whether the arrangement is or contains a lease, based on the uniquefacts and circumstances present. Operating lease assets representour right to use an underlying asset for the lease term(         <font style="font-style: italic">          Right of use assets         </font>         ) andoperating lease liabilities represent our obligation to make leasepayments arising from the lease. Right of use assets and operatinglease liabilities are recognized at the commencement date of thelease based upon the present value of lease payments over the leaseterm. When determining the lease term, we include options to extendor terminate the lease when it is reasonably certain, at inception,that we will exercise that option. The interest rate implicit inlease contracts is typically not readily determinable; accordingly,we use our incremental borrowing rate, which is the rate that wouldbe incurred to borrow on a collateralized basis over a similar terman amount equal to the lease payments in a similar economicenvironment, based upon the information available at thecommencement date. The lease payments used to determine ouroperating lease assets may include lease incentives, stated rentincreases and escalation clauses linked to rates of inflation, whendeterminable, and are recognized in determining our Right of useassets. Our operating lease is reflected in the right-of-use asset– operating lease; operating lease obligation - currentportion; and operating lease obligation - non-current portion inour consolidated balance sheets.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Leaseexpense for minimum lease payments is recognized on a straight-linebasis over the lease term. As a result of our adoption of ASU2016-02, we no longer recognize deferred rent on the consolidatedbalance sheet. Short-term leases, defined as leases that have alease term of 12 months or less at the commencement date, areexcluded from this treatment and are recognized on a straight-linebasis over the term of the lease. Variable lease payments areamounts owed by us to a lessor that are not fixed, such asreimbursement for common area maintenance costs for our facilitylease; and are expensed when incurred.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Financingleases, formerly referred to as capitalized leases, are treatedsimilarly to operating leases except that the asset subject to thelease is included in the appropriate fixed asset category, ratherthan recorded as a Right of use asset, and depreciated over itsestimated useful life, or lease term, if shorter.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -69-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Impairment of Long-Lived Assets        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In accordance with ASC 360-10         </font>         <font style="font-style: italic; color: #000000">          , Property, Plant &amp;Equipment—Overall         </font>         <font style="color: #000000">          , wereview long-lived assets for impairment whenever events or changesin circumstances indicate that the carrying amount of property andequipment may not be recoverable. Determination of recoverabilityis based on an estimate of undiscounted future cash flows resultingfrom the use of the asset and its eventual disposition. In theevent that such cash flows are not expected to be sufficient torecover the carrying amount of the assets, we write down the assetsto their estimated fair values and recognize the loss in theConsolidated Statements of Operations and ComprehensiveLoss.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Research and Development Expenses        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Research and development expenses are composed of both internal andexternal costs.  Internal costs include salaries andemployment-related expenses, including stock-based compensationexpense, of scientific personnel and direct projectcosts.  External research and development expensesconsist primarily of costs associated with clinical and nonclinicaldevelopment of PH94B, PH10,         </font>         <font style="font-weight: bold; color: #000000">         </font>         <font style="color: #000000">          and AV-101, stem cell research and developmentcosts, and costs related to the application and prosecution ofpatents related to AV-101, PH94B, PH10 and our stem cell technologyplatform. All such costs are charged to expense asincurred.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We also record accruals for estimated ongoing clinical trial costs.Clinical trial costs represent costs incurred by contract researchorganizations (         </font>         <font style="font-style: italic; color: #000000">          CRO         </font>         <font style="color: #000000">          s) and clinical trial sites. Progress payments aregenerally made to CROs, clinical sites, investigators and otherprofessional service providers. We analyze the progress of theclinical trial, including levels of subject enrollment, invoicesreceived and contracted costs when evaluating the adequacy ofaccrued liabilities. Significant judgments and estimates must bemade in determining the clinical trial accrual in any reportingperiod. Actual results could differ from those estimates underdifferent assumptions. Revisions are charged to research anddevelopment expense in the period in which the facts that give riseto the revision become known.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Costs incurred in obtaining product or technology licenses arecharged immediately to research and development expense if theproduct or technology licensed has not achieved regulatory approvalor reached technical feasibility and has no alternative futureuses. In September 2018, we acquired an exclusive license todevelop and commercialize PH94B and an option to acquire a licenseto develop and commercialize PH10 by issuing an aggregate of1,630,435 unregistered shares of our common stock having a fairmarket value of $2,250,000.         </font>         In October 2018, we exercisedour option to acquire an exclusive license to develop andcommercialize PH10 by issuing 925,926 shares of our unregisteredcommon stock having a fair market value of $2,000,000.         <font style="color: #000000">          Since, at the date of each acquisition, neitherproduct candidate had achieved regulatory approval and eachrequires significant additional development and expense, werecorded the costs related to acquiring the licenses and the optionas research and development expense.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Stock-Based Compensation        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We recognize compensation cost for all stock-based awards toemployees and non-employee consultants based on the grant date fairvalue of the award.  We record stock-based compensationexpense over the period during which the employee or other granteeis required to perform services in exchange for the award, whichgenerally represents the scheduled vesting period. We have notgranted restricted stock awards to employees or consultants nor dowe have any awards with market or performanceconditions. Prior to our April 1, 2019 adoption of         </font>         ASU2018-07,         <font style="font-style: italic">          Compensation-StockCompensation (Topic 718), Improvements to Nonemployee Share-BasedPayment Accounting         </font>         (         <font style="font-style: italic">          ASU2018-07         </font>         ),         <font style="color: #000000">          we historicallyre-measured the fair value of option grants to non-employees asthey vested and any resulting increase in value was recognized asan expense during the period over which the services wereperformed. Under ASU 2018-17, expense recognition for grants tonon-employees follows the same methodology as for employees.Noncash expense attributable to compensatory grants of our commonstock to non-employees is determined by the quoted market price ofthe stock on the date of grant and is either recognized asfully-earned at the time of the grant or expensed ratably over theterm of the related service agreement, depending on the terms ofthe specific agreement.         </font>        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We use the Black-Scholes option pricing model to estimate the fairvalue of stock-based awards as of the grant date. The Black-Scholesmodel is complex and dependent upon key data input estimates. Theprimary data inputs with the greatest degree of judgment are theexpected term of the stock options and the estimated volatility ofour stock price. The Black-Scholes model is highly sensitive tochanges in these two inputs. The expected term of the optionsrepresents the period of time that options granted are expected tobe outstanding. We use the simplified method in accordance withguidance provided by the Securities and Exchange Commission(         </font>         <font style="font-style: italic; color: #000000">          SEC         </font>         <font style="color: #000000">          ) to estimate the expected term as an input intothe Black-Scholes option pricing model. We determine expectedvolatility using the historical method, which, because of therelatively limited period during which our stock has been publiclytraded on a major exchange and its historically limited tradingvolume, is based on the historical daily trading data of the commonstock of a peer group of public companies over the expected term ofthe option.         </font>        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Warrants Issued in Connection with Equity Financing        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We generally account for warrants issued in connection with equityfinancings as a component of equity, unless there is a deemedpossibility that we may have to settle the warrants in cash or thewarrants contain other features requiring them to be treated asliabilities. For warrants issued with the possibility of cashsettlement or otherwise requiring liability treatment, we recordthe fair value of the issued warrants as a liability at eachreporting period and record changes in the estimated fair value asnoncash gain or loss in the Consolidated Statements of Operationsand Comprehensive Loss.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -70-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Income Taxes        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We account for income taxes using the asset and liability approachfor financial reporting purposes. We recognize deferred tax assetsand liabilities for the future tax consequences attributable todifferences between the financial statement carrying amounts ofexisting assets and liabilities and their respective tax bases andoperating loss and tax credit carryforwards. Deferred tax assetsand liabilities are measured using enacted tax rates expected toapply to taxable income in the years in which those temporarydifferences are expected to be recovered or settled. The effect ondeferred tax assets and liabilities of a change in tax rates isrecognized in income in the period that includes the enactmentdate. Valuation allowances are established, when necessary, toreduce the deferred tax assets to an amount expected to berealized.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Recent Accounting Pronouncements        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         See Note 3 to the Consolidated Financial Statements included inItem 8 in this Annual Report on Form 10-K for information on recentaccounting pronouncements.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Financial Operations Overview and Results ofOperations        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Net Loss        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Althoughwe entered into the AffaMed Agreement in June 2020 and the BayerAgreement in December 2016, we have not yet achieved recurringrevenue-generating status in amounts sufficient to sustain ouroperations and enable our strategic business plans from any of ourproduct candidates or technologies.         <font style="color: #000000">          Since inception, we have devoted substantial timeand effort to developing AV-101 for multiple CNS indications,including manufacturing research, process development andproduction of AV-101 drug substance and finished drug product,preclinical efficacy and safety studies, and clinical efficacy andsafety studies in CNS indications. Since acquiring our exclusiveworldwide licenses to PH94B and PH10 in 2018, we have devotedsubstantial resources focused on research, development andcommercialization of PH94B and PH10, including initiatives toadvance manufacturing research, process development and productionprograms for drug substance and finished drug product, additionalpreclinical safety studies, and clinical efficacy and safetystudies in multiple neuropsychiatry indications. Also,from-time-to-time, we have devoted resources to VistaStem’sstem cell technology research and development, bioassay developmentand small molecule drug rescue initiatives, as well as creating,protecting and patenting intellectual property (         </font>         <font style="font-style: italic; color: #000000">          IP         </font>         <font style="color: #000000">          ) related to our product candidates and stem celltechnologies, with the corollary initiatives of recruiting andretaining personnel and raising working capital.         </font>         As of March31, 2021, we had an accumulated deficit of approximately $242.8million. Our net loss for the fiscal years ended March 31, 2021 and2020 was approximately $17.9 million and $20.8 million,respectively. We expect losses to continue for the foreseeablefuture, primarily as we         <font style="color: #000000">          engage infurther research, development and commercialization activitiesrelated to PH94B, PH10 and AV-101, and pursue VistaStem’spotential drug rescue, drug development and CT and RMopportunities.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">         Summary of the Fiscal Year Ended March 31, 2021        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; background-color: #FFFFFF">          On December 22, 2020, we completed a transformative $100 millionunderwritten public offering (the         </font>         <font style="font-style: italic">          December 2020         </font>         <font style="font-style: italic; color: #000000; background-color: #FFFFFF">          PublicOffering         </font>         <font style="color: #000000; background-color: #FFFFFF">          ) of our securities,consisting of shares of our common stock and shares of our newlycreated Series D Convertible Preferred Stock (         </font>         <font style="font-style: italic; color: #000000; background-color: #FFFFFF">          SeriesD Preferred         </font>         <font style="color: #000000; background-color: #FFFFFF">          ).         </font>         <font style="color: #000000">          After deducting underwriting discounts andcommissions and offering expenses payable by us, we received netproceeds of approximately $93.6 million from the sale of oursecurities in the December 2020 Public Offering.         </font>         <font style="color: #000000; background-color: #FFFFFF">          Combinedwith financing and development and commercialization partneringtransactions completed earlier in our fiscal year, aggregatingapproximately an additional $25 million, the proceeds from theDecember 2020 Public Offering have provided us with working capitalto advance an important stream of potential catalysts across ourCNS pipeline, including, among others, our Phase 3 developmentprogram for PH94B for the acute treatment of anxiety in adults withsocial anxiety disorder (         </font>         <font style="font-style: italic; color: #000000; background-color: #FFFFFF">          SAD         </font>         <font style="color: #000000; background-color: #FFFFFF">          )and, upon successful Phase 3 development, submission of our NewDrug Application to the U.S. Food and Drug Administration andpotential U.S. market approval of PH94B.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          From an operational perspective, during our fiscal year ended March31, 2021 (         </font>         <font style="font-style: italic; color: #000000">          Fiscal 2021         </font>         <font style="color: #000000">          ), we continued to advance our manufacturing,preclinical and clinical development, and regulatory initiativesnecessary for our Phase 3 clinical development of PH94B as apotential acute treatment of anxiety in adults with SAD, PH10 as apotential stand-alone treatment of MDD and AV-101 in combinationwith probenecid as a potential treatment for NMDAR-focusedindications. During the quarter ended March 31, 2021, andthereafter, following the completion of the December 2020 PublicOffering, we increased our headcount with the addition of twelveadditional employees with significant expertise in variousdisciplines including manufacturing, regulatory affairs, clinicaldevelopment, commercial affairs and administrative functions.Further, we accelerated our planning for clinical trials for bothPH94B and PH10, culminating in the start of the PALISADE-1 Phase 3clinical study in late-May 2021. The PALISADE-1 Phase 3 clinicalstudy is part of our PH94B PALISADE Phase 3 program for the acutetreatment of anxiety in adult patients with SAD. Throughout Fiscal2021, we continued to expand our regulatory and intellectualproperty foundation to support broad clinical development and,ultimately, commercialization of our CNS product candidates in theU.S. and foreign markets.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -71-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">         ThroughoutFiscal 2021 and through the date of this Report,         <font style="color: #000000">          a strain of SARS-CoV-2, commonly referred to asCOVID-19, has spread to many countries in the world and theoutbreak was declared a pandemic by the World Health Organization.The U.S. Secretary of Health and Human Services also declared apublic health emergency in the U.S. in response to theoutbreak.         </font>         From time to time during the COVID-19 pandemic,our operations and those of our CROs and CMOs have been and stillmay be impacted by         <font style="color: #000000">          shelter-in-placeorders, social distancing measures, travel bans and restrictions,and certain business and government closures or reductions inservice. Our headquarters operations have been significantlycurtailed and our employees have worked remotely since thebeginning of the COVID-19 pandemic. From time to time         </font>         sincethe beginning of the COVID-19 pandemic, we have experienced delaysin the delivery of supplies of active pharmaceutical product(         <font style="font-style: italic">          API         </font>         ) or other keymaterials required to continue development of PH94B and PH10.Future unexpected delays may result in a significant, materialdelay or disruption to our current clinical development plans,programs, and operations.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-family: Times New Roman; font-size: 13px">          <font style="color: #000000; background-color: #FFFFFF">           During ourfiscal quarter ended June 30, 2020, we completed          </font>          <font style="color: #000000">           a successful and positive meeting withthe FDA regarding Phase 3 clinical development of PH94B for theacute treatment of anxiety in adult patients with SAD, reachingconsensus with the FDA on key aspects of the design of our Phase 3clinical trials of PH94B, which studies will be randomized,double-blind, placebo-controlled, studies involving a single-event,laboratory-simulated public speaking challenge in adult subjectswith SAD. As noted earlier, the initial Phase 3 clinical trial ofPH94B, PALISADE-1, commenced in late-May 2021. Dr. MichaelLiebowitz, Professor of Clinical Psychiatry at Columbia University,director of the Medical Research Network in New York City, andcreator of the Liebowitz Social Anxiety Scale (          </font>          <font style="font-style: italic; color: #000000">           LSAS          </font>          <font style="color: #000000">           ), is the Principal Investigator of PALISADE-1.Target enrollment for PALISADE-1 (completed patients) isapproximately 208 adult patients with SAD. As in the statisticallysignificant (p=0.002) public speaking component of the Phase 2study, the patient-reported Subjective Units of Distress Scale(          </font>          <font style="font-style: italic; color: #000000">           SUDS          </font>          <font style="color: #000000">           ) will be used to assess the primary efficacyendpoint in PALISADE-1. Throughout Fiscal 2021, we have beenactively engaged in formalizing processes and procedures for themanufacture of PH94B for the PALISADE Phase 3 program and Phase 2programs in other anxiety indications, and of PH10 for our plannedPhase 2B clinical study of PH10 in MDD and other Phase 2 andnonclinical studies of PH10.          </font>         </font>         <br/>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="background-color: #FFFFFF">          In June 2020, we entered into a strategic licensing andcollaboration agreement for the clinical development andcommercialization of PH94B (the         </font>         <font style="font-style: italic; background-color: #FFFFFF">          EverInsightAgreement         </font>         <font style="background-color: #FFFFFF">          ) withEverInsight Therapeutics Inc. (         </font>         <font style="font-style: italic; background-color: #FFFFFF">          EverInsight         </font>         <font style="background-color: #FFFFFF">          ),a biopharmaceutical company focused on developing andcommercializing transformative pharmaceutical products for patientsin Greater China and other parts of Asia         </font>         . Subsequent toentering into the EverInsight Agreement, in October 2020,EverInsight merged with AffaMed Therapeutics, Inc., which as acombined, complementary entity is focusing on developing andcommercializing therapeutics to address ophthalmologic and CNSdisorders in Greater China and beyond. Accordingly, we are nowreferring to EverInsight and the EverInsight Agreement as AffaMedand the AffaMed Agreement, respectively.         <font style="background-color: #FFFFFF">          Under the terms of the AffaMedAgreement, AffaMed is responsible for clinical development,regulatory submissions and commercialization of PH94B for thetreatment of SAD, and potentially other anxiety-relatedindications, in key markets in Asia, including markets in GreaterChina, South Korea and Southeast Asia (collectively, the         </font>         <font style="font-style: italic; background-color: #FFFFFF">          Territory         </font>         <font style="background-color: #FFFFFF">          ).Under the terms of the AffaMed Agreement, in August 2020, wereceived a non-dilutive upfront license fee payment of $5.0 millionfrom AffaMed. Upon successful development and commercialization ofPH94B in the Territory, we are eligible to receive up to $172million in additional development and commercial milestonepayments, plus royalties on commercial sales of PH94B in theTerritory. After payment of sublicense fees to PherinPharmaceuticals, Inc. (         </font>         <font style="font-style: italic; background-color: #FFFFFF">          Pherin         </font>         <font style="background-color: #FFFFFF">          )pursuant to our PH94B license from Pherin, and payment ofconsulting fees related to consummation of the AffaMed Agreement,we received net cash proceeds of approximately $4.655million.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">         <font style="font-family: Times New Roman; font-size: 13px">          <font style="color: #000000">           In December 20          </font>          20, we sold63,000,000 shares of our common stock in at a public offering priceof $0.92 per share and 2,000,000 shares of our Series D Preferred          <font style="font-style: italic">          </font>          at a public offering price of$21.16 per share, resulting in gross proceeds to us of $100 million(the          <font style="font-style: italic">           December 2020 PublicOffering          </font>          ). Net proceeds to us from the securities sold inthe December 2020 Public Offering, after deducting underwritingdiscounts and commissions and offering expenses payable by us, wasapproximately $93.6 million.          <font style="color: #000000">           Earlierin Fiscal 2021, in August 2020, we sold, in an underwritten publicoffering (the          </font>          <font style="font-style: italic; color: #000000">           August 2020 PublicOffering          </font>          <font style="color: #000000">           ), an aggregate of15,625,000 shares of our common stock for a public offering priceof $0.80 per share, resulting in gross proceeds to us of$12,500,000. We also granted to the underwriter anover-allotment option to purchase up to an additional2,343,750 shares at a public offering price of $0.80 per share,which option was exercised with respect to 2,243,250 shares(the          </font>          <font style="font-style: italic; color: #000000">           Exercised OptionShares          </font>          <font style="color: #000000">           ). The sale of theExercised Option Shares resulted in additional gross proceeds to usof $1,794,600. Aggregate net proceeds to us from the August 2020Public Offering, after deducting underwriting discounts andcommissions and offering expenses payable by us, was approximately$12.9 million.          </font>         </font>         <br/>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            To satisfy our obligations under the common stockpurchase and registration rights agreements that we entered intowith Lincoln Park Capital Fund (           </font>           <font style="font-style: italic; color: #000000">            LincolnPark           </font>           <font style="color: #000000">            ) in March 2020, we filed aRegistration Statement on Form S-1 (the           </font>           <font style="font-style: italic; color: #000000">            LPC RegistrationStatement           </font>           <font style="color: #000000">            ) with the SEC onMarch 31, 2020 (Registration No. 333-237514), which the SECdeclared effective on April 14, 2020 (the           </font>           <font style="font-style: italic; color: #000000">            CommencementDate           </font>           <font style="color: #000000">            ). Subsequent to theCommencement Date and through July 2020, we sold 6,301,995registered shares of our common stock to Lincoln Park and receivedaggregate cash proceeds of $2,891,200. We have not sold anyadditional shares to Lincoln Park under these agreements since July2020. We terminated the stock purchase agreement with Lincoln Parkeffective on June 25, 2021.           </font>          </font>         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         As amatter of course, we continue to minimize, to the greatest extentpossible, cash commitments and expenditures for both internal andexternal research and development and general and administrativeservices.         <font style="color: #000000">          To further advance thenonclinical and clinical development of PH94B, PH10 and AV-101, aswell as support our operating activities, we continue to carefullymanage our routine operating costs, including our internal employeerelated expenses, as well as external costs relating to regulatoryconsulting, contract research and development, investor relationsand corporate development, legal, acquisition and protection ofintellectual property, public company compliance and otherprofessional services and internal costs.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -72-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Comparison of Fiscal Years Ended March 31, 2021 and2020        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The following table summarizes the results of our operations forthe fiscal years ended March 31, 2021 and 2020 (amounts inthousands).        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                FiscalYears Ended March 31,               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Sublicenserevenue             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,089             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Operatingexpenses:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Research anddevelopment             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              12,476             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              13,374             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              General andadministrative             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              6,547             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              7,427             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Totaloperating expenses             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              19,023             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              20,801             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Loss fromoperations             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (17,934             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (20,801             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Interest income,net             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              30             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Otherincome             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              1             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Loss before incometaxes             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (17,931             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (20,771             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Incometaxes             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (3             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (3             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Netloss             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (17,934             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (20,774             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accrueddividend on Series B Preferred Stock             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (1,386             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (1,264             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px">              <font style="font-family: Times New Roman; font-size: 13px">               Beneficialconversion feature on Series D Preferred Stock              </font>             </div>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">              (23,000             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net lossattributable to common stockholders             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (42,320             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (22,038             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic; color: #000000">          Revenue         </font>         <font style="color: #000000">         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We recognized $1,089,500 in sublicense revenue pursuant to theAffaMed Agreement in Fiscal 2021 compared to none in the fiscalyear ended March 31, 2020 (         </font>         <font style="font-style: italic; color: #000000">          Fiscal 2020         </font>         <font style="color: #000000">          ). As noted earlier, in June 2020, we entered intothe AffaMed Agreement, pursuant to which we received a non-dilutiveupfront license fee payment of $5.0 million in August 2020. Weinitially recorded this payment as         </font>         deferred revenue and weare recognizing it as revenue on a straight-line basis over theperiod in which we expect to perform the services required underthe AffaMed Agreement. We currently estimate that we will completeour performance obligations at the end of calendar 2023.         <font style="color: #000000">          While we may potentially receiveadditional cash payments and royalties in the future under theAffaMed Agreement in the event certain performance-based milestonesand commercial sales are achieved, there can be no assurance thatthe AffaMed Agreement will provide additional revenue beyond thatnoted or cash payments to us in the near term, or atall.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Research and Development Expense        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Research and development (         </font>         <font style="font-style: italic; color: #000000">          R&amp;D         </font>         <font style="color: #000000">          ) expense decreased from $13.4 million in Fiscal2020 to $12.5 million in Fiscal 2021, primarily due to thecompletion of the Elevate Study of AV-101 in Fiscal 2020,noticeably offset by increased developmental expenses in Fiscal2021 for PH94B and PH10. Expenses related to the Elevate Study andother AV-101 related nonclinical activities decreased byapproximately $5.9 million in Fiscal 2021 compared to Fiscal 2020,while expenses for PH94B and PH10 preclinical and clinicalreadiness initiatives increased by $5.2 million in Fiscal 2021compared to Fiscal 2020. Salaries and benefits expense increased inFiscal 2021 as a result of the addition of six new senior-levelemployees during the third and fourth quarters of Fiscal 2021 andbonus payments made in the third quarter of Fiscal 2021. Noncashresearch and development expenses, primarily stock-basedcompensation and equipment depreciation in both periods, accountedfor approximately $841,000 and $1,380,000 in Fiscal 2021 and Fiscal2020, respectively.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -73-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The following table indicates the primary components of R&amp;Dexpense for each of the periods (amounts inthousands):        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                FiscalYears Ended March 31,               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Salaries andbenefits             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,986             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,381             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Stock-basedcompensation             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              747             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,287             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Consulting andother professional services             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              327             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              533             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Technology licensesand royalties             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              551             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              546             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Project-relatedresearch, licenses and supplies:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Elevate study andother AV-101 expenses             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              611             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              6,483             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;">             <font style="font-family: Times New Roman; font-size: 13px">              PH94B and PH10development expenses             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              7,620             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,448             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Stem cell and allother             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              24             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              110             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              8,255             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              9,041             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Rent             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              545             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              535             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Depreciation             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              64             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              49             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Allother             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              1             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              2             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Total Research andDevelopment Expense             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              12,476             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              13,374             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          The increase in salaries and benefits expense in Fiscal 2021reflects (i) the impact of bonus payments made to our Chief MedicalOfficer (         </font>         <font style="font-style: italic; color: #000000">          CMO         </font>         <font style="color: #000000">          ), Chief Scientific Officer (         </font>         <font style="font-style: italic; color: #000000">          CSO         </font>         <font style="color: #000000">          ), and members of our scientific staff in December2020, (ii) modest salary increases to those officers and employeeseffective in the fourth quarter of Fiscal 2021; and (iii) theaddition of six officer-level employees between December 2020 andMarch 2021. There were no changes in base compensation levels forour CMO, CSO, or other members of our scientific staff betweenApril 2019 and December 2020 and no bonus expense or paymentsduring that same period.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Current year stock-based compensation expense reflects theamortization of option grants made to our CMO, CSO, members of ourscientific staff, our new senior-level employees and certainclinical and scientific consultants since June 2016, all earlieroutstanding grants having become fully vested and amortized duringFiscal 2021 or earlier. Grants awarded after March 31, 2020,including those granted during Fiscal 2021, account forapproximately $348,700 of expense in Fiscal 2021, offset by anexpense reduction of approximately $814,400 attributable to certainoptions granted between June 2016 and January 2019 that becamefully vested and amortized during Fiscal 2021 or earlier. Fiscal2021 stock compensation expense is further reduced by approximately$79,500 due to the absence of the impact of immediate vestingattributable to certain options granted in May 2019 or fullyvesting prior to March 31, 2020. Except for grants to newemployees, expense attributable to recent option grants isgenerally being amortized over two-year to three-year vestingperiods, with essentially all of the grants made since May 2019,including those made in Fiscal 2021, being 25% vested and expensedupon grant, in accordance with the terms of the respective grants.Grants to new employees generally vest 25% on the first anniversaryof the grant date and ratably monthly over the next threeyears.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Consulting and other professional services reflects fees incurred,generally on an as-needed basis, for project-based scientific,nonclinical and clinical development and regulatory advisory andanalytical services rendered to us by third parties, including bymembers of our Scientific Advisory Board and CNS Clinical andRegulatory Advisory Board, especially in support of our PH94B andPH10 development initiatives. Fiscal 2021 expense reflects areduction of $110,000 in development support payments to Pherinwhich terminated in April 2020 under the terms of our PH94B andPH10 license agreements and a $95,000 reduction in analytical andother services in support of PH94B and PH10 development compared toFiscal 2020, a portion of which is attributable to the conversionof a consultant to an employee in Fiscal 2021.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Technology license and royalties expense primarily reflects legalcounsel and other costs related to patent prosecution andprotection pursuant to our stem cell technology license agreements,our AV-101 patents, or patents that we have elected to pursue forcommercial purposes, as well as recurring annual license fees.These costs do not occur ratably throughout the year or betweenyears. In both periods, this expense includes legal counsel andother costs we have incurred to advance various patent applicationsin the U.S. and numerous foreign countries, primarily with respectto AV-101 and our stem cell technology platform, but also nominallywith respect to our PH94B and PH10 intellectual property portfoliosduring Fiscal 2021.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         AV-101 project expense for Fiscal 2020 reflects the costs ofactively conducting the Elevate Study in MDD, including variousCROs, investigator and clinical site costs, and determination oftopline study results, as well as CRO support services for AV-101projects for indications other than MDD, and, to lesser extent,expense incurred to manufacture additional quantities of AV-101 foruse in potential future clinical development of AV-101 in a numberof potential CNS indications. AV-101 project expense for Fiscal2021 primarily reflects the cost of certain preclinical studiesrelated to the use of AV-101 with probenecid and certain AV-101manufacturing stability studies, and costs incurred to finalize theresults of the Elevate Study for regulatorysubmission.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         PH94B and PH10 project expenses for both Fiscal 2021 and Fiscal2020 reflect research and development and manufacturing andregulatory initiatives necessary to facilitate Phase 3 clinicaldevelopment and readiness of PH94B for acute treatment of anxietyin adults with SAD and Phase 2B development of PH10 for MDD.Manufacturing, formulation and analysis of sufficient quantities ofdrug substance and drug product have been the key initiativesduring Fiscal 2021 for advancing the further clinical developmentof both PH94B and PH10, with costs for PH94B significantlyexceeding those for PH10 in Fiscal 2021 and in comparison to thoseof Fiscal 2020. From time to time during Fiscal 2021, production,logistics and analytical processes for both of these productcandidates were delayed due to the ongoing COVID-19pandemic.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -74-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Stem cell and other project related expenses reflects costsassociated with drug rescue applications of our stem celltechnology in both years. These expenses are typically incurred byour in-house scientific personnel. As a result of shelter-in-placeand remote working requirements related to the ongoing COVID-19pandemic, such expenses were reduced to an insignificant levelduring Fiscal 2021.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Rent expense for both Fiscal 2020 and Fiscal 2021 reflects ourimplementation of ASC 842 effective April 1, 2019 and therequirement to recognize, as an operating lease related to ourSouth San Francisco office and laboratory facility, a right-of-useasset and a lease liability, both of which must be amortized overthe expected lease term. The underlying lease reflects commercialproperty rents prevalent in the South San Francisco real estatemarket at the time of our November 2016 lease amendment extendingthe lease of our headquarters facilities in South San Francisco byfive years from July 31, 2017 to July 31, 2022. We allocate totalrent expense for our South San Francisco facility between researchand development expense and general and administrative expensebased generally on square footage dedicated to each function.Following our implementation of ASC 842, the modest increase inrent expense between periods is primarily related to Fiscal 2021increases in such items as common area maintenance fees, taxes andinsurance which are generally assessed to us by ourlandlord.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         General and Administrative Expense        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          General and administrative (         </font>         <font style="font-style: italic; color: #000000">          G&amp;A         </font>         <font style="color: #000000">          ) expense decreased to approximately $6.5 millionin Fiscal 2021 from approximately $7.4 million in Fiscal 2020. Cashcompensation in Fiscal 2021 increased by approximately $0.7 millionwhile noncash stock-based compensation decreased by approximately$1.0 million in Fiscal 2021. Further, during Fiscal 2020 wemodified certain outstanding warrants and recognized non-cashwarrant modification expense of $826,900. Noncash G&amp;A expense,approximately $1,731,000 for Fiscal 2021, decreased fromapproximately $3,543,000 for Fiscal 2020, primarily due to thedecreases in stock-based compensation and warrant modificationsnoted above and the noncash components of investor and publicrelations expense in Fiscal 2020 attributable to the amortizationof the fair value of common stock or warrants granted to serviceproviders.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The following table indicates the primary components of G&amp;Aexpense for each of the periods (amounts inthousands):        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                FiscalYears Ended March 31,               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Salaries andbenefits             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,052             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,382             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Stock-basedcompensation             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,559             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,533             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Board fees andother consulting services             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              428             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              185             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Legal, accountingand other professional fees             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              564             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              575             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Investor and publicrelations             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              695             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              933             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Insurance             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              449             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              348             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Travelexpenses             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              4             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              81             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Rent andutilities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              354             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              354             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Sublicense contractamortized acquisition expense             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              102             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Warrantmodification expense             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              827             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              All otherexpenses             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              340             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              209             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              6,547             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              7,427             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          The increase in salaries and benefits expense for Fiscal 2021primarily reflects the impact of (i) bonus payments made to ourChief Executive Officer (         </font>         <font style="font-style: italic; color: #000000">          CEO         </font>         <font style="color: #000000">          ), Chief Financial Officer (         </font>         <font style="font-style: italic; color: #000000">          CFO         </font>         <font style="color: #000000">          ), Vice President-Corporate Development(         </font>         <font style="font-style: italic; color: #000000">          VP-CorporateDevelopment         </font>         <font style="color: #000000">          ) and a non-officermember of our administrative staff in December 2020; (ii) modestsalary increases to those officers and employee effective in thefourth quarter of Fiscal 2021; and (iii) the addition of threesenior-level employees during February 2021 and March 2021. Therewere no changes in base compensation levels for our CEO, CFO, orVP-Corporate Development between April 2019 and December 2020 andno bonus expense or payments to them during that sameperiod.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Current year stock-based compensation expense reflects theamortization of option grants made to our CEO, CFO, VP CorporateDevelopment, administrative staff, independent members of our Boardand certain consultants since June 2016, all earlier outstandinggrants having become fully vested and amortized during Fiscal 2021or earlier. Grants awarded after March 31, 2020 account forapproximately $677,000 of expense in Fiscal 2021, offset by anexpense reduction of approximately $1,515,000 attributable tocertain options granted between June 2016 and January 2019 thatbecame fully vested and amortized during Fiscal 2021 or earlier.Fiscal 2021 stock compensation expense is further reduced byapproximately $141,700 due to the absence of the impact ofimmediate vesting attributable to certain options granted in May2019 or fully vesting prior to March 31, 2020. Except for grants tonew employees, expense attributable to recent option grants isgenerally being amortized over two-year to three-year vestingperiods, with essentially all of the grants made since May 2019,including those made in Fiscal 2021, being 25% vested and expensedupon grant, in accordance with the terms of the respective grants.Grants to new employees generally vest 25% on the first anniversaryof the grant date and ratably monthly over the next threeyears.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -75-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Board fees and other consulting services represent, in bothperiods, fees paid as consideration for Board and Board Committeeservices to the independent members of our Board of Directors and,additionally in the current year, other consulting service feesrelated to commercial analyses of both PH94B and PH10.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Legal, accounting and other professional fees for Fiscal 2021 andFiscal 2020 includes expense related to routine corporate legalfees as well as the accounting expense related to the annual auditof our prior year financial statements and the three quarterlyreviews of our current year financial statements. In Fiscal 2021,we incurred additional consulting fees related to revenuerecognition accounting for the AffaMed Agreement and, in Fiscal2020, we incurred fees attributable to services provided by aninternational business development consultant.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Investor and public relations expense includes the fees of ourvarious external service providers for a broad spectrum of investorrelations, public relations and social media services, and well asmarket awareness and strategic advisory and support functions andinitiatives that, in Fiscal 2020, included numerous in-personmeetings in multiple U.S. and certain foreign markets and othercommunication activities focused on expanding global marketawareness of the Company, our CNS product candidate pipeline andtechnologies and our research and development programs, includingamong registered investment professionals and investment advisors,individual and institutional investors, and prospective strategiccollaborators for development and commercialization of our productcandidates in major pharmaceutical markets worldwide. During Fiscal2021, we curtailed the number and scope of external serviceproviders engaged in these activities compared to the prior year.Further, in Fiscal 2020, in addition to cash fees and expenses weincurred for such activities, we recognized approximately $105,900of noncash expense attributable to the amortization of the fairvalue of stock and warrants granted in previous periods to variouscorporate development, investor relations, and market awarenessservice providers. No such noncash expense was incurred in Fiscal2021.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theincrease in insurance expense for Fiscal 2021 is primarilyattributable to the market-rate increase in the premium for ourdirectors and officers liability insurance upon renewal of ourpolicy in May 2020.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In Fiscal 2020, travel expense reflects costs associated within-person management presentations and meetings held in multipleU.S. markets and certain international markets with existing andpotential individual and institutional investors, investmentprofessionals and advisors, media, and securities analysts, as wellas various investor relations, market awareness and corporatedevelopment and partnering initiatives and in monitoring theprogress of our Elevate Study. As a result of periodicshelter-in-place restrictions and travel and workplace precautionsand restrictions associated with the ongoing COVID-19 pandemic,during Fiscal 2021, such meetings have occurred remotely withoutrequiring in-person business travel by our executives.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Rent expense for both periods presented reflects our implementationof ASC 842 effective April 1, 2019 and the requirement torecognize, as an operating lease related to our South San Franciscooffice and laboratory facility, a right-of-use asset and a leaseliability, both of which must be amortized over the expected leaseterm. The underlying lease reflects commercial property rentsprevalent in the South San Francisco real estate market at the timeof our November 2016 lease amendment extending the lease of ourheadquarters facilities in South San Francisco by five years fromJuly 31, 2017 to July 31, 2022. We allocate total rent expense forour South San Francisco facility between research and developmentexpense and general and administrative expense based generally onsquare footage dedicated to each function. Following ourimplementation of ASC 842, increases or decreases in rent expensebetween periods are primarily related to changes in such items ascommon area maintenance fees, taxes and insurance which aregenerally assessed to us by our landlord.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Beginning in the second quarter of Fiscal 2021, we began toamortize the deferred contract acquisition costs related to ouracquisition of the AffaMed Agreement, composed of the c         </font>         ashpayments of $220,000 for sublicense fees which we were obligated tomake pursuant to our PH94B license from Pherin, and $125,000 ofcash fees and $125,000 fair value of common stock issued forconsulting services, in each case exclusively related to ouracquisition of the AffaMed Agreement. The contract acquisitioncosts are amortized over the expected term of the services to beprovided under the AffaMed Agreement. During Fiscal 2021, weamortized $102,400 of contract acquisition costs.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         During Fiscal 2020, we completed three warrant modificationsresulting in an aggregate of $826,900 of noncash warrantmodification expense as described below.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           OnDecember 4, 2019, we modified outstanding warrants previouslyissued as a part of completed private placements to purchase anaggregate of approximately 6.6 million unregistered shares of ourcommon stock to temporarily reduce, for a period of two years oruntil the expiration of the warrant, if sooner, the exercise priceof such warrants to $0.50 per share, in order to more closely alignthe exercise price of the warrants with the then-current tradingprice of our common stock. Following the two-year period duringwhich the exercise price is reduced, the exercise price will revertto its pre-modification price. We determined that this modificationincreased the fair value of the modified warrants by $702,500,which we recorded as warrant modification expense.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -76-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            Also, on December 4, 2019, we issued additionalwarrants (the           </font>           <font style="font-style: italic; color: #000000">            AdditionalWarrants           </font>           <font style="color: #000000">            ) to purchase anaggregate of 325,000 additional shares of our common stock to theparticipants in our fall 2019 private placement of shares of commonstock and warrants to increase the number of unregistered shares ofcommon stock issuable upon exercise of the warrants from 50% to100% of the number of shares issued in the private placement. TheAdditional Warrants are exercisable through March 31, 2024 at anexercise price of $0.50 per share. We determined that the fairvalue of the Additional Warrants was $88,800, which we alsorecognized as noncash warrant modificationexpense.           </font>          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           Further,on December 19, 2019, we modified additional outstanding warrantspreviously issued as a part of a completed private placement topurchase a total of 80,431 shares of our unregistered common stockto permanently reduce the exercise price of such warrants to $0.805per share and to extend the term of such warrants through December31, 2022, in order to more closely align the exercise price of thewarrants with the then-current trading price of our common stockand to provide additional time for the holders to exercise thewarrants. We determined that these modifications increased the fairvalue of the subject warrants by $35,600, which we also recognizedas noncash warrant modification expense.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px;">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Theshares underlying the modified warrants and the Additional Warrantswere included in a Registration Statement on Form S-3 (File No.333-237968) that was declared effective by the Commission on May13, 2020.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic; color: #000000">          Interest and Other Income, Net         </font>         <font style="color: #000000">         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Interest income, net totaled $1,600 for Fiscal 2021 compared tointerest income, net of $30,100 for Fiscal 2020. The followingtable indicates the primary components of interest income andexpense for each of the periods (amounts inthousands):        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                FiscalYears Ended March 31,               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Interestincome             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              15             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              45             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Interest expense onfinancing lease, insurance premium financing notes             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              andPayroll Protection Program loan (2021)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (13             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (15             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Interest income,net             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              2             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              30             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In bothperiods, interest income relates to cash deposits ininterest-bearing cash equivalent accounts. Although cash balanceswere generally higher during Fiscal 2021, the decline in marketinterest rates during Fiscal 2021 compared to Fiscal 2020 resultedin reduced interest income.         <font style="color: #000000">          Interestexpense in both periods relates to interest paid on insurancepremium financing notes and on our financing lease of officeequipment subject to ASC 842, and in Fiscal 2021, to interestaccrued on our Payroll Protection Program loan prior to itsvoluntary repayment, including interest, in December2020.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Werecognized $1,385,600 and         <font style="color: #000000">          $1,263,600in Fiscal 2021 and Fiscal 2020, respectively, representing the 10%cumulative dividend accrued on outstanding shares of our Series B10% Convertible Preferred Stock (         </font>         <font style="font-style: italic; color: #000000">          Series BPreferred         </font>         <font style="color: #000000">          ) as an additionaldeduction in arriving at net loss attributable to commonstockholders in the         </font>         Consolidated Statement of Operations andComprehensive Loss included in Item 8, Part II of this AnnualReport. In December 2020, one holder of Series B Preferredconverted 28,571 shares of Series B Preferred into an equal numberof unregistered shares of our common stock and we issued anadditional 160,062 unregistered shares of our common stock inpayment of $124,600 of accrued dividends.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            The Series D Preferred that we issued in theDecember 2020 Public Offering contained a beneficial conversionfeature (a           </font>           <font style="font-style: italic; color: #000000">            BCF           </font>           <font style="color: #000000">            ), which arises when a debt or equity security isissued with an embedded conversion option that is deemed beneficialto the investor, that is, in-the-money, at inception because theconversion option has an effective conversion price that is lessthan the market price of the underlying stock at the commitmentdate (with respect to the Series D Preferred, the date the securitywas actually issued rather than the date the agreement to do so wasentered into, referred to as the           </font>           <font style="font-style: italic; color: #000000">            CommitmentDate           </font>           <font style="color: #000000">            ). In accordance withAccounting Standards Codification 470-20,           </font>           <font style="font-style: italic; color: #000000">            Debt- Debt with Conversion andOther Options           </font>           <font style="color: #000000">            (           </font>           <font style="font-style: italic; color: #000000">            ASC 470-20           </font>           <font style="color: #000000">            ), an embedded BCF is required to be recognizedseparately by allocating a portion of the proceeds equal to theintrinsic value of the feature to additional paid-in capital. ASC470-20 also provides that the intrinsic value is to be calculatedas of the Commitment Date. The Series D Certificate of Designationprovides that the Series D Preferred has a conversion price of$0.92 per share on an as-converted basis the (           </font>           <font style="font-style: italic; color: #000000">            ConversionPrice           </font>           <font style="color: #000000">            ). The Conversion Pricecompared to the closing price of $1.42 per share of our commonstock on the Commitment Date results in a difference of $0.50 pershare. That difference multiplied by the 46 million shares of ourcommon stock issuable upon conversion of the Series D Preferredresulted in an aggregate BCF of $23.0 million. We did not recognizethe impact of the BCF at December 31, 2020 because the Series DPreferred was not convertible into common stock prior to theApproval Date (the date of our Special Meeting of Stockholders heldon March 5, 2021). Following approval by our stockholders of theCharter Amendment at the Special Meeting in March 2021, thecontingency of the BCF was eliminated and we recognized the BCF asa noncash charge in arriving at net loss attributable to commonstockholders in our Consolidated Statement of Operations andComprehensive Loss for the fiscal year ended March 31, 2021 and asa corresponding increase in additional paid-in capital in ourConsolidated Statement of Stockholders’ Equity (Deficit). Therecognition of the BCF on the Series D Preferred had no impact inaggregate on our stockholders’ equity or on our cashposition.           </font>          </font>         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -77-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Liquidity and Capital Resources        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Since our inception in May 1998 through March 31, 2021, we havefinanced our operations and technology acquisitions primarilythrough the issuance and sale of our equity and debt securities forcash proceeds of approximately $197.8 million, as well as from anaggregate of approximately $22.7 million of government researchgrant awards (excluding the fair market value of governmentsponsored and funded clinical trials), strategic collaborationpayments, intellectual property licensing and other revenues.Additionally, we have issued equity securities with an approximatevalue at issuance of $38.2         </font>         <font style="font-style: italic; color: #000000">         </font>         <font style="color: #000000">          million in noncash acquisitions of productlicenses and in settlements of certain liabilities, includingliabilities for professional services rendered to us or ascompensation for such services.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Recent Developments        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic; color: #000000">          Jefferies ATM         </font>         <font style="color: #000000">          . On May 14, 2021,we entered into an Open Market Sale Agreement         </font>         <font style="color: #000000; font-size: 13px">          SM         </font>         <font style="color: #000000">          (the         </font>         <font style="font-style: italic; color: #000000">          SalesAgreement         </font>         <font style="color: #000000">          ) with Jefferies LLC,as sales agent (         </font>         <font style="font-style: italic; color: #000000">          Jefferies         </font>         <font style="color: #000000">          ), with respect to an at-the-market offeringprogram under which we may offer and sell, from time to time,shares of our common stock with an aggregate offering price of upto $75.0 million through Jefferies as our sales agent. As of thedate of this Report, we have not completed any sales under the SaleAgreement.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic; color: #000000">          December 2020 Public Offering         </font>         <font style="color: #000000">          .In December 20         </font>         20, we entered into an underwriting agreement(the         <font style="font-style: italic">          December 2020 UnderwritingAgreement         </font>         ) pursuant to which we sold 63,000,000 shares ofour common stock in the December 2020 Public Offering at a publicoffering price of $0.92 per share and 2,000,000 sharesof         <font style="font-style: italic">         </font>         Series DPreferred         <font style="font-style: italic">         </font>         at a publicoffering price of $21.16 per share, resulting in gross proceeds tous of $100 million. Net proceeds to us from the securities sold inthe December 2020 Public Offering, after deducting underwritingdiscounts and commissions and offering expenses payable by us, wasapproximately $93.6 million. Following approval by our stockholdersof the Charter Amendment at the Special Meeting in March 2021 andthrough the date of this Annual Report, we issued 46 million sharesof our common stock upon conversion of all outstanding shares ofSeries D Preferred issued in the December 2020 PublicOffering.         <br/>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic; color: #000000">          August 2020 Public Offering         </font>         <font style="color: #000000">          . InAugust 2020, we entered into an underwriting agreement pursuant towhich we sold, in the August 2020 Public Offering an underwrittenpublic offering (the         </font>         <font style="font-style: italic; color: #000000">          August 2020 PublicOffering         </font>         <font style="color: #000000">          ), an aggregate of15,625,000 shares of our common stock at a public offering price of$0.80 per share, resulting in gross proceeds to us of $12,500,000.Under the terms of the August 2020 Underwriting Agreement, wegranted to the underwriter an over-allotment option(the         </font>         <font style="font-style: italic; color: #000000">          Over-AllotmentOption         </font>         <font style="color: #000000">          ) to purchase up to anadditional 2,343,750 shares of common stock at a public offeringprice of $0.80 per share. The underwriter exercised theOver-Allotment Option with respect to 2,243,250 shares (the         </font>         <font style="font-style: italic; color: #000000">          Exercised OptionShares         </font>         <font style="color: #000000">          ), resulting inadditional gross proceeds to us of $1,794,600. Aggregate netproceeds to us from the August 2020 Public Offering, afterdeducting underwriting discounts and commissions and offeringexpenses payable by us, was approximately $12.9million.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic; background-color: #FFFFFF">          AffaMed Agreement         </font>         <font style="background-color: #FFFFFF">          .In June 2020, we entered into the AffaMed Agreement, a strategiclicensing and collaboration agreement for the clinical developmentand commercialization of PH94B for acute treatment of anxiety inadults with SAD and other potential anxiety-related disorders, withEverInsight, now operating as         </font>         AffaMed Therapeutics.         <font style="background-color: #FFFFFF">          Under the terms of theAffaMed Agreement, AffaMed agreed to make a non-dilutive upfrontlicense payment of $5.0 million to us, which we received in August2020. The $5.0 million upfront license payment resulted in net cashproceeds to us of approximately $4.655 million after the sublicensepayment we agreed to make to Pherin pursuant to our PH94B licensefrom Pherin, and payment for consulting services related to theAffaMed Agreement.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic; color: #000000">          LPC Agreement         </font>         <font style="color: #000000">          . Additionally, onMarch 24, 2020, we entered into the LPC Agreement with LincolnPark, pursuant to which Lincoln Park committed to purchase up to$10,250,000 of our common stock at market-based prices over aperiod of 24 months. To satisfy our obligations under theregistration rights agreement, we filed the LPC RegistrationStatement, which the SEC declared effective on April 14, 2020(Registration No. 333-237514). Subsequent to the effectiveness ofthe LPC Registration Statement and through July 2020, we sold6,301,995 registered shares of our common stock to Lincoln Park andreceived gross cash proceeds of $2,891,200. We have not sold anyshares of our common stock pursuant to the Lincoln Park Agreementsince July 2020.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="background-color: #ffffff">         <font style="font-family: Times New Roman; font-size: 13px">          <font style="font-style: italic; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           Warrant Exercises          </font>          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           .Further, between December 2020 and March 31, 2021, certain holdersof outstanding warrants exercised such warrants to purchase anaggregate of 6,396,302 shares of our common stock and we receivedcash proceeds of $4,924,800 from such exercises. Since March 31,2021 and through the date of this Annual Report, holders ofoutstanding warrants have exercised warrants to purchase anadditional          </font>          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           1,508,768          </font>          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           sharesof our common stock and we have received cash proceeds ofapproximately          </font>          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           $1,105,700          </font>          <font style="color: #000000">           ,resulting in aggregate cash proceeds of $6,030,500 received fromwarrant exercises between December 2020 and the date of this AnnualReport.          </font>          <br/>         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Liquidity and Capital Resources        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         During Fiscal 2021, we received approximately $119 million in netcash proceeds from the transactions described above. At March 31,2021, we had cash and cash equivalents of approximately $103.1million, which we believe is sufficient to fund our plannedoperations for well beyond the twelve months following the issuanceof the financial statements included in Part II, Item 8 of thisAnnual Report, and indicating our ability to continue as a goingconcern. Nevertheless, we have not yet developed products thatgenerate recurring revenue and, assuming successful completion ofour planned clinical and nonclinical programs, we will need toinvest substantial additional capital resources to commercializeany of them.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -78-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">         <font style="font-family: Times New Roman; font-size: 13px">          <font style="color: #000000">           During the next twelve months, we planto (i) continue PALISADE-1 and prepare for and initiate          </font>          multiple studies in our PALISADE          <font style="color: #000000">           Phase3 program for development and commercialization of PH94B as anacute treatment of anxiety in adult patients with SAD, (ii) preparefor and initiate multiple small exploratory          </font>          Phase 2A studiesof PH94B in additional anxiety disorders, (iii) prepare for andinitiate a Phase 2B clinical study of PH10 as a potentialstand-alone treatment for MDD, (iv) prepare for and initiate aPhase 1B clinical study of AV-101 in combination with probenecid toenable assessment of potential exploratory Phase 2A development ofthe combination in MDD and certain neurological disorders,          <font style="color: #000000">           and (v) conduct nonclinical studiesinvolving PH94B, PH10 and AV-101.          </font>         </font>         <br/>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Although we believe our current cash position is sufficient to fundour planned operations for well beyond the next twelve months, whennecessary and advantageous, we may raise additional capital throughthe sale of our equity securities in one or more (i) publicofferings (ii) private placements to accredited investors, and/or(iii) in strategic licensing and development collaborationsinvolving one or more of our drug candidates in markets outside theUnited States, similar to the AffaMed Agreement. Subject to certainrestrictions, our Registration Statement on Form S-3 (RegistrationNo. 333-254299) (the         </font>         <font style="font-style: italic; color: #000000">          S-3 RegistrationStatement         </font>         <font style="color: #000000">          ), which becameeffective on March 26, 2021 remains available for future sales ofour equity securities under the Sales Agreement with Jefferies, orin one or more public offerings from time to time. While we maymake additional sales of our equity securities under the S-3Registration Statement, we do not have an obligation to doso.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In addition to the potential sale of our equity securities, we mayalso seek to enter research, development and/or commercializationcollaborations similar to the AffaMed Agreement and the BayerAgreement to provide funding, including non-dilutive funding, fordevelopment of one or more of our CNS product candidate programs.We may also seek additional government grant awards or agreementssimilar to our prior agreement with the U.S. National Institutes ofHealth (         </font>         <font style="font-style: italic; color: #000000">          NIH         </font>         <font style="color: #000000">          ), Baylor University and the U.S. Department ofVeterans Affairs in connection with certain government-sponsoredstudies of AV-101. Such strategic collaborations may providenon-dilutive resources to advance our strategic initiatives whilereducing a portion of our future cash outlays and working capitalrequirements. We may also pursue intellectual property arrangementssimilar to the AffaMed Agreement and the Bayer Agreement with otherparties. Although we may seek additional collaborations that couldgenerate revenue and/or provide non-dilutive funding fordevelopment of our product candidates, as well as new governmentgrant awards and/or agreements, no assurance can be provided thatany such collaborations, awards or agreements will occur in thefuture.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our future working capital requirements will depend on manyfactors, including, without limitation, potential impacts relatedto the continuing COVID-19 pandemic, the scope and nature ofopportunities related to our success and the success of certainother companies in nonclinical and clinical trials, including ourdevelopment and commercialization of our current product candidatesand various applications of our stem cell technology platform, theavailability of, and our ability to obtain, government grant awardsand agreements, and our ability to enter into collaborations onterms acceptable to us. To further advance the clinical developmentof PH94B, PH10, and AV-101 and, to a lesser extent, our stem celltechnology platform, as well as support our operating activities,we plan to continue to carefully manage our routine operatingcosts, including our employee headcount and related expenses, aswell as costs relating to regulatory consulting, contractmanufacturing, research and development, investor and publicrelations, business development, legal, intellectual propertyacquisition and protection, public company compliance and otherprofessional services and operating costs.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Notwithstanding the foregoing, there can be no assurance that ourcurrent strategic collaborations under the AffaMed Agreement and/orthe Bayer Agreement will generate revenue from future potentialmilestone payments, or that future financings or government orother strategic collaborations will be available to us insufficient amounts, in a timely manner, or on terms acceptable tous, if at all. If we are unable to obtain additional financing on atimely basis when needed, our business, financial condition, andresults of operations may be harmed, the price of our stock maydecline, we may be required to reduce, defer, or discontinuecertain of our research and development activities and we may notbe able to continue as a going concern.  As noted above, theConsolidated Financial Statements included in part II, Item 8 ofthis Annual Report do not include any adjustments that might resultfrom the negative outcome of this uncertainty.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -79-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Cash and Cash Equivalents        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The following table summarizes changes in cash and cash equivalentsfor the fiscal years stated (in thousands):        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                FiscalYears Ended March 31,               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net cash used inoperating activities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (12,074             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (15,757             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net cash used ininvesting activities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (275             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net cash providedby financing activities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              114,102             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              4,012             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net increase(decrease) in cash and cash equivalents             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              101,753             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (11,745             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Cash and cashequivalents at beginning of period             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              1,355             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              13,100             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Cash and cashequivalents at end of period             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              103,108             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,355             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          The decrease in cash used in operations results primarily fromincreased spending on PH94B and PH10 nonclinical development,manufacturing advancements, and, for PH94B in particular, Phase3-enabling initiatives as a part of our preparations for thePALISADE Phase 3 program, combined with expansion of ourinfrastructure by the addition of experienced senior-levelexecutives in manufacturing, clinical and regulatory disciplines inthe fourth quarter of Fiscal 2021, offset by the impact of thecompletion of the Elevate Study, which commenced at the end of thefirst calendar quarter of 2018 and was operationally completedduring the third fiscal quarter of Fiscal 2020. Additionally, cashused in operations during Fiscal 2021 was reduced by the August2020 receipt of the $5.0 million nondilutive upfront payment fromEverInsight under the AffaMed Agreement. Cash used in investingactivities in Fiscal 2021 primarily reflects the purchase ofcertain manufacturing equipment acquired for use by our         </font>         contract development and manufacturing organization         <font style="color: #000000">          in connection with the production of PH94B drugproduct. Cash provided by financing activities in Fiscal 2021primarily reflects net cash proceeds to us from sales of our commonstock and Series D Preferred stock pursuant to the December 2020Public Offering and from sales of our common stock pursuant to theAugust 2020 Public Offering, the LPC Agreement and the Spring 2020Private Placement, as well as from the exercise of outstandingwarrants, net of routine insurance premium financing note andfinancing lease payments. We received a Payroll Protection Programloan in April 2020 and voluntarily repaid all principal and accruedinterest on the loan in December 2020, following the completion ofthe December 2020 Public Offering. Cash provided by financingactivities in Fiscal 2020 reflects the cash proceeds from our Fall2019 Private Placement, our Fall 2019 Warrant Offering, theexercise of certain warrants following the modification of theirexercise prices, proceeds from our January 2020 Registered DirectOffering and initial transactions under the LPC Agreement, net ofroutine payments on our insurance premium financing notes andlease.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Off-Balance Sheet Arrangements        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Other than contractual obligations incurred in the normal course ofbusiness, we do not have any off-balance sheet financingarrangements or liabilities, guarantee contracts, retained orcontingent interests in transferred assets or any obligationarising out of a material variable interest in an unconsolidatedentity. VistaStem has two inactive, wholly owned subsidiaries,Artemis Neuroscience, Inc., a Maryland corporation, and VistaStemCanada, Inc., an Ontario corporation.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Item 7A.          <a name="Quan">           Q          </a>          uan         </font>         <font style="color: #000000">          titative andQualitative Disclosures About Market Risk         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The disclosures in this section are not required because we qualifyas a smaller reporting company under federal securitieslaws.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -80-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Item 8.         <a name="Fina">          F         </a>         inancial Statements andSupplementary Data        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         INDEX TO CONSOLIDATED FINANCIAL STATEMENTS        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 79%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 21%; border-bottom: 2px solid #000000">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Page             </font>            </div>           </td>          </tr>          <tr style="background-color: #cceeff">           <td style="vertical-align: top; width: 79%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#REP">              <font style="color: #0000FF; font-size: 13px; font-family: Times New Roman">               Reportof Independent Registered Public Accounting Firm              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 21%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             82             <br/>            </div>           </td>          </tr>          <tr style="background-color: #ffffff">           <td style="vertical-align: top; width: 79%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#BAL">              <font style="color: #0000FF; font-size: 13px; font-family: Times New Roman">               ConsolidatedBalance Sheets              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 21%">            <div style="text-align: center">             <font style="font-family: Times New Roman; font-size: 13px">              84              <br/>             </font>            </div>           </td>          </tr>          <tr style="background-color: #cceeff">           <td style="vertical-align: top; width: 79%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#consolidated">              <font style="color: #0000FF; font-size: 13px; font-family: Times New Roman">               ConsolidatedStatements of Operations and Comprehensive Loss              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 21%">            <div style="text-align: center">             <font style="font-family: Times New Roman; font-size: 13px">              85              <br/>             </font>            </div>           </td>          </tr>          <tr style="background-color: #ffffff">           <td style="vertical-align: top; width: 79%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#CASH">              <font style="color: #0000FF; font-size: 13px; font-family: Times New Roman">               ConsolidatedStatements of Cash Flows              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 21%">            <div style="text-align: center">             <font style="font-family: Times New Roman; font-size: 13px">              86              <br/>             </font>            </div>           </td>          </tr>          <tr style="background-color: #cceeff">           <td style="vertical-align: top; width: 79%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#EQU">              <font style="font-family: Times New Roman; font-size: 13px">               <font style="color: #0000FF; font-size: 13px">                Consolidated Statements ofStockholders' Equity               </font>               <font style="color: #0000FF; font-size: 13px">                (Deficit)               </font>              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 21%">            <div style="text-align: center">             <font style="font-family: Times New Roman; font-size: 13px">              87              <br/>             </font>            </div>           </td>          </tr>          <tr style="background-color: #ffffff">           <td style="vertical-align: top; width: 79%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#NOTE">              <font style="color: #0000FF; font-size: 13px; font-family: Times New Roman">               Notesto Consolidated Financial Statements              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 21%">            <div style="text-align: center">             <font style="font-family: Times New Roman; font-size: 13px">              88              <br/>             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -81-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         <a name="REP">          R         </a>         EPORT OF INDEPENDENT REGISTERED PUBLICACCOUNTING FIRM        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Stockholdersand Board of Directors        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         VistaGenTherapeutics, Inc.        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         SouthSan Francisco, California        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Opinion on the Financial Statements        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We haveaudited the accompanying consolidated balance sheets of VistaGenTherapeutics, Inc. (the “Company”) as of March 31, 2021and 2020, the related consolidated statements of operations andcomprehensive loss, cash flows, and stockholders’ equity(deficit) for each of the two fiscal years in the period endedMarch 31, 2021, and the related notes (collectively referred to asthe “financial statements”). In our opinion, thefinancial statements present fairly, in all material respects, thefinancial position of the Company at March 31, 2021 and 2020, andthe results of its operations and its cash flows for each of thetwo years in the period ended March 31, 2021         <font style="font-weight: bold">          ,         </font>         in conformity with accountingprinciples generally accepted in the United States ofAmerica.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Basis for Opinion        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theseconsolidated financial statements are the responsibility of theCompany’s management. Our responsibility is to express anopinion on the Company’s consolidated financial statementsbased on our audits. We are a public accounting firm registeredwith the Public Company Accounting Oversight Board (United States)(“PCAOB”) and are required to be independent withrespect to the Company in accordance with the U.S. federalsecurities laws and the applicable rules and regulations of theSecurities and Exchange Commission and the PCAOB.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Weconducted our audits in accordance with the standards of the PCAOB.Those standards require that we plan and perform the audit toobtain reasonable assurance about whether the consolidatedfinancial statements are free of material misstatement, whether dueto error or fraud. The Company is not required to have, nor were weengaged to perform, an audit of its internal control over financialreporting. As part of our audits we are required to obtain anunderstanding of internal control over financial reporting but notfor the purpose of expressing an opinion on the effectiveness ofthe Company’s internal control over financial reporting.Accordingly, we express no such opinion.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ouraudits included performing procedures to assess the risks ofmaterial misstatement of the consolidated financial statements,whether due to error or fraud, and performing procedures thatrespond to those risks. Such procedures included examining, on atest basis, evidence regarding the amounts and disclosures in theconsolidated financial statements. Our audits also includedevaluating the accounting principles used and significant estimatesmade by management, as well as evaluating the overall presentationof the consolidated financial statements. We believe that ouraudits provide a reasonable basis for our opinion.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Critical Audit Matter        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thecritical audit matter communicated below is a matter arising fromthe current period audit of the consolidated financial statementsthat was communicated or required to be communicated to the auditcommittee and that: (1) relates to accounts or disclosures that arematerial to the consolidated financial statements; and (2) involvedour especially challenging, subjective, or complex judgments. Thecommunication of the critical audit matter does not alter in anyway our opinion on the consolidated financial statements, taken asa whole, and we are not, by communicating the critical audit matterbelow, providing separate opinions on the critical audit matter oron the accounts or disclosures to which it relates.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Revenues from Contracts with Customers        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="text-decoration: underline">          Description of the Matter         </font>         <font style="text-decoration: underline; font-family: Times New Roman">          ‒         </font>         <font style="text-decoration: underline">          License Agreement withAffaMed         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Asdiscussed in Note 12 to the consolidated financial statements, theCompany recognized approximately $1.1 million in revenue under thelicense agreement with AffaMed Therapeutics. Inc.(“AffaMed”) during the fiscal year ended March 31,2021. The Company evaluated each of the deliverables identified inthe license agreement and determined the license is not distinctwithin the context of the contract and is combined with developmentand regulatory approval services; as such, the Company combined thelicense and promised services into one combined performanceobligation.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -82-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Auditingmanagement’s identification of performance obligations waschallenging as the license agreement includes implicit and explicitobligations. Significant judgment was required in the evaluation ofthe identification of performance obligations and in thedetermination of whether the identified license and promisedservices meet the criteria of being distinct and capable of beingdistinct within the context of the contract. The Company’srevenue from its licensing agreement is recognized over time, asthe combined performance obligation is satisfied.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Weidentified license revenue recognition as a critical audit matterbecause of the judgments necessary for management to: identifyperformance obligations, determine variable consideration, anddetermine the timing of recognition for such revenue. Because ofthe complexity associated with applying the recognition criteria ofASC 606, notably related to identification of performanceobligations, determination of variable consideration, anddetermination of timing of revenue recognition, this requiredextensive audit effort and a high degree of auditor judgment whenperforming audit procedures and evaluating the results of thoseprocedures.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">         How the Critical Audit Matter Was Addressed in theAudit        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ouraudit procedures related to the recognition of license revenue,included the following, among others:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           We evaluated theCompany’s revenue recognition for the license agreementthrough an inspection of the agreement and an evaluation ofmanagement’s revenue recognition analysis corresponding tothe license agreement. Our objective was to validate that revenuefrom the license agreement was recognized in a manner commensuratewith the terms of the established agreement and the relevantaccounting guidance. Evaluating the reasonableness ofmanagement’s accounting conclusions involved:          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Evaluating theaccuracy and completeness of the performance obligations identifiedby management in the license agreement. Management identified onecombined performance obligation. We analyzed the license agreementto determine if the arrangement terms that may have an impact onrevenue recognition were identified and properly considered in theevaluation of the accounting for the contract. We also inquired ofmanagement, and reviewed source documentation, to assess whetherthe one combined performance obligation identified by managementwas complete and whether the license and promised services withinit were both capable of being distinct and distinct within thecontext of the contract.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Determining thereasonableness of the amounts of variable consideration includedwithin the total transaction price. We analyzed the nature of thecombined performance obligation and the contingencies related tothe variable consideration in assessing management’s methodsin estimating the amount of variable consideration to be includedin the total transaction price.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Testing themeasurement of efforts toward satisfaction of the combinedperformance obligation which included, among otherprocedures:          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 72px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Reviewingmanagement’s revenue schedules for accuracy and completenessby agreeing data to the underlying agreement.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 72px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Evaluating themanner in which the combined performance obligation was satisfied,and corroborating management estimates and judgments through areview of press releases and third-party data as a potential sourceof corroborating or contradictory evidence.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 72px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Discussingmanagement’s judgments with the Company’s research anddevelopment personnel that oversee aspects of the licenseagreement.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         /s/ OUM &amp; CO. LLP        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         San Francisco, California        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         June 29, 2021        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We have served as the Company's auditor since 2006.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -83-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         VISTAGEN THERAPEUTICS, INC.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         CONSOLIDATED         <a name="BAL">          B         </a>         ALANCE SHEETS        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         (Amounts in dollars, except share amounts)        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                March31,               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                March 31,               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="3" style="vertical-align:bottom;width:100%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                ASSETS               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Currentassets:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Cash and cashequivalents             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              103,108,300             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,355,100             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Receivable fromcollaboration partner             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              40,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Prepaid expensesand other current assets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              835,100             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              225,100             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Deferred contractacquisition costs - current portion             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              133,500             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;">             <font style="font-family: Times New Roman; font-size: 13px">              Total currentassets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              104,117,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,580,200             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Property andequipment, net             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              367,400             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              209,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Right of use asset- operating lease             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,219,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,579,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Deferred offeringcosts             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              294,900             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              355,100             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Deferred contractacquisition costs - non-current portion             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              234,100             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Security depositsand other assets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              47,800             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              47,800             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 4px; margin-left: 48px;">             <font style="font-family: Times New Roman; font-size: 13px">              Totalassets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              108,281,300             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              5,772,300             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td colspan="3" style="vertical-align:bottom;width:100%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                LIABILITIESAND STOCKHOLDERS’ EQUITY (DEFICIT)               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Currentliabilities:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accountspayable             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              838,300             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,836,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accruedexpenses             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,562,700             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              561,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Current notespayable             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              56,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Deferred revenue -current portion             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,420,200             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Operating leaseobligation - current portion             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              364,800             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              313,400             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Financing leaseobligation - current portion             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              3,000             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              3,300             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; margin-left: 48px; text-indent: 0px; margin-right: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="font-family: Times New Roman; font-size: 13px">               Total currentliabilities              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">              4,189,000             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">              2,771,300             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">             <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">              <font style="font-family: Times New Roman; font-size: 13px">               <br/>              </font>             </div>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Non-currentliabilities:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accrued dividendson Series B Preferred Stock             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              6,272,700             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              5,011,800             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Deferred revenue -non-current portion             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,490,300             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Operating leaseobligation - non-current portion             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,350,800             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,715,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Financing leaseobligation - non-current portion             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              3,000             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 48px;">             <font style="font-family: Times New Roman; font-size: 13px">              Total non-currentliabilities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              12,113,800             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              8,730,400             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 48px;">             <font style="font-family: Times New Roman; font-size: 13px">              Totalliabilities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              16,302,800             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              11,501,700             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Commitmentsand contingencies (Note 15)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Stockholders’equity (deficit):             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Preferred stock,$0.001 par value; 10,000,000 shares authorized at March 31, 2021and 2020:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;">             <font style="font-family: Times New Roman; font-size: 13px">              Series A Preferred,500,000 shares authorized, issued and outstanding at March 31, 2021and 2020             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;">             <font style="font-family: Times New Roman; font-size: 13px">              Series B Preferred;4,000,000 shares authorized at March 31, 2021 and 2020; 1,131,669shares             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;">             <font style="font-family: Times New Roman; font-size: 13px">              and 1,160,240shares issued and outstanding at March 31, 2021 and 2020,respectively             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,100             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,200             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;">             <font style="font-family: Times New Roman; font-size: 13px">              Series C Preferred;3,000,000 shares authorized at March 31, 2021 and 2020; 2,318,012shares             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;">             <font style="font-family: Times New Roman; font-size: 13px">              issued andoutstanding at March 31, 2021 and 2020             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,300             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,300             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;">             <font style="font-family: Times New Roman; font-size: 13px">              Series D Preferred;2,000,000 shares and no shares authorized at March 31, 2021 and2020, respectively;             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;">             <font style="font-family: Times New Roman; font-size: 13px">              402,149 shares andno shares issued and outstanding at March 31, 2021 and March 31,2020, respectively             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              400             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px;">             <font style="font-size: 13px">              Common stock, $0.001 parvalue; 325,000,000 shares and 175,000,000 shares authorized atMarch 31, 2021 and 2020, respectively;             </font>             <font style="font-size: 13px">              <font style="font-family: Times New Roman;">               180,751,234 and 49,348,707 sharesissued at March 31, 2021 and 2020, respectively              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              180,800             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              49,300             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px;">             <font style="font-size: 13px">              <font style="font-family: Times New Roman;">               Additional paid-incapital              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              315,603,100             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              200,092,800             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Treasury stock, atcost, 135,665 shares of common stock held at March 31, 2021 and2020             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (3,968,100             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (3,968,100             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accumulateddeficit             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (219,841,600             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (201,907,400             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 48px;">             <font style="font-family: Times New Roman; font-size: 13px">              Totalstockholders’ equity (deficit)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              91,978,500             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (5,729,400             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 4px; margin-left: 48px;">             <font style="font-family: Times New Roman; font-size: 13px">              Total liabilitiesand stockholders’ equity (deficit)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              108,281,300             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              5,772,300             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         See accompanying notes to consolidated financialstatements.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -84-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         VISTAGEN THERAPEUTICS, INC.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         <a name="consolidated">          C         </a>         ONSOLIDATEDSTATEMENTS OF OPERATIONS AND COMPREHENSIVE         <a name="LOS">          L         </a>         OSS        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         (Amounts in dollars, except share amounts)        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align: bottom; width: 24%; white-space: nowrap;">            <div>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                FiscalYears Ended March 31,               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Sublicenserevenue             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,089,500             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Totalrevenues             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              1,089,500             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Operatingexpenses:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Research anddevelopment             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              12,476,400             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              13,374,200             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              General andadministrative             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              6,546,900             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              7,427,300             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Totaloperating expenses             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              19,023,300             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              20,801,500             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Loss fromoperations             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (17,933,800             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (20,801,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Other income andexpenses, net:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Interestincome, net             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              30,100             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Otherincome             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              600             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Loss before incometaxes             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (17,931,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (20,771,400             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Incometaxes             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (2,600             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (2,600             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net loss andcomprehensive loss             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (17,934,200             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (20,774,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accrueddividends on Series B Preferred stock             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (1,385,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (1,263,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Beneficialconversion feature on Series D             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Preferredstock             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (23,000,000             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net lossattributable to common stockholders             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (42,319,800             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (22,037,600             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Basic and dilutednet loss attributable to common             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              stockholdersper common share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (0.49             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (0.50             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Weighted averageshares used in computing             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              basic anddiluted net loss attributable to common             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%; padding-bottom: 2px;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%; padding-bottom: 2px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              stockholdersper common share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              86,133,644             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              43,869,523             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         See accompanying notes to consolidated financialstatements.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -85-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         VISTAGEN THERAPEUTICS, INC.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         CONSOLIDATED STATEMENTS OF         <a name="CASH">          C         </a>         ASHFLOWS        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         (Amounts in dollars)        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align: bottom; width: 24%; white-space: nowrap;">            <div>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                FiscalYears Ended March 31,               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Cash flowsfrom operating activities:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Netloss             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (17,934,200             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (20,774,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Adjustmentsto reconcile net loss to net cash used in operatingactivities:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Depreciationand amortization             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              117,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              103,100             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Stock-basedcompensation             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,306,100             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,820,800             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Expenserelated to modification of warrants             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              826,900             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Amortizationof fair value of common stock issued for services             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              92,100             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Amortizationof fair value of warrants issued for services             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              13,800             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Changesin operating assets and liabilities:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Receivablefrom collaboration partner or supplier             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (40,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              300,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Prepaidexpenses and other current assets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (287,800             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              182,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Rightof use asset - operating lease             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              360,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              335,400             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Operatinglease liability             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (313,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (267,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Deferredsublicense revenue, net of deferred contract acquisitioncosts             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,667,900             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:48px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accountspayable and accrued expenses             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              51,000             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (390,700             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Netcash used in operating activities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (12,073,500             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (15,757,000             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Cash flowsfrom property and investing activities:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Purchasesof manufacturing and other equipment             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (275,400             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Netcash used in investing activities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (275,400             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Cash flowsfrom financing activities:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Netproceeds from issuance of common stock and Series D Preferredstock             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              93,675,200             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Netproceeds from issuance of common stock and warrants, includingUnits             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              12,957,800             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,349,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Netproceeds from exercise of warrants             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              5,009,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              410,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Proceedsfrom sale of warrants             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              300,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Netproceeds from sale of common stock under equity line             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,841,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              249,400             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Proceedsfrom issuance of note under Payroll Protection Plan             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              224,400             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Repaymentof capital lease obligations             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (3,300             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (3,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Repaymentof notes payable, including Payroll Protection Plannote             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (603,100             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (293,600             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Netcash provided by financing activities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              114,102,100             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              4,011,800             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net increase(decrease) in cash and cash equivalents             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              101,753,200             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (11,745,200             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Cash and cashequivalents at beginning of period             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              1,355,100             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              13,100,300             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Cash and cashequivalents at end of period             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              103,108,300             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,355,100             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Supplementaldisclosure of cash flow activities:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Cashpaid for interest             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              13,300             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              14,800             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Cashpaid for income taxes             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Supplementaldisclosure of noncash activities:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Insurancepremiums settled by issuing note payable             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              322,200             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              292,800             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accrueddividends on Series B Preferred             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,385,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,263,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accrueddividends on Series B Preferred settled upon conversion byissuance             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              ofcommon stock             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              124,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         See accompanying notes to consolidated financialstatements.        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -86-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         VISTAGEN THERAPEUTICS, INC.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         CONSOLIDATED STATEMENTS OF STOCKHOLDERS’         <a name="EQU">          E         </a>         QUITY (DEFICIT)        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         Fiscal Years Ended March 31, 2020 and 2021        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         (Amounts in dollars, except share amounts)        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:16%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 9px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Additional                </font>               </div>              </font>              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Total                </font>               </div>              </font>              <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 9px;">             </font>            </div>           </td>           <td colspan="2" style="vertical-align:bottom;width:12%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Series APreferred Stock                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td colspan="2" style="vertical-align:bottom;width:12%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Series BPreferred Stock                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td colspan="2" style="vertical-align:bottom;width:12%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Series CPreferred Stock                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td colspan="2" style="vertical-align:bottom;width:12%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Series DPreferred Stock                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td colspan="2" style="vertical-align:bottom;width:12%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 CommonStock                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Paid-in                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Treasury                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Accumulated                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Stockholders’                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 9px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Shares                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Amount                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Shares                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Amount                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Shares                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Amount                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Shares                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Amount                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Shares                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Amount                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Capital                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Stock                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Deficit                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-family: Times New Roman;">                 Equity(Deficit)                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 9px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 9px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-weight: bold; font-family: Times New Roman; font-size: 9px;">              Balances at March 31, 2019             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               500,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               500              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               1,160,240              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               1,200              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               2,318,012              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               2,300              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               42,758,630              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               42,800              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               192,129,900              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               (3,968,100              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">               )              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               (181,133,400              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">               )              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               7,075,200              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td colspan="1" style="vertical-align:bottom;width:16%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 9px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Proceeds from sale of units of common stock andwarrants             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              for cash in private placements             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               650,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               600              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               649,400              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               650,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Proceeds from sale of warrants in private placement             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               300,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               300,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Proceeds from sale of units of common stock andwarrants             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              for cash in public offering and concurrent privateplacement             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               3,870,077              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               3,900              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               2,695,100              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               2,699,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Issuance of commitment shares and net proceeds ofinitial             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              sale of common stock under equity line             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               1,250,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               1,200              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               525,100              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               526,300              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Proceeds from exercise of warrants             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               820,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               800              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               409,200              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               410,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Accrued dividends on Series B Preferred stock             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               (1,263,600              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">               )              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               (1,263,600              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">               )              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Stock-based compensation expense             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               3,820,800              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               3,820,800              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Increase in fair value attributed to warrantmodifications             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              and additional warrants issued             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               826,900              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               826,900              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td colspan="1" style="vertical-align:bottom;width:16%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 9px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Net loss for the fiscal year ended March 31, 2020             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">               -              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               (20,774,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">               )              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               (20,774,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">               )              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td colspan="1" style="vertical-align:bottom;width:16%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 9px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-weight: bold; font-family: Times New Roman; font-size: 9px;">              Balances at March 31, 2020             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>              <font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">              </font>              <font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               500,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">               500              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>              <font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">              </font>              <font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               1,160,240              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">               1,200              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>              <font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">              </font>              <font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               2,318,012              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">               2,300              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>              <font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">              </font>              <font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>              <font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">              </font>              <font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               49,348,707              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">               49,300              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">               200,092,800              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">               (3,968,100              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">               )              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">               (201,907,400              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">               )              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">               (5,729,400              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">               )              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td colspan="1" style="vertical-align:bottom;width:16%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 9px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Net proceeds from sale of common stock under equityline             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               6,301,995              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               6,300              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               2,790,500              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               2,796,800              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Net proceeds from sale of common stock in publicoffering             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               17,868,250              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               17,900              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               12,887,200              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               12,905,100              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Net proceeds from sale of common stock and Series DPreferred             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              stock in public offering             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               2,000,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               2,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               63,000,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               63,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               93,582,900              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               93,647,900              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Net proceeds from exercise of warrants             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               6,624,302              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               6,600              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               5,002,900              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               5,009,500              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Comversion of Series D Preferred stock to common stock             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               (1,597,851              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">               )              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               (1,600              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">               )              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               36,750,573              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               36,800              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               (35,200              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">               )              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Comversion of Series B Preferred stock to common stock andpayment             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              of accrued dividends in common stock             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               (28,571              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">               )              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               (100              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">               )              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               188,633              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               200              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               124,500              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">               -              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">               -              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               124,600              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Accrued dividends on Series B Preferred stock             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               (1,385,600              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">               )              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               (1,385,600              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">               )              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Stock-based compensation expense             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               2,306,100              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               2,306,100              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Sale of common stock pursuant to 2019 Employee Stock PurchasePlan             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               58,125              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               100              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               26,100              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">               -              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">               -              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               26,200              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Issuance of common stock upon cashless exercise of stockoptions             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               222,004              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               200              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               (200              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">               )              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Net proceeds from exercise of stock options for cash             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               30,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               36,500              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               36,500              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Issuance of common stock at fair value for professionalservices             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               233,645              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               200              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               124,800              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">               -              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">               -              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               125,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Beneficial conversion feature on Series D Preferredstock             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               23,000,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">               -              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               23,000,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Deemed dividend from beneficial conversion feature of Series DPreferred Stock             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               (23,000,000)              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">               -              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               (23,000,000)              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 9px;">              Net loss for the fiscal year ended March 31, 2021             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">              </font>              <font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               -              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               (17,934,200              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">               )              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">               (17,934,200              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">               )              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td colspan="1" style="vertical-align:bottom;width:16%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 9px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">              </font>              <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="color: rgb(0, 0, 0); font-weight: bold; font-family: Times New Roman; font-size: 9px;">              Balances at March 31, 2021             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>              <font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">              </font>              <font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               500,000              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 4px double rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 4px double rgb(0, 0, 0);">               500              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>              <font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">              </font>              <font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               1,131,669              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 4px double rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 4px double rgb(0, 0, 0);">               1,100              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>              <font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">              </font>              <font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               2,318,012              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 4px double rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 4px double rgb(0, 0, 0);">               2,300              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>              <font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">              </font>              <font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               402,149              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 4px double rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 4px double rgb(0, 0, 0);">               400              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>              <font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">              </font>              <font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">               180,751,234              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 4px double rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 4px double rgb(0, 0, 0);">               180,800              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 4px double rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 4px double rgb(0, 0, 0);">               315,603,100              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 4px double rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 4px double rgb(0, 0, 0);">               (3,968,100              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">               )              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 4px double rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 4px double rgb(0, 0, 0);">               (219,841,600              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">               )              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:6%;">            <div>             <font style="font-size: 9px">              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 4px double rgb(0, 0, 0);">               $              </font>              <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 4px double rgb(0, 0, 0);">               91,978,500              </font>              <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">              </font>             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         See accompanying notes to consolidated financialstatements.        </font>       </div>       <br/>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -87-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         1.         <a name="NOTE">          D         </a>         escription ofBusiness        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Overview        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: justify">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #333333; background-color: #FFFFFF">          VistaGen Therapeutics,Inc., a Nevada corporation         </font>         <font style="color: #000000">          (which may be referred to as         </font>         <font style="font-style: italic; color: #000000">          VistaGen         </font>         <font style="color: #000000">          , the         </font>         <font style="font-style: italic; color: #000000">          Company         </font>         <font style="color: #000000">          ,         </font>         <font style="font-style: italic; color: #000000">          we         </font>         <font style="color: #000000">          ,         </font>         <font style="font-style: italic; color: #000000">          our         </font>         <font style="color: #000000">          , or         </font>         <font style="font-style: italic; color: #000000">          us         </font>         <font style="color: #000000">          ),         </font>         <font style="color: #333333; background-color: #FFFFFF">          is         </font>         <font style="color: #000000">          a biopharmaceutical company committed todeveloping and commercializing differentiated new generationmedications that go beyond the current standard of care forwidespread anxiety, depression and other central nervous system(         </font>         <font style="font-style: italic; color: #000000">          CNS         </font>         <font style="color: #000000">          ) disorders. Our CNS pipeline includes three CNSproduct candidates, PH94B Nasal Spray, PH10 Nasal Spray and AV-101,each with a differentiated profile, favorable safety resultsobserved in all clinical studies to date and therapeutic potentialin multiple CNS indications. PH94B Nasal Spray (         </font>         <font style="font-style: italic; color: #000000">          PH94B         </font>         <font style="color: #000000">          ) is being developed for multiple anxietydisorders. We recently initiated our PH94B Phase 3 developmentprogram, which we refer to as the PALISADE program, withPALISADE-1, a U.S., multi-center, randomized, double-blind,placebo-controlled Phase 3 clinical study to evaluate the efficacyand safety of PH94B for the acute treatment of anxiety in adultswith social anxiety disorder (         </font>         <font style="font-style: italic; color: #000000">          SAD         </font>         <font style="color: #000000">          ), as well as preparations for the additionalstudies required to support our potential U.S. New Drug Application(         </font>         <font style="font-style: italic; color: #000000">          NDA         </font>         <font style="color: #000000">          ) for that indication should the PALISADE Phase 3program be successful. We are also preparing for exploratory Phase2A clinical studies of PH94B in adults experiencing several otheranxiety disorders. PH10 Nasal Spray (         </font>         <font style="font-style: italic; color: #000000">          PH10         </font>         <font style="color: #000000">          ) is being developed as a stand-alone treatmentfor multiple depression disorders. Exploratory Phase 2A clinicaldevelopment of PH10 for major depressive disorder(         </font>         <font style="font-style: italic; color: #000000">          MDD         </font>         <font style="color: #000000">          ) has been completed. We are now preparing forplanned Phase 2B clinical development of PH10 for this indication.We are preparing for a Phase 1B clinical study of AV-101 incombination with probenecid to assess potential future Phase 2Aclinical development of the combination for MDD or certainneurological indications. Our goal is to become a biopharmaceuticalcompany that develops and commercializes innovative CNS therapiesfor highly prevalent neuropsychiatry and neurology indicationswhere current treatments options are inadequate to meet the needsof millions of patients in markets worldwide.         </font>        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Our Product Candidates        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         PH94Bis a synthetic investigational neurosteroid developed fromproprietary compounds called pherines. With its novel mechanism ofaction, PH94B is an odorless nasal spray administered atmicrogram-level doses to achieve rapid-onset anti-anxiety, oranxiolytic, effects. The pharmacological activity of PH94B isfundamentally differentiated from that of all FDA-approvedanti-anxiety drugs, including all antidepressants approved by theU.S. Food and Drug Administration (         <font style="font-style: italic">          FDA         </font>         ) for treatment of SAD, as well asall benzodiazepines and beta blockers prescribed on an off-labelbasis. PH94B engages peripheral chemosensory receptors in nasalpassages that trigger a subset of neurons in the main olfactorybulbs (         <font style="font-style: italic">          OB         </font>         ) at the base ofthe brain. The OB neurons then stimulate inhibitory GABAergicneurons in the limbic amygdala, decreasing the activity of thesympathetic nervous system, and facilitating fear extinctionactivity of the limbic-hypothalamic system, the main fear andanxiety center in the brain, as well as in other parts of thebrain. Importantly, PH94B does not require systemic uptake anddistribution to produce its rapid-onset anti-anxiety effects.         <font style="color: #000000">          Our ongoing PALISADE Phase 3 programfor PH94B is designed to further demonstrate its potential as afast-acting, non-sedating, non-addictive acute treatment of anxietyin adults with SAD. We believe PH94B also has potential to bedeveloped as a novel treatment for adjustment disorder withanxiety, postpartum anxiety, post-traumatic stress disorder,procedural anxiety, panic and other anxiety disorders. PH94B hasbeen granted Fast Track designation status by the FDA fordevelopment for the acute treatment of SAD.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         PH10 isa synthetic investigational neurosteroid, which also was developedfrom proprietary compounds called pherines. Its novel, rapid-onsetmechanism of action (         <font style="font-style: italic">          MOA         </font>         )is fundamentally differentiated from the MOA of all currenttreatments for MDD and other depression disorders. PH10 isself-administered at microgram-level doses as an odorless nasalspray. PH10 activates nasal chemosensory cells in the nasalpassages, connected to neural circuits in the brain that produceantidepressant effects. Specifically, PH10 engages peripheralchemosensory receptors in the nasal passages that trigger a subsetof neurons in the main OB that stimulate neurons in the limbicamygdala. This is turn increases activity of thelimbic-hypothalamic sympathetic nervous system and increases therelease of catecholamines. Importantly, unlike all currentlyapproved oral antidepressants (         <font style="font-style: italic">          ADs         </font>         ), PH10 does not require systemicuptake and distribution to produce rapid-onset of antidepressanteffects. In all clinical studies to date, PH10 has not causedpsychological side effects (such as dissociation andhallucinations) or safety concerns that may be associated withrapid-onset ketamine-based therapy (         <font style="font-style: italic">          KBT         </font>         ), including intravenous ketamine orintranasal ketamine (esketamine).         <font style="color: #000000">          Webelieve PH10 has potential to be a new stand-alone treatment forMDD and several other depression disorders.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          AV-101 (4-Cl-KYN) targets the NMDAR (N-methyl-D-aspartatereceptor), an ionotropic glutamate receptor in the brain. AbnormalNMDAR function is associated with numerous CNS diseases anddisorders. AV-101 is an oral prodrug of 7-chloro-kynurenic acid(7-Cl-KYNA), which is a potent and selective full antagonist of theglycine co-agonist site of the NMDAR that inhibits the function ofthe NMDAR. However, unlike ketamine and many other NMDARantagonists, 7-Cl-KYNA is not an ion channel blocker. At dosesadministered in all studies to date, AV-101 has been observed to bewell tolerated and has not exhibited dissociative or hallucinogenicpsychological side effects or safety concerns. In light of theseobservations and findings from preclinical studies, we believe thatAV-101, in combination with FDA-approved probenecid, has potentialto become a new oral treatment alternative for certain CNSindications involving the NMDAR. We are currently preparing toevaluate AV-101 in combination with probenecid in a Phase 1Bclinical study. The FDA has granted Fast Track designation fordevelopment of AV-101 as a potential adjunctive treatment for MDDand as a non-opioid treatment for neuropathic pain(         </font>         <font style="font-style: italic; color: #000000">          NP         </font>         <font style="color: #000000">          ).         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -88-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Subsidiaries        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          VistaGen Therapeutics, Inc., a California corporation d/b/aVistaStem (         </font>         <font style="font-style: italic; color: #000000">          VistaStem         </font>         <font style="color: #000000">          ),is our wholly-owned subsidiary. Our ConsolidatedFinancial Statements in this Annual Report on Form 10-K(         </font>         <font style="font-style: italic; color: #000000">          AnnualReport         </font>         <font style="color: #000000">          ) also include theaccounts of VistaStem’s two wholly-owned inactivesubsidiaries, Artemis Neuroscience, Inc., a Maryland corporation,and VistaStem Canada, Inc., a corporation organized under the lawsof Ontario, Canada.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         2.  Basis of Presentation and Going Concern        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The accompanying Consolidated Financial Statements have beenprepared assuming that we will continue as a going concern. As aclinical-stage biopharmaceutical company having not yet developedcommercial products or achieved sustainable revenues, we haveexperienced negative cash flows from operations and recurringlosses resulting in a deficit of $242.8 million accumulated frominception (May 1998) through March 31, 2021. We expect losses andnegative cash flows from operations to continue for the foreseeablefuture as we engage in further development of PH94B, PH10 andAV-101.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Since our inception in May 1998 through March 31, 2021, we havefinanced our operations and technology acquisitions primarilythrough the issuance and sale of our equity and debt securities forcash proceeds of approximately $197.8 million, as well as from anaggregate of approximately $22.7 million of government researchgrant awards (excluding the fair market value of governmentsponsored and funded clinical trials), strategic collaborationpayments, intellectual property licensing and other revenues.Additionally, we have issued equity securities with an approximatevalue at issuance of $38.2         </font>         <font style="font-style: italic; color: #000000">         </font>         <font style="color: #000000">          million in noncash acquisitions of productlicenses and in settlements of certain liabilities, includingliabilities for professional services rendered to us or ascompensation for such services.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Recent Developments        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          As described more completely in Note 9,         </font>         <font style="font-style: italic; color: #000000">          CapitalStock         </font>         <font style="color: #000000">          , in December 20         </font>         20,we entered into an underwriting agreement (the         <font style="font-style: italic">          December 2020 Underwriting Agreement         </font>         )pursuant to which we sold, in an underwritten public offering (the         <font style="font-style: italic">          December 2020 PublicOffering         </font>         ), 63,000,000 shares of our common stock at a publicoffering price of $0.92 per share and 2,000,000 shares of a newlyissued series of convertible preferred stock (         <font style="font-style: italic">          Series D Preferred)         </font>         and, together withthe common stock, the         <font style="font-style: italic">          Securities         </font>         ) at a public offering priceof $21.16 per share, resulting in gross proceeds to us of $100million. Net proceeds to us from the securities sold in theDecember 2020 Public Offering, after deducting underwritingdiscounts and commissions and offering expenses payable by us, wasapproximately $93.6 million.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          As also described more completely in Note 9,         </font>         <font style="font-style: italic; color: #000000">          CapitalStock         </font>         <font style="color: #000000">          , in August 2020, weentered into an underwriting agreement (the August 2020         </font>         <font style="font-style: italic; color: #000000">          UnderwritingAgreement         </font>         <font style="color: #000000">          ) pursuant to which wesold, in an underwritten public offering (the         </font>         <font style="font-style: italic; color: #000000">          August 2020 PublicOffering         </font>         <font style="color: #000000">          ), an aggregate of15,625,000 shares of our common stock at a public offering price of$0.80 per share, resulting in gross proceeds to us of $12,500,000.Under the terms of the August 2020 Underwriting Agreement, wegranted to the underwriter an over-allotment option(the         </font>         <font style="font-style: italic; color: #000000">          Over-AllotmentOption         </font>         <font style="color: #000000">          ) to purchase up to anadditional 2,343,750 shares of common stock at a public offeringprice of $0.80 per share. The underwriter exercised theOver-Allotment Option with respect to 2,243,250 shares (the         </font>         <font style="font-style: italic; color: #000000">          Exercised OptionShares         </font>         <font style="color: #000000">          ), resulting inadditional gross proceeds to us of $1,794,600. Aggregate netproceeds to us from the August 2020 Public Offering, afterdeducting underwriting discounts and commissions and offeringexpenses payable by us, were approximately $12.9million.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="background-color: #FFFFFF">          As more completely described in Note 12,         </font>         <font style="font-style: italic; background-color: #FFFFFF">          Licensing,Sublicensing and Collaboration Agreements         </font>         <font style="background-color: #FFFFFF">          , in June 2020, we entered into astrategic licensing and collaboration agreement for the clinicaldevelopment and commercialization of PH94B for acute treatment ofanxiety in adults with SAD and other potential anxiety-relateddisorders (the         </font>         <font style="font-style: italic; background-color: #FFFFFF">          EverInsightAgreement         </font>         <font style="background-color: #FFFFFF">          ), withEverInsight Therapeutics Inc.,         </font>         (         <font style="font-style: italic">          EverInsight         </font>         ),         <font style="background-color: #FFFFFF">          a biopharmaceutical company focused ondeveloping and commercializing transformative pharmaceuticalproducts for patients in Greater China and other parts ofAsia,         </font>         and funded by CBC Group, a global healthcare-focusedventure capital firm. Subsequent to entering into the EverInsightAgreement, in October 2020, EverInsight merged with AffaMedTherapeutics, also funded by CBC Group, which as a combined,complementary entity is focusing on developing and commercializingtherapeutics to address ophthalmologic and CNS disorders in GreaterChina and beyond. Accordingly, we are now referring to EverInsightand the EverInsight Agreement as AffaMed and the AffaMed Agreement,respectively.         <font style="background-color: #FFFFFF">          Under theterms of the AffaMed Agreement, AffaMed agreed to make anon-dilutive upfront license payment of $5.0 million to us, whichwe received in August 2020. The $5.0 million upfront licensepayment resulted in net cash proceeds to us of approximately $4.655million after the sublicense payment we agreed to make to PherinPharmaceuticals, Inc. (         </font>         <font style="font-style: italic; background-color: #FFFFFF">          Pherin         </font>         <font style="background-color: #FFFFFF">          )pursuant to our PH94B license from Pherin, and payment forconsulting services related to the AffaMedAgreement.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Additionally, as described in Note 9,         </font>         <font style="font-style: italic; color: #000000">          CapitalStock         </font>         <font style="color: #000000">          , on March 24, 2020, weentered into a purchase agreement and a registration rightsagreement with Lincoln Park Capital Fund (         </font>         <font style="font-style: italic; color: #000000">          LincolnPark         </font>         <font style="color: #000000">          ) pursuant to which LincolnPark committed to purchase up to $10,250,000 of our common stock atmarket-based prices over a period of 24 months (the         </font>         <font style="font-style: italic; color: #000000">          LPCAgreement         </font>         <font style="color: #000000">          ). To satisfy ourobligations under the registration rights agreement, we filed aRegistration Statement on Form S-1 (the         </font>         <font style="font-style: italic; color: #000000">          LPC RegistrationStatement         </font>         <font style="color: #000000">          ) with the Securitiesand Exchange Commission (the         </font>         <font style="font-style: italic; color: #000000">          SEC         </font>         <font style="color: #000000">          ) on March 31, 2020, which the SEC declaredeffective on April 14, 2020 (Registration No. 333-237514).Subsequent to the effectiveness of the LPC Registration Statementand through July 2020, we sold 6,301,995 registered shares of ourcommon stock to Lincoln Park and received gross cash proceeds of$2,891,200. We have not sold any shares of our common stockpursuant to the Lincoln Park Agreement since July2020.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -89-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="background-color: #ffffff">         <font style="font-family: Times New Roman; font-size: 13px">          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           Asalso described in Note 9,          </font>          <font style="font-style: italic; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           Capital Stock          </font>          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           ,between December 2020 and March 31, 2021, certain holders ofoutstanding warrants exercised such warrants to purchase anaggregate of 6,396,302 shares of our common stock and we receivedcash proceeds of $4,924,800 from such exercises. As disclosed inNote 16,          </font>          <font style="font-style: italic; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           Subsequent Events          </font>          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           ,since March 31, 2021, holders of outstanding warrants haveexercised warrants to purchase an additional          </font>          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           1,508,768          </font>          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           sharesof our common stock and we have received cash proceeds ofapproximately          </font>          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           $1,105,700.          </font>         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Liquidity and Capital Resources        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         During the fiscal year ended March 31, 2021, we receivedapproximately $119 million in net cash proceeds from thetransactions described above. At March 31, 2021, we had cash andcash equivalents of approximately $103.1 million, which we believeis sufficient to fund our planned operations for well beyond thetwelve months following the issuance of these financial statements,and indicating our ability to continue as a going concern.Nevertheless, we have not yet developed products that generaterecurring revenue and, assuming successful completion of ourplanned clinical and nonclinical programs, we will need to investsubstantial additional capital resources to commercialize any ofthem.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">         <font style="font-family: Times New Roman; font-size: 13px">          <font style="color: #000000">           During the next twelve months, we planto (i) continue PALISADE-1 and prepare for and initiate          </font>          multiple studies in our PALISADE          <font style="color: #000000">           Phase3 program for development and commercialization of PH94B as anacute treatment of anxiety in adult patients with SAD, (ii) preparefor and initiate multiple small exploratory          </font>          Phase 2A studiesof PH94B in additional anxiety disorders, (iii) prepare for andinitiate a Phase 2B clinical study of PH10 as a potentialstand-alone treatment for MDD, (iv) prepare for and initiate aPhase 1B clinical study of AV-101 in combination with probenecid toenable assessment of potential exploratory Phase 2A development ofthe combination in MDD and certain neurological disorders,          <font style="color: #000000">           and (v) conduct nonclinical studiesinvolving PH94B, PH10 and AV-101.          </font>         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Although we believe our current cash position is sufficient to fundour planned operations for more than the next twelve monthsfollowing the issuance of this Annual Report, when necessary andadvantageous, we may raise additional capital through the sale ofour equity securities in one or more (i) public offerings (ii)private placements to accredited investors, and/or (iii) instrategic licensing and development collaborations involving one ormore of our drug candidates in markets outside the United States,similar to the AffaMed Agreement. Subject to certain restrictions,our Registration Statement on Form S-3 (Registration No.333-254299) (the         </font>         <font style="font-style: italic; color: #000000">          S-3 RegistrationStatement         </font>         <font style="color: #000000">          ), which becameeffective on March 26, 2021, remains available for future sales ofour equity securities in one or more public offerings from time totime. While we may make additional sales of our equity securitiesunder the S-3 Registration Statement, we do not have an obligationto do so.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In addition to the potential sale of our equity securities, we mayalso seek to enter research, development and/or commercializationcollaborations similar to the AffaMed Agreement and the BayerAgreement (defined in Note 12, below) to provide funding, includingnon-dilutive funding, for development of one or more of our CNSproduct candidate programs. We may also seek additional governmentgrant awards or agreements similar to our prior agreement with theU.S. National Institutes of Health (         </font>         <font style="font-style: italic; color: #000000">          NIH         </font>         <font style="color: #000000">          ), Baylor University and the U.S. Department ofVeterans Affairs in connection with certain government-sponsoredstudies of AV-101. Such strategic collaborations may providenon-dilutive resources to advance our strategic initiatives whilereducing a portion of our future cash outlays and working capitalrequirements. We may also pursue intellectual property arrangementssimilar to the AffaMed Agreement and the Bayer Agreement with otherparties. Although we may seek additional collaborations that couldgenerate revenue and/or provide non-dilutive funding fordevelopment of our product candidates, as well as new governmentgrant awards and/or agreements, no assurance can be provided thatany such collaborations, awards or agreements will occur in thefuture.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our future working capital requirements will depend on manyfactors, including, without limitation, potential impacts relatedto the current COVID-19 pandemic, the scope and nature ofopportunities related to our success and the success of certainother companies in nonclinical and clinical trials, including ourdevelopment and commercialization of our current product candidatesand various applications of our stem cell technology platform, theavailability of, and our ability to obtain, government grant awardsand agreements, and our ability to enter into collaborations onterms acceptable to us. To further advance the clinical developmentof PH94B, PH10, and AV-101 and, to a lesser extent, our stem celltechnology platform, as well as support our operating activities,we plan to continue to carefully manage our routine operatingcosts, including our employee headcount and related expenses, aswell as costs relating to regulatory consulting, contractmanufacturing, research and development, investor and publicrelations, business development, legal, intellectual propertyacquisition and protection, public company compliance and otherprofessional services and operating costs.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Notwithstanding the foregoing, there can be no assurance that ourcurrent strategic collaborations under the AffaMed Agreement and/orthe Bayer Agreement will generate revenue from future potentialmilestone payments, or that future financings or government orother strategic collaborations will be available to us insufficient amounts, in a timely manner, or on terms acceptable tous, if at all. If we are unable to obtain additional financing on atimely basis when needed, our business, financial condition, andresults of operations may be harmed, the price of our stock maydecline, we may be required to reduce, defer, or discontinuecertain of our research and development activities and we may notbe able to continue as a going concern.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -90-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         3.  Summary of Significant AccountingPolicies        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Use of Estimates        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          The preparation of financial statements in conformity withU.S. generally accepted accounting principles(         </font>         <font style="font-style: italic; color: #000000">          U.S.GAAP         </font>         <font style="color: #000000">          ) requires management tomake estimates and assumptions that affect the reported amounts ofassets and liabilities, the disclosure of contingent assets andliabilities at the date of the financial statements, and thereported amounts of revenues and expenses during the reportingperiod. Actual results could differ from those estimates. Significant estimates include, but are not limited to, thoserelating to stock-based compensation, revenue recognition, researchand development expenses, determination of right of use assetsunder lease transactions and related lease obligations, andthe assumptions used to value warrants, warrant modificationsand useful lives for property and equipment and relateddepreciation calculations.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Principles of Consolidation        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The accompanying consolidated financial statements include theCompany’s accounts, VistaStem’s accounts and theaccounts of VistaStem’s two wholly-owned inactivesubsidiaries, Artemis Neurosciences and VistaStem Canada. Allmaterial intercompany accounts and transactions have beeneliminated in consolidation.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Cash and Cash Equivalents        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Cash and cash equivalents are considered to be highly liquidinvestments with maturities of three months or less at the date ofpurchase.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Property and Equipment        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Property and equipment is stated at cost. Repairs and maintenancecosts are expensed in the period incurred. Depreciation iscalculated using the straight-line method over the estimated usefullives of the assets. The estimated useful lives of laboratory,information technology and office equipment range from three toseven years; the estimated useful lives of manufacturing equipmentranges from five to ten years. Leasehold improvements are amortizedover the shorter of the lease term or the useful life of theimprovements.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Impairment of Long-Lived Assets        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourlong-lived assets consist of property and equipment. Long-livedassets to be held and used are tested for recoverability wheneverevents or changes in business circumstances indicate that thecarrying amount of the assets may not be fully recoverable. Factorsthat we consider in deciding when to perform an impairment reviewinclude significant underperformance of the business in relation toexpectations, significant negative industry or economic trends, andsignificant changes or planned changes in our use of the assets. Animpairment loss would be recognized when estimated undiscountedfuture cash flows expected to result from the use of an asset areless than its carrying amount. The impairment loss would be basedon the excess of the carrying value of the impaired asset over itsfair value, determined based on discounted cash flows. To date, wehave not recorded any impairment losses on long-livedassets.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Deferred Offering Costs        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Deferred offering costs are expenses directly related to ourcurrent S-3 Registration Statement (the         </font>         <font style="font-style: italic; color: #000000">          ShelfRegistration         </font>         <font style="color: #000000">          ), which becameeffective on March 26, 2021, and expenses transferred from ourpredecessor registration statement on Form S-3, and the LPCRegistration Statement which became effective on April 14, 2020.These costs consist of legal, accounting, printing, SEC filingfees, and, as appropriate, Nasdaq filing fees, and, in the case ofthe LPC Registration Statement, the issuance-date fair value ofcertain shares of our common stock issued to Lincoln Park under theterms of the LPC Agreement. Deferred costs associated with theShelf Registration are reclassified to additional paid-in capitalon a pro-rata basis as we complete offerings under the S-3Registration Statement, with any remaining deferred costs to becharged to results of operations at the end of the three-year lifeof the S-3 Registration Statement. During the fiscal years endedMarch 31, 2021 and 2020, we charged deferred offering costs of$15,800 and $300, respectively, to additional paid-in capital as aresult of offerings under the Shelf Registration. Deferred costsassociated with the LPC Registration Statement are reclassified toadditional paid-in capital on a pro-rata basis as we complete salesof our common stock pursuant to the LPC Agreement, with anyremaining deferred costs to be charged to results of operations atthe end of the two-year life of the LPC Agreement. We chargeddeferred offering costs of $94,400 and $8,100 to additional paid-incapital during the fiscal years ended March 31, 2021 and 2020,respectively, as a result of sales of our common stock under theLPC Agreement.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -91-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Revenue Recognition        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourprimary source of revenue for the fiscal year ended March 31, 2021is from the AffaMed Agreement involving clinical development andcommercialization of PH94B for acute treatment of anxiety in adultswith SAD, and potentially other anxiety-related disorders, inGreater China, South Korea, and Southeast Asia.         <font style="font-style: italic">         </font>         The terms of the AffaMedAgreement include a $5.0 million non-refundable upfront license feewhich we received in August 2020, potential payments based uponachievement of certain development and commercial milestones, androyalties on product sales.         <font style="color: #000000">          We havehistorically generated revenue principally from collaborativeresearch and development arrangements, licensing and technologytransfer agreements, including strategic licenses or sublicenses,and government grants.         </font>         We adopted Accounting StandardsUpdate (         <font style="font-style: italic">          ASU         </font>         ) No. 2014-09,         <font style="font-style: italic">          Revenue from Contracts withCustomers (Topic 606)         </font>         and its related amendments,collectively referred to as ASC (         <font style="font-style: italic">          Accounting Standards Codification         </font>         )Topic 606, as of April 1, 2018, using the modified retrospectivetransition method. We did not recognize any revenue under the BayerAgreement (defined in Note 12) which we entered in our fiscal yearended March 31, 2017, in the fiscal years ended March 31, 2021 or2020. Upon adoption of ASC Topic 606, there was no change to theunits of accounting previously identified with respect to the BayerAgreement under legacy GAAP, which are now considered performanceobligations under ASC Topic 606, and there was no change to therevenue recognition pattern for the performance obligation.Accordingly, there was no cumulative effect change to our openingaccumulated deficit upon the adoption of ASC Topic606.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: -4px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         UnderASC Topic 606, we recognize revenue when our customer obtainscontrol of promised goods or services, in an amount that reflectsthe consideration that we expect to receive in exchange for thosegoods or services. To determine revenue recognition forarrangements that we determine are within the scope of Topic 606,we perform the following five steps: (i) identify the contract witha customer; (ii) identify the performance obligations in thecontract; (iii) determine the transaction price, including variableconsideration, if any; (iv) allocate the transaction price to theperformance obligations in the contract; and (v) recognize revenuewhen (or as) we satisfy a performance obligation. We only apply thefive-step model to contracts when it is probable that we willcollect the consideration to which we are entitled in exchange forthe goods or services we transfer to a customer.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: -4px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Once acontract is determined to be within the scope of Topic 606, weassess the goods or services promised within each contract anddetermine those that are performance obligations. Arrangements thatinclude rights to additional goods or services that are exercisableat a customer’s discretion are generally considered options.We assess whether these options provide a material right to thecustomer and if so, they are considered performance obligations.The exercise of a material right may be accounted for as a contractmodification or as a continuation of the contract for accountingpurposes.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: -4px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Weassess whether each promised good or service is distinct for thepurpose of identifying the performance obligations in the contract.This assessment involves subjective determinations and requiresjudgments about the individual promised goods or services andwhether such are separable from the other aspects of thecontractual relationship. Promised goods and services areconsidered distinct provided that: (i) the customer can benefitfrom the good or service either on its own or together with otherresources that are readily available to the customer (that is, thegood or service is capable of being distinct) and (ii) our promiseto transfer the good or service to the customer is separatelyidentifiable from other promises in the contract (that is, thepromise to transfer the good or service is distinct within thecontext of the contract). In assessing whether a promised good orservice is distinct in the evaluation of a collaborationarrangement subject to Topic 606, we consider factors such as theresearch, manufacturing and commercialization capabilities of thecollaboration partner and the availability of the associatedexpertise in the general marketplace. We also consider the intendedbenefit of the contract in assessing whether a promised good orservice is separately identifiable from other promises in thecontract. If a promised good or service is not distinct, we arerequired to combine that good or service with other promised goodsor services until we identify a bundle of goods or services that isdistinct.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: -4px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thetransaction price is then determined and allocated to theidentified performance obligations in proportion to theirstandalone selling prices (         <font style="font-style: italic">          SSP         </font>         ) on a relative SSP basis. SSP isdetermined at contract inception and is not updated to reflectchanges between contract inception and satisfaction of theperformance obligations. Determining the SSP for performanceobligations requires significant judgment. In developing the SSPfor a performance obligation, we consider applicable marketconditions and relevant Company-specific factors, including factorsthat were contemplated in negotiating the agreement with thecustomer and estimated costs. In certain circumstances, we mayapply the residual method to determine the SSP of a good or serviceif the standalone selling price is considered highly variable oruncertain. We validate the SSP for performance obligations byevaluating whether changes in the key assumptions used to determinethe SSP will have a significant effect on the allocation ofarrangement consideration between multiple performanceobligations.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: -4px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If theconsideration promised in a contract includes a variable amount, weestimate the amount of consideration to which we will be entitledin exchange for transferring the promised goods or services to acustomer. We determine the amount of variable consideration byusing the expected value method or the most likely amount method.We include the unconstrained amount of estimated variableconsideration in the transaction price. The amount included in thetransaction price is constrained to the amount for which it isprobable that a significant reversal of cumulative revenuerecognized will not occur. At the end of each subsequent reportingperiod, we re-evaluate the estimated variable considerationincluded in the transaction price and any related constraint, andif necessary, adjust our estimate of the overall transaction price.Any such adjustments are recorded on a cumulative catch-up basis inthe period of adjustment.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -92-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: -4px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If anarrangement includes development and regulatory milestone payments,we evaluate whether the milestones are considered probable of beingreached and estimate the amount to be included in the transactionprice using the most likely amount method. If it is probable that asignificant revenue reversal would not occur, the associatedmilestone value is included in the transaction price. Milestonepayments that are not within our control or the licensee’scontrol, such as regulatory approvals, are generally not consideredprobable of being achieved until those approvals arereceived.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: -4px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Indetermining the transaction price, we adjust consideration for theeffects of the time value of money if the timing of paymentsprovides us with a significant benefit of financing. We do notassess whether a contract has a significant financing component ifthe expectation at contract inception is such that the periodbetween payment by the licensee and the transfer of the promisedgoods or services to the licensee will be one year or less. Forarrangements with licenses of intellectual property that includesales-based royalties, including milestone payments based on thelevel of sales, and the license is deemed to be the predominantitem to which the royalties relate, we recognize royalty revenueand sales-based milestones at the later of (i) when the relatedsales occur, or (ii) when the performance obligation to which theroyalty has been allocated has been satisfied.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: -4px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We thenrecognize as revenue the amount of the transaction price that isallocated to the respective performance obligation when (or as)each performance obligation is satisfied at a point in time or overtime, and if over time, based on the use of an output or inputmethod.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Research and Development Expenses        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Research and development expenses are composed of both internal andexternal costs.  Internal costs include salaries andemployment-related expenses, including stock-based compensationexpense, of scientific personnel and direct projectcosts.  External research and development expensesconsist primarily of costs associated with clinical and nonclinicaldevelopment of PH94B, PH10 and AV-101, stem cell research anddevelopment costs, and costs related to the application andprosecution of patents related to AV-101 and our stem celltechnology platform. All such costs are charged to expense asincurred.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We also record accruals for estimated ongoing clinical trial costs.Clinical trial costs represent costs incurred by contract researchorganizations (         </font>         <font style="font-style: italic; color: #000000">          CRO         </font>         <font style="color: #000000">          s) and clinical trial sites. Progress payments aregenerally made to CROs, clinical sites, investigators and otherprofessional service providers. We analyze the progress of theclinical trial, including levels of subject enrollment, invoicesreceived and contracted costs when evaluating the adequacy ofaccrued liabilities. Significant judgments and estimates must bemade in determining the clinical trial accrual in any reportingperiod. Actual results could differ from those estimates underdifferent assumptions. Revisions are charged to research anddevelopment expense in the period in which the facts that give riseto the revision become known.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Costs incurred in obtaining product or technology licenses arecharged immediately to research and development expense if theproduct or technology licensed has not achieved regulatory approvalor reached technical feasibility and has no alternative futureuses. In September 2018, we acquired an exclusive license todevelop and commercialize PH94B and an option to acquire a licenseto develop and commercialize PH10 by issuing an aggregate of1,630,435 unregistered shares of our common stock having a fairmarket value of $2,250,000.         </font>         In October 2018, we exercisedour option to acquire an exclusive license to develop andcommercialize PH10 by issuing 925,926 shares of our unregisteredcommon stock having a fair market value of $2,000,000.         <font style="color: #000000">          Since, at the date of each acquisition, neitherproduct candidate had achieved regulatory approval and eachrequired significant additional development and expense, werecorded the costs related to acquiring the licenses and the optionas research and development expense.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Stock-Based Compensation        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We recognize compensation cost for all stock-based awards toemployees and non-employee consultants based on the grant date fairvalue of the award.  We record stock-based compensationexpense over the period during which the employee or other granteeis required to perform services in exchange for the award, whichgenerally represents the scheduled vesting period. We have notgranted restricted stock awards to employees or consultants nor dowe have any awards with market or performanceconditions. Prior to our April 1, 2019 adoption of         </font>         ASU2018-07,         <font style="font-style: italic">          Compensation-StockCompensation (Topic 718), Improvements to Nonemployee Share-BasedPayment Accounting         </font>         (         <font style="font-style: italic">          ASU2018-07         </font>         ),         <font style="color: #000000">          we historicallyre-measured the fair value of option grants to non-employees asthey vested and any resulting increase in value was recognized asan expense during the period over which the services wereperformed. Under ASU 2018-17, expense recognition for grants tonon-employees now follows the same methodology as for employees.Noncash expense attributable to compensatory grants of our commonstock to non-employees is determined by the quoted market price ofthe stock on the date of grant and is either recognized asfully-earned at the time of the grant or expensed ratably over theterm of the related service agreement, depending on the terms ofthe specific agreement.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -93-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Income Taxes        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We account for income taxes using the asset and liability approachfor financial reporting purposes. Deferred tax assets andliabilities are recognized for the future tax consequencesattributable to differences between the financial statementcarrying amounts of existing assets and liabilities and theirrespective tax bases and operating loss and tax creditcarryforwards. Deferred tax assets and liabilities are measuredusing enacted tax rates expected to apply to taxable income in theyears in which those temporary differences are expected to berecovered or settled. The effect on deferred tax assets andliabilities of a change in tax rates is recognized in income in theperiod that includes the enactment date. Valuation allowances areestablished, when necessary, to reduce the deferred tax assets toan amount expected to be realized.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Right of Use Assets and Operating Lease Obligations        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We adopted Accounting Standards Update No. 2016-02,“         </font>         <font style="font-style: italic">          Leases (Topic842)”         </font>         <font style="color: #000000">          (         </font>         <font style="font-style: italic; color: #000000">          ASU2016-02         </font>         <font style="color: #000000">          ) effective April 1,2019         </font>         <font style="font-style: italic">          .         </font>         ASU 2016-02requires that we determine, at the inception of an arrangement,whether the arrangement is or contains a lease, based on the uniquefacts and circumstances present. Operating lease assets representour right to use an underlying asset for the lease term(         <font style="font-style: italic">          Right of use assets         </font>         ) andoperating lease liabilities represent our obligation to make leasepayments arising from the lease. Right of use assets and operatinglease liabilities are recognized at the commencement date of thelease based upon the present value of lease payments over the leaseterm. When determining the lease term, we include options to extendor terminate the lease when it is reasonably certain, at inception,that we will exercise that option. The interest rate implicit inlease contracts is typically not readily determinable; accordingly,we use our incremental borrowing rate, which is the rate that wouldbe incurred to borrow on a collateralized basis over a similar terman amount equal to the lease payments in a similar economicenvironment, based upon the information available at thecommencement date. The lease payments used to determine ouroperating lease assets may include lease incentives, stated rentincreases and escalation clauses linked to rates of inflation, whendeterminable, and are recognized in determining our Right of useassets. Our operating lease is reflected in the Right-of-use asset– operating lease; Operating lease obligation - currentportion; and Operating lease obligation - non-current portion inour consolidated balance sheets.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Leaseexpense for minimum lease payments is recognized on a straight-linebasis over the lease term. As a result of our adoption of ASU2016-02, we no longer recognize deferred rent on the consolidatedbalance sheet. Short-term leases, defined as leases that have alease term of 12 months or less at the commencement date, areexcluded from this treatment and are recognized on a straight-linebasis over the term of the lease. Variable lease payments areamounts owed by us to a lessor that are not fixed, such asreimbursement for common area maintenance costs for our facilitylease; and are expensed when incurred.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Financingleases, formerly referred to as capitalized leases, are treatedsimilarly to operating leases except that the asset subject to thelease is included in the appropriate fixed asset category, ratherthan recorded as a Right of use asset, and depreciated over itsestimated useful life, or lease term, if shorter.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Concentrations of Credit Risk        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Financial instruments, which potentially subject us toconcentrations of credit risk, consist of cash and cashequivalents. Our investment policies limit any such investments toshort-term, low-risk instruments. We deposit cash and cashequivalents with quality financial institutions which are insuredto the maximum of federal limitations. Balances in these accountsmay exceed federally insured limits at times.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Fair Value Measurements        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We do not use derivative instruments for hedging of market risks orfor trading or speculative purposes. When applicable, we follow theprinciples of fair value accounting as they relate to our financialassets and financial liabilities. Fair value is defined as theestimated exit price received to sell an asset or paid to transfera liability in an orderly transaction between market participantsat the measurement date, rather than an entry price that representsthe purchase price of an asset or liability.  Whereavailable, fair value is based on observable market prices orparameters or derived from such prices orparameters.  Where observable prices or inputs are notavailable, valuation models are applied.  These valuationtechniques involve some level of management estimation andjudgment, the degree of which is dependent on several factors,including the instrument’s complexity.  Therequired fair value hierarchy that prioritizes observable andunobservable inputs used to measure fair value into three broadlevels is described as follows:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            ●           </font>          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic; color: #000000">            Level 1           </font>           <font style="color: #000000">            —Quoted prices (unadjusted) in active markets that are accessible atthe measurement date for assets or liabilities. The fair valuehierarchy gives the highest priority to Level 1inputs.           </font>          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            ●           </font>          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic; color: #000000">            Level 2           </font>           <font style="color: #000000">            —Inputs other than Level 1 that are observable, either directlyor indirectly, such as quoted prices for similar assets orliabilities; quoted prices in markets that are not active; or otherinputs that are observable or can be corroborated by observablemarket data for substantially the full term of the assets orliabilities.           </font>          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            ●           </font>          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic; color: #000000">            Level 3           </font>           <font style="color: #000000">            —Unobservable inputs (           </font>           <font style="font-style: italic; color: #000000">            i.e.,           </font>           <font style="color: #000000">            inputs that reflect the reporting entity’sown assumptions about the assumptions that market participantswould use in estimating the fair value of an asset or liability)are used when little or no market data is available. The fair valuehierarchy gives the lowest priority to Level 3inputs.           </font>          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -94-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         A financial instrument’s categorization within the valuationhierarchy is based upon the lowest level of input that issignificant to the fair value measurement.  Where quotedprices are available in an active market, securities are classifiedas Level 1 of the valuation hierarchy. If quoted market pricesare not available for the specific financial instrument, then weestimate fair value by using pricing models, quoted prices offinancial instruments with similar characteristics or discountedcash flows. In certain cases where there is limited activity orless transparency around inputs to valuation, financial assets orliabilities are classified as Level 3 within the valuationhierarchy.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We carried no assets or liabilities that are measured on arecurring basis at fair value at March 31, 2021 or2020.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Warrants Issued in Connection with Equity Financing        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We generally account for warrants issued in connection with equityfinancings as a component of equity, unless there is a deemedpossibility that we may have to settle the warrants in cash or thewarrants contain other features requiring them to be treated asliabilities. For warrants issued with the possibility of cashsettlement, or otherwise requiring liability treatment, we recordthe fair value of the issued warrants as a liability at eachreporting period and record changes in the estimated fair value asnoncash gain or loss in the Consolidated Statements of Operationsand Comprehensive Loss.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Comprehensive Loss        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We have no components of other comprehensive loss other than netloss, and accordingly our comprehensive loss is equivalent to ournet loss for the periods presented.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Loss per Common Share Attributable to CommonStockholders        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Basic net loss attributable to common stockholders per share ofcommon stock excludes the effect of dilution and is computed bydividing net loss increased by         </font>         the accrual of dividends onoutstanding shares of our Series B 10% Convertible Preferred Stock(         <font style="font-style: italic">          Series B Preferred         </font>         ) forthe fiscal years ended March 30, 2021 and 2020, respectively, and,in the fiscal year ended March 31, 2021, by the beneficialconversion feature related to our Series D Convertible Stock(         <font style="font-style: italic">          Series D Preferred         </font>         ), asdescribed in Note 9,         <font style="font-style: italic">          CapitalStock         </font>         ,         <font style="color: #000000">          by the weighted-averagenumber of shares of common stock outstanding for the period.Diluted net loss attributable to common stockholders per share ofcommon stock reflects the potential dilution that could occur ifsecurities or other contracts to issue shares of common stock wereexercised or converted into shares of common stock. In calculatingdiluted net loss attributable to common stockholders per share, wehave generally not increased the denominator to include the numberof potentially dilutive common shares assumed to be outstandingduring the period using the treasury stock method because theresult is antidilutive.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         As a result of our net loss for both years presented, potentiallydilutive securities were excluded from the computation of dilutedloss per share, as their effect would be antidilutive.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Basic and diluted net loss attributable to common stockholders pershare was computed as follows:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align: bottom; width: 24%; white-space: nowrap;">            <div>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                FiscalYears Ended March 31,               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Numerator:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net lossattributable to common stockholders for basic and dilutedearnings             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:4px;margin-left:36px;">             <font style="font-size: 13px; font-family: Times New Roman">              pershare             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (42,319,800             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (22,037,600             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Denominator:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:36px;">             <font style="font-family: Times New Roman; font-size: 13px">              Weightedaverage basic and diluted common shares outstanding             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              86,133,644             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              43,869,523             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Basic anddiluted net loss attributable to common stockholders per commonshare             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (0.49             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (0.50             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Potentially dilutive securities excluded in determining diluted netloss per common share for the fiscal years ended March 31, 2021 and2020 are as follows:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -95-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left">        <table cellpadding="0" cellspacing="0" style="text-align: left; font-family:inherit;margin-right:0px;margin-top:0px;margin-left:0px;width:100%;margin-bottom:0px;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                At March 31,               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                At March 31,               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               Series A Preferred stock issued andoutstanding              </font>              <font style="font-size: 70%; vertical-align: top; color: #000000">               (1)              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              750,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              750,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               Series B Preferred stock issued andoutstanding              </font>              <font style="font-size: 70%; vertical-align: top; color: #000000">               (2)              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,131,669             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,160,240             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               Series C Preferred stock issued andoutstanding              </font>              <font style="font-size: 70%; vertical-align: top; color: #000000">               (3)              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              2,318,012             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              2,318,012             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               Series D Preferred stock issued andoutstanding              </font>              <font style="font-size: 70%; vertical-align: top; color: #000000">               (4)              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              402,149             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Outstandingoptions under the Company's Amended and Restated 2016 (formerly2008) Stock Incentive Plan and 2019 Omnibus Equity IncentivePlan             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              14,638,088             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              10,003,088             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Outstandingwarrants to purchase common stock             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              19,362,532             </font>             <font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              26,555,281             </font>             <font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Total             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              38,602,450             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              40,786,621             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="null">        <font>        </font>       </div>       <div style="text-align: left">        <table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-size: inherit; font-family: inherit;">         <tbody>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:80%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ____________             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="3" style="vertical-align:bottom;width:100%;">            <div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;">             <font style="font-size:13px;font-family:Times New Roman;">              <font style="vertical-align:top;font-size:70%;color:#000000;">               (1)              </font>              <font style="color:#000000;">               Assumes exchange under the terms ofthe October 11, 2012 Note Exchange and Purchase Agreement, asamended.              </font>             </font>            </div>           </td>          </tr>          <tr>           <td colspan="3" style="vertical-align:bottom;width:100%;">            <div style="text-align: left; margin-left: 12px; text-indent: -12px; margin-right: 0px;">             <font style="font-size:13px;font-family:Times New Roman;">              <font style="vertical-align:top;font-size:70%;color:#000000;">               (2)              </font>              <font style="color:#000000;">               Assumes exchange under the terms ofthe Certificate of Designation of the Relative Rights andPreferences of the Series B 10% Convertible Preferred Stock,effective May 5, 2015; excludes shares of unregistered common stockissuable in payment of dividends on Series B Preferred uponconversion.              </font>             </font>            </div>           </td>          </tr>          <tr>           <td colspan="3" style="vertical-align:bottom;width:100%;">            <div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;">             <font style="font-size:13px;font-family:Times New Roman;">              <font style="vertical-align:top;font-size:70%;color:#000000;">               (3)              </font>              <font style="color:#000000;">               Assumes exchange under the terms ofthe Certificate of Designation of the Relative Rights andPreferences of the Series C Convertible Preferred Stock, effectiveJanuary 25, 2016.              </font>             </font>            </div>           </td>          </tr>          <tr>           <td colspan="3" style="vertical-align:bottom;width:100%;">            <div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;">             <font style="font-size:13px;font-family:Times New Roman;">              <font style="vertical-align:top;font-size:70%;color:#000000;">               (4)              </font>              <font style="color:#000000;">               Assumes exchange under the terms ofthe Certificate of Designation of the Relative Rights andPreferences of the Series D Convertible Preferred Stock, effectiveDecember 21, 2020.              </font>             </font>            </div>           </td>          </tr>          <tr>           <td colspan="1" style="vertical-align:bottom;width:80%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Recent Accounting Pronouncements        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Webelieve the following recent accounting pronouncements or changesin accounting pronouncements are of significance or potentialsignificance to the Company.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         InAugust 2020, the Financial Accounting Standards Board (         <font style="font-style: italic">          FASB         </font>         ) issued ASU 2020-06, Debt –Debt with Conversion and Other Options (Subtopic 470- 20) andDerivatives and Hedging – Contracts in Entity’s OwnEquity (Subtopic 815-40): Accounting for Convertible Instrumentsand Contracts in an Entity’s Own Equity (         <font style="font-style: italic">          ASU 2020-06         </font>         ), to reduce complexity inapplying GAAP to certain financial instruments with characteristicsof liabilities and equity.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theguidance in ASU 2020-06 simplifies the accounting for convertibledebt instruments and convertible preferred stock by removing theexisting guidance in ASC 470-20, Debt: Debt with Conversion andOther Options, that requires entities to account for beneficialconversion features and cash conversion features in equity,separately from the host convertible debt or preferred stock. Theguidance in ASC 470-20 applies to convertible instruments for whichthe embedded conversion features are not required to be bifurcatedfrom the host contract and accounted for asderivatives.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inaddition, the amendments revise the scope exception from derivativeaccounting in ASC 815-40 for freestanding financial instruments andembedded features that are both indexed to the issuer’s ownstock and classified in stockholders’ equity, by removingcertain criteria required for equity classification. Theseamendments are expected to result in more freestanding financialinstruments qualifying for equity classification (and, therefore,not accounted for as derivatives), as well as fewer embeddedfeatures requiring separate accounting from the hostcontract.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theamendments in ASU 2020-06 further revise the guidance in ASC 260,Earnings Per Share, to require entities to calculate dilutedearnings per share (EPS) for convertible instruments by using theif-converted method. In addition, entities must presume sharesettlement for purposes of calculating diluted EPS when aninstrument may be settled in cash or shares.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theamendments in ASU 2020-06 are effective for our fiscal yearbeginning April 1, 2024. We are evaluating the impact of this newguidance, but do not believe that our adoption of ASU 2020-06 willhave a material impact on our consolidated financialstatements.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Otheraccounting standards that have been issued or proposed by the FASBor other standards-setting bodies that do not require adoptionuntil a future date are not expected to have a material impact onour consolidated financial statements upon adoption.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -96-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         4.  Receivable from Collaboration Partner        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         This amount reflects a payment we made to a contract manufacturingorganization for certain drug substance manufacturing services onbehalf of our collaboration partner. Our collaboration partnerreimbursed us for the payment in May 2021.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         5. Prepaid Expenses and Other Current Assets        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Prepaid expenses and other current assets consists of thefollowing:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                March31,               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                March31,               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Clinical andnonclinical materials and contract services             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              686,900             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              115,200             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Insurance             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              121,800             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              107,200             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Allother             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              26,400             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              2,700             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              835,100             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              225,100             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         6.  Property and Equipment        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Property and equipment consists of the following:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                March 31,               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                March 31,               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Laboratoryequipment             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              937,400             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              892,500             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Tenantimprovements             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              214,400             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              214,400             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Informationtechnology equipment             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              73,900             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              54,600             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Officefurniture and equipment             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              84,600             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              84,600             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Manufacturingequipment             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              211,200             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,521,500             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,246,100             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Accumulateddepreciation and amortization             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (1,154,100             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (1,036,500             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Propertyand equipment, net             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              367,400             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              209,600             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The following table summarizes depreciation and amortizationexpense attributable to owned and leased property and equipment forthe fiscal years ended March 31, 2021 and 2020:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align: bottom; width: 24%; white-space: nowrap;">            <div>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Fiscal Years Ended March 31,               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Ownedassets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              114,600             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              100,200             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Leasedassets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              3,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              2,900             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Totaldepreciation and amortization             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              117,600             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              103,100             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The amount reported above for manufacturing equipment at March 31,2021 reflects the cost of certain process equipment acquired inconnection with the manufacture of PH94B drug product and placed inservice in the fourth quarter of the fiscal year ended March 31,2021. Included in amounts reported above for office furniture andequipment is the right-of-use asset related to a financing lease ofcertain office equipment. Amounts associated with assets subject tothe financing lease at March 31, 2021 and 2020 are asfollows:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                March31,               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                March31,               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Office equipmentsubject to financing lease             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              14,700             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              14,700             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accumulateddepreciation             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (12,400             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (9,400             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net book value ofoffice equipment subject to             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              financinglease             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              2,300             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              5,300             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Other than certain leased office equipment, none of our assets weresubject to third party security interests at March 31, 2021 or2020.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -97-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         7.  Accrued Expenses        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Accrued expenses consist of:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                March31,               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                March31,               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accrued expensesfor clinical and nonclinical             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              materials,development and contract services             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,449,400             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              462,300             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accruedprofessional services             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              85,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              76,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Allother             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              27,800             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              22,700             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,562,700             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              561,500             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         8.  Notes Payable        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The following table summarizes our notes payable:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:28%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="3" rowspan="1" style="vertical-align:bottom;width:36%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:3%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:94%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                March31, 2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:3%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td colspan="3" rowspan="1" style="vertical-align:bottom;width:36%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:3%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:94%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                March31, 2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:3%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:28%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Principal               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Accrued               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Principal               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Accrued               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:28%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Balance               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Interest               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Total               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Balance               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Interest               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Total               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:28%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              7.30% Note payableto insurance premium             </font>             <font style="font-family: Times New Roman; font-size: 13px">              financing company(current)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              56,500             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              56,500             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In February 2020, we executed a 7.30% promissory note in theprincipal amount of $62,600 in connection with certain insurancepolicy premiums. That note was payable in monthly installments of$6,500, including principal and interest, through December 2020 andwas fully paid at March 31, 2021. In May 2020, we executed a 6.30%promissory note in the principal amount of $322,200 in connectionwith other insurance policy premiums. The note was payable inmonthly installments of $33,200, including principal and interest,through March 2021, and was fully paid at March 31,2021.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In April 2020, we entered into a note payable agreement (the         </font>         <font style="font-style: italic; color: #000000">          PPP LoanAgreement         </font>         <font style="color: #000000">          ) with Silicon ValleyBank as lender (the         </font>         <font style="font-style: italic; color: #000000">          Lender         </font>         <font style="color: #000000">          ), pursuant to which we received net proceeds of$224,400 from a potentially forgivable loan from the U.S. SmallBusiness Administration (         </font>         <font style="font-style: italic; color: #000000">          SBA         </font>         <font style="color: #000000">          ) pursuant to the Paycheck Protection Program(         </font>         <font style="font-style: italic; color: #000000">          PPP         </font>         <font style="color: #000000">          ) enacted by Congress under the CoronavirusAid, Relief, and Economic Security Act (the         </font>         <font style="font-style: italic; color: #000000">          CARES Act         </font>         <font style="color: #000000">          ) administered by the SBA (the         </font>         <font style="font-style: italic; color: #000000">          PPP Loan         </font>         <font style="color: #000000">          ). In accordance with its terms, the PPP Loan wasto mature on April 22, 2022. The PPP Loan accrued interest at arate of 1.00% per annum throughout the period it was outstanding.The CARES Act provided that all or a portion of the PPP Loan mightbe forgiven upon our request to the Lender, subject to requirementsin the PPP Loan Agreement and the CARES Act. While we believe ouruse of the PPP Loan proceeds met all of the conditions forforgiveness under the PPP, following the completion of the December2020 Public Offering, on December 23, 2020, we voluntarily repaidin full the outstanding principal balance of the PPP Loan,$224,400, plus accrued interest of approximately$1,500.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         9.  Capital Stock        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Common Stock        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         At ourSpecial Meeting of Stockholders on March 5, 2021, as approved byand recommended to our stockholders by our Board, our stockholdersapproved an amendment to our Restated Articles of Incorporation toincrease the authorized number of shares of common stock that wemay issue from 175.0 million shares to 325.0 million shares. Theamendment became effective on March 5, 2021, upon our filing of acertificate of amendment with the Nevada Secretary of State.Previously, at our Annual Meeting of Stockholders on September 5,2019, as approved by and recommended to our stockholders by ourBoard, our stockholders approved an amendment to our RestatedArticles of Incorporation to increase the authorized number ofshares of common stock that we may issue from 100.0 million sharesto 175.0 million shares. The amendment became effective onSeptember 6, 2019, upon our filing of a certificate of amendmentwith the Nevada Secretary of State. In connection with anunderwritten public offering of our common stock and warrants inMay 2016, our common stock was approved for listing on the NasdaqCapital Market. Our common stock has traded on the Nasdaq CapitalMarket under the symbol “VTGN” since May 11,2016.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Series A Preferred Stock        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In December 2011, our Board authorized the creation of a series ofup to 500,000 shares of Series A Preferred, par value $0.001(         </font>         <font style="font-style: italic; color: #000000">          Series APreferred         </font>         <font style="color: #000000">          ).  Eachrestricted share of Series A Preferred is currently convertible atthe option of the holder into one and one-half restricted shares ofour common stock.  The Series A Preferred ranks prior tothe common stock for purposes of liquidationpreference.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -98-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The Series A Preferred has no separate dividend rights, however,whenever the Board declares a dividend on the common stock, eachholder of record of a share of Series A Preferred shall be entitledto receive an amount equal to such dividend declared on one shareof common stock multiplied by the number of shares of common stockinto which such share of Series A Preferred could be converted onthe applicable record date.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Except with respect to transactions upon which the Series APreferred shall be entitled to vote separately as a class, theSeries A Preferred has no voting rights. The restricted commonstock into which the Series A Preferred is convertible shall, uponissuance, have all of the same voting rights as other issued andoutstanding shares of our common stock.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In the event of the liquidation, dissolution or winding up of ouraffairs, after payment or provision for payment of our debts andother liabilities, the holders of Series A Preferred thenoutstanding shall be entitled to receive         </font>         distributions outof our assets, if any,         <font style="color: #000000">          an amount pershare of Series A Preferred calculated by taking the total amountavailable for distribution to holders of all of our outstandingcommon stock before deduction of any preference payments for theSeries A Preferred, divided by the total of (x), all of the thenoutstanding shares of our common stock, plus (y) all of the sharesof our common stock into which all of the outstanding shares of theSeries A Preferred can be converted before any payment shall bemade or any assets distributed to the holders of the common stockor any other junior stock.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         At March 31, 2021 and 2020, there were 500,000 restricted shares ofSeries A Preferred outstanding, convertible into 750,000 shares ofour common stock at the option of the holders.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Series B Preferred Stock        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In July 2014, our Board authorized the creation of a class ofSeries B Preferred Stock, par value $0.001 (         </font>         <font style="font-style: italic; color: #000000">          Series BPreferred         </font>         <font style="color: #000000">          ). In May 2015, wefiled a Certificate of Designation of the Relative Rights andPreferences of the Series B 10% Preferred Stock of VistaGenTherapeutics, Inc. (         </font>         <font style="font-style: italic; color: #000000">          Series B Certificate ofDesignation         </font>         <font style="color: #000000">          ) with the NevadaSecretary of State to designate 4.0 million shares of ourauthorized preferred stock as Series BPreferred.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Except with respect to transactions upon which the Series BPreferred shall be entitled to vote separately as a class, theSeries B Preferred has no voting rights. The common stock intowhich the Series B Preferred is convertible shall, upon issuance,have all of the same voting rights as other issued and outstandingshares of our common stock.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Each share of Series B Preferred is convertible, at the option ofthe holder (         </font>         <font style="font-style: italic; color: #000000">          VoluntaryConversion         </font>         <font style="color: #000000">          ), into one (1) shareof our common stock, subject to adjustment only for customary stockdividends, reclassifications, splits and similar transactions setforth in the Certificate of Designation. As permitted by the SeriesB Certificate of Designation, approximately 2.4 million shares ofSeries B Preferred were converted automatically into approximately2.4 million shares of our common stock following the completion ofour underwritten public offering in May 2016, which occurredconcurrently with and facilitated the listing of our common stockon the Nasdaq Capital Market (         </font>         <font style="font-style: italic; color: #000000">          AutomaticConversion         </font>         <font style="color: #000000">          ). Both AutomaticConversion and Voluntary Conversion (collectively,         </font>         <font style="font-style: italic; color: #000000">          Conversion         </font>         <font style="color: #000000">          ) are subject to certain beneficial ownershipblockers as set forth in the Certificate of Designation and/orsecurities purchase agreements.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Prior to Conversion, shares of Series B Preferred accrue in-kinddividends (payable only in unregistered shares of our common stock)at a rate of 10% per annum (         </font>         <font style="font-style: italic; color: #000000">          AccruedDividends         </font>         <font style="color: #000000">          ).  TheAccrued Dividends are payable on the date of either a VoluntaryConversion or Automatic Conversion in that number of shares ofcommon stock equal to the Accrued Dividends. We have recognized aliability in the amount of $6,272,700 for Accrued Dividends inthe         </font>         accompanying Consolidated Balance Sheet at March 31,2021,         <font style="color: #000000">          based on the Series B Preferredissued and outstanding through that date. We have recognized adeduction from net loss of $1,385,600 and $1,263,600 related todividends on Series B Preferred in arriving at net lossattributable to common stockholders in the         </font>         accompanyingConsolidated Statement of Operations and Comprehensive Loss for thefiscal years ended March 31, 2021 and 2020,respectively.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In theevent of the liquidation, dissolution or winding-up of our affairs,         <font style="color: #000000">          after payment or provision for paymentof our debts and other liabilities,         </font>         the holders of theSeries B Preferred then outstanding shall be entitled to receivedistributions out of our assets, if any, of an amount equal to theStated Value of the Series B Preferred ($7.00 per share), plus anyaccrued and unpaid dividends thereon,         <font style="color: #000000">          before any distribution or payment shall be madeto the holders of any junior securities, including holders of ourcommon stock. If our assets are insufficient to pay, in full, suchamounts, then the entire assets to be distributed to the holders ofthe Series B Preferred shall be ratably distributed among theholders in accordance with the respective amounts that would bepayable on such shares if all amounts payable thereon were paid infull. Upon liquidation, each share of Series B Preferred rankspari-passu with our Series A Preferred, our Series C Preferred andSeries D Preferred stock (the latter two defined below).         </font>         Theliquidation value of the Series B Preferred at March 31, 2021 isapproximately $14,194,400.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In         </font>         December 2020, an institutional holder of 28,571 sharesof our Series B Preferred converted such shares into an equalnumber of unregistered shares of our common stock. In accordancewith the conversion terms of the Series B Preferred, we also issued160,062 shares of our unregistered common stock in payment of$124,600 of dividends that had accrued on the holder’s SeriesB Preferred since issuance. Following the conversion,         <font style="color: #000000">          at March 31, 2021 there were 1,131,669 shares ofSeries B Preferred outstanding, which are exchangeable at theoption of the holder by Voluntary Conversion into 1,131,669 sharesof our common stock, excluding shares of our common stock which maybe issued in payment of Accrued Dividends uponconversion.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -99-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Series C Preferred Stock        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         InJanuary 2016, our Board authorized the creation of and         <font style="color: #000000">          we filed a Certificate of Designation of theRelative Rights and Preferences of the Series C ConvertiblePreferred Stock of VistaGen Therapeutics, Inc. (the         </font>         <font style="font-style: italic; color: #000000">          Series CPreferred         </font>         <font style="color: #000000">         </font>         <font style="font-style: italic; color: #000000">          Certificate ofDesignation         </font>         <font style="color: #000000">          ) with the NevadaSecretary of State to designate 3.0 million shares of our preferredstock, par value $0.001 per share, as Series C ConvertiblePreferred Stock (         </font>         <font style="font-style: italic; color: #000000">          Series CPreferred         </font>         <font style="color: #000000">          ).         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In the event of the liquidation, dissolution or winding up of ouraffairs, after payment or provision for payment of our debts andother liabilities, the holders of Series C Preferred thenoutstanding shall be entitled to receive, out of our assets, ifany, an amount per share of Series C Preferred calculated by takingthe total amount available for distribution to holders of all ofour outstanding common stock before deduction of any preferencepayments for the Series C Preferred, divided by the total of (x),all of the then outstanding shares of our common stock, plus (y)all of the shares of our common stock into which all of theoutstanding shares of the Series C Preferred can be exchangedbefore any payment shall be made or any assets distributed to theholders of the common stock or any other junior stock. Uponliquidation, each share of Series C Preferred ranks pari-passu withour Series A Preferred, our Series B Preferred and our Series DPreferred (defined below).        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Each share of Series C Preferred is convertible, at the option ofthe holder into one share of our common stock, subject to certainbeneficial ownership limitations as set forth in the Series CPreferred Certificate of Designation. Shares of the Series CPreferred do not accrue dividends, and holders of the Series CPreferred have no voting rights. At March 31, 2021 and 2020, oneholder and its affiliates held all 2,318,012 outstanding shares ofSeries C Preferred.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Series D Preferred Stock        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         OnDecember 17, 2020, in connection with the December 2020 PublicOffering (defined below), our Board authorized the creation of aseries of up to 2,000,000 shares of Series D Preferred Stock, parvalue $0.001 (         <font style="font-style: italic">          Series DPreferred         </font>         ), which became effective with the filing of aCertificate of Designation of the Relative Rights and Preferencesof the Series D Convertible Preferred Stock (         <font style="font-style: italic">          Series D         </font>         <font style="font-style: italic">          Certificate of Designation         </font>         ) with theState of Nevada on December 21, 2020.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Eachshare of our Series D Preferred is initially convertible into 23shares of our common stock at any time at the option of the holder,provided         <font style="font-style: italic">         </font>         that, theSeries D Preferred is not convertible prior to the date on which wehave received approval from our stockholders to increase the totalauthorized shares of our common stock by at least an amountnecessary to reserve shares sufficient to satisfy our conversionobligations in respect of the Series D Preferred and an amendmentto our Restated and Amended Articles of Incorporation reflectingsuch increase becomes effective (the         <font style="font-style: italic">          Approval Date         </font>         ). Additionally, a holderof shares of Series D Preferred will be prohibited, subject tocertain exceptions, from converting such shares into shares of ourcommon stock if, as a result of such conversion, the holder,together with its affiliates and other attribution parties, wouldown more than 9.99% of the total number of shares of our commonstock then issued and outstanding, which percentage may be changedat the holder’s election to a lower percentage at any time orto a higher percentage not to exceed 19.99% upon 61 days’prior notice to us.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Priorto the Approval Date, in the event of our liquidation, dissolution,or winding up of the Company’s affairs, holders of Series DPreferred will receive a payment equal to $0.001 per share beforeany proceeds are distributed to the holders of our common stock. Onand after the Approval Date, the Series D Preferred will have noliquidation preference.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Priorto the Approval Date, holders of shares of our Series D Preferredwill have one vote per share of Series D Preferred and will vote asa single class with our shares of common stock. On and after theApproval Date, shares of Series D Preferred will generally have novoting rights, except to the extent expressly provided in ourRestated and Amended Articles of Incorporation or as otherwiserequired by law.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         For aslong as shares of Series D Preferred are outstanding, theaffirmative consent of holders of a majority of the outstandingshares of Series D Preferred will be required before wecan:        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           amend, alter,modify or repeal (whether by merger, consolidation or otherwise)the Series D Preferred Certificate of Designation, our articles ofincorporation or our bylaws in any manner that adversely affectsthe rights, preferences, privileges or the restrictions providedfor the benefit of, the Series D Preferred;          </font>         </div>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           issue furthershares of Series D Preferred or increase or decrease (other than byconversion) the number of authorized shares of Series D Preferred;or          </font>         </div>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           enter into anyagreement to do any of the foregoing that is not expressly madeconditional on obtaining the affirmative vote or written consent ofthe requisite holders.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -100-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In the event of the liquidation, dissolution or winding up of ouraffairs, t         </font>         he Series D Preferred ranks  senior to anyclass or series of our capital stock hereafter created specificallyranking by its terms junior to the preferred stock; until theApproval Date, senior to our common stock; on parity with any classor series of capital stock hereafter created specifically rankingby its terms on parity with the preferred stock; and junior to anyclass or series of capital stock hereafter created specificallyranking by its terms senior to the preferred stock.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         At thetime of its issuance in connection with the December 2020 PublicOffering (described below), we did not have a sufficient number ofauthorized shares of our common stock to permit the conversion infull of our Series D Preferred and the issuance upon exercise orconversion of all other outstanding series of preferred stock,warrants to purchase common stock or outstanding stock options orshares reserved for issuance of the same. Accordingly, on March 5,2021, we held a Special Meeting of Stockholders (the         <font style="font-style: italic">          Special Meeting         </font>         ) at which ourstockholders approved an amendment to our Restated and AmendedArticles of Incorporation to increase the number of authorizedshares of our common stock from 175 million shares to 325 millionshares (the         <font style="font-style: italic">          CharterAmendment         </font>         ), an amount sufficient to permit the conversion ofall outstanding shares of Series D Preferred. The affirmative voteby a majority of our common stockholders and Series D Preferredholders, voting as a single class, at the Special Meetingconstituted the Approval Date noted above.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Followingthe Special Meeting, between March 12, 2021 and March 31, 2021,holders of an aggregate of 1,597,851 shares of Series D Preferredconverted such shares into 36,750,573 registered shares of ourcommon stock. At March 31, 2021, there were 402,149 shares ofSeries D Preferred outstanding which were convertible into9,249,427 shares of our common stock. See Note 16,         <font style="font-style: italic">          Subsequent Events         </font>         , for informationregarding additional conversions after March 31, 2021.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Duringour fiscal years ended March 31, 2021 and 2020, we completedprivate placement and public offerings as describedbelow.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Common Stock and Warrants Issued in Fall 2019 PrivatePlacement        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Between October 30, 2019 and November 7, 2019, in a self-placedprivate placement and pursuant to subscription agreements receivedfrom certain accredited investors, we sold to such investors units,at a purchase price of $1.00 per unit, consisting of an aggregateof 650,000 unregistered shares of our common stock and warrants,exercisable beginning six months and one day following issuance andthrough November 1, 2023, to purchase 325,000 unregistered sharesof our common stock at an exercise price of $2.00 per share(the         </font>         <font style="font-style: italic; color: #000000">          Fall2019 Private Placement         </font>         <font style="color: #000000">          ). Wereceived cash proceeds of $650,000 from the Fall 2019 PrivatePlacement.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          As further described below under “Winter 2019 WarrantModification,” in December 2019, we modified the warrantsissued in connection with the Fall 2019 Private Placement to (i)reduce the exercise price from $2.00 per share to $0.50 per shareand (ii) to allow for the warrants to become immediatelyexercisable. Further, we issued warrants to purchase an aggregateof 325,000 additional shares of our common stock to theparticipants in the Fall 2019 Private Placement (the         </font>         <font style="font-style: italic; color: #000000">          AdditionalWarrants         </font>         <font style="color: #000000">          ) to increase thenumber of unregistered shares of common stock issuable uponexercise of the warrants from 50% to 100%. The Additional Warrantsare immediately exercisable through March 31, 2024 at an exerciseprice of $0.50 per share.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We calculated the fair value of the Additional Warrants using theBlack Scholes Option Pricing Model and the weighted averageassumptions indicated in the table below, recognizing $88,800 asthe fair value of the new warrants and as warrant modificationexpense, included as a component of general and administrativeexpenses, in our Consolidated Statement of Operations andComprehensive Loss for the fiscal year ended March 31,2020.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:88%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Assumption:             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Additional Warrants               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Marketprice per share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.44             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Exerciseprice per share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.50             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Risk-freeinterest rate             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.59             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Contractualterm in years             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              4.32             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Volatility             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              86.64             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Dividendrate             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.0             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Numberof warrant shares             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              325,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Weighted average fair value per share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">              0.27             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Winter 2019 Warrant Modification        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          On December 4, 2019, we modified outstanding warrants previouslyissued as a part of completed private placements to temporarilyreduce, for a period of two years or, if sooner, until theexpiration of the warrant, the exercise price of such warrants to$0.50 per share, in order to more closely align the exercise priceof the warrants with the trading price of our common stock at suchtime (the         </font>         <font style="font-style: italic; color: #000000">          Winter 2019 WarrantModification         </font>         <font style="color: #000000">          ). Following thetwo-year period during which the exercise price is reduced, theexercise price of each then-outstanding modified warrant willrevert to its pre-modification price. As a result of the Winter2019 Warrant Modification, outstanding warrants to purchase a totalof approximately 6.6 million unregistered shares of our commonstock were modified.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -101-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          We calculated the fair value of the modified warrants, includingthose issued in the Fall 2019 Private Placement, immediately beforeand after the modification using the Black Scholes Option PricingModel for pre-modification valuations and for post-modificationvaluations for warrants expiring in less than two years.         </font>         Forthe warrants expiring after the December 4, 2021 exercise pricereversion date, we ran a binomial model using 24 steps, one foreach month, and lognormal distribution to estimate our stock priceat December 4, 2021, the termination date for the exercise pricereduction. We then compared the exercise value of each warrant ateach estimated stock price to the remaining option value if thewarrant was not exercised on December 4, 2021 and allowed to revertto its original exercise price. For any estimated stock price above$0.50 per share (an in-the-money warrant), we determined that theholders would convert their warrants. For any estimated stock pricebelow $0.50 per share, we determined that the holders wouldcontinue to hold their warrants. Given the significant reductionsin exercise price (the pre-modification exercise prices ranged from$1.50 to $2.24 per share), if the warrants are not exercised priorto December 4, 2021, the Black-Scholes values upon the reversion ofthe exercise prices are very low, such that there is nominaladditional value for continuing to hold the warrants. Accordingly,our estimated post-modification fair value for warrants having anexpiration date later than the two-year exercise price reversiondate, December 4, 2021, is equal to the value of an optiondetermined using the         <font style="color: #000000">          Black ScholesOption Pricing Model having an exercise price of $0.50 per shareand a two-year term and related assumptions. The table belowindicates the pre- and post-modification weighted averageassumptions used in our valuations. We recognized the incrementalfair value, $702,500, as warrant modification expense, included asa component of general and administrative expenses, in ourConsolidated Statement of Operations and Comprehensive Lossfor the fiscal year ended March 31, 2020.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Assumption:             </font>            </div>           </td>           <td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Pre-               </font>              </div>              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                modification               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Post-               </font>              </div>              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                modification               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Marketprice per share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.44             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.44             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Exerciseprice per share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.85             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.50             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Risk-freeinterest rate             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.58             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.58             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Remainingcontractual term in years             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              2.25             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.91             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Volatility             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              87.5             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              88.1             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Dividendrate             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.0             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.0             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Numberof warrant shares             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              6,611,759             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              6,611,759             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Weighted average fair value per share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">              0.08             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">              0.19             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Following the Winter 2019 Warrant Modification, investors holding atotal of 820,000 warrants exercised their warrants at the reducedprice of $0.50 per share, resulting in cash proceeds to us of$410,000 during the quarter ended December 31, 2019.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         December 19, 2019 Warrant Modification        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          On December 19, 2019, we modified additional outstanding warrantspreviously issued as a part of a completed private placement topermanently reduce the exercise price of such warrants to $0.805per share and to extend the term of such warrants through December31, 2022, in order to more closely align the exercise price of thewarrants with the current trading price of our common stock and toprovide additional time for the holders to exercise the warrants(the         </font>         <font style="font-style: italic">          December 19,         </font>         <font style="font-style: italic; color: #000000">          2019 WarrantModification         </font>         <font style="color: #000000">          ). As a result ofthe December 19, 2019 Warrant Modification, we modified outstandingwarrants to purchase a total of 80,431 shares of our commonstock.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We calculated the fair value of the modified warrants immediatelybefore and after the modification using the Black Scholes OptionPricing Model and the weighted average assumptions indicated in thetable below. We recognized the incremental fair value, $35,600, aswarrant modification expense, included as a component of generaland administrative expenses, in our Consolidated Statement ofOperations and Comprehensive Loss for the fiscal year ended March31, 2020.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Assumption:             </font>            </div>           </td>           <td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Pre-               </font>              </div>              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                modification               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Post-modification               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Marketprice per share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.805             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.805             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Exerciseprice per share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              7.00             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.805             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Risk-freeinterest rate             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.57             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.65             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Remainingcontractual term in years             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.58             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              3.034             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Volatility             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              98.7             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              84.9             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Dividendrate             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.0             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.0             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Numberof warrant shares             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              80,431             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              80.431             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Weighted average fair value per share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">              0.00             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">              .044             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -102-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Warrants issued in Winter 2019 Warrant Offering        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In December 2019, we commenced a self-placed private placement ofwarrants to purchase unregistered shares of our common stock at anoffering price of $0.15 per warrant (the         </font>         <font style="font-style: italic; color: #000000">          Winter 2019 WarrantOffering         </font>         <font style="color: #000000">          ). Warrants offered andsold in the Winter 2019 Warrant Offering have an exercise price of$0.50 per share and term of three years from the issuance date.Over the course of the Winter 2019 Warrant Offering, we soldwarrants to purchase a total of 2.0 million unregistered shares ofcommon stock for cash proceeds to us of $300,000, which weaccounted for with a corresponding credit to additional paid-incapital, an equity account.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Registered Direct Offering of Common Stock and Concurrent WarrantOffering        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In January 2020, we entered into a self-placed securitiespurchase agreement with certain accredited investors pursuant towhich we received gross cash proceeds of $2.75 million upon thesale of an aggregate of 3,870,077 shares of our common stock at apurchase price of $0.71058 per share (the         </font>         <font style="font-style: italic; color: #000000">          January 2020Offering         </font>         <font style="color: #000000">          ). Concurrently withthe January 2020 Offering, we also commenced a private placement inwhich we issued and sold warrants (the         </font>         <font style="font-style: italic; color: #000000">          January 2020Warrants         </font>         <font style="color: #000000">          ) exercisable for anaggregate of 3,870,077 unregistered shares of our common stock(the         </font>         <font style="font-style: italic; color: #000000">          WarrantShares         </font>         <font style="color: #000000">          ), having an exerciseprice of $0.73 per Warrant Share. The 3,870,077 shares of commonstock sold in the January 2020 Offering (but not the January 2020Warrants or the Warrant Shares) were offered and sold pursuant to aprospectus, dated September 30, 2019, and a prospectus supplementdated January 24, 2020, in connection with a takedown from ourshelf registration statementon Form S-3 (File No. 333-234025).         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; background-color: #FFFFFF">          The January 2020 Warrants contain customary provisions allowing foradjustment to the exercise price and number of Warrant Sharesissuable only in the event of any stock dividend and split, reversestock split, recapitalization, reorganization or similartransaction, as described in the January 2020 Warrants.         </font>         Inaddition,         <font style="color: #000000; background-color: #FFFFFF">          subject to limitedexceptions, holders of the January 2020 Warrants will not have theright to exercise any portion of their respective January 2020Warrants if the holder, together with any affiliates, wouldbeneficially own in excess of 4.99% of the number of shares of ourcommon stock outstanding immediately after giving effect to suchexercise.         </font>         <font style="color: #000000">          The January 2020Warrants are exercisable from any time after the six-monthanniversary of issuance (the         </font>         <font style="font-style: italic; color: #000000">          Initial ExerciseDate         </font>         <font style="color: #000000">          ) and will expire on thefifth year anniversary of the Initial Exercise Date.         </font>         Refer to Note 16,         <font style="font-style: italic">          SubsequentEvents         </font>         , for disclosure regarding filing of a registrationstatement including the shares of common stock underlying theJanuary 2020 Warrants.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Common Stock Purchase Agreement with Lincoln Park        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          On March 24, 2020, we entered into a purchase agreement and aregistration rights agreement with Lincoln Park Capital Fund(         </font>         <font style="font-style: italic; color: #000000">          LPC         </font>         <font style="color: #000000">          ) pursuant to which LPC committed to purchase upto $10,250,000 of our common stock at market-based prices over aperiod of 24 months (the         </font>         <font style="font-style: italic; color: #000000">          LPCAgreement         </font>         <font style="color: #000000">          ). On March 24, 2020,we sold 500,000 unregistered shares of our common stock (the         </font>         <font style="font-style: italic; color: #000000">          Initial PurchaseShares         </font>         <font style="color: #000000">          ) to LPC under thepurchase agreement at a price of $0.50 per share for gross cashproceeds of $250,000 (the         </font>         <font style="font-style: italic; color: #000000">          InitialPurchase         </font>         <font style="color: #000000">          ) and we also issued750,000 unregistered shares of our common stock to LPC under theterms of the LPC Agreement (the         </font>         <font style="font-style: italic; color: #000000">          CommitmentShares         </font>         <font style="color: #000000">          ). To satisfy ourobligations under the registration rights agreement, we filed aRegistration Statement on Form S-1 (the         </font>         <font style="font-style: italic; color: #000000">          LPC RegistrationStatement         </font>         <font style="color: #000000">          ) with the SEC onMarch 31, 2020 (Registration No. 333-237514), which the SECdeclared effective on April 14, 2020 (the         </font>         <font style="font-style: italic; color: #000000">          CommencementDate         </font>         <font style="color: #000000">          ). The LPC RegistrationStatement included registration of the Initial Purchase Shares andthe Commitment Shares. The fair value of the Commitment Shares,$284,400, determined based on the quoted closing market price ofour common stock on March 24, 2020, is a component of deferredoffering costs attributable to this offering, which costs areamortized ratably to additional paid-in capital as we sell sharesof our common stock to LPC under the LPCAgreement.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Following the Commencement Date, on any business day over the termof the LPC Agreement, we have the right, in our sole discretion, todirect LPC to purchase up to 100,000 shares on such business day(the “         </font>         <font style="font-style: italic; color: #000000">          RegularPurchase         </font>         <font style="color: #000000">          ”) (subject toadjustment under certain circumstances as provided in the LPCAgreement). The purchase price per share for each such RegularPurchase will be based on prevailing market prices of our commonstock immediately preceding the time of sale as computed under theLPC Agreement. In each case, LPC’s maximum commitment in anysingle Regular Purchase may not exceed $1,000,000. In addition toRegular Purchases, provided that we present LPC with a purchasenotice for the full amount allowed for a Regular Purchase, we mayalso direct LPC to make         </font>         <font style="color: #212529">          accelerated purchases and additional acceleratedpurchases as described in the LPC Agreement         </font>         <font style="color: #000000">          . Although         </font>         LPC has no right to require usto sell any shares of our common stock to LPC, LPC is obligated tomake purchases as we direct, subject to certain conditions. In allinstances, we may not sell shares of our common stock to LPC underthe LPC Agreement if such sales would result in LPC beneficiallyowning more than 9.99% of our common stock. There are no upperlimits on the price per share that LPC must pay for shares of ourcommon stock.         <font style="color: #000000">         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Subsequent to the Commencement Date and through July 2020, we soldan additional 6,301,995 registered shares of our common stock toLincoln Park and received aggregate gross cash proceeds of$2,891,200. We have sold no shares of our common stock under theLPC Agreement since July 2020. At March 31, 2021, there wereapproximately 2.04 million registered shares of our common stockremaining available for sale under the LPC Agreement; however, wehave no obligation to sell any additional shares under the LPCAgreement in the future.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -103-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Sale of Common Stock and Warrants in the Spring 2020 PrivatePlacement        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          In April 2020, in a self-directed private placement, we sold unitsof common stock and warrants to an accredited investor to purchasean aggregate of 125,000 unregistered shares of our common stock andfour-year warrants to purchase 125,000 shares of our common stockat an exercise price of $0.50 per share and we received cashproceeds of $50,000 (the         </font>         <font style="font-style: italic; color: #000000">          Spring 2020 PrivatePlacement         </font>         <font style="color: #000000">          ).         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Registration Statement for shares underlying warrants issued inPrivate Placements and warrant exercises        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          On May 1, 2020, we filed a registration statement on Form S-3(Registration No. 333-237968) to register approximately 12.1million shares of common stock underlying outstanding warrants thatwe had issued in earlier private placement offerings, including theSpring 2020 Private Placement, as well as common stock underlyingwarrants that had been previously issued to various consultants asfull or partial compensation for their services. Included in theregistration statement were shares of our common stock underlyingapproximately 5.8 million outstanding warrants to purchase sharesof our common stock that had been modified in December 2019 totemporarily reduce, for a period of two years or, if sooner, untilthe expiration of the warrant, the exercise price of such warrantsto $0.50 per share, in order to more closely align the exerciseprice of the warrants with the trading price of our common stock atthat time (the         </font>         <font style="font-style: italic; color: #000000">          Winter 2019 WarrantModification         </font>         <font style="color: #000000">          ). We alsoregistered approximately 0.8 million shares of unregisteredoutstanding common stock held by former holders of warrants who hadexercised such warrants subsequent to the Winter 2019 WarrantModification. Further, we registered the 125,000 shares of commonstock issued in the Spring 2020 Private Placement. The SEC declaredthe registration statement effective on May 13, 2020 (the         </font>         <font style="font-style: italic; color: #000000">          WarrantRegistration Statement         </font>         <font style="color: #000000">          ). As aresult of the effectiveness of this registration statement, theshares of common stock underlying essentially all of ouroutstanding warrants have been registered.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         During July 2020, holders of warrants to purchase an aggregate of228,000 shares of our common stock exercised such warrants, and wereceived aggregate cash proceeds of $114,000. We issued 228,000registered shares of our common stock upon these exercises pursuantto the effectiveness of the Warrant Registration Statement. BetweenDecember 2020 and March 31, 2021, holders of outstanding warrantsto purchase an aggregate of 6,396,302 registered shares of ourcommon stock exercised such warrants and we received $4,200,900 incash proceeds.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         August 2020 Registered Public Offering of Common Stock        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          On August 2, 2020, we entered into an underwriting agreement(the         </font>         <font style="font-style: italic; color: #000000">          UnderwritingAgreement         </font>         <font style="color: #000000">          ) with Maxim Group,LLC as representative of the underwriters named therein(         </font>         <font style="font-style: italic; color: #000000">          Maxim         </font>         <font style="color: #000000">          ), pursuant to which we sold, in an underwrittenpublic offering (the         </font>         <font style="font-style: italic; color: #000000">          August 2020 PublicOffering         </font>         <font style="color: #000000">          ), an aggregate of15,625,000 shares (the         </font>         <font style="font-style: italic; color: #000000">          Shares         </font>         <font style="color: #000000">          ) of our common stock for a public offering priceof $0.80 per share, resulting in gross proceeds to us of$12,500,000. The August 2020 Public Offering closed on August 5,2020. Under the terms of the Underwriting Agreement, we granted toMaxim a 45-day over-allotment option to purchase up to anadditional 2,343,750 shares at a public offering price of $0.80 pershare, which Maxim elected to exercise on August 5, 2020 withrespect to an aggregate of 2,243,250 shares (the         </font>         <font style="font-style: italic; color: #000000">          Exercised OptionShares         </font>         <font style="color: #000000">          ). We completed the saleof the Exercised Option Shares on August 7, 2020 and receivedadditional gross proceeds of $1,794,600. After deductingunderwriting discounts and commissions and offering expensespayable by us, we received net proceeds of approximately $12.9million from the August 2020 Public Offering.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         December 2020 Registered Public Offering of Common Stock and SeriesD Preferred Stock        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          O         </font>         n December 18, 2020, we entered into an underwritingagreement (the         <font style="font-style: italic">          December 2020Underwriting Agreement         </font>         ) with Jefferies LLC (         <font style="font-style: italic">          Jefferies         </font>         ) and William Blair &amp;Company, L.L.C. (         <font style="font-style: italic">          WillianBlair)         </font>         , as representatives of the underwriters named therein(collectively, the         <font style="font-style: italic">          Underwriters         </font>         ), pursuant to which weagreed to issue and sell to the Underwriters, in an underwrittenpublic offering (the         <font style="font-style: italic">          December 2020Public Offering         </font>         ), 63,000,000 shares of our common stock, ata public offering price of $0.92 per share and 2,000,000 shares ofthe newly created Series D Preferred (together with the commonstock, the         <font style="font-style: italic">          Securities         </font>         ) at apublic offering price of $21.16 per share, resulting in grossproceeds to us of $100.28 million. The December 2020 PublicOffering closed on December 22, 2020 at which time the shares ofcommon stock and Series D Preferred were sold to the Underwriters.         <font style="color: #000000">          After deducting underwriting discountsand commissions and offering expenses payable by us, we receivednet proceeds of approximately $93.6 million from the December 2020Public Offering.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          The Series D Preferred that we issued in the December 2020 PublicOffering contained a beneficial conversion feature (a         </font>         <font style="font-style: italic; color: #000000">          BCF         </font>         <font style="color: #000000">          ), which arises when a debt or equity security isissued with an embedded conversion option that is deemed beneficialto the investor, that is, in-the-money, at inception because theconversion option has an effective conversion price that is lessthan the market price of the underlying stock at the commitmentdate (with respect to the Series D Preferred, the date the securitywas actually issued rather than the date the agreement to do so wasentered into, herein referred to as the         </font>         <font style="font-style: italic; color: #000000">          CommitmentDate         </font>         <font style="color: #000000">          ). In accordance withAccounting Standards Codification 470-20,         </font>         <font style="font-style: italic; color: #000000">          Debt- Debt with Conversion andOther Options         </font>         <font style="color: #000000">          (         </font>         <font style="font-style: italic; color: #000000">          ASC 470-20         </font>         <font style="color: #000000">          ), an embedded BCF is required to be recognizedseparately by allocating a portion of the proceeds equal to theintrinsic value of the feature to additional paid-in capital. ASC470-20 also provides that the intrinsic value is to be calculatedas of the Commitment Date. The Series D Certificate of Designationprovides that the Series D Preferred has a conversion price of$0.92 per share on an as-converted basis (the         </font>         <font style="font-style: italic; color: #000000">          ConversionPrice         </font>         <font style="color: #000000">          ). The Conversion Pricecompared to the closing price of $1.42 per share of our commonstock on the Commitment Date results in a difference of $0.50 pershare. That difference multiplied by the 46 million shares of ourcommon stock issuable upon conversion of the Series D Preferredresulted in an aggregate BCF of $23.0 million. We did not recognizethe impact of the BCF at December 31, 2020 because the Series DPreferred was not convertible into common stock prior to theApproval Date. Following approval by our stockholders of theCharter Amendment at the Special Meeting in March 2021, thecontingency of the BCF was eliminated and we recognized the BCF asa noncash charge in arriving at net loss attributable to commonstockholders in our Consolidated Statement of Operations andComprehensive Loss for the quarter and fiscal year ended March 31,2021 and as a corresponding increase in additional paid-in capitalin our Consolidated Statement of Stockholders’ Equity(Deficit). The BCF was also treated as a deemed dividend in ourConsolidated Statement of Stockholders’ Equity (Deficit).Since we have an accumulated deficit, we recorded the deemeddividend as a reduction in additional paid-in capital, resulting ina net impact of $0 to additional paid-in capital. The recognitionof the BCF on the Series D Preferred had no impact in aggregate onour stockholders’ equity or on our cashposition.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -104-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Stock Option Exercises        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Duringthe fiscal year ended March 31, 2021, holders of outstanding stockoptions, including two members of our Board, exercised options topurchase an aggregate of 252,004 shares of our common stock and wereceived cash proceeds of $36,500. There were no stock optionexercises during the fiscal year ended March 31, 2020.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Warrants Outstanding        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Following the Winter 2019 Warrant Modifications, the December 19,2019 Warrant Modification, the Winter 2019 Warrant Offering, theissuance of the January 2020 Warrants and the warrants included inthe Spring 2020 Private Placement and the warrant exercises notedabove, the following table summarizes outstanding and exercisablewarrants to purchase shares of our common stock as of March 31,2021.  The weighted average exercise price of outstandingand exercisable warrants at March 31, 2021 was $1.78 pershare.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left">        <table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-size: inherit; font-family: inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align: bottom; width: 76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                WarrantsExercisable               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                Exercise               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                andOutstanding               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                Price               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 76%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Expiration             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                atMarch 31,               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                perShare               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 76%;">            <div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Date             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.50             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 76%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              4/30/2021 to3/31/2024             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              4,944,680             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.73             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 76%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              7/25/2025             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,670,077             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.805             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 76%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              12/31/2022             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              80,431             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.50             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 76%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              12/13/2022             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              8,375,530             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.82             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 76%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              3/7/2023             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,388,931             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3.51             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 76%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              12/31/2021             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              50,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              5.30             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 76%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              5/16/2021             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,705,883             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              7.00             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 76%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              3/3/2023             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              147,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="2" style="vertical-align: bottom; width: 88%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="2" style="vertical-align: bottom; width: 88%;">            <div style="margin-left:0px;padding-bottom:4px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:4px double #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:4px double #000000;">              19,362,532             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         At March 31, 2021, with the effectiveness of the WarrantRegistration Statement in May 2020, the shares of common stockunderlying essentially all of the outstanding warrants except thosehaving an exercise price of $7.00 per share have been registeredfor resale by the warrant holders. Additionally, no outstandingwarrant is subject to any down round anti-dilution protectionfeatures and all of the outstanding warrants are exercisable by theholders only by payment in cash of the stated exercise price pershare.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -105-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Reserved Shares        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         At March 31, 2021, we have reserved shares of our common stock forfuture issuance as follows:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <br/>        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              COMMON STOCK RESERVED FOR FUTURE ISSUANCE AT 3/31/21             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               Upon exchange of all shares of Series A Preferredcurrently issued and outstanding              </font>              <font style="font-size: 70%; vertical-align: top; color: #000000">               (1)              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              750,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               Upon exchange of all shares of Series B Preferredcurrently issued and outstanding              </font>              <font style="font-size: 70%; vertical-align: top; color: #000000">               (2)              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              4,000,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               Upon exchange of all shares of Series C Preferredcurrently issued and outstanding              </font>              <font style="font-size: 70%; vertical-align: top; color: #000000">               (3)              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              2,318,012             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               Upon exchange of all shares of Series D Preferredcurrently issued and outstanding              </font>              <font style="font-size: 70%; vertical-align: top; color: #000000">               (4)              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              9,249,427             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Pursuantto warrants to purchase common stock:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Subjectto outstanding warrants             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              19,365,532             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Pursuantto stock incentive plans:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Subjectto outstanding options under the Amended and Restated 2016 StockIncentive             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Planand the 2019 Omnibus Equity Incentive Plan             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              14,638,088             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Availablefor future grants under the 2019 Omnibus Equity IncentivePlan             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,843,158             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Availablefor future issuance under the 2019 Employee Stock PurchasePlan             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              941,875             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              17,423,121             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Reservedfor issuance under Lincoln Park Purchase Agreement             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              320,272             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Totalreserves             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              53,426,364             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="null">        <font>        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:90%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ____________             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:90%;">            <div style="text-align: left; text-indent: -12px; margin-right: 0px; margin-left: 12px;">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="font-size: 70%; vertical-align: top; color: #000000">               (1)              </font>              <font style="color: #000000">               Assumes exchange under the terms ofthe October 11, 2012 Note Exchange and PurchaseAgreement.              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:90%;">            <div style="text-align: left; margin-left: 12px; text-indent: -12px; margin-right: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:90%;">            <div style="text-align: left; text-indent: -12px; margin-right: 0px; margin-left: 12px;">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="font-size: 70%; vertical-align: top; color: #000000">               (2)              </font>              <font style="color: #000000">               Assumes exchange under the terms ofthe Certificate of Designation of the Relative Rights andPreferences of the Series B 10% Convertible Preferred Stock,effective May 5, 2015; includes 2,868,331 shares of common stockreserved for payment of dividends on Series B Preferred uponconversion. Refer to              </font>              <font style="font-style: italic; color: #000000">               Series B PreferredStock,              </font>              <font style="color: #000000">               above, for additionalinformation regarding payment of dividends in commonstock.              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:90%;">            <div style="text-align: left; margin-left: 12px; text-indent: -12px; margin-right: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:90%;">            <div style="text-align: left; text-indent: -12px; margin-right: 0px; margin-left: 12px;">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="font-size: 70%; vertical-align: top; color: #000000">               (3)              </font>              <font style="color: #000000">               Assumes exchange under the terms ofthe Certificate of Designation of the Relative Rights andPreferences of the Series C Convertible Preferred Stock, effectiveJanuary 25, 2016.              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:90%;">            <div style="text-align: left; margin-left: 12px; text-indent: -12px; margin-right: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:90%;">            <div style="text-align: left; text-indent: -12px; margin-right: 0px; margin-left: 12px;">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="font-size: 70%; vertical-align: top; color: #000000">               (4)              </font>              <font style="color: #000000">               Assumes exchange under the terms ofthe Certificate of Designation of the Relative Rights andPreferences of the Series D Convertible Preferred Stock, effectiveDecember 21, 2020.              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:90%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="1" style="vertical-align:bottom;width:90%;">            <div style="margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 10%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -106-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         At March 31, 2021, we have 90,958,067 authorized shares of ourcommon stock not subject to reserves and available for futureissuance.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         10.  Research and Development Expenses        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We recorded research and development expenses of approximately$12.5 million and $13.4 million in the fiscal years ended March 31,2021 and 2020, respectively, including approximately $0.8 millionand $1.4 million of noncash expense in the fiscal years ended March31, 2021 and 2020, respectively. Research and development expenseis composed of employee compensation expenses, includingstock–based compensation, direct project expenses, notablyincluding preclinical and nonclinical projects for PH94B, PH10 andAV-101 in both years and costs attributable to our AV-101 clinicaltrial in MDD in the fiscal year ended March 31, 2020, as well ascosts to maintain and prosecute our intellectual property suite,including patent applications for AV-101 in combination withprobenecid for various indications in the fiscal year ended March31, 2021.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         11.  Income Taxes        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The provision for income taxes for the periods presented in theConsolidated Statements of Operations and Comprehensive Lossrepresents minimum California franchise tax, Maryland and NorthCarolina income tax.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Income tax expense (benefit) differed from the amounts computed byapplying the statutory federal income tax rate of 21% to pretaxincome (loss) as a result of the following:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -107-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:5%;padding-bottom:2px;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;font-weight:bold;width:90%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000;">                Fiscal Years Ended March 31,               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:5%;padding-bottom:2px;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;font-weight:bold;width:80%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000;">                2021               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;font-weight:bold;width:80%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000;">                2020               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Computedexpected tax benefit             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (21.00             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )%             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (21.00             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )%             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Stateincome taxes, net of federal benefit             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.01             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.01             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Taxeffect of warrant modifications             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.84             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Taxeffect of research and development credits             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (1.45             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )%             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (1.60             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )%             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Taxeffect of stock compensation             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              4.71             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              2.39             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Taxeffect of other non-deductible items             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.00             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.00             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Expirednet operating loss carryforwards             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.99             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.36             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Changein valuation allowance (federal only)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              15.74             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              19.02             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Incometax expense             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              0.00             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              0.02             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              %             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Deferred income taxes reflect the net tax effect of temporarydifferences between the carrying amounts of assets and liabilitiesfor financial reporting purposes and the amounts used for incometax purposes. Significant components of our deferred tax assets areas follows:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-weight: bold;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-weight: bold;">              <div>               <font style="font-size: 13px; font-family: Times New Roman; font-weight: bold;">                March 31,               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-weight: bold;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-weight: bold;">              <div>               <font style="font-size: 13px; font-family: Times New Roman; font-weight: bold;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-weight: bold;">              <div>               <font style="font-size: 13px; font-family: Times New Roman; font-weight: bold;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Deferred taxassets:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net operating losscarryovers             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              33,587,300             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              30,607,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Basis differencesin property and equipment             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              12,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              9,100             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Research anddevelopment credit carryforwards             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,589,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,256,400             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Stock basedcompensation             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,515,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,919,900             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Operating leaseRight of Use asset             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              105,300             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              95,400             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accruals andreserves             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              67,000             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              66,500             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Total deferred taxassets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              39,876,600             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              36,954,800             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Valuationallowance             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (39,876,600             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (36,954,800             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net deferred taxassets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Realization of deferred tax assets is dependent upon futureearnings, if any, the timing and amount of which are uncertain.Accordingly, the deferred tax assets have been fully offset by avaluation allowance. The valuation allowance increased by$2,921,800 and $4,202,500 during the fiscal years ended March 31,2021 and 2020, respectively.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; font-family: Times New Roman; font-size: 13px">          Asof March 31, 2021, we had U.S. federal net operating losscarryforwards of approximately $139,175,200. Federal net operatingloss carryforwards of approximately $86,276,400 generated throughour fiscal year ended March 31, 2018 will expire in our fiscalyears ending March 31, 2022 through March 31, 2038. Federal netoperating loss carryforwards of approximately $52,898,800 generatedin fiscal years ending after March 31, 2018 will carry forwardindefinitely, but are subject to an 80% taxable income limitation.As of March 31, 2021, we had state net operating loss carryforwardsof approximately $64,556,500, which will expire in fiscalyears ending in 2029 through 2041. We also have federal andstate research and development tax credit carryforwards ofapproximately $2,415,500 and $1,311,900, respectively. The federaltax credits will expire at various dates beginning with our fiscalyear ending March 31, 2029, unless previously utilized. The statetax credits do not expire and will carry forward indefinitely untilutilized.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          On March 27, 2020 the U.S. enacted the Coronavirus Aid, Relief, andEconomic Security Act (the         </font>         <font style="font-style: italic; color: #000000">          CARES Act         </font>         <font style="color: #000000">          ) to provide economic relief in response to thecoronavirus pandemic. The CARES Act, among other things, includesprovisions to allow certain net operating losses to be carried-backup to five years, to increase interest deduction limitations, andto make technical corrections to tax depreciation methods forqualified improvement property. The CARES Act may affect thecorporate income taxes imposed by state governments and may resultin future responses by state legislatures, some of which could haveretroactive effect. The Company evaluated the provisions of theCARES Act and determined that it did not have a material impact onthe Company’s income tax accounts at March 31, 2021 or2020.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          On June 29, 2020, California Assembly Bill 85 (         </font>         <font style="font-style: italic; color: #000000">          AB 85         </font>         <font style="color: #000000">          ) was signed into law, suspending the use ofCalifornia net operating losses and limiting the use of Californiaresearch tax credits for tax years beginning in 2020 and before2023. The suspension of net operating losses and the restriction ofresearch tax credits did not result in a significant impact on thevalue of our deferred tax assets.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         U.S. federal and state tax laws include substantialrestrictions on the utilization of net operating loss carryforwardsin the event of an ownership change of a corporation. We have notperformed a change in ownership analysis since our inception in1998 and accordingly some or all of our net operating losscarryforwards may not be available to offset future taxable income,if any.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -108-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We file income tax returns in the U.S. federal, Canada andvarious U.S. state jurisdictions. We are subject toU.S. federal and state income tax examinations by taxauthorities for tax years 2002 through 2021 due to net operatinglosses that are being carried forward for tax purposes, but we arenot currently under examination by tax authorities in anyjurisdiction.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Uncertain Tax Positions        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our unrecognized tax benefits at March 31, 2021 and 2020 relateentirely to research and development tax credits. The total amountof unrecognized tax benefits at March 31, 2021 and 2020 is $931,900and $814,600, respectively. If recognized, none of the unrecognizedtax benefits would impact our effective tax rate. The followingtable summarizes the activity related to our unrecognized taxbenefits.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-weight: bold;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-weight: bold;">              <div>               <font style="font-size: 13px; font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">                Fiscal Years Ended March 31,               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-weight: bold;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-weight: bold;">              <div>               <font style="font-size: 13px; font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-weight: bold;">              <div>               <font style="font-size: 13px; font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Unrecognizedbenefit - beginning of period             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              814,600             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              668,700             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Currentperiod tax position increases             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              117,300             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              146,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Priorperiod tax position increases (decreases)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (100             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Unrecognizedbenefit - end of period             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              931,900             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              814,600             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our policy is to recognize interest and penalties related to incometaxes as components of interest expense and other expense,respectively. We incurred no interest or penalties related tounrecognized tax benefits in the years ended March 31, 2021 or2020. We do not anticipate any significant changes of our uncertaintax positions within twelve months of this reportingdate.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         12.  Licensing, Sublicensing and CollaborativeAgreements        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         PH94B Sublicense Agreement with EverInsight        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          On June 24, 2020, we entered into a license and collaborationagreement (the         </font>         <font style="font-style: italic; color: #000000">          EverInsightAgreement         </font>         <font style="color: #000000">          )with         </font>         EverInsight Therapeutics Inc., a companyincorporated under the laws of the British Virgin Islands andfunded by CBC Group, a global healthcare-focused venture capitalfirm (         <font style="font-style: italic">          EverInsight         </font>         ).Subsequent to entering into the EverInsight Agreement, in October2020, EverInsight merged with AffaMed Therapeutics, Inc., alsofunded by CBC Group, which as a combined, complementary entity isfocusing on developing and commercializing therapeutics to addressophthalmologic and CNS disorders in Greater China and beyond.Accordingly, we are now referring to EverInsight and theEverInsight Agreement as AffaMed and the AffaMed Agreement,respectively. Under the AffaMed Agreement, we g         <font style="color: #000000">          ranted AffaMed an exclusive license todevelop and commercialize PH94B, our neuroactive pherin drugcandidate for SAD and other anxiety-related disorders, in GreaterChina (which includes Mainland China, Hong Kong, Macau and Taiwan),South Korea and Southeast Asia (which includes Indonesia, Malaysia,Philippines, Thailand and Vietnam) (collectively, the         </font>         <font style="font-style: italic; color: #000000">          Territory         </font>         <font style="color: #000000">          ). We retain exclusive development andcommercialization rights for PH94B in the rest of theworld.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Underthe terms of the AffaMed Agreement, AffaMed is responsible for allcosts related to developing, obtaining regulatory approval of, andcommercializing PH94B for treatment of SAD, and potentially otheranxiety-related indications, in the Territory. A joint developmentcommittee has been established between AffaMed and us to coordinateand review the development and commercialization plans with respectto PH94B in the Territory.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We areresponsible for pursuing clinical development and regulatorysubmissions of PH94B for acute treatment of anxiety in adults withSAD, and potentially other anxiety-related indications, in theUnited States on a ‘‘best efforts’’ basis,with no guarantee of success. EverInsight has the option toparticipate in the Phase 3 global clinical trial of PH94B and willassume all direct costs and expenses of conducting such clinicaltrial in the Territory and a portion of the indirect costs of theglobal trial. We will transfer all development data (nonclinicaland clinical data) and our regulatory documentation related toPH94B throughout the term as it is developed or generated orotherwise comes into our control. We will grant to AffaMed a Rightof Reference to our regulatory documentation and our developmentdata.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Under the terms of the AffaMed Agreement, AffaMed agreed topay us a non-refundable upfront license payment of $5.0million         </font>         within 30 business days of the effective date of theAffaMed Agreement, and AffaMed paid the $5 million in August 2020.         <font style="color: #000000">          Additionally, upon successfuldevelopment and commercialization of PH94B in the Territory,         </font>         we are eligible to receive milestone payments of up to $172.0million. Further, we are eligible to receive royalty payments on acountry-by-country basis on net sales for the later of ten years orthe expiration of market or regulatory exclusivity in thejurisdiction, except that payments will be reduced on acountry-by-country basis in the event that there is no marketexclusivity in the period. Royalty payments may also be reduced ifthere is generic competitive product in the period.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -109-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We havedetermined that we have one combined performance obligation for thelicense to develop and commercialize PH94B in the Territory andrelated development and regulatory services. In addition, AffaMedhas an option that will create manufacturing obligations for usduring development upon exercise by AffaMed. This option formanufacturing services was evaluated and determined not to includea material right.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Developmentand commercialization milestones were not considered probable atinception and therefore were excluded from the initial transactionprice. The royalties were excluded from the initial transactionprice because they relate to a license of intellectual property andare subject to the royalty constraint.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Werecognize revenue as the combined performance obligation issatisfied over time using an output method. The measure of progressis stand-ready straight-line over the period in which we expect toperform the services related to the sublicense of PH94B.Significant management judgment is required to determine the levelof effort attributable to the AffaMed Agreement and the period overwhich we expect to complete our performance obligations under thearrangement. The performance period or measure of progress isestimated at the inception of the arrangement and re-evaluated insubsequent reporting periods. This re-evaluation may shorten orlengthen the period over which we recognize revenue. Changes tothese estimates are recorded on a cumulative catch up basis. Wecurrently estimate that we will complete our performanceobligations at the end of calendar 2023.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thedifference between the revenue recognized to-date under the AffaMedAgreement, $1,089,500, and the consideration received to-date,$5,000,000, is recorded as a contract liability/deferred revenue(cash received exceeds revenue earned). At March 31, 2021, we haverecorded deferred revenue of $3,910,500. The following tablepresents changes in our contract liabilities for our fiscal yearended March 31, 2021:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:52%;">            <div>             <br/>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Balance at               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                Balanceat               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:52%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                March 31, 2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Additions               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Deductions               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                March 31, 2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              DeferredRevenue - current portion             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,420,200             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,420,200             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              DeferredRevenue - non-current portion             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              3,579,800             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (1,089,500             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              2,490,300             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Total             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              5,000,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (1,089,500             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              3,910,500             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         For thesingle combined performance obligation under the AffaMed Agreement,the measure of progress is stand-ready straight-line over theperiod in which we expect to perform the services related to thesublicense of PH94B. Accordingly, deferred revenue is beingrecognized on a straight-line basis over the period in which weexpect to perform the services.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Contract Acquisition Costs        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Duringthe quarter ended September 30, 2020, we made cash paymentsaggregating $345,000 for sublicense fees, which we were obligatedto make pursuant to our PH94B license from Pherin, and fees forconsulting services exclusively related to the AffaMed Agreement.Additionally, on June 24, 2020, we issued 233,645 unregisteredshares of our common stock, valued at $125,000, as partialcompensation for consulting services exclusively related to theAffaMed Agreement. These sublicense fees and consulting paymentsand the fair value of the common stock issued, aggregating$470,000, were incurred solely as a result of obtaining the AffaMedAgreement, and, accordingly, have been capitalized as deferredcontract acquisition costs in our Consolidated Balance Sheet atMarch 31, 2021. Capitalized contract acquisition costs areamortized over the period in which we expect to satisfy theperformance obligations under the AffaMed Agreement and theamortization expense of $102,400 has been included in general andadministrative expenses in our Consolidated Statement of Operationsand Comprehensive Loss for the fiscal year ended March 31, 2021.There has been no impairment loss in relation to the costscapitalized.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Unless earlier terminated due to certain material breaches of thecontract, or otherwise, the         </font>         AffaMedAgreement         <font style="color: #000000">          will expire ona jurisdiction-by-jurisdiction basis until the latest to occurof the expiration of the last valid claim under a licensed patentof PH94B in such jurisdiction, the expiration of regulatoryexclusivity in such jurisdiction or ten years after the firstcommercial sale of PH94B in such jurisdiction.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -110-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         License Agreements with Pherin Pharmaceuticals, Inc.(Pherin)        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         InSeptember 2018 we issued 1,630,435 shares of our unregisteredcommon stock having a fair market value of $2,250,000 to Pherin toacquire an exclusive worldwide license to develop and commercializePH94B for social anxiety disorder and an option to acquire asimilar license for PH10 for MDD. In October 2018, we exercised ouroption to acquire an exclusive worldwide license to develop andcommercialize PH10 by issuing an additional 925,926 shares of ourunregistered common stock having a fair market value of $2,000,000to Pherin under the terms of the PH10 license agreement. Under theterms of the PH94B and PH10 license agreements, we are obligated tomake additional cash payments and pay royalties to Pherin in theevent that certain regulatory and performance-based milestones andcommercial sales are achieved.         <font style="color: #000000">          Additionally, in connection with the PH94B andPH10 license agreements, we were obligated to pay to Pherin monthlysupport payments of $10,000 for a term of 18 months, however nomonthly support payment was required during the 18-month periodidentified in the PH10 license agreement if support payments werebeing made under the terms of the PH94B license agreement. Thesupport payments required under the PH94B license agreementterminated in March 2020 and in April 2020 under the PH10 licenseagreement. Accordingly, we made support payments of $10,000 underthe PH10 license agreement and $120,000 under the PH94B licenseagreement in the fiscal years ended March 31, 2021 and 2020,respectively.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         BlueRock Therapeutics Sublicense Agreement        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         InDecember 2016, we entered into an Exclusive License and SublicenseAgreement with BlueRock Therapeutics, LP, a next generationregenerative medicine company established in December 2016 by BayerAG and Versant Ventures (         <font style="font-style: italic">          BlueRockTherapeutics         </font>         ), pursuant to which BlueRock Therapeuticsreceived exclusive rights to utilize certain technologiesexclusively licensed by us from University Health Network(         <font style="font-style: italic">          UHN         </font>         ) for the production ofcardiac stem cells for the treatment of heart disease. As a resultof its acquisition of BlueRock Therapeutics in 2019, Bayer AG nowholds the rights to develop and commercialize our hPSC technologiesrelating to the production of heart cells for the treatment ofheart disease (the         <font style="font-style: italic">          BayerAgreement         </font>         ).  We retained rights to cardiac stem celltechnology licensed from UHN related to small molecule, protein andantibody drug discovery, drug rescue and drug development,including small molecules with cardiac regenerative potential, aswell as small molecule, protein and antibody testing involvingcardiac cells. To date, we have recognized $1.25 million insublicense revenue, in our fiscal year ended March 31, 2017, underthe Bayer Agreement.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         13.  Stock Option Plans, Employee Stock Purchase Plan,and 401(k) Plan        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         At March 31, 2021, we have the following share-based compensationplans, which are described below:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-weight: bold; font-style: italic; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">           Amended and Restated 2016 Stock Incentive Plan (the 2016 Plan);and          </font>         </div>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">           2019 Omnibus Equity Incentive Plan (the 2019 Plan)          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Description of the 2016 Plan        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         OurBoard unanimously approved the Company’s Amended and Restated2016 Stock Incentive Plan, formerly titled the 2008 Stock IncentivePlan (the         <font style="font-style: italic">          2016 Plan         </font>         ), onJuly 26, 2016, and the 2016 Plan was approved by our stockholdersat our 2016 Annual Meeting of Stockholders on September 26, 2016,and further amended to increase the number of shares authorized forissuance therefrom at our 2017 Annual Meeting of Stockholders onSeptember 15, 2017. The 2016 Plan provided for the grant of stockoptions, restricted shares of common stock, stock appreciationrights and dividend equivalent rights, collectively referred to as“Awards”. Stock options granted under the 2016 Planwere either incentive stock options under the provisions of Section422 of the Internal Revenue Code of 1986, as amended (the         <font style="font-style: italic">          Code         </font>         ), or non-qualifiedstock options. We could grant incentive stock options only toemployees of the Company or any parent or subsidiary of theCompany. Awards other than incentive stock options could be grantedto employees, directors and consultants. A total of 10.0 millionshares of our common stock were authorized for issuance under the2016 Plan, of which options to purchase approximately 7.6 millionshares remain outstanding at March 31, 2021. Upon the adoption ofour 2019 Plan, no further grants were permissible under the 2016Plan and approximately 1.4 million authorized shares weretransferred to the 2019 Plan and became issuable therefrom. Alloptions granted from the 2016 Plan remain operative under the termsof the respective grants.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Description of the 2019 Plan        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         OurBoard approved the VistaGen Therapeutics, Inc. 2019 Omnibus EquityIncentive Plan on May 27, 2019, and our stockholders adopted it andratified all previously issued grants on September 5, 2019. Theprincipal features of the 2019 Plan are summarizedbelow.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          The 2019 Plan provides for the grant of stock options, stockappreciation rights (         </font>         <font style="font-style: italic; color: #000000">          SARs         </font>         <font style="color: #000000">          ), restricted stock, restricted stock units, andother stock-based awards, and performance awards, collectivelyreferred to as “Awards”. Awards may be granted underthe 2019 Plan to officers, employees and consultants of the Companyand our subsidiaries and to our non-employee directors. Incentivestock options may be granted only to employees of the Company orone of our subsidiaries. The 2019 Plan is administered by theCompensation Committee of the Board. The Compensation Committee, inits discretion, selects the individuals to whom awards may begranted, the time or times at which such awards are granted, andthe terms of such awards. The Compensation Committee may delegateits authority to the extent permitted by applicablelaw.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -111-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The Compensation Committee sets stock option exercise prices andterms, except that stock options must be granted with an exerciseprice not less than 100% of the fair market value of the commonstock on the date of grant. The Compensation Committee may granteither incentive stock options, which must comply with Section 422of the Code, or nonqualified stock options. At the time of grant,the Compensation Committee determines the terms and conditions ofstock options, including the quantity, exercise price, vestingperiods, term (which cannot exceed ten years) and other conditionson exercise.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The Compensation Committee may grant SARs as a right in tandem withthe number of shares underlying stock options granted under the2019 Plan or as a freestanding award. Upon exercise, SARs entitlethe holder to receive payment per share in stock or cash, or in acombination of stock and cash, equal to the excess of theshare’s fair market value on the date of exercise over thegrant price of the SAR.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The Compensation Committee may also grant awards of restrictedstock, which are shares of common stock subject to specifiedrestrictions, and restricted stock units, which represent the rightto receive shares of the common stock in the future. These awardsmay be made subject to repurchase, forfeiture or vestingrestrictions at the Compensation Committee’s discretion. Therestrictions may be based on continuous service with the Company orthe attainment of specified performance goals, as determined by theCompensation Committee. Stock units may be paid in stock or cash ora combination of stock and cash, as determined by the CompensationCommittee.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The Compensation Committee may condition the grant, exercise,vesting, or settlement of any award on such performance conditionsas it may specify. We refer to these awards as “performanceawards.” The Compensation Committee may select such businesscriteria or other performance measures as it may deem appropriatein establishing any performance conditions. At March 31, 2021, theCompensation Committee has not granted any performanceawards.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         A total of 7,500,000 shares of common stock were initiallyauthorized for issuance under the 2019 Plan. As noted previously,all awards outstanding under the 2016 Plan at the time the 2019Plan was adopted remain subject to the 2016 Plan. Upon approval ofthe 2019 Plan, all shares of common stock remaining authorized andavailable for issuance under the 2016 Plan, approximately 1.4million shares, automatically became available for issuance underthe 2019 Plan. Additionally, any shares subject to outstandingawards under the 2016 Plan that subsequently expire, terminate, orare surrendered or forfeited for any reason without issuance ofshares also become available for issuance under the 2019 Plan.Further, if any award under the 2019 Plan is canceled, terminates,expires or lapses for any reason prior to the issuance of shares orif shares are issued under the 2019 Plan and thereafter areforfeited to us, the shares subject to such awards and theforfeited shares will again be available for grant under the 2019Plan. At March 31, 2021, a total of 1,843,158 shares remainavailable for grant under the 2019 Plan.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         No more than 25% of any equity-based awards granted under the 2019Plan may vest on the grant date of such award. This requirementdoes not apply to (i) substitute awards resulting from acquisitionsor (ii) shares delivered in lieu of fully vested cash awards. Inaddition, the minimum vesting requirement does not apply to theCompensation Committee’s discretion to provide foraccelerated exercisability or vesting of any award, including incases of retirement, death, disability or a change in control, inthe terms of the award or otherwise. Awards are not transferableother than by will or the laws of descent and distribution, exceptthat in certain instances transfers may be made to or for thebenefit of designated family members of the participant for noconsideration.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In the event of a change in control of the Company, theCompensation Committee may accelerate the time period relating tothe exercise of any award.  In addition, the CompensationCommittee may take other action, including (a) providing for thepurchase of any award for an amount of cash or other property thatcould have been received upon the exercise of such award had theaward been currently exercisable, (b) adjusting the terms of theaward in a manner determined by the Compensation Committee toreflect the change in control, or (c) causing an award to beassumed, or new rights substituted therefor, by another entity withappropriate adjustments to be made regarding the number and kind ofshares and exercise prices of the award. “Change inControl” is defined under the 2019 Plan and requiresconsummation of the applicable transaction.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Unless earlier terminated by the Board, the 2019 Plan willterminate, and no further awards may be granted, on September 5,2029, which is ten years after the date on which it was approved byour stockholders. The Board may amend, suspend or terminate the2019 Plan at any time.         </font>         To the extent necessary to complywith applicable provisions of U.S. federal securities laws, statecorporate and securities laws, the Code, the rules of anyapplicable stock exchange or national market system, and the rulesof any non-U.S. jurisdiction applicable to Awards granted toresidents therein, we will obtain stockholder approval of any suchamendment to the 2019 Plan in such a manner and to such a degree asrequired.         <font style="color: #000000">          The amendment, suspension ortermination of the 2019 Plan or the amendment of an outstandingaward generally may not, without a participant’s consent,materially impair the participant’s rights under anoutstanding award.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         During our fiscal year ended March 31, 2021, we granted options topurchase an aggregate of 4,990,000 shares of our common stock fromthe 2019 Plan as follows:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 12px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           optionsto purchase an aggregate of 1,580,000 shares of our common stock ata price of $0.398 per share to independent members of our Board,our officers and employees and certain consultants and advisors inApril 2020. The options vested 25% upon grant with the remainingshares vesting ratably over two years;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -112-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 12px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           optionsto purchase an aggregate of 365,000 shares of our common stock atprices of between $0.42 and $0.55 per share to various investor andpublic relations and scientific consultants in May and June 2020.The options vested 25% upon grant with the remaining shares vestingratably monthly over one year;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 12px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           optionsto purchase an aggregate of 195,000 shares of our common stock atprices of between $0.62 and $0.73 per share to various investor andpublic relations and scientific consultants in August throughOctober 2020. Certain grants vested 25% upon grant with theremaining shares vesting ratably over one year or three years;other options vested monthly over a period of one year or twoyears;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 12px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           optionsto purchase 200,000 shares of our common stock at a price of$0.7889 per share to a new research and development employee inDecember 2020. The options vest 25% on the first anniversary of thegrant date with the remaining shares vesting ratably monthly overthe next 4 years;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 12px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           optionsto purchase an aggregate of 1,375,000 shares of our common stock ata price of $1.77 per share to independent members of our Board, ourofficers and employees in December 2020 following the December 2020Public Offering. The options vested 25% upon grant with theremaining shares vesting ratably over two years; and          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 12px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           optionsto purchase 1,275,000 shares of our common stock at prices from$1.99 to $2.55 per share to new employees during February and March2021. The options vest 25% on the first anniversary of the grantdate with the remaining shares vesting ratably monthly over thenext 3 years.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         During our fiscal year ended March 31, 2020, we granted options topurchase an aggregate of 3,455,000 shares of our common stock fromthe 2019 Plan and the 2016 Plan as follows:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 12px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           optionsfrom the 2016 Plan to purchase an aggregate of 1,220,000 shares ofour common stock at a then above-market exercise price of $1.00 pershare to the independent members of our Board, our officers andemployees and certain consultants in May 2019. The options vested25% upon grant with the remaining shares vesting ratably over threeyears for independent directors, officers and employees, and overtwo years for consultants;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 12px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           optionsfrom the 2019 Plan to one of our officers to purchase 170,000shares of our common stock at a then above-market exercise price of$1.00 per share, which May 2019 grant was contingent upon theapproval of the 2019 Plan by our stockholders. Our stockholdersapproved the 2019 Plan at our Annual Meeting in September 2019 andratified the contingent grant. The option vested 25% upon approvalof the 2019 Plan and the remaining shares are vesting ratably overthree years;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 12px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           optionsfrom our 2019 Plan to the independent members of our Board, ourofficers and employees and certain consultants to purchase anaggregate of 1,990,000 shares of our common stock at exerciseprices ranging from $0.50 per share to $1.41 per share during thequarter ended December 31, 2019. Options granted to Board members,officers, employees and most consultants were vested 25% at grant,with the remaining options vesting ratably over the following 24months. In the case of options granted to certain consultants, theoptions were vested 25% at grant but the remaining vesting periodwas less than 24 months to coincide with remaining contractualterms;          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 12px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="color: #000000; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           optionsfrom our 2019 Plan to purchase 75,000 shares of our common stock atan exercise price of $0.7074 per share to a consultant as partialcompensation under a professional services contract in January2020. The options were vested 25% upon grant with the remainingshares vesting ratably over the next twelve months.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The following table summarizes stock-based compensation expenserelated to option grants to our officers, independent directors,consultants and service providers included in the accompanyingConsolidated Statement of Operations and Comprehensive Loss for theyears ended March 31, 2021 and 2020.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align: bottom; width: 24%; white-space: nowrap;">            <div>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Fiscal Years Ended March 31,               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Researchand development expense             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              746,900             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,287,200             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 2px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Generaland administrative expense             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 2px;">             </font>             <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 2px solid rgb(0, 0, 0);">             </font>             <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 2px solid rgb(0, 0, 0);">              1,559,200             </font>             <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 2px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 2px;">             </font>             <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 2px solid rgb(0, 0, 0);">             </font>             <font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 2px solid rgb(0, 0, 0);">              2,533,600             </font>             <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 2px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Totalstock-based compensation expense             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              2,306,100             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              3,820,800             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -113-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Expense amounts reported above include $7,500 and $2,500 inresearch and development expense for the fiscal years ended March31, 2021 and 2020, respectively, and $6,800 and $1,500 in generaland administrative expense for the fiscal years ended March 31,2021 and 2020, respectively, attributable to our 2019 EmployeeStock Purchase Plan (the         </font>         <font style="font-style: italic; color: #000000">          2019 ESPP         </font>         <font style="color: #000000">          ), described below.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We used the Black-Scholes Option Pricing model with the followingweighted average assumptions to determine share-based compensationexpense related to option grants during the fiscal years endedMarch 31, 2021 and 2020:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Fiscal Years Ended March 31,               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;color:#000000;">                (weightedaverage)               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;color:#000000;">                (weightedaverage)               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Exerciseprice             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.27             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.14             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Marketprice on date of grant             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.27             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.05             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Risk-freeinterest rate             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.53             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.79             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Expectedterm (years)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              5.58             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              5.41             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Volatility             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              83.79             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              86.99             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Expecteddividend yield             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.00             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.00             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Fairvalue per share at grant date             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.87             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.73             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          The expected term of options represents the period that ourshare-based compensation awards are expected to be outstanding. Wehave calculated the weighted-average expected term of the optionsusing the simplified method as prescribed by Securities andExchange Commission Staff Accounting Bulletins No. 107 andNo. 110 (         </font>         <font style="font-style: italic; color: #000000">          SAB No. 107 and110         </font>         <font style="color: #000000">          ). The utilization of SABNo. 107 and 110 is based on the lack of relevant historical optionexercises and relevant historical data due to the relativelylimited period during which our stock has been publicly traded on amajor exchange and the historical lack of liquidity infreely-tradable shares of our common stock. Those factors alsoresulted in our decision to utilize the historical volatilities ofa peer group of public companies’ stock over the expectedterm of the option in determining our expected volatilityassumptions.  The risk-free interest rate for periodsrelated to the expected life of the options is based on theU.S. Treasury yield curve in effect at the time of grant. Theexpected dividend yield is zero, as we have not paid any dividendsand do not anticipate paying dividends in the near future. Werecognize the effect of forfeitures as theyoccur.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The following table summarizes stock option activity for the fiscalyears ended March 31, 2021 and 2020 under the 2019 Plan and the2016 Plan:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:52%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="4" rowspan="1" style="vertical-align:bottom;width:48%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:2%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:96%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font>               </font>               <font>                <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                 Fiscal Years Ended March 31,                </font>               </font>               <font>               </font>               <font>               </font>               <font>                <font style="font-size:13px;font-family:Times New Roman;">                </font>               </font>               <font>               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:2%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:52%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font>               </font>               <font>                <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                 2021                </font>               </font>               <font>               </font>               <font>               </font>               <font>                <font style="font-size:13px;font-family:Times New Roman;">                </font>               </font>               <font>               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td colspan="2" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font>               </font>               <font>                <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                 2020                </font>               </font>               <font>               </font>               <font>               </font>               <font>                <font style="font-size:13px;font-family:Times New Roman;">                </font>               </font>               <font>               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;color:#000000;">                Weighted               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;color:#000000;">                Weighted               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;color:#000000;">                Average               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;color:#000000;">                Average               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;color:#000000;">                Numberof               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;color:#000000;">                Exercise               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;color:#000000;">                Numberof               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;color:#000000;">                Exercise               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:52%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;color:#000000;">                Shares               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;color:#000000;">                Price               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;color:#000000;">                Shares               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;color:#000000;">                Price               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Optionsoutstanding at beginning of period             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              10,003,088             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.36             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              6,626,088             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.48             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Optionsgranted             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              4,990,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.27             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              3,455,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1.14             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Optionsexercised             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (355,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.89             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Optionsforfeited             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:24px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Optionsexpired             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px; padding-bottom: 2px;">              $             </font>             <font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px; padding-bottom: 2px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (78,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              1.50             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Optionsoutstanding at end of period             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              14,638,088             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px; padding-bottom: 4px;">              $             </font>             <font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px; padding-bottom: 4px;">              1.34             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              10,003,088             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              1.36             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Optionsexercisable at end of period             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              10,732,059             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px; padding-bottom: 4px;">              $             </font>             <font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px; padding-bottom: 4px;">              1.29             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              7,936,290             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              1.39             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Weightedaverage grant-date fair value of             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:24px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              optionsgranted during the period             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%; padding-bottom: 4px;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%; padding-bottom: 4px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              0.87             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%; padding-bottom: 4px;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%; padding-bottom: 4px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              0.73             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -114-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The following table summarizes information on stock optionsoutstanding and exercisable under the 2019 Plan and the 2016 Planas of March 31, 2021:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">             </font>            </div>           </td>           <td colspan="3" rowspan="1" style="vertical-align:bottom;width:36%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:3%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:94%;border-bottom:2px solid #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                OptionsOutstanding               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:3%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:2px solid #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                OptionsExercisable               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Weighted               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Average               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Weighted               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Weighted               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Remaining               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Average               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Average               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Exercise               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Number               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Yearsuntil               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Exercise               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Number               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Exercise               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Price               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Outstanding               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Expiration               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Price               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Exercisable               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                Price               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.398 to $0.89             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,590,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              9.12             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.48             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,574,795             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.45             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.90 to $1.18             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,240,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              7.42             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.09             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,871,049             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.10             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.19 to $1.46             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,500,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              8.13             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.36             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,155,468             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.35             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.47 to $1.63             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,177,253             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              5.85             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.52             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,177,253             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.52             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">              $             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">              1.64 to $15.00             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">              3,130,835             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">              9.40             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">              $             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">              2.14             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">              953,494             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">              $             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">              2.38             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:4px double #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:4px double #000000;">              14,638,088             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">              7.92             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">              $             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">              1.34             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:4px double #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:4px double #000000;">              10,732,059             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">              $             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">              1.29             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         At March 31, 2021, there were 1,843,158 registered shares of ourcommon stock remaining available for grant under the 2019Plan.  Two members of our Board and certain consultantsexercised options to purchase an aggregate of 355,000 shares of ourcommon stock during the fiscal year ended March 31, 2021. Therewere no option exercises during the fiscal year ended March 31,2020.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Aggregate intrinsic value is the sum of the amount by which thefair value of the underlying common stock exceeds the aggregateexercise price of the outstanding options (         </font>         <font style="font-style: italic; color: #000000">          in-the-money-options         </font>         <font style="color: #000000">          ).Based on the $2.13 per share quoted closing market price of ourcommon stock on March 31, 2021, there was approximately $12,205,000of intrinsic value in our outstanding options at thatdate.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         As of March 31, 2021, there was approximately $3,852,300 ofunrecognized compensation cost related to non-vested share-basedcompensation awards from the 2019 Plan and the 2016 Plan, whichcost is expected to be recognized through November2023.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         2019 Employee Stock Purchase Plan        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our Board approved the VistaGen Therapeutics, Inc. 2019 EmployeeStock Purchase Plan (the 2019 ESPP) on June 13, 2019. Ourstockholders approved the 2019 ESPP at our annual meeting onSeptember 5, 2019. The principal terms of our 2019 ESPP aresummarized below.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The 2019 ESPP is intended to qualify as an “employee stockpurchase plan” under Section 423 of the Code. TheCompensation Committee of the Board administers the 2019 ESPP. TheCompensation Committee has authority to construe, interpret andapply the terms of the 2019 ESPP. As approved by our stockholders,a maximum of 1,000,000 shares of our common stock may be purchasedunder the 2019 ESPP.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The 2019 ESPP is generally expected to operate in consecutivesemi-annual periods referred to as “option periods.”The first option period commenced on January 1, 2020 and ended onthe last trading day in the semi-annual period ended June 30, 2020,with successive option periods expected to begin on the first dayof January and July and to terminate on the last trading day ofJune and December, respectively. Option periods may not last longerthan the maximum period permitted under Section 423 of theCode, which generally limits the length of such offerings to either5 years or 27 months, depending on the terms of the offering.Generally, all full-time employees of the Company and itssubsidiaries are eligible to participate in an optionperiod.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          On the first day of each option period (the         </font>         <font style="font-style: italic; color: #000000">          Grant Date         </font>         <font style="color: #000000">          ), each eligible employee for that option periodwill be granted an option to purchase shares of our common stock.Each participant’s option will permit the participant topurchase a number of shares determined by dividing theemployee’s accumulated payroll deductions for the optionperiod by the applicable purchase price. A participant mustdesignate the percentage (if any) of compensation to be deductedduring that option period for the purchase of stock under the 2019ESPP. The participant’s payroll deduction election willgenerally remain in effect for future option periods unlessterminated by the participant. A participant may elect to withdrawfrom any option period prior to the last day of the option period,in which case the participant’s payroll deductions will berefunded and the participant’s outstanding options willterminate.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Each participant’s payroll deductions under the 2019 ESPPwill be credited to a liability account in his or her name underthe 2019 ESPP. The aggregate liability for participant payrolldeductions at March 31, 2021 and 2020 was $18,600 and $14,700,respectively, which amounts are included in accrued expenses in theaccompanying Consolidated Balance Sheet at thosedates.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -115-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Each option granted under the 2019 ESPP will automatically beexercised on the last day of the respective option period (referredto as the         </font>         <font style="font-style: italic; color: #000000">          ExerciseDate         </font>         <font style="color: #000000">          ). The number of sharesacquired by a participant upon exercise of his or her option willbe determined by dividing the participant’s 2019 ESPP accountbalance as of the Exercise Date for the option period by thepurchase price of the option. The purchase price for each option isgenerally equal to the lesser of (i) 85% of the fair marketvalue of a share of our common stock on the applicable Grant Date,or (ii) 85% of the fair market value of a share of our commonstock on the applicable Exercise Date. A participant’s 2019ESPP account will be reduced upon exercise of his or her option bythe amount used to pay the purchase price of the shares acquired bythe participant. Following exercise of the option, any excessamount in a participant’s account will be refunded followingthe Exercise Date. No interest will be paid to any participantunder the 2019 ESPP.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Participation in the 2019 ESPP is subject to the followinglimits:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr style="background-color: #ffffff">           <td style="vertical-align: middle; width: 4%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 3%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: top; width: 93%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              A participant cannot contribute less than 1% or more than 15% ofhis or her compensation to the purchase of stock under the 2019ESPP in any one payroll period;             </font>            </div>           </td>          </tr>          <tr style="background-color: #ffffff">           <td style="vertical-align: middle; width: 4%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 3%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: top; width: 93%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              A participant cannot accrue rights to purchase more than $25,000 ofstock (valued at the Grant Date of the applicable offering periodand without giving effect to any discount reflected in the purchaseprice for the stock) for each calendar year in which an option isoutstanding; and             </font>            </div>           </td>          </tr>          <tr style="background-color: #ffffff">           <td style="vertical-align: middle; width: 4%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 3%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              ●             </font>            </div>           </td>           <td style="vertical-align: top; width: 93%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              A participant will not be granted an option under the 2019 ESPP ifit would cause the participant to own stock and/or hold outstandingoptions to purchase common stock constituting 5.0% or more of thetotal combined voting power or value of all classes of stock of theCompany or of one of its subsidiaries or to the extent it wouldexceed certain other limits under the Code.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The $25,000 annual purchase and the 5% ownership limitationsreferred to above are required under the Code.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         As is customary, the number of shares of stock available under the2019 ESPP or subject to outstanding options, is subject toadjustment in the event of certain reorganizations, combinations,recapitalization of shares, stock splits, reverse stock split,subdivision or other similar change in respect of our common stock.A participant’s rights with respect to options or thepurchase of shares under the 2019 ESPP, as well as payrolldeductions credited to his or her 2019 ESPP account, may not beassigned, transferred, pledged or otherwise disposed of in any wayexcept by will or the laws of descent anddistribution.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The Board generally may amend, suspend, or terminate the 2019 ESPPat any time and in any manner, except that stockholder approval isrequired to increase the number of shares authorized for issuanceunder the 2019 ESPP and for certain other amendments. No amendmentto the 2019 ESPP may materially adversely affect the option rightspreviously granted to a participant under the 2019 ESPP, except asrequired by law or regulation.        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our 2019 ESPP became effective on January 1, 2020 and will continuein effect until the earlier of such time as all of the shares ofthe Company’s common stock subject to the 2019 ESPP have beensold or December 31, 2030, unless terminated earlier by the Board.During the fiscal year ended March 31, 2021, employees purchased anaggregate of 58,125 shares of common stock under the 2019 ESPP andthe Company received proceeds of $26,200.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         401(k) Plan        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Through a third-party agent, we maintain a retirement and deferredsavings plan for our employees. This plan is intended to qualify asa tax-qualified plan under Section 401(k) of the InternalRevenue Code. The retirement and deferred savings plan providesthat each participant may contribute a portion of his or herpre-tax compensation, subject to statutory limits. Under the plan,each employee is fully vested in his or her deferred salarycontributions. Employee contributions are held and invested by theplan’s trustee. The retirement and deferred savings plan alsopermits us to make discretionary contributions, subject toestablished limits and a vesting schedule. To date, we have notmade any discretionary contributions to the retirement and deferredsavings plan on behalf of participating employees.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         14.  Related Party Transactions        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Consulting Agreement        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We havewe engaged a consulting firm headed by one of the independentmembers of our Board to provide various market research studies,competitive analyses, and commercial advisory projects for certainof our CNS pipeline candidates pursuant to which we recordedexpense of $193,000 and $108,400 for the fiscal years ended March31, 2021 and 2020, respectively. We recorded no accounts payable oraccrued expenses related to such services at March 31, 2021 or2020.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         15.  Commitments, Contingencies, Guarantees andIndemnifications        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Fromtime to time, we may become involved in claims and other legalmatters arising in the ordinary course of business. Management isnot currently aware of any claims made or other legal matters thatwill have a material adverse effect on our consolidated financialposition, results of operations or our cash flows.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -116-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Weindemnify our officers and directors for certain events oroccurrences while the officer or director is or was serving at ourrequest in such capacity. The term of the indemnification period isfor the officer’s or director’s lifetime. We willindemnify the officers or directors against any and all expensesincurred by the officers or directors because of their status asone of our directors or executive officers to the fullest extentpermitted by Nevada law. We have never incurred costs to defendlawsuits or settle claims related to these indemnificationagreements.  We have a director and officer insurance policywhich limits our exposure and may enable us to recover a portion ofany future amounts paid.  We believe the fair value of theseindemnification agreements is minimal. Accordingly, there are noliabilities recorded for these agreements at March 31, 2021 or2020.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In thenormal course of business, we provide indemnifications of varyingscopes under agreements with other companies, typically clinicalresearch organizations, investigators, clinical sites, suppliersand others.  Pursuant to these agreements, we generallyindemnify, hold harmless, and agree to reimburse the indemnifiedparties for losses suffered or incurred by the indemnified partiesin connection with the use or testing of our product candidates orwith any U.S. patents or any copyright or other intellectualproperty infringement claims by any third party with respect to ourproduct candidates.  The terms of these indemnificationagreements are generally perpetual.  The potential futurepayments we could be required to make under theseindemnification agreements is unlimited.  We maintainliability insurance coverage that limits our exposure.  Webelieve the fair value of these indemnification agreements isminimal.  Accordingly, we have not recorded any liabilitiesfor these agreements at March 31, 2021 or 2020.        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Leases        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Financing Lease        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         At March 31, 2021 and 2020, the following assets are subject tofinancing lease obligations and included in property andequipment:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                March31,               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                March31,               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Office equipmentsubject to financing lease             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              14,700             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              14,700             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accumulateddepreciation             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (12,400             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (9,400             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net book value ofoffice equipment subject to             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              financinglease             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              2,300             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              5,300             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Amortization expense for assets recorded under financing leases isincluded in depreciation expense.  Future minimum payments, byyear and in the aggregate, required under our financing lease areas follows:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td colspan="1" rowspan="1" style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              FiscalYear Ending March 31,             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              2022             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              3,200             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Futureminimum lease payments             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              3,200             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Lessimputed interest included in minimum lease payments             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (200             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Presentvalue of minimum lease payments             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              3,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Lesscurrent portion             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (3,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Financinglease obligation - non-current portion             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Operating Lease        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We lease our headquarters office and laboratory space in South SanFrancisco, California under the terms of a lease that expires onJuly 31, 2022 and that provides an option to renew for anadditional five years at then-current market rates. Consistent withthe guidance in ASC 842, effective beginning April 1, 2019, we haverecorded this lease in our Consolidated Balance Sheet as anoperating lease. For the purpose of determining the right-of-useasset and associated lease liability, upon our adoption of ASC 842,we determined that the renewal of this lease was reasonablyprobable. The lease of our South San Francisco facilities doesnot include any restrictions or covenants requiring specialtreatment under ASC 842.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -117-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The following table summarizes the presentation of the operatinglease in our Condensed Consolidated Balance Sheet at March 31, 2021and 2020:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                As of March 31, 2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                As of March 31, 2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">              Assets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:24px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Rightof use asset – operating lease             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              3,219,600             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              3,579,600             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">              Liabilities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Currentoperating lease obligation             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              364,800             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              313,400             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:24px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Non-currentoperating lease obligation             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              3,350,800             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              3,715,600             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Totaloperating lease liability             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              3,715,600             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              4,029,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The following table summarizes the effect of operating lease costsin our consolidated statements of operations:        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                For the Fiscal Year Ended               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                For the Fiscal Year Ended               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                March 31, 2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                March 31, 2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Operatinglease cost             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;display:inline-block;width:10%;font-family:Times New Roman;color:#000000;">             </font>             <font style="text-align: left; vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;color:#000000;">              $             </font>             <font style="text-align: right; vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;color:#000000;">              838,200             </font>             <font style="text-align: left; vertical-align:bottom;display:inline-block;width:10%;font-family:Times New Roman;color:#000000;">             </font>            </div>           </td>           <td colspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              822,300             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 36px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The minimum (base rental) lease payments related to our South SanFrancisco operating lease are expected to be asfollows:        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:88%;">            <div style="border-bottom: 2px solid rgb(0, 0, 0);">             <div>              <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">               <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">                Fiscal Years Ending March 31,               </font>              </div>             </div>            </div>           </td>           <td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              2022             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              668,400             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              2023             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              726,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              2024             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              766,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              2025             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              789,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              2026             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>             <font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">             </font>             <font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">              812,700             </font>             <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Thereafter             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              1,118,700             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Totallease expense             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              4,880,800             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Lessimputed interest             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (1,165,200             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:24px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Presentvalue of operating lease liabilities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              3,715,600             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The remaining lease term, including the assumed five-year extensionat the expiration of the current lease period, and the discountrate assumption for our South San Francisco operating lease is asfollows:        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr style="background-color: #ffffff">           <td style="vertical-align: bottom; width: 60%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 36%; border-bottom: 2px solid #000000">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">              As of March 31, 2021             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: #cff0fc">           <td style="vertical-align: top; width: 60%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Assumed remaining lease term in years             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 36%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              6.33             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: #ffffff">           <td style="vertical-align: top; width: 60%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Assumed discount rate             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 36%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              8.54%             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 1%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The interest rate implicit in lease contracts is typically notreadily determinable and, as such, we used our estimatedincremental borrowing rate based on information available at theadoption of ASC 842, which represents an internally developed ratethat would be incurred to borrow, on a collateralized basis, over asimilar term, an amount equal to the lease payments in a similareconomic environment.        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Supplemental disclosure of cash flow information related to ouroperating leases included in cash flows used by operatingactivities in the consolidated statements of cash flows is asfollows:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                For the Fiscal Year Ended               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                For the Fiscal Year Ended               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                March 31, 2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                March 31, 2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:-36px;margin-right:0px;padding-bottom:4px;margin-left:36px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Cashpaid for amounts included in the measurement of leaseliabilities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px;">             </font>             <font style="text-align: left; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">              $             </font>             <font style="text-align: right; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">              791,600             </font>             <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px;">             </font>            </div>           </td>           <td colspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px;">             </font>             <font style="text-align: left; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">              $             </font>             <font style="text-align: right; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">              753,900             </font>             <font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         During the fiscal years end March 31, 2021 and 2020, other than theApril 1, 2019 initial adoption of ASC 842 that required right ofuse assets and lease liabilities to be recorded, we recorded no newright of use assets arising from new leaseliabilities.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We also lease a small office in the San Francisco Bay Area under amonth-to-month arrangement at insignificant cost and have made anaccounting policy election not to apply the ASC 842 operating leaserecognition requirements to such short-term lease. We recognize thelease payments for this lease in general and administrative expenseover the lease term. We recorded rent expense of $14,200 and$14,000 for the fiscal years ended March 31, 2021 and 2020,respectively, attributable to this lease.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         16.  Subsequent Events        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         We have evaluated subsequent events through the date of this AnnualReport and have identified the following material events andtransactions that occurred after March 31, 2021:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -118-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">           VISTAGEN THERAPEUTICS, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Conversion of Series D Preferred Stock        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         From April 5, 2021 to April 22,2021, holders of an aggregate of402,149 shares of our Series D Preferred converted such shares into9,249,427 shares of our registered common stock, following which noshares of Series D Preferred remained outstanding.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Exercise of Warrants        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="background-color: #ffffff">         <font style="font-family: Times New Roman; font-size: 13px">          From April 1, 2021through the date of this Annual Report,          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           holdersof outstanding warrants have exercised warrants to purchase anaggregate of          </font>          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           1,508,768          </font>          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           sharesof our common stock and we have received cash proceeds ofapproximately $1,105,700          </font>          <font style="color: #000000">           . OnMay 16, 2021, warrants to purchase 2,705,883 shares of our commonstock at $5.30 per share expiredunexercised.          </font>         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Grant of Options from 2019 Plan        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         FromApril 1, 2021 through the date of this Annual Report, we grantedoptions to purchase 575,000 shares of our common stock under theterms of our 2019 Plan to three newly-hired executives and a newindependent member of our Board. The options have an exercise priceequal to the quoted closing market price of our common stock on theNasdaq Capital Market on the respective date of grant, a term often years and vest 25% on the first anniversary of the grant dateand ratably on a monthly basis for three yearsthereafter.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Termination of LPC Agreement        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         On June25, 2021, in accordance with its provisions, we voluntarilyterminated the LPC Agreement and we will sell no additional sharesof our common stock under that agreement.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         17. Supplemental Financial Information (Unaudited)        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The following table presents the unaudited statements of operationsdata for each of the eight quarters in the period ended March 31,2021. The information has been presented on the same basis as theaudited financial statements and all necessary adjustments,consisting only of normal recurring adjustments, have been includedin the amounts below to present fairly the unaudited quarterlyresults when read in conjunction with the audited financialstatements and related notes. The operating results for any quartershould not be relied upon as necessarily indicative of results forany future period.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Quarterly Results of Operations (Unaudited)        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         (in thousands, except share and per shareamounts)        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:40%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="4" rowspan="1" style="vertical-align:bottom;width:48%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:2%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:96%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Three Months Ended               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:2%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Total               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:40%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                June 30,               </font>              </div>              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                September 30,               </font>              </div>              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                December 31,               </font>              </div>              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                March 31,               </font>              </div>              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Fiscal Year               </font>              </div>              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:40%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Sublicenserevenue             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              334             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              314             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              442             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              1,090             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Totalrevenue             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              334             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              314             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              442             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              1,090             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Operatingexpenses:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Research anddevelopment             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,731             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              2,358             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              3,496             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              4,891             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              12,476             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              General andadministrative             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              1,391             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              1,270             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              2,117             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              1,770             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              6,548             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Totaloperating expenses             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              3,122             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              3,628             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              5,613             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              6,661             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              19,024             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Loss fromoperations             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (3,122             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (3,294             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (5,299             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (6,219             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (17,934             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Other income(expense), net:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Interestincome (expense), net             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (3             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (4             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              8             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              2             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Otherincome             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              1             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              1             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Loss before incometaxes             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (3,124             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (3,298             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (5,298             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (6,211             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (17,931             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Incometaxes             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (3             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (3             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net loss andcomprehensive loss             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (3,127             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (3,298             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (5,298             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (6,211             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (17,934             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accrueddividend on Series B Preferred stock             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (336             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (347             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (354             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (349             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (1,386             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Beneficialconversion feature on Series D             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Preferredstock             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (23,000             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (23,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Netloss attributable to common stockholders             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (3,463             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (3,645             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (5,652             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (29,560             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (42,320             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Basic and dilutednet loss per common share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              attributableto common stockholders             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (0.07             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (0.05             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (0.07             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (0.20             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (0.49             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Weighted averageshares used in computing             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              basic anddiluted net loss per common share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              attributableto common stockholders             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              51,321,355             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              67,082,935             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              81,086,105             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              145,966,502             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              86,133,644             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="null">        <font>        </font>       </div>       <div style="null">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="null">        <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        </div>        <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">         <div id="ftr">          <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">           <font style="font-family: Times New Roman; font-size: 13px">           </font>          </div>          <div id="pn" style="text-align: center">           <font style="font-family: Times New Roman; font-size: 13px">            -119-           </font>          </div>         </div>         <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         </div>         <div id="hdr">          <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">           <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">            VISTAGEN THERAPEUTICS, INC.           </font>          </div>          <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">           <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS           </font>          </div>          <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">           <font style="font-family: Times New Roman; font-size: 13px">           </font>          </div>         </div>        </div>        <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          <br/>         </font>        </div>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:40%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="4" rowspan="1" style="vertical-align:bottom;width:48%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:2%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:96%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Three Months Ended               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:2%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Total               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:40%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                June 30,               </font>              </div>              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2019               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                September 30,               </font>              </div>              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2019               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                December 31,               </font>              </div>              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2019               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                March 31,               </font>              </div>              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                Fiscal Year               </font>              </div>              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:40%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Operatingexpenses:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Research anddevelopment             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              4,314             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              4,205             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              3,015             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,840             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              13,374             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              General andadministrative             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              1,910             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              1,146             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              2,948             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              1,423             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              7,427             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Totaloperating expenses             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              6,224             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              5,351             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              5,963             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              3,263             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              20,801             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Loss fromoperations             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (6,224             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (5,351             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (5,963             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (3,263             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (20,801             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:40%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Other expenses,net:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Interestincome (expense), net             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              16             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              15             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              2             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (3             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              30             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:40%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Loss before incometaxes             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (6,208             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (5,336             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (5,961             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (3,266             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (20,771             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Incometaxes             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (2             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (1             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (3             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net loss andcomprehensive loss             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (6,210             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (5,336             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (5,961             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (3,267             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (20,774             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:40%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accrueddividend on Series B Preferred stock             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (302             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (314             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (322             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (326             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (1,264             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Netloss attributable to common stockholders             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (6,512             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (5,650             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (6,283             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (3,593             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (22,038             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:40%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Basic and dilutednet loss per common share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              attributableto common stockholders             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (0.15             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (0.13             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (0.15             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (0.08             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (0.50             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Weighted averageshares used in computing             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#CCEEFF;">           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              basic anddiluted net loss per common share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              attributableto common stockholders             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              42,622,965             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              42,622,965             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              43,158,889             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              47,094,781             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              43,869,523             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -120-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Item 9.         <a name="Chan">          C         </a>         hanges in andDisagreements With Accountants on Accounting and FinancialDisclosure        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         None.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Item 9A.         <a name="Cont">          C         </a>         ontrols andProcedures        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Disclosure Controls and Procedures.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Asrequired by Rule 13a-15(b) under the Securities Exchange Act of1934, as amended, (the         <font style="font-style: italic">          ExchangeAct         </font>         ) our Chief Executive Officer (         <font style="font-style: italic">          CEO         </font>         ) and our Chief Financial Officer(         <font style="font-style: italic">          CFO         </font>         ) conducted anevaluation as of the end of the period covered by this AnnualReport on Form 10-K, of the effectiveness of our disclosurecontrols and procedures as defined in Rules 13a-15(e) and 15d-15(e)under the Exchange Act. Based on that evaluation, our CEO and ourCFO each concluded that our disclosure controls and procedures areeffective to provide reasonable assurance that information requiredto be disclosed in the reports that we file or submit under theExchange Act, (i) is recorded, processed, summarized and reportedwithin the time periods specified in the Securities and ExchangeCommission's rules and forms and (ii) is accumulated andcommunicated to our management, including our CEO and our CFO, asappropriate to allow timely decisions regarding requireddisclosure.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Management's Report on Internal Control Over FinancialReporting.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourmanagement is responsible for establishing and maintaining adequateinternal control over financial reporting, as such term is definedin Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal controlsystem is designed to provide reasonable assurance to ourmanagement and Board of Directors regarding the reliability offinancial reporting and the preparation and fair presentation offinancial statements for external purposes in accordance with U.S.generally accepted accounting principles.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Becauseof its inherent limitations, internal control over financialreporting may not prevent or detect misstatements. Therefore, eventhose systems determined to be effective can provide onlyreasonable assurance of achieving their control objectives. Smallerreporting companies may face additional limitations in achievingcontrol objectives. Smaller reporting companies typically employfewer individuals who are often tasked with a wide range ofresponsibilities, making it difficult to segregate duties. Often,one or two individuals control many, or all, aspects of the smallerreporting company’s general and financial operations, placingsuch individual(s) in a position to override any system of internalcontrol. Additionally, projections of an evaluation of currenteffectiveness to future periods are subject to the risk thatcontrols may become inadequate because of changes in conditions, orthat the degree of compliance with the controls maydeteriorate.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Managementhas assessed the effectiveness of our internal control overfinancial reporting for our fiscal year ended March 31, 2021.Management's assessment was based on criteria set forth in         <font style="font-style: italic">          Internal Control - IntegratedFramework (2013)         </font>         , issued by the Committee of SponsoringOrganizations of the Treadway Commission (         <font style="font-style: italic">          COSO         </font>         ). Based upon this assessment,management concluded that, as of March 31, 2021, our internalcontrol over financial reporting was not effective, based uponthose criteria, as a result of the material weaknesses identifiedbelow.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Amaterial weakness is a deficiency or combination of deficiencies ininternal control over financial reporting, such that there is areasonable possibility that a material misstatement of the annualor interim financial statements will not be prevented or detectedon a timely basis.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Specifically,management identified the following control weaknesses existingduring our fiscal year ended March 31, 2021: (i) the size of theCompany’s staff did not permit appropriate segregation ofduties to (a) permit appropriate review of accounting transactionsand/or accounting treatment by multiple qualified individuals, and(b)         <font style="color: #FF0000">         </font>         prevent one individualfrom overriding the internal control system by initiating,authorizing and completing all transactions; and (ii) the Companyutilized accounting software that did not prevent erroneous orunauthorized changes to previous reporting periods and/or could beadjusted so as to not provide an adequate audit trail of entriesmade in the accounting software.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Beginning in April 2021, we have begun to address these materialweaknesses by retaining additional accounting staff to facilitateappropriate review of accounting transactions and/or accountingtreatment by multiple qualified individuals and by implementingstate-of-the-art accounting software to prevent erroneous orunauthorized changes to previous reporting periods and/oradjustments and to provide an adequate auditing trail of entriesmade in the accounting software.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheCompany does not believe that these control weaknesses haveresulted in any deficient financial reporting because each of ourCEO and CFO is aware of his responsibilities under the SEC'sreporting requirements and personally certifies our financialreports. Further, the Company had implemented a series of manualchecks and balances to verify that no previous reporting period hadbeen improperly modified and that no unauthorized entries had beenmade in the current reporting period.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Accordingly,while the Company has identified certain material weaknesses in itssystem of internal control over financial reporting during itsfiscal year ended March 31, 2021, it believes that it has takenreasonable and sufficient steps to ascertain that the financialinformation contained in this Annual Report is in accordance withU.S. generally accepted accounting principles.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         As a result of the enactment of the Dodd-Frank Wall Street Reformand Consumer Protection Act of 2010, and the resulting amendment ofSection 404 of the Sarbanes-Oxley Act of 2002, as a smallerreporting company, we are not required to provide an attestationreport by our independent registered public accounting firmregarding internal control over financial reporting for our fiscalyear ended March 31, 2021 or thereafter, until such time as we areno longer eligible for the exemption for smaller issuers set forthwithin the Sarbanes-Oxley Act.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Item 9B.         <a name="Oth">          O         </a>         therInformation        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Termination of LPC Agreement        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         On June25, 2021, in accordance with its provisions, the Companyvoluntarily terminated the Purchase Agreement dated March 24, 2020between the Company and LPC Capital Fund, LLC prior to its March2022 contractual expiration and will sell no additional shares ofits common stock under such agreement.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Change in Board of Directors Membership        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         On June24, 2021, Dr. H. Ralph Snodgrass notified the Company’s Boardof Directors of his intention to step down from his position as amember of the Company’s Board of Directors, effective June30, 2021. Dr. Snodgrass will continue to serve as theCompany’s President and Chief ScientificOfficer.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -121-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         PART III        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Item 10.         <a name="Dir">          D         </a>         irectors, Executive Officersand Corporate Governance        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theinformation required by this Item is incorporated herein byreference to the information that will be contained in our proxystatement related to the 2021 Annual Meeting of Stockholders, whichwe intend to file with the Securities and Exchange Commission on orbefore July 29, 2021 pursuant to General Instruction G(3) of Form10-K.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Item 11.         <a name="Exe">          E         </a>         xecutiveCompensation        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theinformation required by this Item is incorporated herein byreference to the information that will be contained in our proxystatement related to the 2021 Annual Meeting of Stockholders, whichwe intend to file with the Securities and Exchange Commission on orbefore July 29, 2021 pursuant to General Instruction G(3) of Form10-K.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Item 12.         <a name="Sec">          S         </a>         ecurity Ownership of CertainBeneficial Owners and Management and Related StockholderMatters        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theinformation required by this Item is incorporated herein byreference to the information that will be contained in our proxystatement related to the 2021 Annual Meeting of Stockholders, whichwe intend to file with the Securities and Exchange Commission on orbefore July 29, 2021 pursuant to General Instruction G(3) of Form10-K.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Item 13.         <a name="Cer">          C         </a>         ertain Relationships andRelated Transactions, and Director Independence        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theinformation required by this Item is incorporated herein byreference to the information that will be contained in our proxystatement related to the 2021 Annual Meeting of Stockholders, whichwe intend to file with the Securities and Exchange Commission on orbefore July 29, 2021 pursuant to General Instruction G(3) of Form10-K.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Item 14.         <a name="Prin">          P         </a>         rincipal Accounting Fees andServices        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theinformation required by this Item is incorporated herein byreference to the information that will be contained in our proxystatement related to the 2021 Annual Meeting of Stockholders, whichwe intend to file with the Securities and Exchange Commission on orbefore July 29, 2021 pursuant to General Instruction G(3) of Form10-K.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -122-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         PART IV        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         Item 15.         <a name="Exh">          E         </a>         xhibits, FinancialStatement Schedules        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         (a)(1) Financial Statements        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="background-color: #ffffff">         <font style="font-family: Times New Roman; font-size: 13px">          <font style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);">           SeeIndex to Financial Statements under Item 8 onpage 82          </font>          <font style="color: #000000">           .          </font>         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         (a)(2) Consolidated Financial Statement Schedules        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Consolidated financial statement schedules are omitted because theyare not applicable or are not required or the information requiredto be set forth therein is included in the Consolidated FinancialStatements or notes thereto.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         (a)(3) Exhibits        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The exhibits listed in the Exhibit Index below are filed orincorporated by reference as part of this report.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         <a name="Exhi">          E         </a>         xhibit Index        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 11%; border-bottom: 2px solid rgb(0, 0, 0);">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              ExhibitNo.             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%; border-bottom: 2px solid rgb(0, 0, 0);">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Description             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px;">              <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495421005701/ex1-1.htm">               1.1              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              OpenMarket Sale Agreement              <font style="font-size: 70%; vertical-align: top;">               SM              </font>              , dated May 14,2021, by and between VistaGen Therapeutics, Inc. and Jefferies LLC,incorporated by reference from Exhibit 1.1 to the Company’sCurrent Report on Form 8-K filed on May 14, 2021.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588911000362/ex2-1.htm">              <font style="font-family: Times New Roman; font-size: 13px">               <font style="font-size: 13px;">                2.1               </font>               <font style="font-size: 16px;">                *               </font>              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Agreementand Plan of Merger by and among Excaliber Enterprises, Ltd.,VistaGen Therapeutics, Inc. and Excaliber Merger Subsidiary,Inc.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman;">              <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588911000445/exhibit3-1.htm">               3.4              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Articlesof Merger filed with the Nevada Secretary of State on May 24, 2011,incorporated by reference from Exhibit 3.1 to the Company’sCurrent Report on Form 8-K filed on May 31, 2011.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman;">              <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588911000445/exhibit3-1.htm">               3.5              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Certificateof Designations Series A Preferred, incorporated by reference fromExhibit 3.1 to the Company’s Current Report on Form 8-Kfiled on December 23, 2011.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman;">              <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588914002464/ex3-1.htm">               3.6              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Certificateof Change filed with the Nevada Secretary of State on August 11,2014 incorporated by reference from Exhibit 3.1 to theCompany’s Current Report on Form 8-K filed on August 14,2014.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman;">              <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588915001677/ex3-1.htm">               3.7              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Certificateof Designation of the Relative Rights and Preferences of the SeriesB 10% Convertible Preferred Stock of VistaGen Therapeutics, Inc.,filed with the Nevada Secretary of State on May 7, 2015,incorporated by reference from Exhibit 3.1 to theCompany’s Current Report on Form 8-K filed on May 13,2015.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman;">              <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588916004564/ex3-01292016_020121.htm">               3.9              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Certificateof Designation of the Relative Rights and Preferences of the SeriesC Convertible Preferred Stock of VistaGen Therapeutics, Inc., datedJanuary 25, 2016, incorporated by reference from Exhibit 3.1 to theCompany’s Current Report on Form 8-K filed on January 29,2016.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman;">              <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588916006879/ex3-1.htm">               3.10              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              RestatedArticles of Incorporation of VistaGen Therapeutics, Inc., datedAugust 16, 2016, incorporated by reference from Exhibit 3.1 to theCompany’s Current Report on Form 8-K, filed on August 17,2016.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 13px; font-family: Times New Roman;">              <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588916006879/ex3-2.htm">               3.11              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              SecondAmended and Restated Bylaws of VistaGen Therapeutics, Inc., datedAugust 16, 2016, incorporated by reference from Exhibit 3.2 to theCompany’s Current Report on Form 8-K, filed on August 16,2016.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px;">              <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495417008632/ex3-1.htm">               <font style="font-size: 13px;">                3.12               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Certificateof Amendment to the Restated and Amended Articles of Incorporationof VistaGen Therapeutics, Inc., dated September 15, 2017;incorporated by reference from Exhibit 3.1 to the Company’sCurrent Report on Form 8-K, filed on September 20,2017.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px;">              <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495419010432/ex3-1.htm">               3.13              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Certificateof Amendment to the Restated and Amended Articles of Incorporation,as amended, of VistaGen Therapeutics, Inc., dated September 6,2019; incorporated by reference from Exhibit 3.1 to theCompany’s Current Report on Form 8-K, filed on September 6,2019.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px;">              <a href="http://www.sec.gov/Archives/edgar/data/0001411685/000165495420013839/ex3-1.htm">               3.14              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px;">              Certificateof Designation of the Relative Rights and Preferences of the SeriesD Convertible Preferred Stock of VistaGen Therapeutics, Inc., filedwith the Nevada Secretary of State on December 21, 2020,incorporated by reference from Exhibit 3.1 to the Company’sCurrent Report on Form 8-K filed on December 22, 2020.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/0001411685/000165495421002420/ex3-1.htm">              <font style="font-family: Times New Roman; font-size: 13px;">               3.15              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Certificateof Amendment to the Restated and Amended Articles of Incorporation,as amended, of VistaGen Therapeutics, Inc., dated March 5, 2021,incorporated by reference from Exhibit 3.1 to the Company’sCurrent Report on Form 8-K, filed on March 5, 2021.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588911000362/ex10-22.htm">              <font style="font-family: Times New Roman; font-size: 13px">               <font style="font-size: 13px;">                10.22*               </font>              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              LicenseAgreement by and between Mount Sinai School of Medicine of New YorkUniversity and the Company, dated October 1, 2004.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588911000362/ex10-26.htm">              <font style="font-family: Times New Roman; font-size: 13px">               <font style="font-size: 13px;">                10.26*               </font>              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              LicenseAgreement, dated October 24, 2001, by and between the University ofMaryland, Baltimore, Cornell Research Foundation and ArtemisNeuroscience, Inc.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588911000362/ex10-40.htm">              <font style="font-family: Times New Roman; font-size: 13px">               <font style="font-size: 13px;">                10.40*               </font>              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              EmploymentAgreement, by and between, VistaGen and Shawn K. Singh, dated April28, 2010, as amended May 9, 2011.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -123-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588911000362/ex10-41.htm">              <font style="font-family: Times New Roman; font-size: 13px">               <font style="font-size: 13px;">                10.41               </font>               <font style="font-size: 13px">                *               </font>              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              EmploymentAgreement, by and between, VistaGen and H. Ralph Snodgrass, PhD,dated April 28, 2010, as amended May 9, 2011.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588911001342/ex10-11302011_101124.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.49              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              LicenseAgreement No. 1, dated as of October 24, 2011 between UniversityHealth Network and VistaGen Therapeutics, Inc., incorporated byreference from Exhibit 10.1 to the Company’s Current Reporton Form 8-K filed on November 30, 2011.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588912000973/ex10-57.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.57              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              LicenseAgreement No. 2, dated as of March 19, 2012 between UniversityHealth Network and VistaGen Therapeutics, Inc., incorporated byreference from Exhibit 10.57 to the Company’s Annual Reporton Form 10-K filed on July 2, 2012.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588912001496/ex10-1.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.67              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              NoteExchange and Purchase Agreement dated as of October 11, 2012 by andbetween VistaGen Therapeutics, Inc. and Platinum Long Term GrowthVII, LLP, incorporated by reference from Exhibit 10.1 to theCompany’s Current Report on Form 8-K filed on October 16,2012.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588912001749/ex10-11202012_021125.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.73              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Amendmentto Note Exchange and Purchase Agreement as of November 14, 2012between VistaGen Therapeutics Inc. and Platinum Long Term GrowthVII, LLP, incorporated by reference from Exhibit 10.1 to theCompany’s Current Report on Form 8-K filed on November 20,2012.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588913000263/npeaamend.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.75              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              AmendmentNo. 2 to Note Exchange and Purchase Agreement as of January 31,2013 between VistaGen Therapeutics Inc. and Platinum Long TermGrowth VII, LLP, incorporated by reference from Exhibit 10.1to the Company’s Quarterly Report on Form 10-Q filed onFebruary 14, 2013.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588913000316/ex10-02282013_010201.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.76              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              AmendmentNo. 3 to Note Exchange and Purchase Agreement as of February 22,2013 between VistaGen Therapeutics Inc. and Platinum Long TermGrowth VII, LLP, incorporated by reference from Exhibit 10.1to the Company’s Current Report on Form 8-K filed onFebruary 28, 2013.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588913000363/ex10-03062013_040313.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.77              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofWarrant to Purchase Common Stock issued to independent members ofthe Company’s Board of Directors and its executive officerson March 3, 2013, incorporated by reference from Exhibit 10.1 tothe Company’s Current Report on Form 8-K filed on March 6,2013.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588913001409/leasebaysidevistagen.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.83              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Leasebetween Bayside Area Development, LLC and VistaGen Therapeutics,Inc. (California) dated April 24, 2013, incorporated by referencefrom Exhibit 10.83 to the Company’s Annual Report on Form10-K filed July 18, 2013.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588913001409/saxeindemnification.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.84              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              IndemnificationAgreement effective May 20, 2013 between the Company and Jon S.Saxe, incorporated by reference from Exhibit 10.84 to theCompany’s Annual Report on Form 10-K filed on July 18,2013.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588913001409/singhindemnification.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.85              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              IndemnificationAgreement effective May 20, 2013 between the Company and Shawn K.Singh, incorporated by reference from Exhibit 10.85 to theCompany’s Annual Report on Form 10-K filed on July 18,2013.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588913001409/snodgrassindemnification.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.86              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              IndemnificationAgreement effective May 20, 2013 between the Company and H. RalphSnodgrass, incorporated by reference from Exhibit 10.86 to theCompany’s Annual Report on Form 10-K filed on July 18,2013.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588913001409/underdownindemnification.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.87              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              IndemnificationAgreement effective May 20, 2013 between the Company and Brian J.Underdown, incorporated by reference from Exhibit 10.87 to theCompany’s Annual Report on Form 10-K filed on July 18,2013.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588913001409/dotsonindemnification.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.88              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              IndemnificationAgreement effective May 20, 2013 between the Company and Jerrold D.Dotson, incorporated by reference from Exhibit 10.88 to theCompany’s Annual Report on Form 10-K filed on July 18,2013.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588916004564/ex10-01292016_020122.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.111              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              ExchangeAgreement, by and between VistaGen Therapeutics, Inc., and PlatinumLong Term Growth VII, LLC and Montsant Partners, LLC, dated January25, 2016, incorporated by reference from Exhibit 10.1 to theCompany’s Current Report on Form 8-K filed on January 29,2016.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588916006331/ex10-112.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.112              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              IndemnificationAgreement effective April 8, 2016 between the Company and Jerry B.Gin, incorporated by reference from Exhibit 10.112 to theCompany’s Annual Report on Form 10-K filed on June 24,2016.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588916005945/ex1-1.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.113              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              UnderwritingAgreement, by and between Chardan Capital Markets, LLC andWallachBeth Capital, LLC, as representatives of the severalunderwriters, and VistaGen Therapeutics, Inc., dated May 10, 2016,incorporated by reference from Exhibit 1.1 to the Company’sCurrent Report on Form 8-K filed on May 16, 2016.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588916005945/ex4-1.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.114              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              WarrantAgency Agreement, by and between Computershare, Inc. and VistaGenTherapeutics, Inc., dated May 16, 2016, incorporated by referencefrom Exhibit 4.1 to the Company’s Current Report on Form 8-Kfiled on May 16, 2016.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588916005945/ex4-2.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.115              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofWarrant; incorporated by reference from Exhibit 4.2 to theCompany’s Current Report on Form 8-K filed on May 16,2016.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588916006331/ex10-116.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.116              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              SecondAmendment to Employment Agreement by and between VistaGenTherapeutics, Inc. and Shawn K. Singh, dated June 22, 2016,incorporated by reference from Exhibit 10.116 to theCompany’s Annual Report on Form 10-K filed on June 24,2016.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588916006331/ex10-117.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.117              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              SecondAmendment to Employment Agreement by and between VistaGenTherapeutics, Inc. and H. Ralph Snodgrass, Ph.D., dated June 22,2016, incorporated by reference from Exhibit 10.117 to theCompany’s Annual Report on Form 10-K filed on June 24,2016.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588916007413/ex10-1.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.118              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              SecondAmendment to Lease between Bayside Area Development and theCompany, effective November 10, 2016, incorporated by referencefrom Exhibit 10.1 to the Company’s Quarterly report on Form10-Q filed on November 15, 2016.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000141588916007413/ex10-2.htm">              <font style="font-size: 13px; font-family: Times New Roman;">               10.119              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              IndemnificationAgreement effective November 10, 2016 between the Company and MarkA. Smith, incorporated by reference from Exhibit 10.2 to theCompany’s Quarterly report on Form 10-Q filed on November 15,2016.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -124-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495417004468/ex10-1.htm">              <font style="font-family: Times New Roman; font-size: 13px">               <font style="font-size: 13px;">                10.120               </font>               <font style="font-size: 13px">                +               </font>              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              ExclusiveLicense and Sublicense Agreement by and between VistaGenTherapeutics, Inc. and Apollo Biologics LP, effective December 9,2016, incorporated by reference from Exhibit 10.1 to theCompany’s Quarterly Report on Form 10-Q filed on May 11,2017.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495417003815/ex10-2.htm">              <font style="font-family: Times New Roman; font-size: 13px">               <font style="font-size: 13px;">                10.121               </font>               <font style="font-size: 13px">                +               </font>              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              PatentLicense Amendment Agreement between VistaGen Therapeutics Inc. andUniversity Health Network effective December 9, 2016, incorporatedby reference from Exhibit 10.2 to the Company’s QuarterlyReport on Form 10-Q/A filed on May 1, 2017.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px;">              <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495417005976/ex10-122.htm">               <font style="font-size: 13px;">                10.122               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Amendedand Restated 2016 Stock Incentive Plan (formerly the VistaGenTherapeutics, Inc. 2008 Stock Incentive Plan), incorporated byreference from Exhibit 10.122 to the Company’s Annual Reporton Form 10-K filed on June 29, 2017.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px;">              <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495417008025/vsta_ex11.htm">               <font style="font-size: 13px;">                10.123               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              UnderwritingAgreement, dated as of August 31, 2017, by and between VistaGenTherapeutics, Inc. and Oppenheimer &amp; Co. Inc., incorporated byreference from Exhibit 1.1 to the Company’s Current Report onForm 8-K filed on August 31, 2017.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px;">              <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495417008025/ex4-1.htm">               <font style="font-size: 13px;">                10.124               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofSeries A1 Warrant, incorporated by reference from Exhibit 4.1 tothe Company’s Current Report on Form 8-K filed on August 31,2017.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495417011630/ex4-1.htm">              <font style="font-family: Times New Roman; font-size: 13px;">               10.126              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px;">              UnderwritingAgreement, dated as of December 11, 2017, by and between VistaGenTherapeutics, Inc. and Oppenheimer &amp; Co. Inc., incorporated byreference from Exhibit 1.1 to the Company’s Current Report onForm 8-K filed on December 13, 2017.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495417011630/ex4-1.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.127              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofWarrant, incorporated by reference from Exhibit 4.1 to theCompany’s Current Report on Form 8-K filed on December 13,2017.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495418008742/ex10-1.htm">              <font style="font-family: Times New Roman; font-size: 13px;">               10.128              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px;">              Formof Summer 2018 Private Placement Subscription Agreement,incorporated by reference from the Company’s Current Reporton Form 8-K filed on August 9, 2018.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495418008742/ex10-2.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.129              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofSummer 2018 Private Placement Warrant, incorporated by referencefrom the Company’s Current Report on Form 8-K filed on August9, 2018.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495418010158/ex10-1.htm">              <font style="font-family: Times New Roman; font-size: 13px;">               10.130+              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px;">              LicenseAgreement (PH94B), by and between VistaGen Therapeutics, Inc. andPherin Pharmaceuticals, Inc., dated September 11, 2018,incorporated by reference from Exhibit 10.1 to the Company’sCurrent Report on Form 8-K filed on September 13, 2018             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495418010158/ex10-2.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.131+              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              OptionAgreement, by and between VistaGen Therapeutics, Inc. and PherinPharmaceuticals, Inc., dated September 11, 2018, incorporated byreference from Exhibit 10.2 to the Company’s Current Reporton Form 8-K filed on September 13, 2018.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495418011715/ex10-3.htm">              <font style="font-family: Times New Roman; font-size: 13px;">               10.132+              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px;">              LicenseAgreement (PH10), by and between VistaGen Therapeutics, Inc. andPherin Pharmaceuticals, Inc., dated October 24, 2018, incorporatedby reference from Exhibit 10.3 to the Company’s QuarterlyReport on Form 10-Q/A filed on October 30, 2018.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495418011665/ex10-4.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.133              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofFall 2018 Private Placement Subscription Agreement, incorporated byreference from Exhibit 10.4 to the Company’s Quarterly Reporton Form 10-Q filed on October 29, 2018.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495418011665/ex10-5.htm">              <font style="font-family: Times New Roman; font-size: 13px;">               10.134              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px;">              Formof Fall 2018 Private Placement Warrant, incorporated by referencefrom Exhibit 10.5 to the Company’s Quarterly Report on Form10-Q filed on October 29, 2018.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495419000496/ex10-1.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.135              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              IndemnificationAgreement, dated January 10, 2019, by and between VistaGenTherapeutics, Inc. and Ann Cunningham, incorporated by referencefrom Exhibit 10.1 to the Company’s Current Report on Form 8-Kfiled on January 15, 2019.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495419007632/ex10_136.htm">              <font style="font-family: Times New Roman; font-size: 13px;">               10.136              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              IndemnificationAgreement, dated November 10, 2016, by and between VistaGenTherapeutics, Inc. and Mark A. McPartland, incorporated byreference from Exhibit 10.136 to the Company’s Annual Reporton Form 10-K filed on June 25, 2019.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495419002248/ex1-1.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.137              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              UnderwritingAgreement, dated as of February 26, 2019, by and between VistaGenTherapeutics, Inc. and William Blair &amp; Company, LLC,incorporated by reference from Exhibit 1.1 to the Company’sCurrent Report on Form 8-K filed on March 4, 2019.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495419007632/ex10-138.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.138              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              MasterServices Agreement, dated July 11, 2017, by and between VistaGenTherapeutics, Inc. and Cato Research Ltd., incorporated byreference from Exhibit 10.138 to the Company’s Annual Reporton Form 10-K filed on June 25, 2019.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495419008434/def14a_july262019.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.139              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              VistaGenTherapeutics, Inc. 2019 Omnibus Equity Incentive Plan, incorporatedby reference from Exhibit 99.1 to the Company’s RegistrationStatement on Form S-8 filed on October 1, 2019.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495419008434/def14a_july262019.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.140              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              VistaGenTherapeutics, Inc. 2019 Employee Stock Purchase Plan, incorporatedby reference from Exhibit 99.2 to the Company’s RegistrationStatement on Form S-8 filed on October 1, 2019.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495419012431/ex10-1.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.141              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofFall 2019 Private Placement Subscription Agreement, incorporated byreference from Exhibit 10.1 to the Company’s Quarterly Reporton Form 10-Q filed on November 7, 2019.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495419012431/ex10-2.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.142              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofFall 2019 Private Placement Warrant, incorporated by reference fromExhibit 10.2 to the Company’s Quarterly Report on Form 10-Qfiled on November 7, 2019.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495420000744/ex10-1.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.143              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofSecurities Purchase Agreement, dated January 24, 2020 between theCompany and each purchaser named in the signature pages thereto,incorporated by reference from Exhibit 10.1 to the Company’sCurrent Report on Form 8-K filed on January 27, 2020.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495420000744/ex10-2.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.144              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofWarrant, dated January 24, 2020, incorporated by reference fromExhibit 10.2 to the Company’s Current Report on Form 8-Kfiled on January 27, 2020.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -125-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center">        <table cellpadding="0" cellspacing="0" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495420003246/ex10-1.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.145              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              PurchaseAgreement, by and between VistaGen Therapeutics, Inc. and LincolnPark Capital Fund, LLC, dated March 24, 2020, incorporated byreference from Exhibit 10.1 to the Company's Current Report on Form8-K, filed March 26, 2020.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495420003246/ex10-2.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.146              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              RegistrationRights Agreement, by and between VistaGen Therapeutics, Inc. andLincoln Park Capital Fund, LLC, dated March 24, 2020, incorporatedby reference from Exhibit 10.2 to the Company's Current Report onForm 8-K, filed March 26, 2020             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495420004484/ex10-1.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.147              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              NotePayable Agreement by and between VistaGen Therapeutics, Inc. andSilicon Valley Bank, dated April 22, 2020, incorporated byreference from Exhibit 10.1 to the Company's Current Report on Form8-K, filed April 27, 2020.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495420007024/ex10-1.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.148#              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Licenseand Collaboration Agreement between VistaGen Therapeutics, Inc. andEverInsight Therapeutics Inc. incorporated by reference fromExhibit 10.1 to the Company’s Current Report on Form 8-K,filed June 26, 2020.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495420008543/ex1-1.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.149              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              UnderwritingAgreement, dated August 2, 2020, by and between VistaGenTherapeutics, Inc. and Maxim Group, LLC incorporated by referencefrom Exhibit 1.1 to the Company’s Current Report on Form 8-Kfiled on August 6, 2020.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495420013839/ex1-1.htm">              <font style="font-family: Times New Roman; font-size: 13px">               10.150              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              UnderwritingAgreement, dated December 18, 2020 by and among VistaGenTherapeutics, Inc., Jefferies LLC and William Blair &amp; Company,L.L.C. incorporated by reference from Exhibit 1.1 to theCompany’s Current Report on Form 8-K filed on December 22,2020.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="http://www.sec.gov/Archives/edgar/data/1411685/000165495421004680/ex10-1.htm">              <font>               <font style="font-family: Times New Roman; font-size: 13px;">                10.151               </font>              </font>             </a>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 13px;">               IndemnificationAgreement, dated April 26, 2021, by and between VistaGenTherapeutics, Inc. and Joanne Curley, Ph.D. incorporated byreference from Exhibit 10.1 to the Company’s Current Reporton Form 8-K filed on April 27, 2021.              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <a href="vtgn_ex211.htm">             21.1            </a>            <br/>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="font-family: Times New Roman; font-size: 13px">               List of Subsidiaries, filed herewith.              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="vtgn_ex231.htm">              <font style="font-family: Times New Roman; font-size: 13px">               23.1              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Consentof Independent Registered Public Accounting Firm, filedherewith.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="vtgn_ex311.htm">              <font style="font-family: Times New Roman; font-size: 13px">               31.1              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Certificationof the Company’s Chief Executive Officer pursuant to Section302 of the Sarbanes-Oxley Act of 2002, filed herewith.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="vtgn_ex312.htm">              <font style="font-family: Times New Roman; font-size: 13px">               31.2              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Certificationof the Company’s Chief Financial Officer pursuant to Section302 of the Sarbanes-Oxley Act of 2002, filed herewith.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="vtgn_ex32.htm">              <font style="font-family: Times New Roman; font-size: 13px">               32.1              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Certificationof the Company’s Chief Executive Officer and Chief FinancialOfficer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,filed herewith.             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              101.INS             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              XBRLInstance Document, filed herewith             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              101.SCH             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              XBRLTaxonomy Extension Schema, filed herewith             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              101.CAL             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              XBRLTaxonomy Extension Calculation Linkbase, filedherewith             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              101.DEF             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              XBRLTaxonomy Extension Definition Linkbase, filed herewith             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              101.LAB             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              XBRLTaxonomy Extension Label Linkbase, filed herewith             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 11%;">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              101.PRE             </font>            </div>           </td>           <td style="vertical-align: top; width: 89%;">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              XBRLTaxonomy Extension Presentation Linkbase, filedherewith             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         _______________        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            *           </font>          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           Incorporatedby reference from the like-numbered exhibit filed with our CurrentReport on Form 8-K on May 16, 2011.          </font>         </div>        </div>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            +           </font>          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           Confidentialtreatment has been granted for certain confidential portions ofthis agreement.          </font>         </div>        </div>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            #           </font>          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           Pursuantto Item 601(b)(10) of Regulation S-K, certain confidentialportions of this exhibit (indicated by “[*****]”)have been omitted as the Company has determined (i) the omittedinformation is not material and (ii) the omitted information wouldlikely cause harm to the Company if publiclydisclosed.          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -126-          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         <a name="SIG">          S         </a>         IGNATURES        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          Pursuant to the requirements of Section 13 or 15(d) of theSecurities Exchange Act of 1934, the Registrant has duly causedthis report to be signed on its behalf by the undersigned,thereunto duly authorized, in the City of South San Francisco,State of California, on the         </font>         <font style="color: rgb(0, 0, 0);">          29th         </font>         <font style="color: #000000">          dayof June, 2021.         </font>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 33%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 5%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 62%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">              VistaGen Therapeutics, Inc.             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 33%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 5%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 62%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 33%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               Date: June              </font>              <font style="color: rgb(0, 0, 0);">               29,2021              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 5%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              By:             </font>            </div>           </td>           <td style="vertical-align: top; width: 62%; border-bottom: 2px solid #000000">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <font style="color: #000000">               /s/              </font>              <font style="font-style: italic; color: #000000">               Shawn K.Singh              </font>              <font style="color: #000000">              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 33%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 5%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 62%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Shawn K. Singh, J.D.             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">              Chief Executive Officer             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 33%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 5%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 62%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          I         </font>         <font style="color: #000000; background-color: #FFFFFF">          naccordance with the Exchange Act, this report has been signed belowby the following persons on behalf of the registrant and in thecapacities and on the dates indicated.         </font>         <font style="font-weight: bold; color: #000000">         </font>        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 27%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Signature             </font>            </div>           </td>           <td style="vertical-align: top; width: 4%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Title             </font>            </div>           </td>           <td style="vertical-align: top; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Date             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: top; width: 50%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: top; width: 23%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="text-decoration: underline">              <font style="font-family: Times New Roman; font-size: 13px">               <font style="color: #000000">                /s/    Shawn K.Singh                <br/>               </font>              </font>             </font>            </div>            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Shawn K. Singh, JD             </font>            </div>           </td>           <td style="vertical-align: top; width: 4%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Chief Executive Officer, and Director             </font>            </div>            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">              (Principal Executive Officer)             </font>            </div>           </td>           <td style="vertical-align: top; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              June 29, 2021             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: top; width: 50%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: top; width: 23%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="text-decoration: underline">              <font style="font-family: Times New Roman; font-size: 13px">               <font style="color: rgb(0, 0, 0); text-decoration: underline;">                /s/    JerroldD. Dotson               </font>               <font style="color: #000000">                <br/>               </font>              </font>             </font>            </div>            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Jerrold D. Dotson             </font>            </div>           </td>           <td style="vertical-align: top; width: 4%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Vice President and Chief Financial Officer             </font>            </div>            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">              (Principal Financial and Accounting Officer)             </font>            </div>           </td>           <td style="vertical-align: top; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              June 29, 2021             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: top; width: 50%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: top; width: 23%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="text-decoration: underline">              <font style="color: #000000; font-family: Times New Roman; font-size: 13px">               /s/    H.RalphSnodgrass              </font>             </font>            </div>            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              H. Ralph Snodgrass, Ph.D             </font>            </div>           </td>           <td style="vertical-align: top; width: 4%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              President, Chief Scientific Officer and Director             </font>            </div>           </td>           <td style="vertical-align: top; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              June 29, 2021             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: top; width: 50%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: top; width: 23%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="text-decoration: underline">              <font style="color: #000000; font-family: Times New Roman; font-size: 13px">               /s/    JonS. Saxe               <br/>              </font>             </font>            </div>            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Jon S. Saxe             </font>            </div>           </td>           <td style="vertical-align: top; width: 4%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Chairman of the Board of Directors             </font>            </div>           </td>           <td style="vertical-align: top; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              June 29, 2021             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: top; width: 50%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: top; width: 23%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="text-decoration: underline">              <font style="font-family: Times New Roman; font-size: 13px">               <font style="color: #000000">                /s/    Ann M.Cunningham                <br/>               </font>              </font>             </font>            </div>            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">              Ann M. Cunningham             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 4%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Director             </font>            </div>           </td>           <td style="vertical-align: top; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              June 29, 2021             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 4%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="text-decoration: underline">              <font style="font-family: Times New Roman; font-size: 13px">               <font style="color: #000000">                /s/    Joanne Curley,Ph.D                <br/>               </font>              </font>             </font>            </div>            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">              Joanne Curley, Ph.D.             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 4%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Director             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              June29, 2021             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 4%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%">            <div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="text-decoration: underline">              <font style="font-family: Times New Roman; font-size: 13px">               <font style="color: #000000">                /s/    Jerry B. Gin,Ph.D                <br/>               </font>              </font>             </font>            </div>            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">              Jerry B. Gin, Ph.D.             </font>            </div>           </td>           <td style="vertical-align: top; width: 4%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Director             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              June29, 2021             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 4%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%">            <div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%;">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="text-decoration: underline">              <font style="font-family: Times New Roman; font-size: 13px">               <font style="color: #000000">                /s/    Brian J.Underdown                <br/>               </font>              </font>             </font>            </div>            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">              Brian J. Underdown, Ph. D             </font>            </div>           </td>           <td style="vertical-align: top; width: 4%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Director             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              June29, 2021             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 27%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 4%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 3%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         <br/>        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           -127-          </font>         </div>        </div>        <div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">         <!--page break-->        </div>       </div>      </text>     </description>    </filename>   </sequence>  </type> </document></body>